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Abstract 
Congenital  thrombotic  thrombocytopenic  purpura  (TTP)  is  a  thrombotic 
microangiopathy,  usually  involving  ADAMTS13  gene  defects.  ADAMTS13 
processes the multimeric plasma glycoprotein Von Willebrand factor making it less 
reactive  to  platelets.  Patients  differ  in  terms  of  disease  severity  and  evidence 
suggests a relationship between ADAMTS13 genotype and disease phenotype. Over 
140 mutations have been identified in patients but only ~30% of these has been 
expressed  in  vitro.  The  aim  of  this  thesis  was  to  study  certain  ADAMTS13 
mutations identified in a homozygous form in congenital TTP patients to assess in 
vitro their effect on the secretion and activity of ADAMTS13 and to assess their 
contribution to disease phenotype. ADAMTS13 mutants (p.R102H, p.I143T and 
p.Y570C) and wild type (WT) were expressed in HEK293T cells. The p.R102H 
mutation partially affected the secretion of ADAMTS13 and reduced the catalytic 
efficiency of the mutant but not to the extent predicted based upon levels measured 
in patient plasma. Expressing this mutant with three ADAMTS13 polymorphisms 
(p.Q448E, p.P618A and p.A900V) which were also identified in the patient with 
this mutation further reduced the secretion and activity of ADAMTS13. When these 
three polymorphisms were expressed separately in WT ADAMTS13, the p.P618A 
polymorphism reduced the secretion and subsequently the activity of ADAMTS13 
suggesting that this polymorphism in particular was responsible for the reduction 
observed. These results highlight the importance of ADAMTS13 polymorphisms. 
The  p.I143T  and  p.Y570C  mutations  severely  affected  ADAMTS13  secretion. 
Immunofluorescence studies showed localisation of these mutants within the ER 
but less extensive localisation within the cis Golgi compared to WT ADAMTS13. 
The p.I143T mutant was characterised further and was shown to be degraded by the 
cell proteasome. Addition of a chemical chaperone (betaine) appeared to rescue the 
secretion defect caused by the p.I143T mutation. This may have future therapeutic 
implications for the treatment of some congenital TTP patients. 
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Chapter 1   Introduction 
1.1  Von Willebrand Factor  
1.1.1  VWF gene, synthesis, secretion 
The gene encoding Von Willebrand factor (VWF) is situated on chromosome 12 
(Ginsburg et al, 1985) and spans ~178 kilobases, containing 52 exons (Mancuso et 
al,  1989).  The  9kb  VWF  messenger  RNA  (mRNA)  encodes  a  2813  amino  acid 
precursor that contains a 22 amino acid long signal peptide, a 741 amino acid long 
propeptide and a 2050 amino acid long mature subunit (Sadler, 1998) (Figure 1-1). 
VWF  is  synthesised  within  vascular  endothelial  cells  (Jaffe  et  al,  1973)  and 
megakaryocytes  (Sporn  et  al,  1985;Nachman  et  al,  1977)  and  is  stored  within 
endothelial cells in Weibel-Palade bodies (Wagner et al, 1982) and within α-granules 
in megakaryocytes (Cramer et al, 1985).  
During synthesis VWF undergoes glycosylation with the addition of twelve N-linked 
and ten O-linked glycan side chains on each mature monomer unit  (Titani et al, 
1986). A small proportion of the N-linked and O-linked glycans contain the ABO 
(H) group antigen (Matsui et al, 1992;Canis et al, 2010). ABO blood group is an 
important  determinant  of  plasma  VWF  levels.  Blood  group  O  is  associated  with 
lower mean WVF antigen levels compared to groups A, B and AB. These levels 
however are still within the normal range (Gill et al, 1987).  
Covalent dimerisation of VWF monomers occurs in the endoplasmic reticulum (ER) 
(Wagner & Marder, 1984), with the formation of disulphide bonds between cysteine 
residues in the cysteine knot (CK) domain of VWF (Katsumi et al, 2000) (Figure 
1-1). Multimerisation of these dimers occurs in the Golgi (Wagner & Marder, 1984) 
with the formation of disulphide bonds between the D3 domains of VWF dimers 
(Marti et al, 1987) (Figure 1-1). The propeptide D1-D2 domains are required for 
VWF multimerisation, acting as a disulphide isomerase (Mayadas & Wagner, 1992). 
  22 
 
 
Figure 1-1 VWF domain structure  
The domain structure of VWF is shown. Regions important for interaction with other proteins are also 
shown. Image from: (Yee & Kretz, 2014). 
After glycosylation, furin removes the VWF propeptide, which then assists in the 
trafficking of both mature multimeric VWF and the cleaved propeptide to Weibel-
Palade bodies (endothelial cells) or α-granules (platelets) (Wagner et al, 1991). Each 
VWF  monomer  is  ~250kDa,  stored  ultra  large  forms  of  VWF  (ULVWF)  are 
typically >20,000 kDa in size (Sadler, 1998). 
ULVWF multimers  are  secreted into the bloodstream from endothelial  cells in  a 
constitutive-like  manner  (Giblin  et  al,  2008)  and  in  response  to  agonists.  The 
majority of VWF within endothelial cells is secreted constitutively. In contrast to 
endothelial cells, megakaryocytes do not constitutively secrete VWF, but release it in 
response to agonists. In cultured endothelial cells, VWF secretion is stimulated by a 
variety of agents including histamine (Hamilton & Sims, 1987), thrombin (Levine et 
al, 1982), fibrin (Ribes et al, 1987), calcium ionophore A23187 (Loesberg et al, 
1983),  the  vasopressin  analogue  1-desamino-8-D-arginine  vasopressin  (DDAVP) 
(Mannucci et al, 1975) and phorbol myristate acetate (Loesberg et al, 1983).  
1.1.2  VWF function 
VWF exists both in the circulation and in the extracellular matrix (ECM) (Rand et al, 
1980;Rand  et  al,  1982)  and  plays  an  important  role  in  primary  haemostasis  by 
recruiting platelets to sites of vessel injury. A deficiency of VWF can lead to Von 
Willebrand  disease  (VWD),  one  of  the  most  common  inherited  human  bleeding 
disorders. 
Shear stress is an important determinant of VWF function as it has the ability to 
significantly change the confirmation of VWF. This structural change modulates the 23 
 
exposure  of  ligand  binding  sites  within  the  VWF  protein.  Within  the  circulation 
VWF can exist in a globular and an extended form (Siedlecki et al, 1996) (Figure 
1-2). 
 
Figure 1-2 VWF changes its shape in response to shear stress 
VWF can adopt a globular shape under low shear stress and with increasing shear stress can unfold. 
Image from: (Siedlecki et al, 1996). 
As blood flows through a vessel, velocity is maximal in the centre and falls to zero at 
the vessel wall. Conversely the gradient of velocity, or shear rate is maximal at the 
vessel wall and falls to zero at the centre. Typical shear rates in small arteries where 
the procoagulant activity of VWF is predominant, is typically within the range of 
1,000s
-1 (Schneider et al, 2007). VWF was shown to display a reversible globule-
stretch  transition  at  a  critical  shear  rate  (γcrit)  of  5,000s
-1  in  the  absence  of  any 
adsorbing surface (Schneider et al, 2007). At γcrit  VWF changed from its globular 
(estimated diameter 2μM) to stretched form (15μM) (Schneider et al, 2007). In the 
presence of platelets γcrit decreased to 3,500s
-1 (Schneider et al, 2007). The γcrit in 
vivo is expected to be lower than this due to the increased viscosity of blood and the 
binding or adsorption of platelets to the surface of VWF. Larger VWF multimers 
unravel more readily in response to shear stress (Zhang et al, 2009).  24 
 
Vessel wall damage leads to the exposure of collagen rich matrix which normally lies 
beneath the cell monolayer. Globular VWF can recognise newly exposed collagen 
(via its A3 domain) which leads to its recruitment to the damaged vessel wall. The 
major binding site for type I and type III collagen lies within the A3 domain of VWF 
(Cruz et al, 1995;Lankhof et al, 1996;Romijn et al, 2001). Binding sites within the 
A1 domain for type I and type III collagen have also been identified (Morales et al, 
2006;Bonnefoy et al, 2006b). VWF can additionally bind to collagen VI via its A1 
domain  (Mazzucato  et  al,  1999).  These  different  types  of  collagen  are  situated 
predominantly in different regions of the ECM, enabling VWF to participate in the 
initiation  of  coagulation  when  the  vessel  wall  is  damaged  to  different  degrees 
(Vanhoorelbeke  &  Deckmyn,  2003).  The  A1  domain  of  VWF  can  also  bind  to 
heparin-like molecules (Fujimura et al, 1987) and to sulfatides (Christophe et al, 
1991), playing a potentially important role in the immobilisation of soluble VWF 
onto complex ECMs (Ruggeri, 1997). 
Once VWF is immobilised it can subsequently unfold by local shear stress exerted on 
the  tethered  VWF  molecule  by  flowing  blood  (Siedlecki  et  al,  1996)  revealing 
previously  hidden  ligand  binding  sites  such  as  platelet  binding  sites.  VWF  is 
important  for  initial  platelet  tethering  and  subsequent  platelet  adhesion  (Sadler, 
1998).  Initial contact  occurs  between the  glycoprotein (GP)  Ib-IX-V complex on 
platelets (Sakariassen et al, 1986) and the A1 domain of VWF (Fujimura et al, 1986) 
(Figure 1-1). Blocking GPIb prevents the binding of platelets to VWF strings (Dong 
et al, 2002). This platelet receptor is exposed on the surface of unactivated platelets 
and has significant affinity for VWF, whereas the VWF A1 domain binding site is 
not exposed when VWF is in its globular state. This receptor binds to endothelial 
anchored VWF in the presence of venous and arterial fluid shear stress (Dong et al, 
2002).  
The GPIIb-IIIa complex on platelets is important for platelet aggregation but is not 
sufficient for platelet adhesion as this interaction is relatively slow (Savage et al, 
1996). VWF does not promote thrombus growth when platelet GPIIb-IIIa is absent 
(Chauhan et al, 2006). The GPIIb-IIIa complex on resting platelets does not bind to 
VWF. This receptor is exposed after platelet activation by thrombin or other agonists 25 
 
(Fujimoto  et  al,  1982).  The  binding  site  for  GPIIb-IIIa  lies  within  the  VWF  C2 
domain (Girma et al, 1986).  
Savage et al showed that platelet binding to fibrinogen was fully efficient only at 
wall shear rates below 600-900s
-1, with maximal platelet deposition at 50s
-1 (Savage 
et al, 1996). Conversely adhesion to VWF was minimal at 50s
-1 and maximal at 
1500s-1. VWF is therefore important for platelet adhesion (via GPIb) and platelet 
aggregation (via GPIIb-IIIa) under high shear stress. Larger VWF multimers have an 
increased  ability  to  support  platelet  adhesion  and  aggregation  (Federici  et  al, 
1989;Moake et al, 1986). 
VWF acts as a carrier for Factor VIII (FVIII) stabilising the protein (Weiss et al, 
1977). In the absence of VWF, Factor VIII is rapidly removed from the circulation 
(Tuddenham et al, 1982). This is evident in patients with severe VWD, who not only 
have  undetectable  levels  of  VWF  but  have  Factor  VIII  levels  <10%  of  normal 
(Sadler,  1998).  A  minimal  proteolytic  fragment  compromising  the  D’  and  D3 
domains of VWF has been reported to bind to FVIII (Foster et al, 1987).  
VWF has been shown to self-associate at the interface of soluble and surface bound 
VWF (Savage et al, 2002;Barg et al, 2007). VWF formed a web like structure (Barg 
et al, 2007) and this association was rapidly reversible (Savage et al, 2002). The 
ability of VWF multimers to self-associate may further contribute to its ability to 
prevent bleeding.   
1.1.3  ADAMTS13 regulates the size of VWF 
VWF is stored and released from platelets and endothelial cells as ULVWF. ULVWF 
however is not normally detected in blood, but instead a series of lower molecular 
weight  multimeric  forms,  ranging  in  size  typically  from  500  to  20,000  kDa  are 
present  (Zhou  et  al,  2010).  These  lower  molecular  weight  forms  exist  because 
ULVWF  is  cleaved  by  the  enzyme  ADAMTS13  (A  disintegrin-like  and 
metalloprotease with thrombospondin type 1 motif) (Furlan et al, 1998b;Furlan et al, 
1997;Furlan et al, 1998a;Tsai & Lian, 1998). By cleaving VWF, ADAMTS13 down-
regulates platelet aggregation and prevents excessive thrombus growth.  26 
 
ADAMTS13  cleaves  VWF  at  the  Tyr1605-Met1606  peptide  bond  within  the  A2 
domain of VWF (Furlan et al, 1996;Tsai, 1996). The scissile bond is unavailable for 
cleavage  when  VWF  is  in  its  native,  globular  state.  Unfolding  of  the  VWF  A2 
domain exposes the scissile bond and cryptic exosites (Figure 1-3).  
 
Figure 1-3 Shear flow leads to the unfolding of VWF  
The molecular structure of the A1-A2-A3 domain is shown. In its globular form (far right), the A3 
domain collagen binding site is exposed. Shear stress leads to unravelling of the A2 domain exposing 
the site for ADAMTS13 cleavage and platelet binding sites.  Image adapted from (Crawley et al, 
2011). 
ADAMTS13 cleaves ULVWF during secretion from endothelial cells and further 
cleaves VWF in the circulation. Endothelial cell derived ULVWF strings bind to 
platelets and are cleaved within seconds to minutes in the presence of normal plasma 
or partially purified ADAMTS13.  In contrast the strings persist in the absence of 
ADAMTS13 (Dong et al, 2002), suggesting that cleavage of VWF occurs on the 
surface of endothelial cells. ADAMTS13 has been shown to bind to endothelial cells 
which  may  facilitate  the  ability  of  ADAMTS13  to  cleave  ULVWF  (Vomund  & 
Majerus, 2009). This interaction may potentially involve CD36 on the surface of 
endothelial cells, as in vitro ADAMTS13 has been shown to bind to CD36 (Davies et 
al, 2006).  
VWF can be cleaved by ADAMTS13 in the circulation. Under shear flow the tensile 
force on a VWF multimer increases with the square of multimer length and is highest 27 
 
in the middle, providing a mechanism for haemostatic regulation of VWF size in the 
circulation (Zhang et al, 2009). A VWF A2 domain typically unfolds at 11pN, this 
tensile force may correspond to the force encountered by a 200mer VWF multimer in 
arterioles  and  capillaries  (Zhang  et  al,  2009).  ADAMTS13  can  limit  thrombus 
growth directly at the site of ongoing thrombus generation (Shida et al, 2008) and so 
may further regulate the size of VWF under these circumstances. 
1.2  The ADAMTS13 gene, synthesis and secretion 
1.2.1  Gene  
The human ADAMTS13 gene is located on chromosome 9 at position 9q34, spanning 
37  kb  and  contains  29  exons  (Levy  et  al,  2001).  Seven  isoforms  produced  by 
alternative splicing have been described (Zheng et al, 2001). The ADAMTS13 mRNA 
of the primary isoform is approximately 5 kb and encodes a protein of 1,427 amino 
acids (Zheng et al, 2001).  
The  ADAMTS13  gene  consists  of  a  signal  peptide,  propeptide,  metalloprotease, 
disintegrin- like, thrombospondin-1 repeat (TSP-1), cysteine-rich, ADAMTS spacer, 
seven additional TSP-1 repeats and two complement C1r/C1s, sea urchin epidermal 
growth factor and bone morphogenetic protein 1 (CUB) domains (Zheng et al, 2001) 
(Figure 1-4). 
 
Figure 1-4 ADAMTS13 from gene to protein 
ADAMTS13 gene organisation is shown along with the protein domain structure. Image adapted from 
(Zheng et al, 2001). 28 
 
1.2.2  Synthesis 
ADAMTS13  is  mainly  synthesised  in  hepatic  stellate  cells  (Zheng  et  al, 
2001;Uemura et al, 2005;Zhou et al, 2005) but ADAMTS13 mRNA or protein has 
been detected in several other cells and tissues including megakaryocytes/platelets 
(Suzuki et al, 2004;Liu et al, 2005), endothelial cells (Turner et al, 2006) and renal 
podocytes (Manea et al, 2007a). Plasma ADAMTS13 is highly glycosylated, with 
ten  potential  N-linked  glycosylation  sites  (Zheng  et  al,  2001),  two  in  the 
metalloprotease domain, one in the cysteine-rich, three in the spacer, one in the TSP-
1:2, one in the TSP-1:4, one in the CUB-1 and one in the CUB-2 domain. Nine of 
these sites have been identified as glycosylation sites within plasma and recombinant 
ADAMTS13 (Sorvillo et al, 2014) (TSP-1:4 was not identified). ADAMTS13 has 
seven predicted O-fucosylation sites, one in each TSP-1 domain with the exception 
of TSP-1:4 (Zheng et al, 2001). Six of these sites (TSP-1:2, TSP-1:3, TSP-1:5, TSP-
1:6,  TSP1-7,  TSP1-8)  have  been  identified  as  glycosylation  sites  in  human  and 
recombinant  ADAMTS13  (Ricketts  et  al,  2007;Sorvillo  et  al,  2014).  Several 
potential C-mannosylation sites have been identified within ADAMTS13. There is 
evidence  to  suggest  the  existence  of  two  putative  C-mannosylation  sites  within 
plasma and recombinant ADAMTS13 (Sorvillo et al, 2014).  
1.2.3  Secretion 
ADAMTS13 circulates in plasma at a concentration of 0.5-1 μg/ml (Soejima et al, 
2006),  with  an  estimated  half-life  of  two  to  three  days  (Furlan  et  al,  1999). 
Glycosylation  is  important  for  the  secretion  of  ADAMTS13.  Disruption  of  O-
fucosylation  has  been  reported  to  reduce  ADAMTS13  secretion  from  transfected 
HEK293 cells (Ricketts et al, 2007) and N-glycosylation in the ER is also critical for 
the efficient secretion of ADAMTS13 from HEK293T cells (Zhou & Tsai, 2009). 
Amino acid substitution at a potential C-mannosylation site in the TSP-1 domain 
(p.W387A)  led  to  reduced  secretion  of  ADAMTS13,  suggesting  that  C-
mannosylation at this site is also important for secretion (Ling et al, 2013). 
In endothelial cells, ADAMTS13 secretion is targeted to the vascular lumen which is 
mediated  by  an  interaction  between  the  CUB  domains  of  ADAMTS13  and  the 29 
 
detergent-resistant and cholesterol-enriched lipid rafts in the apical surface of these 
cells (Shang et al, 2006;Zhou et al, 2009b). 
1.3  The ADAMTS13 protein 
1.3.1  The ADAMTS family 
ADAMTS13 is a metalloprotease belonging to the ADAMTS family (Levy et al, 
2001). The ADAMTS family includes nineteen soluble multi-domain zinc-proteases, 
which  share  a  conserved  multi-domain  structure  with  sequence  similarity  to  the 
ADAM (A disintegrin and metalloprotease) proteases (Andreini et al, 2005). Both 
protein families have a conserved catalytic metalloprotease domain, a signal peptide, 
a  propeptide,  a  disintegrin-like  domain  and  a  cysteine-rich  region  (Figure  1-5). 
ADAMTS proteins lack the epidermal growth factor (EGF) like and transmembrane 
domains present in ADAM proteins and instead contain a TSP-1 sequence repeat 
motif and an ADAMTS spacer domain (Figure 1-5). The C-terminal region contains 
a variable number of additional TSP-1 repeats (from fourteen in ADAMTS9 and 20, 
to none in ADAMTS4) (Apte, 2004). 
 
Figure 1-5 Domain structure of the ADAM and ADAMTS protease family and ADAMTS13  
Signal peptide (S), propeptide (P), metalloprotease  domain (M) (location of the zinc-binding motif is shown in 
red), disintegrin-like domain (Dis), cysteine-rich domain (Cys-R), EGF domain (EGF), transmembrane domain 
(TM), first TSP-1 repeat (1), spacer domain (Spa), TSP-1 repeats 2 to 8 (2-8), two CUB domains (C1, C2). Image 
adapted from (Lancellotti & De Cristofaro, 2011). 30 
 
ADAMTS13 developed before the divergence of fish and tetrapod lineages at least 
360 million years ago (Majerus et al, 2003). ADAMTS13 is most closely related to 
ADAMTS2,  3  and  14,  which  process  collagen  (Huxley-Jones  et  al,  2005).  The 
function  of  the  other  ADAMTS  proteases  includes  cleavage  of  the  matrix 
metalloproteoglycans aggrecan, versican and brevican (ADAMTS1, 4, 5, 8, 9 and 
15) and inhibition of angiogenesis (ADAMTS1 and 8) (Jones & Riley, 2005).  
1.3.2  ADAMTS13 
The  crystal  structure  of  the  region  encompassing  the  disintegrin-like,  TSP-1, 
cysteine-rich and spacer domain (DTCS) of ADAMTS13 has been solved (Akiyama 
et  al,  2009)  and  the  metalloprotease  domain  modelled  based  upon  the  crystal 
structure  of  ADAMTS1,  4  and  5.  The  3D  molecular  structure  of  ADAMTS13 
(metalloprotease→spacer domain) is shown in Figure 1-6 along with the VWF A2 
domain ribbon structure which interacts with these domains.   
 
 
Figure 1-6 ADAMTS13 DTCS 
Figure A shows the folded and unfolded structure of the VWF A2 domain. The molecular structure of 
the modelled metalloprotease domain along with the DTCS model is shown in B. The dotted green 
line represents a VWF molecule. Exosites important for VWF binding are shown in red and yellow. 
Image from: (Akiyama et al, 2009). 31 
 
1.3.3  Propeptide 
The ADAMTS13 propeptide domain is shorter compared to other ADAMTS family 
proteins. Deletion of this region does not appear to affect the secretion, folding or 
enzymatic activity of ADAMTS13 in vitro (Majerus et al, 2003) and so this domain 
appears to be dispensable for these purposes. 
1.3.4  Metalloprotease domain 
The metalloprotease domain of the ADAMTS family members are characterised by a 
reprolysin-type zinc (Zn
2+)
 binding signature (HEXXHXXGXXHD) which consists 
of three conserved histidine (H) residues and a catalytic glutamic acid. The glutamic 
acid polarises a water molecule which is stabilised by the Zn
2+ ion. The Zn
2+ binding 
motif is followed by a tight methionine turn (Zheng et al, 2001).  
The metalloprotease domain has two potential calcium (Ca
2+) binding sites. One of 
these  sites  (low  affinity  site)  does  not  appear  to  be  important  for  ADAMTS13 
function (Gardner et al, 2009) but may be structurally important. The second Ca
2+ 
binding site (high affinity site) appears to be important for ADAMTS13 function. 
The amino acids important for Ca
2+ binding at the second site are present in a loop 
close to the ADAMTS13 active site suggesting that Ca
2+ binding provides structural 
integrity to this loop (Gardner et al, 2009).  
ADAMTS13 cleaves VWF at the position Tyr1605-Met1606. Substitution of these 
residues  with  alanine  was  shown  to  greatly  reduce  the  proteolytic  efficiency  of 
ADAMTS13 (Pruss et al, 2008). Substitution of methionine with leucine showed no 
significant change in activity using a VWF115 peptide but a 26% decrease when 
using  full  length  VWF.  This  data  highlights  the  requirement  for  a  large  and 
hydrophobic  amino  acid  at  this  position  (P1’  residue)  (Pruss  et  al,  2008).  The 
proteolysis of Tyr1605Phe and Tyr1605Trp variants was comparatively normal to 
wild type (WT) demonstrating the importance of the aromatic side chain at position 
1605 (P1 residue) (Pruss et al, 2008).  
There are a number of VWF binding subsites within the metalloprotease domain. The 
ADAMTS13  S1  pocket  which  accommodates  P1  may  involve  the  hydrophobic 32 
 
residues Leu151 and Val195 (Xiang et al, 2011) and the functional Ca
2+ ion. Amino 
acids Asp252-Pro256 of ADAMTS13 are important in shaping the docking site of 
P1’ contributing  to  the S1’ pocket (de Groot  et  al, 2010). The VWF P3 residue 
(Leu1603) appears to have an essential role in the proteolysis of the scissile bond 
whereas the adjacent P2 residue (Val1604) plays a minor role (Xiang et al 2010). 
Mutagenesis studies identified the amino acid residues Leu198, Leu232 and Leu 274 
as important elements of the S3 subsite (Xiang et al, 2011).  
Studies using C-terminal truncated recombinant ADAMTS13 constructs showed that 
the metalloprotease domain alone is unable to cleave plasma VWF (Soejima et al, 
2003;Zheng  et  al,  2003)  or  a  short  A2  domain  peptide,  GST-VWF73-His  at  the 
correct  site  (Ai  et  al,  2005),  suggesting  that  the  domains  downstream  of  the 
metalloprotease domain are responsible for determining substrate specificity. Indeed 
a chimeric variant of ADAMTS5 (which normally cleaves aggrecan), engineered to 
contain the ADAMTS13 TSP-1, cysteine-rich and spacer domains, was shown to 
cleave VWF (although at a different peptide bond within the A2 domain) (Gao et al, 
2012). This demonstrates the importance of these domains for substrate specificity. 
1.3.5  Disintegrin-like domain 
The disintegrin-like domain of ADAMTS proteins share sequence similarity to snake 
venom disintegrins but lack the canonical disintegrin cysteine arrangement (Apte, 
2004). The disintegrin-like domain of ADAMTS13 does not appear to function like a 
disintegrin-like  domain  but  bears  greater  structural  similarity  to  the  cysteine-rich 
domain, with folding similarities existing between the disintegrin-like domain and 
the N-terminal portion of the cysteine-rich domain (residues 440-531, designated the 
CA domain) of ADAMTS13 (Akiyama et al, 2009).  
Additionally unlike the ADAM family metalloproteases the ADAMTS disintegrin-
like  domain  contains  a  linker  region  that  extends  around  the  back  of  the 
metalloprotease domain and positions the disintegrin-like domain at one end of the 
active-site cleft (Gerhardt et al, 2007;Mosyak et al, 2008). The crystal structure of 
the ADAMTS13 disintegrin-like domain shows that the disintegrin domain abuts the 
metalloprotease domain catalytic site, suggesting that the surface of the disintegrin-33 
 
like domain leading to the catalytic site functions as a VWF binding site (Akiyama et 
al, 2009).  
The disintegrin-like domain appears to be important for VWF binding. Addition of 
the disintegrin-like domain to the ADAMTS13 metalloprotease domain restored the 
specific cleavage of GST-VWF73-His at the Tyr-Met bond (Ai et al, 2005). This 
domain also bound dose dependently to GST-VWF73-His and also dose dependently 
inhibited cleavage of FRETS-VWF73 by full length ADAMTS13.  
Indeed  a  VWF  binding  exosite  exists  within  the  disintegrin-like  domain  of 
ADAMTS13 (exosite 1), consisting of the amino acids: Arg326, Glu327, His328, 
Asp330, Arg349, Leu350 and Val352 (Akiyama et al, 2009). The cluster of charged 
residues may collaboratively interact with Asp1614, Glu1615 and Lys1617 within 
VWF.  These  ADAMTS13  amino  acids  and  the  corresponding  interacting  amino 
acids  within  VWF  have  been  previously  shown  in  vitro  to  be  important  for  the 
interaction between ADAMTS13 and VWF (Zanardelli et al, 2006;de Groot et al, 
2009).  
1.3.6  TSP-1 domain 
The TSP-1 domain is homologous to the type 1 repeat of thrombospondin-1 and -2 
and contains six cysteine amino acids. The TSP-1 domain of ADAMTS13 is stiff and 
rod-like (Akiyama et al, 2009). The core of TSP-1 is stabilised by stacked layers of 
tryptophan, arginine and hydrophobic residues and is capped by disulphide bonds at 
bond ends. This stacked structure is referred to as the CWR layered core (Akiyama et 
al, 2009). 
The addition of the TSP-1 domain to the metalloprotease domain of ADAMTS13 
restored the specific cleavage of GST-VWF73-His at the Tyr-Met bond. Additionally 
the  TSP-1  domain  alone  bound  dose  dependently  to  GST-VWF73-His  and  dose 
dependently inhibited cleavage of FRETS-VWF73 by full length ADAMTS13 and 
an ADAMTS13 variant truncated after the spacer domain (Ai et al, 2005). The TSP-
1  domain  may  interact  with  VWF  residues  Gln1624-Val1630  (Gao  et  al,  2008). 
However this interaction appears to be non-essential and the primary role of the TSP-34 
 
1 domain may be to spatially position the VWF binding exosites within the other 
ADAMTS13 domains (Akiyama et al, 2009). 
1.3.7  Cysteine-rich domain 
The cysteine-rich domain contains ten conserved cysteine residues; the N-terminal 
portion of the cysteine-rich domain CA, has a fold structurally homologous to that of 
the cysteine-rich domains of ADAMs, despite the lack of sequence similarity. The 
disintegrin-like  and  CA  domains  have  only  17%  identity  in  their  amino  acid 
sequences however their tertiary structures are similar. They share an N-terminal α-
helix, two pairs of double-stranded antiparallel β-sheets and three disulphide bonds, 
constituting the core structure of these domains (Akiyama et al, 2009). 
The remaining C-terminal portion of the cysteine-rich domain (resides 532-555, CB) 
is  highly  conserved  in  amino  acid  sequence  among  ADAMTS  family  proteins. 
Although the CB domain has no apparent secondary structure it has a series of turns 
stabilised by a pair of disulphide bonds and forms a rod shape with its C and N 
termini ~25A apart (Akiyama et al, 2009). 
This domain appears to be important for VWF binding. The cysteine-rich domain 
alone  was  shown  to  bind  dose  dependently  to  GST-VWF73-His  and  to  dose 
dependently inhibit cleavage of FRETS-VWF73 by full length ADAMTS13 (Ai et 
al, 2005). A VWF binding exosite (exosite 2) may exist in the cysteine-rich region, 
consisting  of  amino  acids:  His476,  Ser477,  Gln478,  Arg448,  Phe494-Met496 
(Akiyama et al, 2009). This may interact with the VWF region encompassing amino 
acids: Ile1642-Gln1652 (Gao et al, 2008). 
1.3.8  Spacer domain 
The  spacer  domain  contains  no  cysteine  amino  acids,  has  a  variable  length  in 
ADAMTS family members and is the least homologous domain. It folds into a single 
globular domain with ten β-strands in a jelly roll topology, forming two antiparallel 
β-sheets that lie almost parallel to each other. The hydrophobic aromatic residues 
forming the core of the β-sandwich are highly conserved. In contrast loops located on 
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among ADAMTS proteins. The N and C-termini of the spacer domain are in close 
proximity and thus the TSP-1:2 domain following the spacer domain should be in 
close proximity to the CA/spacer domain junction, not at the distal side of the spacer 
domain (Akiyama et al, 2009). The B6-B7 loop in the spacer domain plays a pivotal 
role in the interactions between the CA and spacer domain (Akiyama et al, 2009). 
Addition of the spacer domain to the metalloprotease domain restored the specific 
cleavage  of  GST-VWF73-His  at  the  Tyr-Met  bond  (Ai  et  al,  2005).  The  spacer 
domain  additionally  bound  dose  dependently  to  GST-VWF73-His  and  dose 
dependently inhibited the cleavage of FRETS-VWF73 by full length ADAMTS13 
and ADAMTS13 truncated after the spacer domain (Ai et al, 2005). 
A VWF binding site, exosite 3, consisting of the residues Arg568, Pro590, Leu591, 
Phe592, Leu637, Pro638, Leu591, Phe592, Arg660, Tyr661, Tyr665, and Leu688 
exists within the spacer domain. Some of these amino acids lie on two distal loops on 
the spacer domain (Akiyama et al, 2009). The importance of some of these residues 
for this interaction has been demonstrated in vitro (Pos et al, 2010). The amino acid 
Arg659 may also contribute to the ADAMTS13 spacer-VWF A2 domain interaction 
(Jin et al, 2010). This region binds to Asp1653-Arg1668 in the VWF A2 domain 
(Akiyama et al, 2009).  
Exposure of cryptic binding sites within the VWF A2 domain requires the extraction 
of the adjacent molecular plug formed  by the vicinal disulphide bond (Cys1669-
Cys1670)  and  uncoupling  of  the  C-terminal  α-helix  in  which  residues  Glu1660-
Arg1668 reside. As this region is predicted to unfold first, even partial unfolding of 
the VWF A2 domain could be sufficient for the spacer domain to bind (Chen et al, 
2009).    
1.3.9  TSP-1:2→TSP-1:8, CUB-1 and CUB-2 domains 
The TSP-1 repeats are homologues to the type 1 repeat of thrombospondin-1 and -2. 
The TSP-1:2→TSP-1:8 repeats are variable in sequence. The TSP-1:4 domain of 
ADAMTS13 contains just four cysteine residues, two of which are predicted to be 
unpaired.  All  of  the  TSP-1  repeats  except  for  TSP-1:4  are  predicted  to  be  O-
glycosylated. There are six potential CD36 binding sites within the TSP-1 repeats, 36 
 
with CSVSCG recognition sites in four TSP-1 repeats and two CSASCG recognition 
sites  in  two  of  the  TSP-1  repeats  (Davis  et  al,  2009).  ADAMTS13  is  the  only 
member  of  the  ADAMTS  family  to  contain  CUB  domains.  These  domains  are 
present within proteins known to be important for developmental regulation, such as 
bone morphogenetic protein-1 (Bork & Beckmann, 1993).  
The  TSP-1:2→8  and  CUB  domains  have  been  shown  to  mediate  binding  of 
recombinant  ADAMTS13  to  a  constitutively  exposed  surface  on  globular  VWF. 
Interaction  occurs  between  the  TSP-1:5→TSP-1:8  and/or  the  CUB  domains 
(Zanardelli et al, 2009). This interaction does not result in ADAMTS13 cleavage 
(Zanardelli et al, 2009;Feys et al, 2009a) and is reversible and non-covalent (Feys et 
al, 2009a). This interaction also occurs in normal human plasma, with ADAMTS13-
VWF complexes representing approximately 3% of total ADAMTS13 (Feys et al, 
2009a). This domain may be important for the initial docking of ADAMTS13 to 
VWF and its localisation at the site of the growing thrombus in vivo, but dispensable 
when ADAMTS13 activity is measured under static conditions. 
The importance of the C-terminal domains has been demonstrated in mice. Mice 
encode two forms of the ADAMTS13 gene, some mouse strains encode full length 
ADAMTS13 (129/Sv) and some strains of mice such as C57BL/6 encode a short 
form of ADAMTS13 lacking the distal C-terminal domains due to the insertion of a 
retrotransposon in intron 23 of the ADAMTS13 gene (Banno et al, 2004;Zhou et al, 
2007).  Banno  et  al  analysed  and  generated  129/Sv-genetic  background  congenic 
mice that carried the short form of ADAMTS13 (ADAMTS13
S/S) and compared this 
to the WT mice with the long form (ADAMTS13
L/L). In vitro thrombogenesis using 
blood from both mice was measured under flow by perfusing whole blood over a 
collagen-coated  surface  in  a  parallel  flow  chamber.  At  a  shear  rate  of  5000s-1, 
thrombogenesis was accelerated in ADAMTS13
S/S compared to ADAMTS13
L/L,
 but
 
there was no significant difference at 1000s
-1. Both in vivo thrombus formation in 
ferric-chloride  injured  arterioles  and  thrombocytopenia  induced  by  collagen  plus 
epinephrine challenge was more dramatic in ADAMTS13
S/S than in ADAMTS13
L/L but 
less than in ADAMTS13
-/- (Banno et al, 2009).  37 
 
It  has  been  proposed  that  the  TSP-1:2→8  domains  may  negatively  regulate 
ADAMTS13 activity. In mice the proteolysis of endothelial platelet decorated strings 
by  ADAMTS13  truncated  after  the  spacer  domain  was  similar  to  full  length 
ADAMTS13.  In  contrast  removal  of  the  CUB  domains  was  found  to  abolish 
proteolysis  of  endothelial  platelet-decorated  VWF  strings.  Activity  of  an 
ADAMTS13 variant truncated after the TSP-1:6 domain resulted in reduced activity 
when compared to ADAMTS13 truncated after the spacer domain (De Maeyer et al, 
2010).  The  authors  hypothesise  that  the  catalytic  site  and/or  spacer  domain  of 
ADAMTS13 are shielded by the TSP2-8 tail, an interaction that could be disrupted 
after the initial docking of the CUB domains, enabling interaction of the catalytic site 
and  spacer  domain  with  the  A2  domain  of  VWF.  Alternatively  conformational 
changes that may occur in ADAMTS13 after the deletion of these regions could 
explain  the  differences  observed.  It  is  unclear  therefore  whether  the  TSP-1:2→8 
domains negatively regulate ADAMTS13 activity (De Maeyer et al, 2010).   
1.4  ADAMTS13 cleavage of VWF 
As described VWF binding exosites exist in the metalloprotease domain and within 
the disintegrin-like domain, cysteine-rich region and spacer domain of ADAMTS13. 
These exosites interact with discontinuous regions of VWF (Akiyama et al, 2009). 
The overall structure of the ADAMTS13 DTCS resembles a distorted W-shape in 
which three protruding regions: disintegrin-like, CA and spacer domain are connected 
by 2 elongated structural modules: TSP-1 and CB. The homologous disintegrin-like 
and CA domains are separated and related by a pseudo-90° screw rotation with a 
~45A translation along TSP-1. The VWF-binding exosites are on the linearly aligned 
discontinuous surface of the disintegrin-like, CA and spacer domains transversing the 
W-shaped molecule (Akiyama et al, 2009). 
The multiple interactions that exist between VWF and ADAMTS13 are illustrated in 
Figure 1-7. According to this model (Crawley et al, 2011) ADAMTS13 and VWF 
make contact through their C-terminal domains. As a consequence of changes in 
local shear stress conditions, confirmational changes in VWF lead to the exposure 
and binding of exosites present in the N-terminal region of the VWF A2 domain and 
ADAMTS13, which positions the scissile bond in the catalytic cleft of ADAMTS13.  38 
 
  
Figure 1-7 ADAMTS13 cleavage of VWF 
Crawley  et  al  proposed  that  the  cleavage  of  ADAMTS13  occurs  in  7  distinct  steps,  as  follows: 
ADAMTS13 can reversibly bind to globular VWF (step 1). When shear stress induces the unfolding 
of VWF, additional exosite binding sites on VWF are revealed (step 2). The ADAMTS13 spacer 
domain recognises residues Glu1660-Arg1668 (step 3) revealed when the vicinal Cys disulphide bind 
plug  is  extracted  from  the  hydrophobic  core  of  the  A2  domain.  This  increases  the  affinity  of 
ADAMTS13  for  VWF.  An  ADAMTS13  disintegrin-like  exosite  involving  Arg349  recognises  a 
complementary site of VWF compromising VWF1614 in a critical but low affinity interaction (step 
4). Thereafter an essential contact is made between VWF Leu1603 and a complementary S3 subsite in 
ADAMTS13 involving Leu198, Leu232 and Leu274 (step 5). Together these interactions bring the 
Tyr1605-Met1606 scissile bond over the ADAMTS13 active site. This allows the P1 (1605) and P1’ 
(1606) residues to engage their respective S1 and S1’ subsite pockets involving Leu151/Val195 (S1) 
and Asp252-Pro256 (S1’) respectively (step 6). Once cleavage has taken place (step 7) there is a 
reduction in the affinity between ADAMTS13 and VWF, enabling ADAMTS13 to recycle. Image 
from: (Crawley et al, 2011). 39 
 
Deletion  of  residues  Gln1624-Arg1641  within  a  VWF  peptide  substrate  (GST-
VWF73-His) did not change the rate of cleavage of VWF by various ADAMTS13 
variants (Gao et al, 2008). These residues therefore do not appear to be essential for 
enzyme recognition, at least in the context of VWF73. As deletion of these amino 
acids reduced the distance between the scissile bond and auxiliary binding sires in 
the ADAMTS13 cysteine-rich and spacer domains, it suggests that ADAMTS13 does 
not require a fixed spatial relationship between the scissile bond and auxiliary exosite 
binding  sites  on  the  substrate.  This  ability  to  accommodate  a  large  change  in 
substrate structure suggests that ADAMTS13 is relatively flexible and can alter the 
relationships between the distal domains that bind VWF, which may be important for 
substrate  recognition.  Fluid  shear  stress  in  vivo  may  induce  a  spectrum  of 
conformational changes in VWF. The flexibility of ADAMTS13 would enable it to 
bind to VWF in a variety of contexts and combinations (Gao et al, 2008).  
The ADAMTS13 DTCS crystal structure supports this hypothesis. VWF73 is more 
than 200Å long at its maximum extension which is almost twice the distance between 
the catalytic site and the distal exosite-3 in the current ADAMTS13 model (Akiyama 
et  al,  2009).  ADAMTS13  appears  to  be  able  to  accommodate  by  an  induced  fit 
mechanism, a partially unfolded VWF73 segment. 
1.4.1  Factors affecting cleavage of VWF by ADAMTS13 
ADAMTS13 is constitutively secreted as an active enzyme (Majerus et al, 2003) and 
no specific physiological inhibitor is known. Several factors have been shown to 
affect  the  interaction  between  ADAMTS13  and  VWF  (both  positively  and 
negatively). Some of these factors may only play a role under certain pathological 
circumstances. 
The  substrate  VWF  is  an  important  determinant  of  ADAMTS13  cleavage.  VWF 
glycans have been shown to both positively and negatively affect VWF cleavage by 
ADAMTS13. O-linked glycans, N-linked glycans and more specifically ABO blood 
group antigens and terminal sialic acid on VWF influence binding and ADAMTS13 
proteolysis  (Bowen  &  Collins,  2004;O'Donnell  et  al,  2005;McKinnon  et  al, 
2008;McGrath et al, 2010;McGrath et al, 2013;Nowak et al, 2014) .  In  fact  platelet 40 
 
derived  VWF  has  a  different  glycosylation  profile  rendering  it  more  resistant  to 
proteolysis by ADAMTS13 (McGrath et al, 2013). 
Mutations within the VWF A2 domain (such as those present in patients with type 
2A  VWD)  can  increase  the  susceptibility  of  VWF  to  ADAMTS13  cleavage 
(Hassenpflug et al, 2006). Similarly, mutations within the VWF A1 domain (such as 
those present in patients with type 2B VWD), increase the affinity by which VWF 
can bind to GpIb, which in turn enhances ADAMTS13 cleavage (De Cristofaro et al, 
2006;Rayes et al, 2007;Rayes et al, 2010). In vitro oxidation of Met1606 impairs 
ADAMTS13 mediated VWF proteolysis by reducing substrate binding affinity (Chen 
et al, 2010;Lancellotti et al, 2010;Pozzi et al, 2012) 
Inorganic ions have been shown to affect both ADAMTS13 and VWF. Ca
2+ and Zn
2+ 
ions, bind to the metalloprotease domain of ADAMTS13, exerting both a functional 
and  structural  effect  (Furlan  et  al,  1996;Anderson  et  al,  2006;Gardner  et  al, 
2009;Pozzi  et  al,  2012).  However  concentrations  of  Zn
2+>3mM  can  inhibit 
ADAMTS13 activity (Anderson et al, 2006). A Ca
2+ binding site exists within the 
A2  domain  of  VWF  stabilising  it  and  impeding  its  unfolding,  consequently 
protecting it from cleavage (Zhou et al, 2011). Chloride ions can bind to the VWF 
A1 domain, stabilising the folded conformation of VWF A1-A2-A3 domains (De 
Cristofaro  et  al,  2005;De  Cristofaro  et  al,  2006).  At  concentrations  exceeding 
physiological levels, Mg
2+ ions can enhance cleavage of ULVWF under flow (Dong 
et al, 2008). 
Other proteins present within the circulation may also affect the interaction between 
ADAMTS13 and VWF. Factor H, a regulator of complement activation, was shown 
in one study to bind to VWF and enhance its proteolysis (Feng et al, 2013b). In 
contrast in another study it inhibited VWF proteolysis by ADAMTS13 (Rayes et al, 
2014) and therefore its role needs to be further clarified. 
Heparin  has  been  shown  to  bind  to  the  VWF  A1  domain  and  enhance  VWF 
proteolysis (Nishio et al, 2004). However heparin could indirectly inhibit proteolysis 
by    binding  to  endothelial  cells  (Vomund  &  Majerus,  2009),  as  the  binding  of 
ADAMTS13 to endothelial cells, enhances VWF proteolysis.  41 
 
 
Platelet GpIb  binding to the VWF A1 domain promotes A2 domain unfolding by 
inducing conformational changes in the A1-A2 domains increasing the tensile force 
experienced by VWF multimers under shear stress  (Nishio  et  al,  2004;Shim  et  al, 
2008). P-selectin has been shown to interact with ULVWF strings on the surface of 
activated endothelium, potentially facilitating ADAMTS13 cleavage in vitro (Padilla 
et al, 2004). However it appears to have no effect in vivo in P-selectin knock-out 
(KO) mice (Chauhan et al, 2007). 
The  light  chain  of  FVIII  has  been  shown  to  accelerate  VWF  proteolysis  by 
ADAMTS13  in  vitro  (Cao  et  al,  2008a;Cao  et  al,  2012;Skipwith  et  al,  2010). 
However patients with severe haemophilia A display normal cleavage of VWF by 
ADAMTS13 in vivo (Chen et al, 2013).  
 
Thrombospondin-1  has  been  shown  to  protect  VWF  from  proteolysis,  competing 
with  ADAMTS13  for  binding  to  VWF  A2  and  A3  domains  (Bonnefoy  et  al, 
2006a;Wang  et  al,  2010).  The  binding  of  haemoglobin  to  the  VWF  A2  domain 
prevents the cleavage of VWF (Studt et al, 2005;Zhou et al, 2009a) and shigatoxin 1 
and 2 have been shown to bind to VWF A1 and A2 domains and inhibit cleavage of 
ULVWF strings (Nolasco et al, 2005;Lo et al, 2013).  
1.4.2  Disulphide bond reduction of VWF by ADAMTS13 
In addition to cleaving VWF, ADAMTS13 has been shown to reduce  disulphide 
bonds that may form between VWF multimers under high shear conditions. This is 
hypothesised  to  inhibit  self-association  of  plasma  VWF  multimers  into  fibrillar 
structures which have an increased ability to bind to platelets (Yeh et al, 2010). Free 
thiols within ADAMTS13 which appear to be responsible for this disulphide bond 
reducing activity are mainly situated within the C-terminal TSP-1 and CUB domains 
(Yeh et al, 2010;Bao et al, 2014). The free thiols present in these distal domains 
inhibit thrombus formation under high shear stress in vitro and in vivo, independent 
of  ADAMTS13  proteolytic  activity  (Bao  et  al,  2014).  The  concentrations  of 
ADAMTS13 used in these experiments were higher than the physiological quantities 
normally  present  in  the  circulation  and  so  its  role  under  physiological  and 
pathological conditions still remains to be determined. 42 
 
1.4.3  VWF and ADAMTS13 cleavage 
Coagulation (thrombin, plasmin, FXa) (Crawley et al, 2005) and leukocyte proteases 
(Ono et al, 2006;Hiura et al, 2010) have been shown to cleave ADAMTS13, but this 
may only occur under specific pathological conditions. 
Proteases  other  than  ADAMTS13  have  been  shown  to  cleave  VWF  such  as 
leukocyte proteases (Buzza et al, 2008;Raife et al, 2009;Hollestelle et al, 2011) and 
plasmin (Tersteeg et al, 2014). Plasmin, generated by plasminogen activation via the 
urokinase  plasminogen  activator  or  the  thrombolytic  drug  streptokinase,  cleaves 
VWF and degrades platelet VWF complexes in the absence of ADAMTS13, both in 
vitro and in vivo (Tersteeg et al, 2014). Plasmin has been suggested as a potential 
alternative mechanism to cleave VWF when there is severe ADAMTS13 deficiency. 
1.5  Thrombotic thrombocytopenic purpura  
1.5.1  Signs and symptoms  
The  original  description  of  TTP  described  a  pentad  of  thrombocytopenia, 
microangiopathic  haemolytic  anemia  (MAHA),  neurological  symptoms,  renal 
impairment  and  fever  (Moschcowitz,  1924).  However  TTP  patients  can  present 
without the full pentad, up to 35% of patients  do not have neurological signs at 
presentation and renal abnormalities and fever are not prominent features (Scully et 
al,  2012).  TTP  is  characterised  today  by  thrombocytopenia,  MAHA,  widespread 
microvascular thrombi and consequent clinical sequelae due to ischaemic end organ 
damage. The presence of thrombocytopenia and MAHA is not specific to TTP, but is 
characteristic of a number of other diseases known as thrombotic microangiopathies 
(TMAs).  TMAs  include  haemolytic  uraemia  syndrome  (HUS),  disseminated 
intravascular coagulation, haemolysis, elevated liver enzymes and low platelet count 
(HELLP)  and  antiphospholipid  syndrome.  The  pathophysiology  of  these  diseases 
however differs from that of TTP, which is characterised generally by a deficiency of 
ADAMTS13.  The  diagnosis  of  TTP  remains  clinical  but  the  measurement  of 
ADAMTS13 activity within patient plasma can help to confirm the diagnosis and 
monitor the course of the disease. 43 
 
Patients  may  present  with  TTP  with  thrombocytopenia;  central  neurological 
problems  (confusion,  headache,  paresis,  aphasia,  dysarthria,  visual  problems, 
encephalopathy,  and  coma);  jaundice;  renal  impairment  (proteinuria, 
microhaematuria); cardiac involvement (chest pain, heart failure, and hypotension); 
gastrointestinal tract (abdominal pain) or fever  (Scully  et al, 2012). Neurological 
involvement was the most prevalent symptom (78% of cases) in one cohort of TTP 
patients with 10% of patients presenting with coma. Cardiac involvement accounted 
for 42% of presenting features (Scully et al, 2008). 
Median  platelet  count  in  patients  is  normally  10-30x10
9/l;  median  haemoglobin 
levels  on  admission  are  typically  80-100g/l  with  schistocytes  on  the  blood  film. 
Patients have low haptoglobulin levels, raised reticulocyte counts due to haemolysis, 
along  with  a  negative  direct  Coombs  test  and  elevated  levels  of  lactate 
dehydrogenase (LDH) (Scully et al, 2012).  
1.5.2  Incidence 
The annual incidence of TTP has been estimated as 2-6 per million of the population 
(Terrell et al, 2005;Scully et al, 2008;Miller et al, 2004). These estimates are based 
on studies from the USA and the UK. The incidence of TTP in the USA in one study 
was 3.8 (95% confidence interval [CI]:2.4-5.1) (Miller et al, 2004) and in another 
study the incidence of TTP-HUS patients with severe ADAMTS13 deficiency was 
1.74  (95%  CI:  2.4-5.1)  (Terrell  et  al,  2005).  The  incidence  of  TTP  has  been 
estimated as 6 cases per million population per year in the UK (Scully et al, 2008).  
The median age of acute TTP presentation is during the third to fourth decade, in one 
cohort of TTP patients 7% presented during childhood (<18 years) whereas 93% 
presented as adults (>18 years) (Moatti-Cohen et al, 2012). The disease typically 
affects women, with a ratio of approximately 2:1 (Moatti-Cohen et al, 2012). At least 
half of all acute episodes of TTP are in women of childbearing age (Scully et al, 
2014). 
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1.5.3  Pathophysiology 
Patients  with  thrombotic  thrombocytopenia  purpura  (TTP)  generally  have  a 
deficiency in the enzyme ADAMTS13. This deficiency leads to the accumulation of 
ULVWF multimers  within the circulation.  Larger molecular weight  multimers of 
VWF have an increased affinity for platelet receptors such as glycoproteins Ib/V/IX 
and IIb/IIIa (Federici et al, 1989) and unfold more readily in response to shear stress 
(Zhang et al, 2009). ULVWF is therefore more effective than the largest normal 
forms of plasma VWF in supporting shear-induced platelet aggregation (Moake et al, 
1986). The consequence of this is uncontrolled formation of platelet-rich thrombi in 
the microcirculation, which can lead to occlusion. These thrombi contain little fibrin 
but are abundant in VWF (Asada et al, 1985). 
TTP  occurs  in  two  forms:  congenital  TTP,  due  to  homozygous  or  compound 
heterozygous mutations in the ADAMTS13 gene (Levy et al, 2001), or acquired TTP, 
often  characterised  by  the  development  of  anti-ADAMTS13  autoantibodies. 
Congenital TTP accounts for approximately 5% of TTP cases (Scully et al, 2008). 
1.5.4  Triggers:infection 
Patients with TTP can have single or recurrent TTP episodes. Infection is recognised 
to be a triggering causal factor for acute TTP as it can precipitate an episode in 
patients with other predisposing causal factors (such as low ADAMTS13 activity). In 
one cohort 41% of acute TTP episodes were associated with infection (Morgand et 
al,  2014).  Some  in  vitro  studies  suggest  that  inflammatory  cytokines  may  affect 
ADAMTS13 and VWF levels and also their interaction. The release of VWF from 
HUVECS  was  shown  to  be  dose  dependently  increased  in  the  presence  of  the 
inflammatory cytokines TNF-α and IL-8 (Bernardo et al, 2004).  However another 
study did not find the same effect of TNFα (Cao et al, 2008b).  
The cytokines IFN-γ, IL-4 and TNF-α reduced ADAMTS13 mRNA and proteolytic 
activity  in  hepatic  stellate  cells  and  HUVECs,  in  a  dose  dependent  manner. 
Incubation  of  IFN-γ,  IL-4  and  TNF-α  with  purified  recombinant  ADAMTS13 
however did not inhibit its proteolytic activity (Cao et al, 2008b). In contrast the 
effect of TNF-α was not confirmed in another study (Claus et al, 2005). Additionally 45 
 
cleavage  of  endothelial  VWF  by  ADAMTS13  in  the  presence  of  IL-6  under 
conditions of flow (but not under static conditions) has been shown to be inhibited 
(Bernardo  et  al,  2004),  suggesting  that  some  cytokines  can  affect  ADAMTS13 
mediated  cleavage.  Together  these  in  vitro  studies  suggest  that  inflammation 
associated with infection may affect normal levels of VWF and/or ADAMTS13 and 
their interaction, precipitating a TTP episode. 
1.5.5  Triggers: Pregancy 
Pregnancy also appears to be a triggering causal factor for the onset of TTP in a 
number of patients. Pregnancy associated TTP is reported to represent 5-10% of all 
adult  TTP  cases  (George  et  al,  2008;Scully  et  al,  2008;Fujimura  &  Matsumoto, 
2010;Moatti-Cohen et al, 2012) and is estimated to occur in 1 in 198,000 pregnancies 
(Moatti-Cohen et al, 2012).  
Patients  present  with  TTP  primarily  from  the second trimester to  the postpartum 
period (Moatti-Cohen et al, 2012;Scully et al, 2014) but fetal loss/morbidity appears 
to be highest in the first (Moatti-Cohen et al, 2012) and second trimester (Scully et 
al,  2014)  of  pregnancy.  If  pregnant  TTP  patients  are  untreated  it  can  lead  to 
significant morbidity and mortality for the child (Fujimura et al, 2009;Moatti-Cohen 
et al, 2012;Scully et al, 2014). 
In  normal  pregnancies  plasma  VWF  increases  steadily  during  gestation  with  the 
appearance of ULVWF (Stirling et al, 1984). Treatment of endothelial cells with 
oestrogens (Harrison & McKee, 1984) has been shown to increase VWF synthesis. 
Healthy, pregnant women have lower ADAMTS13 activity compared to women who 
are not pregnant (Sanchez-Luceros et al, 2004;Mannucci et al, 2001). ADAMTS13 
may be consumed under these conditions due to the high levels of VWF released 
during pregnancy, precipitating a TTP episode. 
1.5.6  Treatment 
Patients  with  TTP are treated with  plasma exchange or infusion  which acts  as  a 
source  of  ADAMTS13  for  the  patients.  In  patients  with  acquired  TTP  plasma 
exchange also removes antibodies which may bind and inhibit ADAMTS13. Patients 46 
 
with  acquired  TTP  may  also  be  treated  with  immunosuppressive  drugs  (George, 
2010). ADAMTS13 has a half-life of two to three days (Furlan et al, 1999), however 
the regular infusion of plasma approximately every two to three weeks appears to be 
sufficient in most congenital patients to prevent episodes (Kinoshita et al, 2001). 
1.6  Congenital TTP 
Congenital TTP is suspected in patients with TTP and an ADAMTS13 activity level 
below 5% of normal, in the absence of anti-ADAMTS13 antibodies. These patients 
can  therefore  also  be  described  as  having  a  congenital  ADAMTS13  deficiency. 
There are over 100 congenital TTP patients worldwide (Scully et al, 2012). Although 
congenital  TTP  patients  have  persistently  low  levels  of  ADAMTS13  in  the 
circulation some patients may be asymptomatic until childhood or adulthood. Based 
on information gathered from reported congenital TTP patients in the literature, 48% 
developed TTP in the neonatal period, 31% during childhood (2 months to 18 years) 
and 21% during adulthood (Lotta et al, 2010).   
Neonates  typically  have  severe  neonatal  jaundice  and  blood  examinations  show 
schistocytes  together  with  red  cell  anisocytosis  (Scully  et  al,  2006).  Patients 
presenting during the neonatal period or childhood typically have thrombocytopenia, 
MAHA,  jaundice  and  elevated  LDH,  although  some  children  may  have  isolated 
thrombocytopenia (Scully et al, 2012).  
Patients may also present during adulthood. Pregnancy is commonly associated with 
disease onset (Fujimura et al, 2009;Moatti-Cohen et al, 2012;Scully et al, 2014). 
Rarely patients may not develop symptoms until their 50s or 60s (Fujimura et al, 
2011).  Asymptomatic  male  cases  have  been  reported  usually  because  they  have 
affected relatives (Bestetti et al, 2003;Garagiola et al, 2008;Palla et al, 2009).  
The p.R1060W mutation is commonly found in Caucasian patients who first present 
with TTP during pregnancy. This mutation was present in 73% of patients in one 
cohort (Scully et al, 2014) and 80% of patients in another cohort (Moatti-Cohen et 
al, 2012). However this mutation has not been identified in Japanese pregnancy onset 
patients  (Fujimura  et  al,  2009).  Congenital  TTP  presents  more  frequently  than 47 
 
acquired TTP during pregnancy. In one cohort 66% of women presenting with TTP 
for the first time had late onset TTP (Scully et al, 2014). 
The  clinical  severity  of  disease  episodes  varies  between  patients.  Some  have 
asymptomatic episodes of thrombocytopenia and anemia, whereas others have multi-
organ failure (Schneppenheim et al, 2003).  
1.6.1  ADAMTS13 mutations 
Genetic defects within ADAMTS13 were first identified in 2001 (Levy et al, 2001) in 
patients with familial, congenital TTP. These genetic defects were inherited in an 
autosomal recessive manner. Since then over 140 mutations have been identified 
within the ADAMTS13 gene in patients with congenital TTP (Hing et al, 2013;Feys 
et al, 2009b;Klukowska et al, 2010;He et al, 2010;Deal et al, 2012;Rossio et al, 
2013;Lotta et al, 2012;Ma et al, 2006;Scully et al, 2014) (Table S 6). Patients have 
homozygous or compound heterozygous mutations in the ADAMTS13 gene. These 
mutations  are  distributed  throughout  the  gene.  The  majority  of  mutations  are 
missense mutations, causing either secretion and/or catalytic activity defects of the 
ADAMTS13 protein (Lotta et al, 2010).  
1.6.2  ADAMTS13 polymorphisms 
A number of non-synonymous coding polymorphisms have been identified within 
the  ADAMTS13  gene.  The  effect  of  these  polymorphisms  on  the  secretion  and 
activity of ADAMTS13 has been studied for some of these polymorphisms (p.R7W, 
p.Q448E,  p.P475S,  p.P618A,  p.A732V,  p.A900V,  p.A1033T)  (Kokame  et  al, 
2002;Plaimauer et al, 2006;Tao et al, 2006;Rurali et al, 2013;Edwards et al, 2012). 
Notably  two  of  the  polymorphisms,  p.P475S  and  p.P618A  lead  to  significantly 
reduced  ADAMTS13  activity  in  vitro  compared  to  WT  (Kokame  et  al, 
2002;Plaimauer et al, 2006). Certain polymorphisms are more common in certain 
ethnic groups for example the p.P475S polymorphism is common in the Japanese 
population but not Caucasians (Kokame et al, 2002;Levy et al, 2001). 48 
 
1.6.3  Mouse models of congenital TTP 
ADAMTS13  KO  mice  have  been  produced  to  replicate  the  severe  deficiency  of 
ADAMTS13 found in patients with congenital TTP. These models have contributed 
to our understanding of the disease, demonstrating ADAMTS13 cleavage of VWF in 
vivo.  In  mice  ADAMTS13  deficiency  is  necessary  but  not  sufficient  for  the 
development of TTP.  
ADAMTS13 KO mice do not spontaneously develop TTP (Motto et al, 2005;Banno 
et al, 2006). Pregnancy, a TTP trigger in humans, does not induce the disease in 
ADAMTS13 KO mice (Motto et al, 2005;Banno et al, 2006). In ADAMTS13 KO 
mice no schistocytes were found in WT or KO mice (Motto et al, 2005;Banno et al, 
2006), there was no thrombocytopenia and histopathological analysis showed that 
WT and KO mouse tissue was indistinguishable (Motto et al, 2005). There were no 
significant differences in blood cell counts, plasma haptoglobin levels and platelet 
aggregation in response to collagen and botrocetin (Banno et al, 2006). There was a 
difference in multimeric pattern with the presence of ULVWF in the KO but not the 
WT mice in Banno’s model, but ULVWF was present in both WT and KO mice in 
Motto’s  model.  In  Motto’s  model  mice  expressed  the  truncated  version  of 
ADAMTS13 (ADAMTS13
S/S) whereas in Banno’s model they expressed full length 
ADAMTS13 (ADAMTS13
L/L).  
Although ADAMTS13 KO mice do not spontaneously develop TTP they are in a 
prothrombotic state (Motto et al, 2005;Banno et al, 2006). After perfusion of the 
calcium ionophore A23187 (to stimulate ULVWF release),  ADAMTS13 KO mice 
showed significantly prolonged adhesion of platelets compared to WT mice (Motto 
et al, 2005). After 3.5 minutes of perfusion of blood from WT and KO mice over a 
collagen coated surface in a parallel flow chamber,  the thrombus grew rapidly in 
ADAMTS13 KO mice, which was significantly different to WT mice (Banno et al, 
2006).  When  mice  were  challenged  with  collagen,  mortality  was  not  different 
between WT and KO mice but platelet counts were significantly lower in KO mice 
compared  to  WT  mice  (Banno  et  al,  2006).  Furthermore  when  tested  in  vivo 
thrombosis  models,  ADAMTS13 KO mice showed accelerated arterial thrombosis 49 
 
formation  leading  to  faster  occlusion  of  injured  blood  vessels  (Chauhan  et  al, 
2006;Banno et al, 2009;Laje et al, 2009;Niiya et al, 2009). 
In one of the ADAMTS13 KO models, mice (on a C57BL/6J background)  were 
backcrossed  with  CASA/Rk  mice  (Motto  et  al,  2005),  a  strain  which  has 
approximately 5 to 10 fold higher VWF levels compared to the C57BL/6J mouse 
strain used (Mohlke et al, 1999). Mean plasma levels increased 40 to 50% after this 
backcross and multimeric VWF was different between WT and KO mice. There was 
a significant decrease in platelet count in KO mice compared to WT mice with 21% 
of  the  KO  mice  severely  thrombocytopenic  at  baseline.  The  KO  mice  exhibited 
significantly decreased survival compared to WT mice. In some of the ADAMTS13 
KO mice there was spontaneous development of severe microangiopathic changes in 
the  peripheral  blood  along  with  widespread  VWF  rich  and  fibrin-poor  hyaline 
thrombi  in  the  small  vessels  of  multiple  organs.  However  the  mice  still  did  not 
develop TTP. 
A  TTP  like  disease  however  developed  in  some  mice,  on  a  specific  genetic 
background  after  challenge  with  shigatoxin  (Motto  et  al,  2005).  Challenge  of 
C57BL/6J WT and KO mice with shigatoxin led to no consistent change in red blood 
cell or platelet count in both mice, with similar mortality in both groups. However 
differences were observed between ADAMTS13 WT and KO mice on the CASA/Rk 
background, with significant difference in survival and platelet cont. Also some of 
the  ADAMTS13  KO  mice  developed  TTP  like  symptoms  (Motto  et  al,  2005). 
However  there  was  no  correlation  between  elevated  plasma  VWF  levels  and 
mortality, baseline platelet count or thrombocytopenia. The requirement for VWF in 
this model was experimentally confirmed by showing that CASA/Rk mice deficient 
in  both  VWF  and  ADAMTS13  were  not  susceptible  to  shigatoxin  induced  TTP 
(Chauhan et al, 2008).  
In another ADAMTS13 KO model, TTP could be induced in mice after they were 
challenged  with  recombinant  VWF  containing  ULVWF  (Schiviz  et  al,  2012). 
Recombinant  human  ADAMTS13  protected  the  mice  from  developing  TTP. 
Recently a new mouse model of TTP has been developed, with the development of 
TTP in mice expressing a VWF mutant resistant to ADAMTS13 cleavage (Morioka 50 
 
et al, 2014). The authors found lower molecular weight forms of VWF present in the 
circulation of these mice, suggesting that other proteases may have cleaved VWF in 
these mice.  
ADAMTS13  KO  mice  therefore  do  not  spontaneously  develop  TTP  but  are  in  a 
prothrombotic  state.  They  require  an  additional  trigger  for  disease  development, 
suggesting  that  other  environmental  and  genetic  factors  are  important  in  the 
development of TTP. This resembles somewhat the situation in humans as some 
patients only develop TTP after a trigger such as infection of pregnancy but does not 
explain apparent spontaneous TTP development.  
Furthermore ADAMTS13 KO mice do not develop TTP during pregnancy which is a 
well-known trigger for TTP development in humans. The hameodynamics formed by 
anatomical differences in the vasculature network of mice and humans significantly 
differ and so there are limitations in using mice as a model. Although mouse models 
have aided our understanding they do not fully reflect the disease as seen in humans.  
1.6.4  Residual ADAMTS13 activity 
Despite having severe ADAMTS13 deficiency the clinical presentation of patients 
with  congenital  TTP  is  highly  variable.  Patients  vary  with  respect  to  the  age  of 
disease onset, number of relapses and need for plasma exchange/infusion. Some may 
initially present with TTP during the neonatal period or during infancy (Assink et al, 
2003) whilst others may present as adults (Camilleri et al, 2008;Tao et al, 2006). 
Some patients require regular prophylactic plasma infusions whereas others rarely 
require plasma infusion (Fujimura et al, 2011). The onset of TTP in some patients 
may be spontaneous with no identifiable trigger, whilst in other cases it may be the 
result of an environmental trigger such as infection or pregnancy (Donadelli et al, 
2006;Fujimura et al, 2011;Palla et al, 2009).  
Evidence suggests that there may be a relationship between ADAMTS13 genotype 
and phenotype, with the particular ADAMTS13 mutations present in congenital TTP 
patients  accounting  for  some  of  the  heterogeneity  observed  in  patients  with 
congenital TTP. It has been observed that the age of disease onset is similar between 
both  siblings  and  unrelated  patients  with  the  same  ADAMTS13  genotype  (Figure 51 
 
1-8). The p.R1060W mutation has been observed in a relatively large number of 
patients  and  has  been  mainly  identified  in  patients  with  pregnancy  onset  TTP 
(Moatti-Cohen et al, 2012;Scully et al, 2014). The p.E1382RfsX6 (Schneppenheim 
et al, 2006) and p.R692C (Levy  et al, 2001;Snider  et al, 2004;Kim et al, 2014) 
mutation have been predominantly found in patients that present with TTP during 
childhood.  
 
Figure 1-8 Relationship between ADAMTS13 genotype and age of disease phenotype 
Circles represent patients with neonatal disease onset, triangles childhood onset (>2 months to 18 
years), diamond patients with adult onset. Image adapted from (Lotta et al, 2010). 
Residual ADAMTS13 activity currently undetectable by routine ADAMTS13 assays 
has been measured using SELDI-TOF (surface-enhanced laser desorption/ionization 
time-of-flight) to investigate the relationship between residual ADAMTS13 activity 
and disease phenotype (Lotta et al, 2012). ADAMTS13 activity >0.5% of PNP was 
measured in 90% of patients studied (26/29). Median plasma activity was 3.08% 
range <0.5%-6.77%.  
Lower levels of ADAMTS13 activity were associated with an earlier age at first TTP 
episode  requiring  plasma  infusion.  Lower  levels  were  associated  with  a  higher 
annual incidence of TTP episodes and with the prescription of fresh frozen plasma 
(FFP)  prophylaxis  (Lotta  et  al,  2012).  ADAMTS13  activity  <2.74%  appeared  to 
discriminate between patients who had a first episode requiring FFP under 18 and 52 
 
prescription of FFP. The relationship between ADAMTS13 genotypes (that occurred 
more than once in the literature) and residual ADAMTS13 activity and age at first 
TTP episode requiring FFP is shown in Figure 1-9. Siblings with the same genotype 
and unrelated individuals (with the p.R1060W mutation) had a similar age of disease 
onset. 
 
Figure 1-9 Relationship between ADAMTS13 genotype and residual ADAMTS13 activity and 
age at first episode requiring FFP 
Image from: (Lotta et al, 2012). 
Patients with homozygous mutations in the N-terminal region (n=4) displayed lower 
residual activity compared to those with homozygous mutations in the C-terminal 
region (n=8) (Figure 1-10).  
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Figure 1-10 Residual ADAMTS13 activity in patients homozygous for ADAMTS13 mutations 
Image from: (Lotta et al, 2012). 
There  were  some  exceptions  with  some  patients  having  relatively  high  residual 
activity  with  an  early  age  of  disease  at  first  episode  requiring  FFP  or  frequent 
recurrences  demonstrating  the  importance  of  other  factors  (genetic  and 
environmental) (Lotta et al, 2012). These studies were performed in a small number, 
often related individuals, so although they suggest a relationship may exist it would 
need  to  be  confirmed  in  a  larger  number  of  unrelated  patients,  however  this  is 
difficult because of the rarity of the disease.  
Environmental triggers (e.g. infections) and associated physiological or pathological 
conditions (e.g. pregnancy and autoimmune disorders) are hypothesised to induce an 
increase  in  VWF  antigen  levels  which  exceed  the  levels  which  residual  active 
ADAMTS13 enzyme can normally degrade, leading to the precipitation of an acute 
TTP episode. 54 
 
1.7  Acquired TTP 
Acquired TTP  patients  may have TTP  secondary to  other diseases  such as  HIV, 
infection, drugs or transplantation. However the majority of patients have acquired 
acute idiopathic TTP. It is not associated with a specific underlying precipitating 
factor and antibodies to ADAMTS13 can be detected. In up to 90% of cases these are 
IgG (Rieger et al, 2005) although IgM (Scheiflinger et al, 2003) and IgA (Ferrari et 
al, 2007) antibodies have also been described. Antibodies which inhibit the activity 
of  ADAMTS13  (Tsai  &  Lian,  1998;Peyvandi  et  al,  2004;Ferrari  et  al,  2007)  or 
possibly  increase  its  clearance  (Scheiflinger  et  al,  2003)  have  been  identified  in 
patients with idiopathic acquired TTP.  
Not all acquired TTP patients have an acquired ADAMTS13 deficiency, with some 
patients having normal or moderately reduced ADAMTS13 activity (Bettoni et al, 
2012;Mori et al, 2002;Bohm et al, 2005). The incidence of acquired TTP-HUS in the 
US has been estimated as 4.46 cases per million of the population per year (95% 
CI:3.43-5.50) (Terrell et al, 2005).  
The  ADAMTS13  cysteine-rich  and  spacer  domains  have  been  shown  to  be  the 
primary autoimmune target in patients with TTP (Soejima et al, 2003;Klaus et al, 
2004;Luken et al, 2005). Residues Pro660, Tyr661 and Tyr665 in the spacer domain 
represent a core binding site for antibodies (Pos et al, 2010). Antibodies directed 
towards other regions of ADAMTS13 such as the propeptide, TSP-1, TSP-1:2→8 
and CUB have also been detected less frequently (Klaus et al, 2004;Zheng et al, 
2010).  
Early studies performed before the identification of ADAMTS13 demonstrated the 
presence  of  anti-CD36  antibodies  in  patients  with  acquired  TTP  (Tandon  et  al, 
1994;Schultz  et  al,  1998).  This  has  not  been  investigated  further  since  the 
identification of ADAMTS13, but is an interesting finding given that CD36 may be 
the binding site for ADAMTS13 on endothelial cells (Davis et al, 2009).  
There have been no studies to analyse whether ADAMTS13 genetic defects could 
contribute to anti-ADAMTS13 antibody formation in patients with acquired TTP. By 55 
 
definition patients with congenital TTP do not have anti-ADAMTS13 antibodies so 
the ADAMTS13 gene is normally only analysed in patients with no anti-ADAMTS13 
autoantibodies. Three patients heterozygous for the p.R1060W mutation were also 
reported  to  have  detectable  antibodies  to  ADAMTS13  (Camilleri  et  al,  2008). 
However  this  may  have  been  coincidental  as  the  p.R1060W  mutation  has  been 
detected  in  a  number  of  congenital  TTP  patients  with  no  anti-ADAMTS13 
antibodies,  both  in  a  heterozygous  and  homozygous  form  (Camilleri  et  al, 
2012;Moatti-Cohen et al, 2012;Scully et al, 2014). The antibodies detected may have 
been transient non-specific or low titre antibodies.  
1.7.1  Baboon models of acquired TTP 
In  baboons,  four  days  of  ADAMTS13  functional  inhibition  using  a  mouse 
monoclonal antibody directed towards the metalloprotease domain was sufficient to 
induce a TTP-like disease, in the absence of inciting triggers (Feys et al, 2010). The 
baboons had severe thrombocytopenia, MAHA, a rise in serum LDH levels and the 
presence of platelet and VWF-rich thrombi in the kidneys, heart, brain and spleen, 
thus providing a model for acquired TTP.  
The situation in baboons appears to be different to ADAMTS13 KO mice which do 
not  spontaneously  develop  TTP.  The  authors  proposed  that  the  discrepancies 
between this model and mouse models may be due to differences in the physiology 
of  mice  and  primates.  This  model  mimicked  the  early  stages  of  the  disease  and 
demonstrated the importance of ADAMTS13 in disease development. 
1.8  New therapeutic options for TTP 
New  therapeutic  options  are  currently  being  explored  for  the  treatment  of  TTP. 
Plasma  exchange  has  significantly  improved  the  outcome  of  patients  with  TTP. 
Death in TTP patients has been dramatically reduced from 90% to approximately 10-
20%  (Scully  et  al,  2012).  Plasma  exchange/infusion  however  does  have  its 
disadvantages.  It  is  time  consuming  and  expensive,  citrate  reactions  and  allergic 
reactions can occur and there is also the risk of venous thromboembolism, which 
occurred in 6.5% of patients in one cohort (McGuckin et al, 2014). 56 
 
Recombinant ADAMTS13 is currently in development for use as an alternative to 
plasma exchange/infusion in patients (Plaimauer & Scheiflinger, 2004). It could be 
used to treat congenital TTP patients who have little or no functional ADAMTS13. 
In an ADAMTS13 KO model of TTP administration of ADAMTS13 prevented the 
onset of TTP symptoms (Schiviz et al, 2012). In acquired TTP inhibitory antibodies 
may inhibit the infused recombinant ADAMTS13. An in vitro study showed that 
reasonable  doses  of  recombinant  ADAMTS13  could  overcome  neutralising 
inhibitors and restore ADAMTS13 activity, and so its use in patients with acquired 
TTP may also be beneficial (Plaimauer et al, 2011).  
The efficacy and safety of the nanobody ALX-0081 as adjunctive therapy to plasma 
exchange in patients with acquired TTP is now being assessed in the TITAN trial, 
which is a Phase II, single-blind, randomised, placebo-controlled trial (Holz, 2012). 
This nanobody is directed towards the A1 domain of VWF and specifically inhibits 
its interaction with the GPIb-IX-V platelet receptor glycoprotein, thereby preventing 
VWF-mediated platelet aggregation. A humanised nanobody (ALX-0681) targeting 
the A1 domain of VWF has been tested in the baboon TTP model (Callewaert et al, 
2012).  This  nanobody  targets  the  same  region  as  ALX-0081,  but  its  mode  of 
administration  is  slightly  different.  Prophylactic  administration  of  ALX-0681  not 
only prevented the rapid onset of thrombocytopenia after ADAMTS13 inhibition but 
prevented the appearance of schistocytes, intravascular haemolysis and an increase in 
LDH levels. Administration of this drug soon after the onset of TTP was not able to 
dissolve already formed thrombi within the vessels of various organs but prevented 
the progressive formation of aggregates. This drug when administered to humans is 
anticipated to reduce the time to normalisation of platelet count and the number of 
plasma exchange sessions to achieve remission. Importantly there was no indication 
of  relevant  bleeding  or  signs  of  intracranial  bleeding  or  internal  organ  bleeding 
(Callewaert et al, 2012).  
A similar drug to ALX-0081 (ARC1779) has been tested previously in a clinical trial 
which  was  unfortunately  prematurely  terminated.  ARC1779  is  a  nucleic  acid 
macromolecule  (aptamer)  targeting  the  A1  domain  of  VWF  preventing  the 
interaction  between  VWF  and  the  GPIb-IX-V  receptor.  Prior  to  the  premature 
termination of the clinical trial, nine patients were treated with either ARC1779 or 57 
 
placebo as an adjunct to plasma exchange (two placebo, seven ARC1779). Clinical 
response was achieved in four of seven subjects in the ARC1779 treated subjects and 
in none of the placebo treated patients during the two week infusion protocol. The 
number of patients included in this trial was too small to enable conclusions to be 
drawn regarding the efficacy of this drug. However the drug did not appear to lead to 
bleeding and sustained suppression of VWF activity was achieved during the two 
week treatment period (Cataland et al, 2012). 
Rituximab is a chimeric monoclonal antibody that targets CD20 on the surface of B-
lymphocytes. It has been successfully used in the treatment of some TTP patient’s 
refractory  to  immunosuppressive  drugs  (Sallah  et  al,  2004;Ahmad  et  al, 
2004;Fakhouri et al, 2005;Scully et al, 2007). It may ameliorate the symptoms of 
TTP  by  eradicating  specific  B-cell  clones  responsible  for  the  production  of 
ADAMTS13 autoantibodies (Stasi, 2010). It has not been tested in a randomised 
Phase III trial but has been tested in a phase II trial (Scully et al, 2011). In Caucasian 
patients  treatment  with  rituximab  led  to  a  reduction  in  the  number  of  plasma 
exchanges required to achieve remission and an overall reduction in inpatient days 
(excluding  those  patients  in  intensive  care).  There  were  no  serious  side  effects 
reported with this drug.   
N-acetylcysteine (NAC) is an FDA approved drug which is also approved for use in 
pregnancy  (George  et  al,  2014).  It  is  commonly  used  to  reduce  the  viscosity  of 
mucous secretion in respiratory disorders. NAC’s free sulfhydryl group allows it to 
decrease  the  molecular  size  of  mucin  and  therefore  viscosity  by  reducing  the 
disulphide bonds that produce mucin polymers (Von Langenbeck, 1966). NAC has 
been shown to cleave VWF in vitro and in vivo in mice (Chen et al, 2011). NAC 
reduced  multimers  under  static  conditions  and  endothelial  VWF  strings  under 
conditions  of  flow.  It  reduced  disulphide  bonds  within  the  A1  domain  of  VWF, 
inhibited platelet agglutination in a concentration dependent manner in the presence 
of ristocetin and it inhibited collagen binding in a concentration dependent manner. 
NAC also reduced circulating VWF multimers in vivo in mice and reduced thrombi 
formation  in  WT  and  ADAMTS13  KO  mice  treated  with  NAC.  There  was  no 
difference  in  bleeding  time  between  the  mice  treated  with  NAC  compared  to 58 
 
controls. NAC also prevented in vitro platelet aggregation in response to ADP and 
collagen.  
A recent case report has suggested it may potentially be a useful therapeutic option 
(Li et al, 2014). A patient with acquired TTP who did not respond to corticosteroids 
or  rituximab,  was  treated  with  success  with  NAC  in  conjunction  with  plasma 
exchange, corticosteroids and rituximab (Li et al, 2014). The patient’s platelet count 
began  to  improve  two  to  three  days  after  NAC  treatment  (within  six  days  or 
rituximab treatment). The Puget Sound blood centre has begun a pilot study of NAC 
in  patients  with  suspected  TTP  (NCT01808521,  URL:  https://clinicaltrials.gov/, 
accessed 17
th June 2014), to determine if changes in VWF function can be detected 
in  humans  receiving  NAC  and  if  NAC  is  tolerated  when  administered  between 
plasma exchange procedures. 
Substitution of four to five residues in exosite 3 of ADAMTS13 has been shown to 
generate  ADAMTS13  variants  (M4:R660K/F592Y/R568K/Y661F  and  M5: 
R660K/F592Y/R568K/Y661F/Y665F)  with  increased  specific  activity  to  FRETS-
VWF73 and multimeric VWF. Levels were increased 4- to 5- fold and 10- to 12- fold 
respectively  (Jian  et  al,  2012).  These  variants  were  more  resistant  than  WT 
ADAMTS13 to inhibition by anti-ADAMTS13 antibodies from a number of patients 
with acquired TTP. This variant has not been tested in animal models but may be a 
promising therapeutic option in the future to treat patients with acquired TTP. 
Gene therapy has been investigated in ADAMTS13 KO mice as a potential therapy 
for patients with congenital TTP. Systemic administration of adenovirus encoding 
ADAMTS13 (Trionfini et al, 2009;Jin et al, 2013) and in utero lentiviral transfer of 
ADAMTS13 (Niiya et al, 2009) have been successfully performed in ADAMTS13 KO 
mice.  Additionally  autologous  transplantation  of  haematopoietic  progenitor  cells, 
transduced ex vivo with a lentiviral vector encoding ADAMTS13 (Laje et al, 2009) 
has  led  to  ADAMTS13  expression  in  ADAMTS13  KO  mice.  In  these  models 
functional  ADAMTS13  was  effectively  expressed  in  the  mice.  Furthermore  gene 
transfer of ADAMTS13 was shown to prevent the development of shigatoxin induced 
TTP in mice (Jin et al, 2013). However the use of gene therapy to treat TTP does not 
appear to be a possible therapeutic option in the near future. 59 
 
1.9  ADAMTS13 deficiency in the setting of other diseases  
Some  case  control  studies  have  found  an  association  between  low  ADAMTS13 
antigen and risk of myocardial infarction (MI) (Bongers et al, 2009;Crawley et al, 
2008;Andersson  et  al,  2012)  and  ischaemic  stroke  (IS)  (Lambers  et  al, 
2013;Andersson  et  al,  2012).  However  it  remains  to  be  determined  whether  the 
reduced levels of ADAMTS13 measured in these studies was a cause or consequence 
of  the  pathogenesis  of  these  diseases.  With  this  is  mind,  some  groups  have 
investigated the effect of ADAMTS13 deficiency in vivo in mouse models of these 
diseases to assess the contribution of ADAMTS13 to disease pathogenesis. 
In ischaemia/reperfusion models  of MI and IS the absence of ADAMTS13 led to an 
increase in the size of the infarct (De Meyer et al, 2012;Doi et al, 2012;Gandhi et al, 
2012b;Khan et al, 2012;Fujioka et al, 2010;Fujioka et al, 2012;Zhao et al, 2009) and 
an  increased  number  of  inflammatory  cells  entering  the  site  (Fujioka  et  al, 
2010;Khan et al, 2012;Gandhi et al, 2012b). Addition of recombinant ADAMTS13 
to WT or KO mice reduced the infarct and number of inflammatory cells at the site 
(De Meyer et al, 2012;Doi et al, 2012;Zhao et al, 2009). The anti-thrombotic and 
anti-inflammatory effects appeared to be mediated through VWF as VWF KO and 
VWF/ADAMTS13 double KO mice had smaller infarcts and a decreased number of 
inflammatory  cells  (Zhao  et  al,  2009;Kleinschnitz  et  al,  2009;Gandhi  et  al, 
2012b;Khan et al, 2012). 
ADAMTS13 deficiency in ApoE KO, atherosclerosis prone mice led to the formation 
of larger atherosclerotic plaques containing more inflammatory cells (Gandhi et al, 
2012a;Jin et al, 2012). These effects appeared to be mediated through VWF (Gandhi 
et al, 2014) as VWF KO and VWF/ADAMTS13 KO mice appeared to have smaller 
lesion sizes and a reduced number of inflammatory cells. 
Together these mouse models suggest that a severe deficiency in ADAMTS13 may 
contribute  to  the  pathogenesis  of  diseases  such  as  MI  and  IS  by  potentially 
preventing  the  thrombotic  occlusion  of  the  microvasculature  during  the  post-
ischaemic  reperfusion  stage  (Doi  et  al,  2012).  Ischaemia  is  a  rapid  inducer  of 
Weibel-Palade  body  release  thus  making  the  infarct  area  highly  thrombogenic 60 
 
(Pinsky  et  al,  1996).  ADAMTS13  has  been  shown  to  have  anti-inflammatory 
properties  (Chauhan  et  al,  2008)  and  its  deficiency  leads  to  a  worse  disease 
phenotype in a mouse model of atherosclerosis. These results have implications for 
patients with congenital TTP, who may have a worse prognosis after development of 
these diseases. 
1.10 ADAMTS13 genetic variation in diseases other than TTP 
Mutations  or  polymorphisms  within  ADAMTS13  have  been  described  for  some 
diseases such as HUS (Feng et al, 2013a), venous thrombosis (Lotta et al, 2013), 
coronary heart disease (Schettert et al, 2010), IS (Hanson et al, 2009), response to 
ACE inhibitors (Rurali et al, 2013) and malaria (Kraisin et al, 2014). However many 
of the studies were performed in a small number of patients and the effect of some of 
these polymorphisms or mutations in vivo still remains to be determined. 
1.11 Aims of thesis 
I hypothesise that the clinical and laboratory phenotype of patients with congenital 
TTP will relate to their ADAMTS13 mutations and the effect that these mutations 
have on ADAMTS13 expression and activity in vitro. The aim of this study was to 
express ADAMTS13 mutations identified in a homozygous form in congenital TTP 
patients to assess their effect on the secretion and activity of ADAMTS13. For the 
mutations that severely affected the secretion of ADAMTS13 I aimed to investigate 
the  localisation  of  these  mutations  within  the  cell.  For  those  mutants  that  were 
secreted I aimed to analyse the catalytic activity of the secreted protein. Finally for 
those mutations which were predicted to affect splicing of the ADAMTS13 gene, I 
aimed to create a mini gene to analyse this in vitro.  61 
 
Chapter 2   Materials and methods 
2.1  In silico analysis of ADAMTS13 missense mutations 
Human  ADAMTS13  was  aligned  with  ADAMTS13  orthologs  using  clustalW2 
multiple sequence alignment tool (URL: http://www.ebi.ac.uk/Tools/msa/clustalw2/; 
accessed 17
th June 2014). The amino acid sequence of Homo Sapiens ADAMTS13 
was  aligned  with  the  amino  acid  sequence  of  ADAMTS13  from  the  following 
species:  Taeriopygia  guttata  (zebra  finch),  Gallus  gallus  (chicken),  Bos  taurus 
(cattle), Ovis aries (sheep), Gorilla gorilla gorilla (western lowland gorilla), Pan 
troglodytes (chimpanzee), Nomascus leucogenys (northern white cheeked gibbon), 
Pango abelli (Sumatran orangutan), Papio anubis (olive baboon), Calithrix jacchus 
(white  tufted  ear  marmoset),  Saimiri  boliviensis  boliviensis  (Bolivian  squirrel 
monkey),  Otolemur  garretti  (small-eared  galago),  Mus  musculus  (house  mouse), 
Cricetulus griseus (Chinese hamster), Cavia porcellus (domestic guinea pig), Canis 
lupus familiaris (domestic dog), Felis catus (domestic cat), Ailuropoda melanoleuca 
(giant  panda),  Equus  caballus  (domestic  horse),  Sarophilus  harrisii  (Tasmanian 
devil)  and  Danio  Rerio  (zebra  fish).  Sequences  within  the  region  affected  by 
mutations  or  non-synonymous  polymorphisms  in  the  patients  studied  are  only 
shown. The affected amino acids are highlighted in yellow. 
Similarly the ADAMTS13 amino acid sequence of Homo sapiens was aligned with 
the  ADAMTS13  sequence  of  paralogs  using  the  clustalW2  multiple  sequence 
alignment tool. ADAMTS13 was aligned with the sequences of ADAMTS1, 2, 3, 4, 
5, 6, 7, 8, 9, 10, 12, 13, 14, 15, 16, 17, 18, 19, 20 (all from Homo Sapiens). The GI 
numbers of all sequences are shown in the appendix (Table S 1). 
SNPs3D  (URL:  http://www.snps3d.org/;  accessed  17
th  June  2014),  SIFT  human 
SNPs  tool  (URL:  http://sift.jcvi.org/www/SIFT_chr_coords_submit.html;  accessed 
17
th  June  2014)  and  Polyphen-2  (URL:  http://genetics.bwh.harvard.edu/pph2/; 
accessed 17
th June 2014) were used to predict the functional effect of mutations and 
non-synonymous polymorphisms on ADAMTS13. 62 
 
2.2  Creation of ADAMTS13 missense mutations 
2.2.1  Sequencing ADAMTS13 cDNA 
ADAMTS13 missense mutations and polymorphisms were introduced into a pcDNA 
3.1/V5-His TOPO ® vector (Life technologies) containing the complete ADAMTS13 
cDNA  sequence  (kindly  provided  by  Dr.  F.  Scheiflinger,  Baxter  Bioscience). 
ADAMTS13 was therefore expressed with a C-terminal V5 epitope and polyhistidine 
tag (6xHis tag). The entire ADAMTS13 cDNA within the vector was first sequenced 
to ensure there were no unexpected deletions or mutations within its sequence. The 
primers used are shown in the appendix (Table S 2). 
Sequencing was carried out using the principle of dye-terminator DNA sequencing, 
originally described by Sanger (Sanger et al, 1977). This was set up with the big dye 
terminator v3.1 cycle sequencing kit (Life technologies) using 3.2μM of primer and 
1µg of plasmid DNA. The cycle sequencing reaction was set up as follows: 
96⁰C  10 seconds 
} 
x 25 cycles  50⁰C  5 seconds                                              
60⁰C  4 minutes 
 
Polymerase chain reaction (PCR) products were purified using sephadex and loaded 
onto an automated ABI Prism 310 genetic analyser (Life technologies). 
2.2.2  Site directed mutagenesis 
Missense  mutations  and  polymorphisms  were  introduced  by  site  directed 
mutagenesis.  The  primers  used  for  site  directed  mutagenesis  are  shown  in  the 
appendix (Table S 3 and Table S 4). The mutagenesis reaction was set up using the 
QuickChange II XL site directed mutagenesis kit (Agilent technologies) using 10-
50ng of DNA in the absence or presence of 5% dimethyl sulfoxide (DMSO). 
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The PCR conditions used were as follows:  
95⁰C  1 minute         x1 cycle 
95⁰C  50 seconds 
} 
x18 cycles  60⁰C  50 seconds                                              
68⁰C  5 minutes 
68⁰C  7 minutes         x1 cycle 
2.2.3  DpnI digestion and agarose gel electrophoresis 
The restriction enzyme DpnI (1μl) was added to the reaction mix for 1 hour at 37⁰C 
to digest unmutated vector. The DpnI digested DNA was run on a 1.5% agarose gel 
prepared in TBE (Tris-Borate-EDTA (Ethylenediaminetetraacetic acid), 89mM Tris, 
89mM  boric  acid,  2mM  EDTA,  pH  8.3).  To  100ml  of  prepared  agarose  1μl  of 
ethidium  bromide  was  added  and  for  loading  5μl  of  loading  buffer  (0.25% 
bromophenol blue, 10% glycerol in TBE) was added to 5μl of water and 1μl of DpnI 
digested DNA. This was run at 120V for ~30 minutes.  
2.2.4  Transformation 
Transformation was performed after detection of a band on a 1.5% agarose gel, after 
DpnI  digestion.  Transformation  was  carried  out  either  using  TOP10  one  shot 
chemically  competent  Escherichia  Coli  (E.  coli)  (Life  technologies),  XL10-Gold 
ultracompetent  E.  coli  (Agilent  technologies)  or  Sure  2  supercompetent  E.  coli 
(Agilent  technologies).  Briefly  cells  were  incubated  with  1-2µl  of  DpnI  digested 
DNA  (after  addition  of  beta  mercaptoethanol  to  the  XL10-Gold  and  Sure  2 
supercompetent cells) for 30 minutes on ice. The cells were then heated at 42⁰C for 
30  seconds  followed  by  incubation  on  ice  for  2  minutes.  S.O.C  medium  (Life 
technologies) was added to Top10 cells and NZY
+ broth (prepared according to the 
manufacturer’s instructions) was added to the XL10-Gold ultracompetent cells and 
Sure 2 supercompetent cells (as recommended by the manufacturers). E. coli were 
then incubated at 37⁰C for 1 hour with shaking (250rpm). After this E. coli were 
plated onto LB (Luria-Bertani) agar (Anachem Ltd) containing 50μg/ml ampicillin 
and  left  overnight  at  37⁰C  (~16  hours).  Plates  were  stored  at  4⁰C  until  further 
analysis.   64 
 
2.2.5  Mini preparation 
For  mini  preparation  a  single  E.  coli  colony  was  picked  using  a  1μl  sterile 
inoculation loop (Greiner Bio-One Ltd) and added to 5ml of LB media (Anachem 
Ltd) containing 50μg/ml ampicillin. The cultures were left to grow overnight at 37⁰C 
with shaking at 250rpm for approximately 16 hours.  
The next day cultures underwent mini preparation using a commercial kit, according 
to the manufacturer’s instructions (Qiagen). Before mini preparation glycerol stocks 
of the E. coli were prepared by adding 190μl of 80% glycerol (MP Biomedicals) to 
810μl of culture.  
In brief the cultures were centrifuged at 15,700g for 3 minutes and the supernatant 
removed. The pelleted  E. coli were resuspended in  250μl  of  resuspension  buffer 
containing  RNase.  After,  250μl  of  alkaline  lysis  buffer  was  added,  followed  by 
neutralisation buffer (350μl) 5 minutes later. Samples were spun at 15,700g for 10 
minutes to precipitate and remove proteins, cell debris and chromosomal DNA from 
the cell lysate samples.  
The cell supernatant was then passed through a silica membrane column, to which 
the plasmid DNA bound. The column was washed with PE buffer containing ethanol, 
to wash away impurities, followed by elution with 30μl of water.  
The extracted plasmid DNA was quantified using a nano-drop spectrophotometer 
(ThermoFischer Scientific) and the purity assessed by running on a 1% agarose gel 
(Chapter 2.2.3).    
2.2.6  Sequencing of construct to confirm presence of mutation 
After site directed mutagenesis ADAMTS13 was sequenced to confirm the presence 
of the nucleotide change introduced. Sequencing was either carried out using the ABI 
Prism 310 genetic analyser (Life technologies) as described (Chapter 2.2.1) or using 
a Ceq™ 8000 genetic analysis system (Beckman Coulter). Reactions were set up 
using GenomeLab DTCS Quick start kit (Beckman Coulter).  65 
 
The cycle sequencing PCR was set up as follows:  
96⁰C  30 seconds 
} 
x 30 cycles  50⁰C  30 seconds                                              
60⁰C  4 minutes 
 
PCR products were purified as recommended by the manufacturer. The primers used 
to  sequence  ADAMTS13  cDNA  to  confirm  the  presence  of  these  nucleotide 
variations are shown in the appendix (Table S 2). 
2.2.7  Large scale plasmid preparation 
Once it was confirmed that the desired nucleotide change had been introduced into 
the  plasmid  without  disrupting  the  surrounding  ADAMTS13  sequence,  maxi-
preparation was carried out in order to produce large quantities of plasmid DNA for 
subsequent  experiments.  As  with  mini  preparation  (Chapter  2.2.5)  this  was 
performed using a commercial kit (Qiagen).  
Briefly E. coli were resuspended in buffer P1, followed by addition of buffer P2 to 
enable cell lysis. This was neutralised by the addition of buffer P3. The lysates were 
cleared by centrifugation and then loaded onto an anion-exchange tip where plasmid 
DNA  selectively  bound.  RNA,  proteins  and  other  impurities  were  removed  by  a 
medium salt wash and pure plasmid DNA was eluted using a high salt solution. The 
DNA was concentrated and desalted by isopropanol precipitation and collected by 
centrifugation.  
The  quantity  of  plasmid  DNA  extracted  was  measured  using  a  nano-drop 
(ThermoFischer  Scientific)  and  the  quality  was  assessed  on  a  1%  agarose  gel 
(Chapter 2.2.3). 66 
 
2.3  Transient transfection of ADAMTS13 variants 
2.3.1  HEK 293T cells 
HEK293T cells (LGC standards) were seeded in T75 flasks (VWR) and maintained 
in DMEM media containing L-glutamine (Dulbecco’s Modified Eagle’s Medium, 
Life  technologies)  with  the  addition  of  10%  fetal  bovine  serum  (FBS,  Life 
technologies) and 100 units/ml of penicillin and 0.1mg/ml streptomycin.   
2.3.2  Transient transfection 
Confluent HEK293T cells (~80% confluent) seeded in 90mm petri dishes (VWR) 
were  used  for  transient  transfection.  Approximately  one  hour  before  transfection 
media was exchanged for OptiMEM reduced serum media containing glutamax (Life 
technologies)  and  1%  L-glutamine  (Life  technologies).  For  transfection  33μg  of 
ADAMTS13 vector DNA was diluted in 625μl of 150mM sodium chloride (NaCl). In 
addition  1μg  of  the  pRL-TK  plasmid  (Promega)  was  added,  in  order  to  enable 
normalisation of the transfection efficiency for subsequent experiments. Similarly 
75μl of 10mM PEI (polyethylenimine, prepared in water, Polysciences Europe) was 
diluted  in  625μl  of  150mM  NaCl.  After  this  700μl  of  diluted  PEI  was  added 
dropwise to the diluted DNA and left for 15-20 minutes to form the transfection 
complex. This transfection complex was then added slowly dropwise to the cells.  
After four days supernatant and cell lysate samples from the transiently transfected 
cells  were  harvested.  A  protease  inhibitor  PMSF  (phenylmethylsulfonyl  fluoride) 
was  added  to  the  supernatant  samples  (final  concentration  1mM).  Supernatant 
samples were spun at 3000g for 10 minutes to remove cell debris and then stored at   
-80⁰C.  
Cell lysate samples were harvested using a cell lysis buffer from a commercial kit 
(Renilla  luciferase  assay  system,  Promega)  according  to  the  manufacturer’s 
instructions. In brief cells were washed with PBS (phosphate buffered saline, Life 
technologies) followed by incubation on ice for 15 minutes with 1ml of 1x lysis 
buffer containing 1mM PMSF. Cells were scraped off the surface of the petri dish 
and frozen at -80⁰C. Cells were later freeze thawed three times followed by spinning 67 
 
at 15,700g for 15 minutes at 4⁰C. The supernatant obtained after spinning was used 
for subsequent analysis and stored at -80⁰C.  
2.3.3  Normalisation after transient transfection 
In order to normalise the transfection efficiency luminescence was measured in cell 
lysate samples. This luminescence was produced by the Renilla luciferase reporter 
enzyme that the pRL-TK co-transfected vector expressed when it was incubated with 
its  substrate.  This  luminescence  was  subsequently  measured  using  the  Renilla 
luciferase assay system (Promega).  
Luminescence was measured using a BMG Fluostar Optima microplate reader (BMG 
Labtech)  set  to  luminescence  mode.  A  protocol  was  created  on  the  machine  to 
automate the measurement of luminescence. The temperature of the machine was set 
to 25⁰C. 
The production and measurement of luminescence was measured according to the 
recommendations in the Renilla luciferase assay system (Promega). In brief Renilla 
luciferase  solution  was  prepared  by  adding  1x  Renilla  luciferase  substrate  to  1x 
Renilla luciferase buffer. A sufficient quantity was prepared so that 100µl could be 
added to each sample and also so that there was a final dead volume of 600µl. The 
pump of the microplate reader was primed with this solution. Following this 20µl of 
each cell lysate sample was added to a well of a white 96 well plate (ThermoFischer 
Scientific).  Background  luminescence  was  measured  using  negative  control  cell 
lysate  samples  (samples  which  had  not  been  transfected  with  either  pRL-TK  or 
ADAMTS13). This background luminescence was measured every time luminescence 
was measured for a given experiment at least five times. The average value was then 
subtracted from the value of the other test samples. 
The  pump  injected  100μl  of  Renilla  luciferase  solution  into  each  well  and 
luminescence readings were taken over a period of 24 seconds every 0.5 seconds. 
The change in luminescence was calculated over the period 4 to 14 seconds. This 
meant that luminescence was calculated approximately 2 seconds after the Renilla 68 
 
luciferase solution had been added to the cell lysate sample, over a period of 10 
seconds as recommended by the manufacturer (Promega). 
The values calculated for the change in luminescence were used to normalise results. 
Values were normalised according to the lowest luminescence value measured, taken 
as 1. The remaining samples were expressed as a proportion of this based on their 
luminescence.   
2.3.4  Concentrating media 
Supernatant samples were concentrated 20 -100 fold using centrifugal filter devices 
with a ~100kDa cut-off (Millipore). Samples were spun at 3000g for 10-15 minutes 
at 4⁰C. 
2.4  Creation of stable lines 
HEK 293 cells  (LGC  standards)  were cultured as  described  for HEK 293T cells 
(Chapter  2.3.1).  Confluent  cells  (~70%)  were  seeded  in  90mm  petri  dishes,  two 
plates of cells were used for each transfection. Media was removed from the cells, 
followed by washing with PBS. Trypsin (Life technologies) was then added to both 
plates to remove the cells from the surface. The cells from both plates were then 
resuspended in 800μl of DMEM (not containing FBS or penicillin/streptomycin). 
After this 30μg of DNA was added to the cells and left for 1 minute. 
The  cell  suspension  was  transferred  to  a  4mm  electroporation  cuvette 
(ThermoFischer  Scientific)  and  immediately  pulsed  at  280V  with  a  resistance  of 
1500μF using an Equibio/Easyject plus electroporator (ThermoFischer Scientific). 
Cells were then immediately resuspended in 10ml of DMEM media (with 10% FBS 
and penicillin/streptomycin) and were then seeded in petri dishes. 
One week after transfection the antibiotic geneticin (Life technologies) was added to 
the media of cells in order to select for clones stably expressing ADAMTS13. A 
number  of  clones  were  picked  and  the  quantity  of  ADAMTS13  produced  was 
measured  using  an  ADAMTS13  antigen  ELISA.  A  clone  was  selected  which 
expressed the greatest quantity of ADAMTS13 and used for subsequent experiments. 69 
 
For  the  secretion  defect  mutant,  a  clone  was  picked  based  on  the  quantity  of 
ADAMTS13 that could be detected within the cell using western blotting. 
2.5  Western blotting 
Cell lysate or supernatant samples were loaded onto Criterion XT 4-12% Bis-Tris 
precast  polyacrylamide  gels  (Bio-Rad  laboratories).  Cell  lysate  samples  (unless 
otherwise stated) were loaded under reducing conditions, 3x cell lysate was loaded 
with 1x reducing buffer (150mM Tris-HCl pH 6.8, 40% glycerol, 8% SDS (sodium 
dodecyl  sulphate),  10%  beta  mercaptoethanol,  0.25%  bromophenol  blue).  Unless 
otherwise stated, 3x supernatant was loaded with 1x non-reducing buffer (150mM 
Tris-HCl pH 6.8, 20% glycerol, 8% SDS, 0.25% bromophenol blue). The volume of 
supernatant or cell lysate obtained after transient transfection was loaded according 
to the transfection efficiency (up to 15μl of cell lysate and 40μl of supernatant). 
Samples were heated at 100°C for 5 minutes, and then briefly vortexed before they 
were  loaded  onto  the  gel.  Precision  plus  dual  colour  standard  ladder  (Bio-Rad 
laboratories) was run with samples to ensure that the ADAMTS13 detected was of 
the correct size.  
SDS gels were run using XT MOPS buffer (Bio-Rad laboratories). Gels were run at 
100V for 15 minutes in order to concentrate the samples in the stacking part of the 
gel. Following this the voltage was increased to 200V for a further 45 minutes.  
Protein  was  transferred  onto  Amersham  Hybond  ECL  (enhanced 
chemiluminescence)  0.45μm  nitrocellulose  membranes  (GE  Healthcare)  using  the 
Criterion trans blot system (Bio-Rad laboratories). Samples were transferred for 30 
minutes at 100V with Towbin blotting buffer (25mM Tris, 192mM glycine, 20% 
methanol). An ice pack was added also to reduce the temperature and a magnetic 
stirrer was placed inside the buffer to ensure a homogenous solution during transfer.  
After transfer, membranes were blocked with TBS (Tris Buffered saline, 20mM Tris, 
100mM NaCl, pH 7.4) containing 5% milk for 1 hour with agitation (45rpm). After 
blocking the membrane was incubated overnight at 4⁰C with a monoclonal mouse 
anti-V5  (Life  technologies)  antibody  (directed  against  the  C-terminal  V5  tag  the 70 
 
recombinant protein expressed), diluted 1/2000 in TBST (TBS with 0.05% Tween 
20) (Sigma) containing 5% milk. Membranes were then washed three times with 
TBST  followed  by  incubation  for  90  minutes  with  an  ECL  anti-mouse  IgG 
polyclonal HRP (horseradish peroxidase) antibody (GE Healthcare) diluted 1/500 in 
TBST containing 5% milk. Membranes were washed again three times followed by 
incubation with supersignal west pico chemiluminescent substrate (ThermoFischer 
Scientific).  The  signal  was  captured  using  Amersham  Hyperfilm  ECL  (GE 
Healthcare) and developed manually using Carestream ® Kodak ® autoradiography 
GBX fixer/replenisher and developer/replenisher (Sigma).  
2.6  ADAMTS13 antigen ELISA 
Supernatant samples were analysed using either an in-house ADAMTS13 antigen 
ELISA (Feys et al, 2007) or a commercial kit: Imubind ADAMTS13 ELISA (Sekisui 
Diagnostics). 
2.6.1  In-house ADAMTS13 antigen ELISA 
For the in-house ADAMTS13 antigen ELISA microplates were coated with 4μg/ml 
of the monoclonal antibody 20A5 (Katholieke Universiteit Leuven, directed again 
ADAMTS13 TSP-1:2→TSP-1:5 domains) diluted in PBS, 120μl per well. This was 
left overnight at 4⁰C. The next day the primary antibody was removed and the wells 
were washed three times in PBST (PBS containing 0.1% Tween 20), followed by 
blocking with PBS containing 3% milk for 90 minutes.  
Wells were then washed five times in PBST followed by incubation with 100μl of 
sample.  The  default  dilution  for  all  samples,  including  the  standard  was  1  in  2. 
Samples were diluted in PBS containing 0.3% milk. After an hour samples were 
removed and the plate was washed five times with PBST. The biotinylated secondary 
antibody, 5C11 (Katholieke Universiteit Leuven, directed against TSP-1:2→TSP-1:5 
domains of ADAMTS13) was next added (100μl per well), diluted in PBS to a final 
concentration of 2μg/ml.   
Following  this  the  plate  was  washed  five  times,  followed  by  incubation  with 
streptavidin  peroxidase  conjugate  (Merck  Chemicals),  diluted  1/10,000  in  PBS 71 
 
containing 0.3% milk for 1 hour. After the plate was washed 4 times in PBST and the 
substrate  was  added  to  the  plate:  one  15mg  OPD  tablet  (O-phenylenediamine 
dihydrochloride) dissolved in citrate phosphate buffer (0.1M, pH 5), with hydrogen 
peroxide. The colour was left to develop for ~30 minutes. The reaction was stopped 
using 2M sulphuric acid and the absorbance was measured at 490nm.  
The standard curve was created using pooled normal plasma (PNP). PNP was diluted 
one in two in PBS (containing 0.3% milk) to give the 100% standard.  This was 
diluted  by  doubling  dilutions  (100%,  50%,  25%,  12.5%,  6.25%,  and  3.125%). 
ADAMTS13 antigen levels in samples were expressed as a percentage of PNP. Two 
controls (with normal and low ADAMTS13 antigen levels) were run on each ELISA.   
The  5C11  antibody  was  biotinylated  using  EZ-Link  Sulfo-NHS-SS-biotin 
(ThermoFischer  Scientific)  kit  according  to  the  manufacturer’s  recommendations. 
The  antibody  was  dialysed  in  PBS  before  biotinylation  (dialysis  tubing  with  a 
>12,000 molecular weight cut off, Sigma). The detection limit of the ELISA was 3% 
of PNP and the normal range 44-148%.  
The intra and inter assay coefficient of variation (CV) was 2% and 6% respectively 
at normal ADAMTS13 antigen levels (90% of PNP). The intra and inter assay CV 
was 8% and 12% respectively, when measured at low ADAMTS13 antigen levels 
(3% of PNP).  
2.6.2  Commercial ADAMTS13 antigen ELISA 
The laboratory normal range for the commercial kit: Imubind ADAMTS13 ELISA 
(Sekisui  Diagnostics)  is  485-1242ng/ml.  The  coating  antibody  is  a  polyclonal 
antibody and the capture antibody a biotinylated antibody both directed against the 
TSP-1:5→TSP-1:7  domains  of  ADAMTS13.  Low  ADAMTS13  antigen  samples 
were diluted 1 in 5. By modifying the default dilution (1 in 20) to a 1 in 5 dilution 
ADAMTS13 antigen as low as 10ng/ml could be detected.  
The  intra  and  inter  assay  CV  was  4%  and  7%  respectively  as  stated  by  the 
manufacturers. In house the intra and inter assay CV calculated at low antigen levels 72 
 
(120ng/ml) was 6% and 10% respectively and at very low antigen levels (calculated 
at 10ng/ml) was 18% and 19% respectively.  
2.7  ADAMTS13 activity assay: FRETS-VWF73 
ADAMTS13  activity  was  measured  using  FRET  (fluorescence  resonance  energy 
transfer) (Kokame et al, 2005) with minor modifications (Mackie et al, 2013). In 
brief,  a  modified  VWF  peptide  (FRETS-VWF73)  was  used  as  a  substrate  for 
ADAMTS13  in  this  assay.  When  cleaved  by  ADAMTS13  this  peptide  produced 
fluorescence which was measured. Fluorescence was measured every 5 minutes for 
75 minutes.  
ADAMTS13 activity values were expressed as a percentage of PNP.  The detection 
limit and normal range of the assay was 2.5% and 60-123% respectively. For low 
activity samples the incubation time of samples with substrate was increased and 
calculated using the linear portion of the rate curve (5-145 minutes).  
The intra  and inter  assay CV was 2% and 6% respectively  at 98% ADAMTS13 
activity (5-75 minutes). The intra and inter assay CV at 5% ADAMTS13 activity was 
22%  and  21%  respectively  and  at  10%  ADAMTS13  activity  was  13%  and  7% 
respectively (5-145 minutes). 
2.8  Immunofluorescence 
Localisation  of  WT  and  mutant  ADAMTS13  within  the  cell  ER  and  Golgi  was 
investigated using immunofluorescent labelled antibodies and confocal microscopy. 
Antibodies directed against ADAMTS13 and either the ER or Golgi were used.  
2.8.1  Culturing and transfecting cells 
Each  cover  glass  (22x22mm,  thickness:  0.13-0.16mm,  VWR)  was  placed  into 
separate wells of a six well culture plate (VWR) and sterilised by submersion in 
100% ethanol. After 30 minutes the cover glasses were transferred to a new sterile 
six well plate using sterile tweezers and left to air dry in a sterile cabinet. HEK293T 
cells were then seeded onto the cover glasses.  73 
 
Confluent HEK 293T cells (~80%) seeded onto cover glasses underwent transient 
transfection  as  described  previously  with  minor  modifications  (Chapter  2.3.2). 
OptiMEM media was not added to cells before transfection took place. The volumes 
of DNA and PEI were scaled down (0.66μg DNA, 12.5μl of 150mM NaCl, 1.5μl 
PEI).   
2.8.2  Immunofluorescent staining of cells 
Media was removed from the cells 24 hours after transfection and the cells were 
washed  with  PBS.  Following  this  cells  were  fixed  with  4%  paraformaldehyde 
(dissolved in PBS by heating, Sigma), 400µl was added slowly, dropwise to each 
cover glass. Paraformaldehyde cross-links proteins via methylene bridges preserving 
cellular structure (Jamur & Oliver, 2010). After 30 minutes the paraformaldehyde 
was removed and the cells were washed three times in PBS for 10 minutes.  
Cells were then permeabilised to enable antibody entry into the cell, by incubating 
the fixed cells with 0.2% Triton X-100 (Sigma) for 10 minutes. Following this cells 
were blocked overnight at 4°C by incubation with 3% bovine serum albumin (BSA) 
(Sigma) containing 0.3M glycine (VWR) (dissolved in PBS). The next day, cells 
were incubated for 10 minutes at room temperature with PBS containing 10% heat 
inactivated serum from rabbit and from goat, (heat inactivated by heating at 56°C for 
20 minutes, then spun at 15,700g for 15 minutes) (Sigma). The cells were washed 
again  in  PBS,  then  incubated  simultaneously  with  two  primary  antibodies:  i)  a 
chicken  polyclonal  anti-V5  antibody  (diluted  1/500)  (Bethyl  Laboratories  Inc)  in 
order to detect ADAMTS13; along with either  ii) a mouse monoclonal anti-GM130 
antibody  (diluted  1/250)  (BD  Biosciences)  (cis  Golgi  marker),  or  iii)  a  mouse 
monoclonal anti-protein disulphide isomerase (PDI) antibody (diluted 1/200) (RL90, 
Abcam) as a marker of the ER. Antibodies were diluted in 3% BSA; 100µl of diluted 
antibody was added to each cover glass. Cells were incubated with antibodies for 
three hours at 4°C.   
Cells were then washed three times for 10 minutes, followed by permeabilisation 
again for 10 minutes with 0.2% Triton X-100. Following this cells were incubated in 
the  dark,  for  30  minutes  at  4⁰C  with  100μl  of  diluted  fluorescently  labelled 74 
 
secondary  antibody.  A  rabbit  FITC  (Fluorescein  isothiocyanate)  conjugated 
polyclonal anti-chicken antibody (Life technologies, diluted 1/50) was used to detect 
the primary anti-V5 antibody. A goat polyclonal Cy3 (Cyanine 3) conjugated anti-
mouse  antibody  (Millipore,  diluted  1/200)  was  used  to  detect  the  ER  or  Golgi 
primary antibody. The stock Cy3 was diluted 1 in 2 in glycerol and stored at -20⁰ C 
(as recommended by the manufacturer) to give the Cy3 working solution and so the 
antibody was diluted 1/100 from the working Cy3 solution.  When preparing the 
dilutions for the fluorescently conjugated antibodies, light was excluded as much as 
possible. Antibodies were diluted in PBS containing 3% BSA. 
The  cells  were  washed  in  the  dark,  four  times  with  PBS,  for  10  minutes  (all 
remaining steps were carried out in the dark). One drop of Vectashield ® mounting 
media containing 4’, 6-diamidino-2-phenylindole (DAPI) (Vector Laboratories) to 
stain for nuclei was added to each cover glass. A clean microscope slide (76x26mm, 
0.8-1, Appelton Woods) was then placed on top of the cover glass, centering the 
cover glass onto the microscope slide. The microscope slide was carefully inverted 
so that the cover glass was on top. The cover glass was sealed onto the microscope 
slide using nail polish. The slides were then stored in the fridge in the dark before 
viewing.  
2.8.3  Confocal microscopy 
Cells were viewed using a spinning disk confocal microscope (Perkin Elmer) with a 
Volocity acquisition system, built on a Zeiss inverted microscope. Cells were imaged 
as soon as possible, normally one or two days after staining, a maximum of two 
weeks  after  staining.  Cover  glasses  were  cleaned  with  ethanol  before  they  were 
viewed.  
Images  were  captured  using  either  a  x63  or  x100  immersion  oil  objective. 
Representative  images  of  the  cells  were  taken  from  two  to  three  slides  for  each 
experiment to minimise the amount of bleaching taking place. Images were taken 
from a number of different fields in each slide, well separated from each other again 
to  minimise  bleaching.  The  confocal  microscope  takes  images  at  different  levels 
within a specimen producing ‘optical’ sections. This sequence of ‘optical sections’ is 75 
 
known as a z series. The z series is collected by coordinating the movement of the 
fine focus of the microscope with image collection. When images of a desired cell 
(or group of cells) within a field of view were to be taken the microscope was set to 
image from the region just above the cells down to the region just below the cells. 
This ensured that only the images required were taken (i.e. so that images of areas 
devoid of cells were not taken). This was to prevent bleaching, exposing the cells to 
as little light as possible.  
The spacing between each image in a z series (the z-space) was set to 0.359μm for 
each x63 and x100 objective. This spacing fulfilled the Nyquist criteria. According to 
the Nyquist sampling theorem (Oppenheim et al, 1983) in order to resolve two points 
and to  avoid  under or  over-sampling, the z-spacing should be equal to  the axial 
resolution  between  the  two  points  divided  by  at  least  two.  Voxels  (the  three 
dimensional equivalent of pixels), larger than those specified by the Nyquist criteria 
would  under  sample  an  image,  create  artefacts  and  result  in  false  colocalisation. 
Collecting images with voxels smaller than the Nyquist value would result in the re-
imaging of sections and longer exposure times which could lead to photobleaching. 
Untransfected, unlabelled cells were imaged to assess whether autofluorescence was 
produced  by  the  cells.  There  was  no  apparent  autofluorescence.  Single  labelled 
controls (i.e. FITC or Cy3 staining alone) were used to assess bleed-through. Bleed-
through is the passage of fluorescence emission in an inappropriate detection channel 
caused by an overlap of emission spectra (Bolte & Cordelieres, 2006). There was no 
apparent bleed-through.   
Cross-talk occurs when several fluorochromes are excited with the same wavelength 
at  a  time  because  their  excitation  spectra  partially  overlap  (Bolte  &  Cordelieres, 
2006). Cross talk was minimised by sequentially scanning the sample: one laser was 
activated and the corresponding emission collected, followed by excitation of the 
next laser and detection of emission.  
For each experiment the exposure times were first set for each channel to be imaged 
using a randomly chosen cell expressing WT ADAMTS13. The same exposure times 
were then used to image negative control samples. Test samples (WT and mutant 76 
 
protein) were then imaged using the same exposure times. At each position images 
were taken in the order FITC, Cy3 and then DAPI. The objective then moved to the 
next position to take the next image. This method of imaging the cells as opposed to 
imaging  all  the  FITC  staining  of  each  z  stack  followed  by  imaging  all  the  Cy3 
staining is  more suitable  for  colocalisation analysis  as  it prevents  the shifting of 
voxels between images. 
To view DAPI staining, excitation was at 405nm and emission at 455/460nm. To 
view FITC staining, excitation was at 488nm and emission at 527/555nm. Finally for 
Cy3 staining excitation was at 568nm and emission at 615/670nm.  
2.9  Immunofluorescence quantitation 
The degree of colocolisation between ADAMTS13 and the Golgi  was quantified 
using  Volocity  3D  image  analysis  software  (Perkin  Elmer).  The  ‘co-localization’ 
option was selected under the quantitation tab.   
The  images  obtained  after  confocal  microscopy  were  represented  as  a  series  of 
voxels, akin to pixels but representing space in addition to length and width. These 
voxels  were  given  a  value  for  each  channel  (wavelength)  in  which  images  were 
taken. A 14 bit channel was used to image the cells so each voxel was given a value 
between 0 and 16384 depending upon the intensity of the signal captured by the 
microscope,  in  this  case  having  three  different  values  for  the  three  different 
wavelengths at which the images were viewed. For colocalisation analysis channel 1 
was set to show the values obtained at a wavelength of 568nm. At this wavelength 
the fluorescently labelled Golgi was measured. Channel 2 was set to show the values 
obtained at a wavelength of 488nm. At this wavelength the fluorescently labelled 
ADAMTS13 could be measured.  
Thresholds  were  first  set  to  exclude  voxels  from  the  analysis  which  constituted 
background ‘noise.’ These were set by selecting a region of the image in which there 
were no cells. The software then calculated the threshold value for each channel 
separately  by  calculating  the  mean  value  of  the  voxel  intensities  (in  a  particular 77 
 
channel)  in  the  region  of  interest  plus  three  standard  deviations  (SD).  The  same 
threshold for each channel was used throughout the analysis. 
Clearly  defined  cells  within  an  image  were  selected  for  analysis.  The  region  of 
interest was selected using the freehand tool. Only cells with no saturated voxels 
were used to carry out the quantitation analysis. If there were other cells or parts of 
cells within the same region of the Z-stack, in the region of interest, these cells were 
excluded from the analysis.  
2.10 Proteasome/lysosome inhibition 
Confluent HEK 293 cells plated in 90mm petri dishes (VWR), stably expressing 
ADAMTS13  were  incubated  with  either  10M  MG132  (carbobenzoxy-Leu-Leu-
leucinal)  (Merck  Chemicals),  6M  ALLN  (N-acetyl-L-leucinyl-L-leucinyl-
norleucinal) (Merck chemicals, prepared in DMSO according to the manufacturer’s 
instructions), 0.1µM Bafilomycin A1 (Sigma, prepared in DMSO according to the 
manufacturer’s instructions), 50mM ammonium chloride (prepared in sterile water) 
or with 0.1% DMSO (Sigma). After 5 hours cell lysate and supernatant samples were 
harvested as described (Chapter 2.3.2). Supernatant was concentrated as described 
above ~100 fold (Chapter 2.3.4). For SDS gel electrophoresis, 15µl of cell lysate and 
30µl of supernatant was loaded.  
2.11 Betaine experiments 
Betaine is a chemical chaperone and has been recently shown to aid the secretion of a 
Factor VIII mutant (Roth et al, 2012). In order to investigate whether betaine could 
aid the secretion of an ADAMTS13 secretion defect mutant, confluent HEK 293 
cells  plated  in  90mm  petri  dishes  (VWR)  stably  expressing  ADAMTS13  were 
incubated in the presence or absence of 100mM betaine (prepared in sterile water). 
After  96  hours  cell  lysate  and  supernatant  samples  were  harvested  as  described 
previously  (Chapter  2.3.2). Supernatant  was  concentrated as  described  previously 
~100 fold (Chapter 2.3.4).  78 
 
2.11.1  SDS-PAGE  
For SDS-PAGE (polyacrylamide gel electrophoresis), 15µl of cell lysate and 30µl of 
supernatant was loaded. To ensure better separation of cell lysate samples, samples 
were also run on Criterion XT tris-acetate 3-8% precast polyacrylamide gel, with XT 
tricine running buffer (Bio-Rad Laboratories). These samples were run with laemmli 
buffer (Bio-Rad laboratories) with 5% beta mercaptoethanol, 10μl cell lysate, 20μl of 
supernatant. 
2.11.2  Deglycosylation experiments 
Cell lysate samples (10μl) were digested with PNGase F (New England BioLabs) 
according to the manufacturer’s instructions. The digested and undigested products 
then underwent gel electrophoresis on 3-8% Tris-acetate gels. Similarly cell lysate 
and  supernatant  samples  (10μl)  were  digested  with  the  restriction  enzyme 
Endoglycosidase  H  (New  England  Biolabs)  according  to  the  manufacturer’s 
instructions.  
2.12 Purification of ADAMTS13 
ADAMTS13 expressed by stable line cells was purified using a Fast Performance 
Liquid Chromatography (FPLC) system (GE Healthcare) using a 5ml HisTrap HP 
affinity column (GE Healthcare). The column was first stripped of its Ni
2+ ions using 
stripping solution (20mM sodium phosphate, 0.5M NaCl, 50mM EDTA, pH 7.4) 
followed by washing (20mM sodium phosphate, 20mM imidazole, 0.5M NaCl, pH 
7.4). The column was then recharged with zinc using 100mM ZnCl solution. The 
column was stripped and recharged with Zn
2+ as during the purification procedure in 
previous experiments  it was  found that the  Ni
2+ within the column  displaced the 
ADAMTS13 Zn
2+ ions.  
The  column  was  washed  with  binding  buffer  (20mM  HEPES,  20mM  imidazole, 
500mM NaCl, pH 7.4). After this 20mM imidazole was added to the stable line 
supernatant to prevent non-specific binding and this was then passed through the 
column.  Following  this,  elution  buffer  was  passed  through  the  column  (20mM 
HEPES, 500mM imidazole, 0.5M NaCl, pH 7.4). The eluted protein was collected in 79 
 
2.5ml  fractions  and  the  fractions  containing  ADAMTS13  were  identified  by  an 
increased absorbance of UV light.  
Fractions  containing  the  eluted  protein  were  pooled  together  and  the  buffer 
exchanged (20mM HEPES, 150mM NaCl, pH 7.4) using an Ecno-Pac 10G column 
(Bio-Rad). 
After  purification  the  purity  was  confirmed  using  SDS  electrophoresis  and  the 
quantity  of  ADAMTS13  purified  was  measured  using  an  Imubind  ADAMTS13 
antigen ELISA (Sekisui Diagnostics). 
2.12.1  Coomassie blue staining 
SDS-PAGE  was  carried  out  using  equal  volumes  of  the  following:  i.  unpurified 
supernatant (collected from WT or p.R102H mutant ADAMTS13 stable lines), ii. 
flow  through  supernatant  obtained  after  purification  (of  both  WT  and  p.R102H 
mutant) and iii. purified WT and p.R102H mutant ADAMTS13. SDS-PAGE was 
carried out as described in Chapter 2.5 under reducing conditions. After SDS-PAGE 
the gel was removed from its casing and placed briefly in distilled water followed by 
incubation  with  Coomassie  dye  (Bio-Rad)  for  45  minutes  with  gentle  agitation 
(45rpm).  The  Coomassie  dye  was  removed  and  the  gel  was  then  washed  with 
distilled water twice for one hour to remove the Coomassie stain (agitated at 45rpm). 
The gel was then washed overnight with distilled water.  
2.12.2  Western blotting  
Western  blotting  was  carried  out  as  described  in  Chapter  2.5,  with  minor 
modifications.  A  rabbit  anti-human  polyclonal  anti-ADAMTS13  antibody  diluted 
1/200 (Santa Cruz Biotechnology, Inc) was used for the primary antibody. For the 
secondary  antibody  an  anti-rabbit  HRP  conjugated  secondary  antibody,  diluted 
1/20,000 was used (Dako UK Ltd).  80 
 
2.13 ADAMTS13 catalytic activity in purified ADAMTS13 
VWF  multimer  analysis  and  time  course  experiments  were  performed  with  the 
assistance of Dr. Stefano Lancellotti 
2.13.1  VWF multimer analysis 
ADAMTS13  (2nM)  was  incubated  with  full  length  pooled  VWF  (10μg/ml)  and 
ristocetin (1.5mg/ml) with 20mM HEPES, 5mM CaCl2, pH 7.5. This was incubated 
at 37⁰C. At 30 minute intervals, 10μl sub samples were removed and added to 290μl 
of sample buffer (10mM Tris, 1mM Na2EDTA, 2% SDS, 0.006% bromophenol blue, 
pH 8.0).  
Samples underwent agarose gel electrophoresis. Samples were heated at 56⁰C for 30 
minutes before loading. Agarose gels were prepared fresh. For stacking an agarose 
concentration  of  0.8%  was  prepared  (0.125M  Tris,  0.1%  SDS,  pH  6.8)  and  for 
running a concentration of 2% was prepared (0.375M Tris, 0.1% SDS, pH 8.8).  
Electrophoresis was carried out at 10⁰C (electrophoresis buffer: 0.05M Tris, 0.384M 
Glycine, 0.1% SDS, pH 8.3/8.6). The gel was run at 32mA for ~30 minutes. The 
current was then decreased to 10mA and the gel was run overnight.  
Transfer was carried out at 2A at 10⁰C for 4 hours (transfer buffer: 0.05M Na2HPO4, 
0.05M NaH2PO4, 0.04% SDS, pH 7.4). After transfer the membrane was blocked 
with 5% milk for 1 hour. The membrane was incubated with a polyclonal rabbit anti 
VWF antibody  (Dako),  diluted 1/7500  in  3% milk.  This  was  left  overnight  with 
shaking at 4⁰C.  
The  next  day  the  membrane  was  washed  three  times  in  TBST,  followed  by 
incubation  with  a  goat  polyclonal  anti  rabbit  HRP  conjugated  antibody  diluted 
1/20,000 in 1% milk (Dako) for one hour. The membranes were then washed three 
times in TBST followed by incubation with ECL western blotting detection reagents 
(GE  Healthcare).  Chemiluminescence  was  measured  using  a  ChemiDoc  XRS+ 
system (Bio-Rad). 81 
 
2.13.2  Time course experiment 
Time  course  experiments  under  pseudo  first  order  conditions  were  set  up  using 
FRETS-VWF73 as a substrate to analyse Kcat/Km values. ADAMTS13 (2nm) was 
incubated with FRETS-VWF73 (2μM) for 480 minutes. Fluorescence was measured 
every 5 minutes.  
2.14 In silico analysis of splice site mutation 
The  effect  of  the  mutation  predicted  to  affect  splicing  was  analysed  using  two 
different  online tools:  Berkeley Drosophila Genome Project  splice site prediction 
(URL:  http://www.fruitfly.org/seq_tools/splice.html;  accessed  17
th  June 2014)  and 
CRYP-SKIP  (URL:  cryp-skip.img.cas.cz/;  accessed  17
th  June  2014).  Both  tools 
indicate regions  within the DNA sequence under analysis which are likely to  be 
donor  or  acceptor  sites  and  assign  a  score  to  these  sites.  The  higher  the  score 
assigned to a given site the more likely this site is to be used for splicing. 
2.15 Whole blood RNA extraction 
2.15.1  Blood collection 
Blood was collected separately from two healthy volunteers in PAXgene Blood RNA 
tubes  according  to  the  manufacturer’s  instructions  (PreAnalytix).  The  PAXgene 
Blood RNA tubes were incubated for two hours to ensure lysis of the blood cells.  
2.15.2  RNA extraction 
The RNA from blood collected in the PAX gene RNA tubes was extracted using 
PAXgene blood RNA kit (PreAnalytix) according to the manufacturer’s guidelines. 
Blood was centrifuged at 3000g for 10 minutes and the supernatant removed. To the 
pellet 4ml of RNase-free water was added, followed by mixing with a vortex. This 
was centrifuged for 10 minutes at 3000g, the supernatant was removed and the pellet 
was  resuspended  in  350μl  of  resuspension  buffer  by  vortex  mixing.  This  was 
followed by the addition of 300μl of binding buffer and 40μl proteinase K and mixed 
using a vortex for 5 seconds. The samples were then incubated for 10 minutes at 
55⁰C at 400rpm.  82 
 
The lysate was then added to a PAXgene shredder spin column and centrifuged at 
16,000g for 3 minutes. Flow through was transferred to a new tube followed by the 
addition of 350μl of absolute ethanol and mixing with a vortex. The samples were 
then transferred to the PAXgene RNA spin column and centrifuged at 16,000g. The 
flow through was discarded and the column was washed with 350μl of wash buffer 1, 
followed by centrifugation at 16,000g. Following this 80μl of DNase I incubation 
mix was added to the spin column and left for 15 minutes. After, 350μl of wash 
buffer I was added to the column and the column was spun at 16,000g for 1 minute. 
The flow through was discarded and the column was washed twice with 500μl of 
wash buffer 2, followed by centrifugation at 16,000g for 1 minute.  
After, 40μl of elution buffer was added to the membrane of the spin column and 
centrifuged at 16,000g for 1 minute to elute the RNA. This was repeated and the 
eluted samples were incubated at 65⁰C for 5 minutes, followed by immediate transfer 
to  ice.  The  quantity  of  RNA  extracted  was  measured  using  a  nano-drop 
spectrophotometer (ThermoFischer Scientific).  
2.15.3  Reverse transcription 
Reverse transcription (RT) of the RNA was carried out using an Advantage RT-for-
PCR kit according to the manufacturer’s instructions (Takara Bio Europe/Clontech). 
To  12.5μl  of  the  purified  RNA,  1μl  of  the  random  hexamer  primer  was  added. 
Control RNA (human placental total RNA) was also reverse transcribed. To 1μl of 
this, 11.5μl of diethylpyrocarbonate (DEPC) treated water (provided in the kit) was 
added and 1μl of random hexamer primer. Hexamer primers are oligonucleotides of 
six base pairs synthesised randomly to  cover a range of sequences that have the 
potential to bind and anneal to random points within an mRNA sequence.  
The  RNA  was  heated  to  enable  primer  binding  at  70⁰C  for  2  minutes  and  then 
immediately placed on ice. Reaction buffer, dNTPs, recombinant RNase inhibitor 
and MMLV reverse transcriptase was added to the RNA, which was then incubated 
at 42⁰C for 1 hour to enable RT to take place.  83 
 
Following this samples were heated at 94⁰C for 5 minutes to stop RT and to destroy 
any  DNase  activity.  The  samples  were  diluted  in  DEPC-treated  water  to  a  final 
volume of 100μl.      
2.15.4  PCR amplification of cDNA 
The cDNA obtained after  RT (5 or 10μl) was  added to  1x reaction buffer (Life 
technologies), 1.5mm MgCl2 (Life technologies), 400µM dNTPs (Life technologies), 
200nM of primer, 1U of amplitaq DNA polymerase (Life technologies) and made up 
to a final volume of 50μl with sterile water. For each PCR reaction, two normal 
controls, a positive and negative control were set up also. The primer pairs used were 
F6/RevJP and F6/R6 (primer sequences are shown in the appendix Table S 5) along 
with glyceraldehyde 3-phosphate dehydrogenase (G3PDH) forward (F’) and reverse 
(R’) primers (provided by the kit) which bind to the housekeeping G3PDH gene. 
G3PDH  is  an  enzyme  important  in  glycolysis.  Housekeeping  genes  are  genes 
expressed in all cells of an organism. Primer F6 bound within exon 2, primer R6 
bound within exon 3 and primer RevJP bound within exon 6. The PCR was set up as 
follows: 
94⁰C  3 minutes         x1 cycle 
94⁰C  30 seconds 
} 
x30 cycles  62⁰C  30 seconds                                              
72⁰C  30 seconds 
72⁰C  4 minutes         x1 cycle 
 
The  products  were  run  on  a  2%  agarose  gel  prepared  in  TBE  (Chapter  2.2.3). 
Samples  were  run  with  one  of  the  following  DNA  ladders:  pUC  mix  marker  8 
(ThermoFischer Scientific), DNA ladder marker X (Roche) or gene ruler 100bp plus 
DNA ladder (ThermoFischer Scientific).  
2.16 PCR amplification of genomic DNA for cloning 
2.16.1  PCR using primers SpliceA/B and SpliceA/C 
Genomic DNA from a control with normal (WT) ADAMTS13 or from the patient 
with the splice site mutation was used for PCR. To 2μl of genomic DNA, 1x reaction 84 
 
buffer  (ThermoFischer  Scientific),  100µM  dNTPs  (Life  technologies),  200nM  of 
primer and 1U of Pfu DNA polymerase (ThermoFischer Scientific) was added and 
made up to a final volume of 50μl with sterile water. PCR was carried out in the 
absence of DMSO and a negative control was set up with each PCR reaction. The 
conditions which were used for the PCR set up using primer SpliceA/B and Splice 
A/C were as follows:  
95⁰C  3 minutes         x1 cycle 
95⁰C  30 seconds 
} 
x25 cycles  58⁰C  30 seconds                                              
72⁰C  4 minutes 
72⁰C  7 minutes         x1 cycle 
 
The PCR products were run on a 2% agarose gel as described in Chapter 2.15.4. 
Primer sequences are shown in the appendix (Table S 5). 
2.16.2  PCR using primers SpliceD/E and SpliceA/F 
Genomic DNA from a control with normal (WT) ADAMTS13 or from the patient 
with  the  splice  site  mutation  was  used  for  PCR.  To  1.5μl  of  genomic  DNA  1x 
reaction  buffer  (ThermoFischer  Scientific),  125µM  dNTPs  (Life  technologies),  
400nM  of  primer,  5%  DMSO  and  1U  of  Pfu  DNA  polymerase  (ThermoFischer 
Scientific) was added and made up to a final volume of 50μl with water. A negative 
control was set up with each PCR reaction.  
The conditions which were used for the PCR set up using primers SpliceD/E were as 
follows:  
95⁰C  2 minutes         x1 cycle 
95⁰C  30 seconds 
} 
x30 cycles  58⁰C  30 seconds                                              
72⁰C  2 minutes 
72⁰C  10 minutes         x1 cycle 
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The conditions used for nested PCR using primers SpliceA/F were as follows: 
95⁰C  2 minutes         x1 cycle 
95⁰C  30 seconds 
} 
x30 cycles  61⁰C  30 seconds                                              
72⁰C  2 minutes 
72⁰C  10 minutes         x1 cycle 
 
Primer sequences are shown in the appendix (Table S 5). 
2.16.3  Purification of PCR products 
PCR products were purified using a QIAquick purification kit (Qiagen) according to 
the manufacturer’s instructions. In brief PBI buffer was added to the PCR mix, which 
was then added to the QIAqick column and spun at 17,900g for 1 minute to bind the 
DNA. The DNA was washed using buffer PE and spun at 17,900g for 1 minute. The 
DNA was eluted in 30µl water by spinning the column for 1 minute at 17,900g.  The 
purified product was visualised on a 2% agarose gel, as described in Chapter 2.15.4. 
2.16.4  Gel purification 
DNA was extracted from agarose gels using a QIAquick gel extraction kit (Qiagen). 
In  brief  buffer  BG  was  added  to  the  gel  containing  the  DNA  to  be  extracted, 
followed  by  incubation  at  50⁰C  for  10  minutes  with  mixing  using  a  vortex  in 
between to dissolve the gel. Once this had dissolved isopropanol was added to the 
sample and mixed. This was applied to a QIAquick column and centrifuged for 1 
minute at 10,000g to bind the DNA. The flow through was discarded and the DNA 
was washed with buffer QG by spinning for 1 minute at 10,000g to remove any 
traces of agarose. The DNA was washed again with buffer PE by centrifuging at 
10,000g for 1 minute. The DNA was eluted with 40μl water. The purified product 
was visualised on a 2% agarose gel, as described in Chapter 2.15.4. 
2.17 Topoisomerase (TOPO) cloning  
PCR fragments were cloned using a pcDNA
TM 3.1 Directional TOPO ® Expression 
kit (Life technologies). This kit enables directional blunt-end PCR product cloning 86 
 
into the pcDNA3.1D/V5-His-TOPO® vector. This vector is supplied linearised with 
both ends adapted with topoisomerase. The vector is shown in Figure 2-1. 
Figure 2-1 pcDNA3.1D/V5-His-TOPO® vector 
The CMV promoter/enhancer allows high level expression of the inserted protein within mammalian 
cells. The V5-epitope enables the recombinant protein to express a C-terminal V5 epitope tag for 
protein detection, the 6xhistidine tag enables the protein to express a C-terminal polyhistidine tag for 
protein purification. The T7 promoter allows for  in vitro transcription of the protein in the sense 
direction  and  the  BGH  polyadenylation  signal  enables  efficient  transcription  termination  and 
polyadenylation  of  the  mRNA.  The  SV40  early  promoter  and  SV40  early  polyadenylation  signal 
enable expression of the neomycin resistance gene and episomal replication in cells expressing the 
SV40 large T antigen. The neomycin gene enables selection of cells containing the vector using the 
antibiotic geneticin. The pUC origin enables high copy number replication and growth of the vector in 
E.  coli.  The  bla  promoter  enables  expression  of  the  ampicillin  resistance  gene.  The  ampicillin 
resistance gene enables selection of E. coli expressing the vector. Note that this vector is the same 
vector  that  contains  ADAMTS13  full  length  cDNA.  Image  is  adapted  from  (URL: 
https://www.lifetechnologies.com/order/catalog/product/K490001?ICID=search-product,  accessed 
17
th June 2014).  
Topoisomerase I functions as both a restriction enzyme and a ligase. Biologically it 
cleaves and rejoins DNA during replication. Topoisomerase I from Vaccina virus 
recognises the sequence 5’-(C/T)CCTT-3’, cleaving it and forming a covalent bond 
with the phosphate group of the 3’ thymidine (Shuman, 1991). This enzyme cleaves 
one DNA strand enabling the DNA to unwind,  religates the ends of the cleaved 
strands and then releases itself from the DNA. The ability of this enzyme to religate 
together DNA is harnessed in this vector.  87 
 
This  kit requires  the PCR product  to  be cloned to  start  with  the DNA sequence 
CACC. The vector contains a single strand GTGG overhang at the 5’ end of the 
linearised  vector  and  a  blunt  end  (no  GTGG)  at  the  3’  end.  This  4  nucleotide 
overhang invades the double stranded DNA of the PCR product and anneals to the 
CACC sequence introduced into the PCR product by the primer. The Topoisomerase 
I  can  subsequently  ligate  the  PCR  product  into  the  correct  direction.  This  is 
illustrated in Figure 2-2. 
 
Figure 2-2 Overview of TOPO cloning process 
Image  is  adapted  from  (URL:  http://www.lifetechnologies.com/uk/en/home/life-
science/cloning/topo/topo-resources/the-technology-behind-topo-cloning.html,  accessed  17
th  June 
2014). 
The TOPO cloning reaction was set up by adding 1-4μl of the PCR product, 1μl of 
salt solution and 1μl of TOPO vector (final volume 6μl). The reaction was incubated 
for 5 minutes at room temperature, and then placed on ice. Following this 2μl of the 
cloning reaction was transformed into TOP10 one shot chemically competent E. coli 
(Life technologies) as described Chapter 2.2.4. 
2.17.1  Restriction digest 
Some of the cloned PCR products formed using primers SpliceA/C were digested 
with the following restriction enzymes: StuI (New England Biolabs), BstXI (New 
England Biolabs) and XbaI (Takara Bio Europe/Clontech). A total volume of 20μl 
was used, along with 1μl of the restriction enzyme, 1x restriction enzyme buffer and 
2-17μl of the DNA obtained from mini preparation.  
For StuI digestion of the cloned PCR product formed using primers SpliceA/F, 1μl of 
enzyme (New England Biolabs) was added to 1x NE buffer 4, with 10μl of the DNA 88 
 
to be digested (with concentrations varying from 20-100ng/μl) and made up to a final 
volume of 50μl with sterile water.  89 
 
Chapter 3    Transient transfection of ADAMTS13 
missense mutants  
3.1  Introduction 
3.1.1  Congenital TTP and ADAMTS13 mutations 
To  date  over  140  different  mutations  within  the  ADAMTS13  gene  have  been 
identified in patients with congenital TTP (Table S 6). These genetic defects are 
inherited in an autosomal recessive manner (Levy et al, 2001). Of those identified, 
62% are missense mutations, 19% are deletions, 3% are insertions, 6% are splice site 
and 10% are nonsense mutations. These mutations are distributed throughout the 
whole of the ADAMTS13 gene.  
 
Figure 3-1 Location of ADAMTS13 gene mutations identified in patients with congenital TTP 
Mutations  that  have  been  expressed  in  vitro  are  underlined  and  in  bold.  Schematic  ADAMTS13 
diagram modified from (Zheng et al, 2001). 90 
 
Evidence suggests that there is an association between residual ADAMTS13 activity 
and ADAMTS13 genotype. Residual ADAMTS13 activity in turn has been associated 
with clinical severity of disease in terms of the first episode requiring fresh frozen 
plasma (FFP) and the annual rate of TTP episodes (Lotta et al, 2012). Therefore, it is 
important  to  understand  the  mechanisms  and  to  what  extent  different  mutations 
within ADAMTS13 affect its function. Of the mutations identified, approximately 
30% have been expressed in vitro (Figure 3-1 and Table S 7). ADAMTS13 mutations 
affect the secretion and/or the activity of ADAMTS13 (Figure 3-2). The majority of 
mutants  expressed  in  vitro  (86%)  lead  to  reduced  secretion  (<50%)  of  WT 
ADAMTS13. 
 
Figure 3-2 In vitro expression of ADAMTS13 mutants 
Activity defect is defined as a specific activity <50% of WT and a secretion defect as ADAMTS13 
antigen <50% of WT. The 50% cut-off was arbitrarily chosen. ‘Secretion defect only’ are mutants 
with <50% ADAMTS13 antigen but >50% specific activity. ‘Activity defect only’ are those mutants 
with >50% ADAMTS13 antigen but <50% ADAMTS13 activity. ‘Secretion and activity defect’ are 
those  mutants  with  <50%  ADAMTS13  antigen  and  <50%  specific  activity.  In  some  cases  no 
ADAMTS13 was secreted or levels were very low (<10%) and so it is unknown whether the specific 
activity was reduced in addition to the secretion. These mutations are shown in blue and are described 
as ‘secretion defect’ mutants. The c.330+1G>A splicing mutation was not included in this analysis. 
For mutations analysed in more than one study average values were used.  91 
 
3.1.2  Congenital ADAMTS13 deficient patients homozygous for ADAMTS13 
mutations 
It is particularly desirable to study patients homozygous for ADAMTS13 mutations in 
order  to  study  genotype/phenotype  relationships  that  may  exist.  Although  useful 
information can also be obtained by studying compound heterozygotes, there is the 
possibility that the ADAMTS13 gene on a particular chromosome may be expressed 
more  often  than  the  corresponding  ADAMTS13  gene  on  the  other  homologous 
chromosome.  For  example,  ADAMTS13  mutant  a  on  chromosome  9a  may  be 
expressed 70% of the time whereas ADAMTS13 mutant b on chromosome 9b may 
be expressed 30% of the time. Therefore, assuming that the ADAMTS13 antigen and 
activity measured in the plasma of a compound heterozygote patient is the result of 
50/50 expression of each mutant, may not be strictly correct.    
The majority of mutations that have been expressed in vitro were identified in a 
compound heterozygous state. Of the 43 mutations which have been  analysed in 
vitro, only 16 have been found in a homozygous state in at least one patient in the 
literature,  highlighting  the  need  to  characterise  more  mutations  which  have  been 
identified in a homozygous state in patients (Table 3-1). 92 
 
No  Protein/cDNA change  Domain  Age  Antigen*  Reference  In vitro 
1  p.S36_C37delfs*102  MP  8 months  <1% 
#  (Lotta et al, 2012), this study  This study 
2 
p. R102H 
MP  18 years  42% 
#  (Camilleri et al, 2012), this study  This study 
 (Camilleri et al, 2012)  3  MP  Adult, preg  NA  (Scully et al, 2014) 
4 
p.S119F 
MP  14 years  5% 
# 
(Feys et al, 2009b), personal 
communication  Antigen <10% of WT, specific activity 50% of 
WT (Feys et al, 2009b)  5  MP  17 years  NA  (Meyer et al, 2008) 
6  c.414+1G>A  MP  4 years  <3%  (Matsumoto et al, 2004)  Splice site analysed in vivo (Matsumoto et al, 2004) 
7  p.I143T  MP  7 years  <1%  (Lotta et al, 2012)  This study 
8  p.R193W  MP  NA, preg  11%  (Fujimura et al, 2009)  Antigen ~25% of WT, no activity detected 
(Matsumoto et al, 2004) 
9  p.T196I  MP  3 years  <10ng/ml  (Camilleri et al, 2012)  Antigen 4% of WT, no activity detected 
(Camilleri et al, 2012) 
10  c.687-2 A>G  MP  Neonatal  NA  (Studt et al, 2005)  - 
11  p.L232Q  MP  Neonatal  NA  (Schneppenheim et al, 2003)  - 
12 
p.D235H 
MP  21 months  NA  (Assink et al, 2003)  - 
13  MP  12 months  NA  (Assink et al, 2003)  - 
14  p.G236C  MP  Adult, preg  <60ng/ml  (Moatti-Cohen et al, 2012)  - 
15  p.C311Y  Dis  23 months  NA  (Assink et al, 2003)  - 
16  p.R349C  Dis  22 years, preg  NA  (He et al, 2010)  - 
17  p.R409W  TSP-1  Neonatal  <10ng/ml  (Camilleri et al, 2012)  Antigen <3% of WT, no activity detected  
(Camilleri et al, 2012) 
18  p.Q436HfsX23  TSP-1  Neonatal  <1% 
#  (Lotta et al, 2012)  - 
19 
p.Q449X 
Cys  Neonatal  <3% 
(Ishizashi et al, 2007;Kokame et al, 
2002)  Antigen similar to WT but minimal activity 
(Kokame et al, 2002)  20  Cys  Childhood  NA 
(Fujimura et al, 2011;Kokame et al, 
2002) 
21  c.1584+5G>A  Cys  4 years  NA  (Levy et al, 2001)  - 
22 
p.D551QfsX58 
Cys  13 months  22ng/ml  (Alsultan et al, 2013) 
- 
23  Cys  Neonatal  NA  (Alsultan et al, 2013) 
24  p.L595GfsX19  Spa  Neonatal  NA  (Savasan et al, 2003)  - 
25  p.Y570C  Spa  10 years  <1%  (Metin et al, 2013)  This study 
26 
p.A596V 
Spa  Neonatal  NA  (Veyradier et al, 2004)  Antigen <3% of WT, no detectable activity 
(Camilleri et al, 2012)  27  Spa  18 months  11ng/ml   (Camilleri et al, 2012) 
28  p.E641GfsX57  Spa  4 years   Undetectable  (Alsultan et al, 2013)  - 
29  p.Y658C  Spa  34 years, preg  NA  (Lee et al, 2011)  - 93 
 
30  p.R692C  TSP-1:2  Neonatal  NA  (Levy et al, 2001)  - 
31  Neonatal  NA  (Levy et al, 2001) 
32  Neonatal  NA  (Levy et al, 2001) 
33  2 months  NA  (Snider et al, 2004) 
34  2 days  Undetectable   (Kim et al, 2014) 
35  17 months  Undetectable  (Kim et al, 2014) 
36  p.E735X  TSP-1:2  2 years  Undetectable  (Borgi et al, 2013)  - 
37  p.C754AfsX24  TSP-1:3  4 months  NA  (Fujimura et al, 2011)  - 
38  Neonatal  NA  (Fujimura et al, 2011) 
39  p.C754R  TSP-1:3  5 years  <10ng/ml  (Camilleri et al, 2012)  Antigen 4% of WT, undetectable activity 
 (Camilleri et al, 2012)  40  3 years  <10ng/ml  (Camilleri et al, 2012) 
41  p.G760AfsX18  TSP-1:3  7 months   NA  (Assink et al, 2003)  - 
42  p.C977_R979delinsW  TSP-1:6  23 years  <1% 
#  (Palla et al, 2009)  1% antigen, specific activity 6% of WT   
(Palla et al, 2009)  43  29 years  <1% 
#  (Palla et al, 2009) 
44  p.C977F  TSP-1:6  24 years, preg  38ng/ml  (Camilleri et al, 2012)  Antigen <3% WT, undetectable activity 
(Camilleri et al, 2012)  
45  p.C1024R  TSP-1:7  63 years  0.7% 
#  (Fujimura et al, 2011;Taguchi et al, 
2012) 
Antigen 10% of WT, activity 30% WT.  
(Taguchi et al, 2012) 
46  p.R1060W  TSP-1:7  33 years  11ng/ml  (Camilleri et al, 2008)  Antigen <5% of WT, activity similar to WT 
(Camilleri et al, 2012) 
- 
47  18 years  5% 
#  (Lotta et al, 2010) 
48  Adult, preg  NA  (Scully et al, 2014) 
49  Adult, preg  NA  (Scully et al, 2014) 
50  Adult, preg  NA  (Scully et al, 2014) 
51  Adult, preg  NA  (Scully et al, 2014) 
52  Adult, preg  NA  (Scully et al, 2014) 
53  p.W1081X  TSP-1:8  11 years  NA  (Fujimura et al, 2011) 
54  p.R1123C  TSP-1:8  Neonatal  <62.5ng/ml 
#  (Donadelli et al, 2006)  Ag similar to WT no detectable activity 
(Donadelli et al, 2006) 
55  p.R1219W  CUB-2  35 years  <62.5ng/ml 
#  (Donadelli et al, 2006)  Undetectable antigen, activity 62% of WT 
(Donadelli et al, 2006)  56  21 years  <62.5ng/ml 
#  (Donadelli et al, 2006) 
57  p.D1362V  CUB-2  31 years, preg  2%
 #  (Calderazzo et al, 2012)  - 
58  p.E1382RfsX6  CUB-2  Neonatal  NA  (Manea et al, 2007a)  Antigen 3-14%, activity 10% of WT  
(Garagiola et al, 2008;Pimanda et al, 2004)  59  3 years  Undetectable 
#  (Manea et al, 2007b) 
60  18 months  Undetectable 
#  (Manea et al, 2007b) 94 
 
61  2 years  Undetectable 
#  (Manea et al, 2007b) 
62  14 years  NA  (Schneppenheim et al, 2006) 
63  NA  NA  (Schneppenheim et al, 2006) 
64  4 years  NA  (Schneppenheim et al, 2006) 
65  4.5 years  NA  (Schneppenheim et al, 2006) 
66  Neonatal  NA  (Schneppenheim et al, 2006) 
67  Neonatal  NA  (Klukowska et al, 2010) 
68  Neonatal  NA  (Klukowska et al, 2010) 
69  18 years  NA  (Lotta et al, 2012) 
 
Table 3-1 Patients in the literature with homozygous genotype  
Patients in the literature with homozygous genotype published after this thesis was commenced are highlighted in pink. NA- not available either not measured or could not 
obtain information. Preg indicates pregnancy onset. MP: metalloprotease, Dis: Disintegrin-like, Cys: cysteine-rich, Spa: spacer.*Antigen is expressed as a % of PNP or in 
ng/ml depending on the ADAMTS13 antigen ELISA used to measured antigen in vivo. 100% PNP is approximately 740 +/-110ng/ml (Imubind assay).
# indicates where it is 
known that antigen was measured in the patient during remission. 
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I  aimed  to  study  in  vitro,  ADAMTS13  mutations  which  had  been  identified  in  a 
homozygous  state  in  patients  with  congenital  TTP.  I set  out  to  study a range of 
different  mutations  falling  into  three  categories:  i.)  mutations  causing  a  severe 
secretion  defect  by  reduced  antigen  and  activity  levels  without  altering  splicing 
(which  I  have  defined  here  as  a  type  1a  defect),  ii.)  mutations  with  a  modestly 
reduced or normal secretion level but dysfunctional protein (which I have defined 
here as a type 2 defect) and iii.) mutations affecting splicing and causing a severe 
secretion defect by reduced antigen and activity (which I have defined here as a type 
1b defect). A severe secretion defect was characterised by a severe reduction in both 
antigen and activity levels. Antigen level values <10% of normal WT ADAMTS13 
was  arbitrarily  chosen to describe a severe reduction in  antigen levels. A severe 
activity defect was defined here as an activity level <5% of WT. This value was 
chosen as  congenital  TTP  patients  have  an ADAMTS13 activity  <5% of normal 
(Scully et al, 2012). 
A number of mutations have been identified in a homozygous state in patients with 
congenital  TTP  in  the  UCL  Haemostasis  Research  Unit  and  the  Angelo  Bianchi 
Bonomi Hemophilia and Thrombosis Centre, Milan. The majority of these mutations 
were predicted to lead to a type 1 deficiency based on antigen levels measured in 
patient  plasma.  Therefore,  there  were  a  number  of  potential  type  1  mutations 
available to work with. Of all the mutations present in both centres there was one 
(p.R102H),  which  appeared  to  a  type  2  defect.  In  order  to  identify  other  type  2 
defects  that  could  be  studied,  I  carried  out  a  literature  search,  examining  the 
ADAMTS13 antigen levels measured in the plasma of patients with homozygous 
ADAMTS13  gene  mutations.  Where  this  information  was  unavailable  the  authors 
were contacted for further information. Results of this search are shown in Table 3-1. 
This literature search was performed in July 2010. New patients with homozygous 
mutations  which  have  been  identified  since  then  are  also  shown  in  the  table, 
highlighted in pink.  
At the time I found that the only known type 2 defects that had been described were 
the p.R102H and p.R193W mutations. The p.R193W mutation had been expressed 
previously by other groups. This exercise suggested that type 2 defects are rare and 
most ADAMTS13 gene mutations lead to a secretion defect and a type 1 deficiency. 96 
 
3.1.3  Congenital TTP patients with missense mutations 
I attempted to characterise in vitro four mutations using both transient and stable line 
transfections. Three of these were missense mutations and will be described within 
this Chapter and in Chapters 4-7. The fourth mutation, a splice site mutant will be 
discussed separately in Chapter 8. 
The clinical history of  patients 1 and 2 (Metin et al, 2013) and patient 3 (Camilleri et 
al, 2012) have been previously described and are summarised in Table 3-2. All three 
patients  had undetectable ADAMTS13  activity  in  their plasma in the absence of 
detectable anti-ADAMTS13 antibodies. The ADAMTS13 activity of patient 1 was 
also  measured  using  a  more  sensitive  SELDI-TOF  mass  spectrometry  assay 
(detection  limit  <0.5%  PNP).  The  patient  had  undetectable  plasma  ADAMTS13 
activity when measured with this assay also (Lotta et al, 2012). 
Patients  1  and  2  had  undetectable  ADAMTS13  antigen  levels  in  their  plasma, 
whereas  ADAMTS13  antigen  could  be  detected  in  patient  3.  The  ADAMTS13 
antigen level was measured in patient plasma before treatment or more than three 
weeks after plasma exchange/infusion in patients 1 and 3. Plasma was not available 
in patient 2 during this time and so was measured during the acute phase of disease.  
Patients 1 and 2 presented with TTP during adolescence. Patient 3 developed TTP 
during  her  third  trimester  of  pregnancy.  The  mutations  present  in  these  patients 
localise within different regions of the ADAMTS13 gene (Figure 3-3). Patients 1 and 
3 have mutations which localise within the metalloprotease domain of ADAMTS13, 
while patient 2 has a mutation within the spacer domain.  
The parents of patients  1 and 2 were consanguineous and both were Turkish.  In 
Turkey  20-29%  of  marriages  are  consanguineous  (Hamamy,  2012).  Two  further 
Turkish patients, with a homozygous ADAMTS13 genotype have been identified and 
published in the literature (Table 3-1) (Metin et al, 2013;Studt et al, 2005;Lotta et al, 
2012). Therefore, approximately 6% of patients (4/69) with homozygous ADAMTS13 
mutations are Turkish.  This number may be an underestimate as the ADAMTS13 
gene in patients with suspected ADAMTS13 deficiency, is normally sequenced in 
specialised centres in other countries.  97 
 
The parents of patient 3 are not consanguineous but the patient came from a small 
community.  Interestingly  another  patient  with  the  same  mutations  and  non-
synonymous polymorphisms as patient 3 has been identified (Table 3-1). This patient 
also comes from a similar small community as patient 3. 
Offspring  of  consanguineous  unions  may  be  at  increased  risk  of  expression  of 
autosomal recessive disorders. Therefore, patients from consanguineous unions with 
a  congenital  ADAMTS13  deficiency  may  have  homozygous  mutations  in  other 
genes  which  could  potentially  contribute  to  the  disease  severity  and  possibly 
ADAMTS13 levels. 
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Patient  1  2  3 
Sex/ Ethnicity/Consanguinity  Male/Turkish/Yes  Female/Turkish/Yes  Female/Caucasian/No 
Consanguineous  Yes  Yes  No, but both parents from the same small 
community  
Current age  25  20  27 
Age at presentation/ diagnosis  7/13  10/13  18 
Episodes: age and triggers  i.7, ii.8 (infection), iii.11, iv.13*,v.16 
(unknown)  i.10 (unknown), ii.13* (menarche)  i.18* (Pregnancy), ii.unrelated to 
pregnancy 
Other  No persistent renal or neurological 
involvement 
Neurological involvement at diagnosis 
but no sequelea  Patient has had three live births 
Treatment  Plasma infusion every 6 weeks  Plasma infusion every 3 weeks 
Plasma exchange every two weeks 
during pregnancy, plasma exchange after 
episode 
ADAMTS13 activity (% PNP)  <6% 
a  <6% 
a  <5% 
b 
ADAMTS13 antigen (% PNP)  <1% 
c  <1% 
c  42%±5.4 (mean±SD) 
d, $ 
ADAMTS13 antibodies  Negative  Negative  Negative 
ADAMTS13 mutations  p.I143T (Isoleucine→ Threonine)  p.Y570C (Tyrosine → Cysteine)  p.R102H (Arginine →  Histidine) 
ADAMTS13 polymorphisms  p.Q448E (Glutamine → Glutamic acid)  p.R7W (Arginine → Tryptophan) 
p.P618A (Proline → Alanine) 
p.Q448E (Glutamine → Glutamic acid) 
p.P618A (Proline → Alanine) 
p.A900V (Alanine → Valine) 
 
Table 3-2 Clinical characteristics of patients   
*Episode TTP diagnosed; 
adetection limit 6%, normal range: 46-160%; 
bdetection limit 5%, normal range: 50-160%;  
cdetection limit 1%, normal :>45%; 
ddetection limit 3%, 
normal range:44-148%; 
$antigen measured on four separate occasions.
 ADAMTS13 activity
 measured
 using collagen binding assay, all mutations and polymorphisms present 
are homozygous in patients.  99 
 
Patient 1 
 
Patient 2 
 
Patient 3 
 
Figure  3-3  Location  of  ADAMTS13  mutations  and  polymorphisms  in  the  ADAMTS13  gene, 
mRNA and protein in patients 1, 2 and 3  
Image adapted from: (Zheng et al, 2001). 100 
 
3.2  In silico analysis of mutations and polymorphisms 
Conservation  of  the  amino  acids  affected  by  mutations  in  the three  patients  was 
investigated by aligning the protein sequence of human ADAMTS13 with either the 
protein sequence of ADAMTS13 in other animals (ADAMTS13 orthologs) or with 
the protein sequence of other human ADAMTS proteins (ADAMTS13 paralogs). 
Results are shown in Figure 3-4 and Figure 3-5, in the regions affected by these 
amino acids. The amino acids affected by mutations in the patients are highlighted in 
yellow. 
All three mutations are highly conserved in ADAMTS13 orthologs (Figure 3-4). The 
Y  (tyrosine)  residue  at  position  570  (patient  2)  is  also  conserved  in  ADAMTS 
paralogs. The I (isoleucine) residue at position 143 (patient 1) is present in most 
ADAMTS13 proteins but is replaced with a valine (V) residue in ADAMTS 1, 4, 5, 8 
and 15 (Figure 3-5). Both isoleucine and valine are neutral amino acids whereas 
threonine (T) is polar.  
The conservation of the R (arginine) in ADAMTS paralogs is more variable. An R is 
present in ADAMTS 4, 13, 17, 19; a histidine (H) residue in ADAMTS1, 5, 6, 9, 15; 
an asparagine (N) in ADAMTS 3, 8, 14, 20; a serine in ADAMTS 7, 12; a threonine 
in ADAMTS 16, 18; a leucine in ADAMTS2 and a glutamine in ADAMTS 10.  All 
of these amino acids are polar.  
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p.I143 
Taeniopygia 166 VAGPDVYLYHREDTERYILANLNIGAELLRDASLGAHFRVHLMQMLVLREPEAEVNITTN 225 
Gallus      30  VAGPDVYMYHQEDTERYILTNLNIGAELLRDASLGAHFRVHLMQMLVLREPEVNVNITTN 89 
Bos         73  AVGPDVHRTHGEETERYVLTNLNMGSELLRDPSLGAQFRVHLVKMVILTQPEDAPEITAN 132 
Ovis        179 AVGPDVQRTHGEETERYVLTNLNMGSELLRDPSLGAQFRVHLVKMVILTQPEDAPKITAN 238 
Gorilla     91  AVGPDVFQAHQEDTERYVLTNLNIGAELLRDPSLGAQFRVHLVKMVILTEPEGAPNITAN 150 
Pan         91  AVGPDVFQAHQEDTERYVLTNLNIGAELLRDPSLGAQFRVHLVKMVILTEPEGAPNITAN 150 
ADAMTS13    87  AVGPDVFQAHQEDTERYVLTNLNIGAELLRDPSLGAQFRVHLVKMVILTEPEGAPNITAN 146 
Nomascus    89  AVGLMSFQAHQEDTERYVLTNLNIGAELLRDPSLGAQFRVHLVKMVILTEPEGAPNITAN 148 
Pango       87  AVGPDVFQAHQEDTERYVLTNLNIGAELLRDPSLGAQFRVHLVKMVILTEPEGAPNITAN 146 
Papio       89  AVGPDVFQAHQEDTERYVLTNLNIGAELLRDPSLGAQFRVHLVKMVILTEPEGAPNITAN 148 
Callithrix  85  AVGPDVFQAHQEDTERYVLTNLNIGAELLRDPSLGVQFRVHLVKMVILTEPE-------- 136 
Saimin      87  AVGPDVFQAHQEDTERYVLTNLNIGAELLRDPSLGAQFRVHLVKMVILTEPESAPNITAN 146 
Otolemur    71  AVGPDVYQAHQEDTERYVLTNLNIGSELLRDPSLGTQFQMHLVKMVILREPQDAPNITAN 130 
Mus         89  AVGPDVSRAHQEDTERYVLTNLNIGSELLRNPSLGVQFQVHLVKLITLSDSESTPNITAN 148 
Cricetulus  89  AVGPDVYQVHQEDTERYVLTNLNIGSKLLRDPSLGAQFQVHLVKLIILSDSESIPNITTN 148 
Cava        87  AVGPDVHQAHQEDTERYVLTNLHIGSDLLRDPSLGVQVQVYLVKLLILTEPEDAPNITAN 146 
Canus       237 AVGPDVYQAHQEDTERYVLTNLNMGSELLRDPSLGAQFQVHLVKMVILTQPEDAPNITAN 296 
Felis       228 AVGPDVYQAHQEDTERYVLTNLNMGSELLRDPSLGTQFQVHLVKMVTLTQPEDAPNITAN 287 
Ailuropoda  182 AVGPDVYQAHQEDTERYVLTNLNTGSELLRDPSLGAQFRVHLVKLVILTQPEDAPNITAN 241 
Equus       78  AVGPDVYQAHQDDTERYVLTNLNMGSELLRDPSLGAQFRVHLVKMVILTRPEDAPDITAN 137 
Sarcophilus 194 VVGHDVYEYHKEDTERYILTNLNIGAELLRDISIGVPFRVHLIKMIILTEPEAGLNITTN 253 
Danio       68  VVGPDVYEVHRQDTERYILTNLNIASELLRDVTLGANIRVHLVRMIILTEPEPDIQISEN 127 
                                                                              
p.Y570                                                               
Taeniopygia 594 HLCVMGSCRA----FGCDGQMGSRKAMDACKVCGGENSTCTEVSGSYTEG-KAKEYVTFL 648 
Gallus      457 HLCVAGSCRA----FGCDGQMNSKRAMDSCKVCGGDNTTCMEVSGSYTEG-KAKEYVTFL 511 
Bos         510 RLCVSGSCRT----FGCDGRMDSGQVRDVCQVCGGDNSTCQPQSGSFTAG-RAREYVTFL 564 
Ovis        549 SLCVSGSCRT----FGCDGRMDSGQVRDVCQVCGGDSSTCRPQNGSFTAG-RAREYVTFL 603 
Gorilla     524 SLCVSGSCRT----FGCDGRMDSQQVWDRCQVCGGDNSTCSPRKGSFTAG-RAREYVTFL 578 
Pan         478 SLCVSGSCRT----FGCDGRMDSQQVWDRCQVCGGDNSTCSPRKGSFTAG-RAREYVTFL 532 
ADAMTS13    520 SLCVSGSCRT----FGCDGRMDSQQVWDRCQVCGGDNSTCSPRKGSFTAG-RAREYVTFL 574 
Nomascus    511 SLCVSGSCRT----FGCDGRMDSQQVQDACQVCGGDNSTCSPQKGSFTAG-RAREYVTFL 565 
Pango       548 SLCVSGSCRVRHVHLRCDGRMDSQQVWDACQVCGGDNSTCSPRKGSFHSWQSERKYVTFL 607 
Papio       522 SLCVSGSCRT----FGCDGRMDSQQVRDMCQVCGGDNSTCSPRNGSFTAG-RAREYVTFL 576 
Callithrix  500 SLCVSGSCRT----FGCDGRMDSQQVWDVCHVCGGDNSTCSPRKGSFTAG-KAGEYVTFL 554 
Saimin      485 SLCVSGSCRT----FGCDGRMDSQQVWDACHVCGGDNSTCSPRKGSFTAG-RAGEYVTFL 539 
Otolemur    504 SLCVSGSCRT----FGCDGRMDSQQMWDVCQVCGGDNSTCSPQNGSFTDG-RAKEYVTFL 558 
Mus         525 SLCLLGSCRT----FGCDGRMDSQKVWDACQVCGGDNSTCSSRNGSFTAG-RAREYVTFL 579 
Cricetulus  525 SLCVLGSCRT----FGCDGRMDSQKVWDVCQVCGGDNSTCSSQNGSFTGG-RAREYVTFL 579 
Cava        521 SLCVLGSCRM----FGCDGRMDSQQVWDVCQVCGGDNSTCSLQNGSFTGG-AAREYVTFL 575 
Canus       671 SLCMLGSCKT----FGCDGRMDSQQVRDVCQVCGGDNSTCSPQNGSFTAG-RAREYVTFL 725 
Felis       650 SLCVSGSCRT----FGCDGRMDSQQVRDACQVCGGDNSTCSPRNGSFTAG-RAREYVTFL 704 
Ailuropoda  603 SLCVLGSCRT----FGCDGRMDSPQVRDVCQVCGGDNSTCSPRNGSFTAG-RAREYVTFL 657 
Equus       512 SLCVSGHCRT----FGCDGRMDSQQVRDVCQVCGGDNSTCSRQSGSFTAG-RAREYVTFL 566 
Sarcophilus 623 NLCVMGRCRA----FGCDGGMDSGYVKDVCQVCGGDNTTCSKVSGFYSGG-KAQEYVTFL 677 
Danio       496 SACLSGKCQL----FGCDGALHSGKVEDVCGVCGGNGSTCHLISNTYSGG-KAGEYVTFL 550 
                                                                              
p.R102 
Taeniopygia 166 VAGPDVYLYHREDTERYILANLNIGAELLRDASLGAHFRVHLMQMLVLREPEAEVNITTN 225 
Gallus      30  VAGPDVYMYHQEDTERYILTNLNIGAELLRDASLGAHFRVHLMQMLVLREPEVNVNITTN 89 
Bos         73  AVGPDVHRTHGEETERYVLTNLNMGSELLRDPSLGAQFRVHLVKMVILTQPEDAPEITAN 132 
Ovis        179 AVGPDVQRTHGEETERYVLTNLNMGSELLRDPSLGAQFRVHLVKMVILTQPEDAPKITAN 238 
Gorilla     91  AVGPDVFQAHQEDTERYVLTNLNIGAELLRDPSLGAQFRVHLVKMVILTEPEGAPNITAN 150 
Pan         91  AVGPDVFQAHQEDTERYVLTNLNIGAELLRDPSLGAQFRVHLVKMVILTEPEGAPNITAN 150 
ADAMTS13    87  AVGPDVFQAHQEDTERYVLTNLNIGAELLRDPSLGAQFRVHLVKMVILTEPEGAPNITAN 146 
Nomascus    89  AVGLMSFQAHQEDTERYVLTNLNIGAELLRDPSLGAQFRVHLVKMVILTEPEGAPNITAN 148 
Pango       87  AVGPDVFQAHQEDTERYVLTNLNIGAELLRDPSLGAQFRVHLVKMVILTEPEGAPNITAN 146 
Papio       89  AVGPDVFQAHQEDTERYVLTNLNIGAELLRDPSLGAQFRVHLVKMVILTEPEGAPNITAN 148 
Callithrix  85  AVGPDVFQAHQEDTERYVLTNLNIGAELLRDPSLGVQFRVHLVKMVILTEPE-------- 136 
Saimin      87  AVGPDVFQAHQEDTERYVLTNLNIGAELLRDPSLGAQFRVHLVKMVILTEPESAPNITAN 146 
Otolemur    71  AVGPDVYQAHQEDTERYVLTNLNIGSELLRDPSLGTQFQMHLVKMVILREPQDAPNITAN 130 
Mus         89  AVGPDVSRAHQEDTERYVLTNLNIGSELLRNPSLGVQFQVHLVKLITLSDSESTPNITAN 148 
Cricetulus  89  AVGPDVYQVHQEDTERYVLTNLNIGSKLLRDPSLGAQFQVHLVKLIILSDSESIPNITTN 148 
Cava        87  AVGPDVHQAHQEDTERYVLTNLHIGSDLLRDPSLGVQVQVYLVKLLILTEPEDAPNITAN 146 
Canus       237 AVGPDVYQAHQEDTERYVLTNLNMGSELLRDPSLGAQFQVHLVKMVILTQPEDAPNITAN 296 
Felis       228 AVGPDVYQAHQEDTERYVLTNLNMGSELLRDPSLGTQFQVHLVKMVTLTQPEDAPNITAN 287 
Ailuropoda  182 AVGPDVYQAHQEDTERYVLTNLNTGSELLRDPSLGAQFRVHLVKLVILTQPEDAPNITAN 241 
Equus       78  AVGPDVYQAHQDDTERYVLTNLNMGSELLRDPSLGAQFRVHLVKMVILTRPEDAPDITAN 137 
Sarcophilus 194 VVGHDVYEYHKEDTERYILTNLNIGAELLRDISIGVPFRVHLIKMIILTEPEAGLNITTN 253 
Danio       68  VVGPDVYEVHRQDTERYILTNLNIASELLRDVTLGANIRVHLVRMIILTEPEPDIQISEN 127 
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p.I143 
                                 
ADAMTS1    295  ------------HPSIRNSVSLVVVKILVIHDEQKGPEVT-SNAALTLRNFCNWQKQ--- 338 
ADAMTS4    255  ------------HPSIRNPVSLVVTRLVILGSGEEGPQVG-PSAAQTLRSFCAWQRG--- 298 
ADAMTS15   255  ------------HPSILNPINIVVVKVLLLRDRDSGPKVT-GNAALTLRNFCAWQKK--- 298 
ADAMTS8    256  ------------HPSIKNSINLMVVKVLIVEDEKWGPEVS-DNGGLTLRNFCNWQRR--- 299 
ADAMTS5    304  ------------HASIENHIRLAVVKVVVLGDKDKSLEVS-KNAATTLKNFCKWQHQ--- 347 
ADAMTS9    330  ------------DPSIGNLINIVIVNLIVIHNEQDGPSIS-FNAQTTLKNFCQWQHS--- 373 
ADAMTS20   296  ------------DPSIGNLIHIVVVKLVMIHREEEGPVIN-FDGATTLKNFCSWQQT--- 339 
ADAMTS3    294  ------------DESLGVHINVVLVRMIMLGYAKSISLIERGNPSRSLENVCRWASQ--- 338 
ADAMTS14   297  ------------DESLGVHINIALVRLIMVGYRQSLSLIERGNPSRSLEQVCRWAHS--- 341 
ADAMTS2    304  ------------DESLGAHINVVLVRIILLSYGKSMSLIEIGNPSQSLENVCRWAYL--- 348 
ADAMTS6    288  ------------DSSLGNVVNIIVARLIVLTEDQPNLEIN-HHADKSLDSFCKWQKSILS 334 
ADAMTS10   277  ------------DSSLGSTVNILVTRLILLTEDQPTLEIT-HHAGKSLDSFCKWQKSIVN 323 
ADAMTS7    280  ------------DPSIGNPIHITIVRLVLLEDEEEDLKIM-HHADNTLKSFCKWQKSINM 326 
ADAMTS12   284  ------------NPSIGNAIHIVVVRLILLEEEEQGLKIV-HHAEKTLSSFCKWQKSINP 330 
ADAMTS16   328  ------------DGTIGGNINIAIVGLILLEDEQPGLVIS-HHADHTLSSFCQWQSGLMG 374 
ADAMTS18   331  ------------DGTIGSDINVVVVSLILLEQEPGGLLIN-HHADQSLNSFCQWQSALIG 377 
ADAMTS17   270  ------------HQSLGIKINIQVTKLVLLRQRPAKLSIG-HHGERSLESFCHWQNEEYG 316 
ADAMTS19   363  ------------HKSLGVQVNLRVIKLILLHETPPELYIG-HHGEKMLESFCKWQHEEFG 409 
ADAMTS13   117  ------------DPSLGAQFRVHLVKMVILTEPEGAPNIT-ANLTSSLLSVCGWSQT--- 160 
                                                                       
p.Y570 
ADAMTS1    714  ---------------------------------CGVCGGNGSTCKKISGSVTSA--KPGY 738 
ADAMTS4    675  ---------------------------------CMVCGGDGSGCSKQSGSFRKF--RYGY 699 
ADAMTS15   672  ---------------------------------CGVCGGDNKSCKKVTGLFTKP--MHGY 696 
ADAMTS8    679  ---------------------------------CGVCGGKGNSCRKVSGSLTPT--NYGY 703 
ADAMTS5    721  ---------------------------------CGVCGGDNSSCTKIVGTFNKK--SKGY 745 
ADAMTS9    742  ---------------------------------CGVCGGDNSSCKTVAGTFNTV--HYGY 766 
ADAMTS20   710  ---------------------------------CGVCGGDNSSCKTITGVFNSS--HYGY 734 
ADAMTS3    702  ---------------------------------CGVCGGDNSHCRTVKGTFTRTPRKLGY 728 
ADAMTS14   703  ---------------------------------CGVCGGDNSHCRTVKGTLGKASKQAGA 729 
ADAMTS2    712  ---------------------------------CGVCGGDNSHCKVVKGTFTRSPKKHGY 738 
ADAMTS6    706  ---------------------------------CRVCGGDGSTCDAIEGFFNDSLPRGGY 732 
ADAMTS10   695  ---------------------------------CRVCGGDGSACETIEGVFSPASPGAGY 721 
ADAMTS7    687  ---------------------------------CGVCHGNGSTCHTVSGTFEEAE-GLGY 712 
ADAMTS12   691  ---------------------------------CGVCLGDGSSCQTVRKMFKQKE-GSGY 716 
ADAMTS16   735  ---------------------------------CGVCNGNNSACTIHRGLYTKHHHTNQY 761 
ADAMTS18   738  ---------------------------------CGVCKGDNSTCKFYKGLYLNQHKANEY 764 
ADAMTS17   689  ---------------------------------CGVCSGDGKTCHLVKGDFS-HARGT-- 712 
ADAMTS19   779  ---------------------------------CGVCNGNGKSCKIIKGDFN-HTRGAGY 804 
ADAMTS13   545  ---------------------------------CQVCGGDNSTCSPRKGSFTAG-RAREY 570 
 
p.R102 
ADAMTS1    256  SHR------------YVETMLVADQSMAEFHG-SGLKHYLLTLFSVAARLYK-------- 294 
ADAMTS4    216  LSR------------FVETLVVADDKMAAFHG-AGLKRYLLTVMAAAAKAFK-------- 254 
ADAMTS15   216  IPR------------YVETLVVADESMVKFHG-ADLEHYLLTLLATAARLYR-------- 254 
ADAMTS8    217  EAR------------FVETLLVADASMAAFYG-ADLQNHILTLMSVAARIYK-------- 255 
ADAMTS5    265  RAR------------QVELLLVADASMARLYG-RGLQHYLLTLASIANRLYS-------- 303 
ADAMTS9    291  YPR------------FVEVLVVADNRMVSYHG-ENLQHYILTLMSIVASIYK-------- 329 
ADAMTS20   257  YPR------------YIEIMVTADAKVVSAHG-SNLQNYILTLMSIVATIYK-------- 295 
ADAMTS3    254  NDY------------NIEVLLGVDDSVVRFHGKEHVQNYLLTLMNIVNEIYH-------- 293 
ADAMTS14   257  GSY------------SIEVLLVVDDSVVRFHGKEHVQNYVLTLMNIVDEIYH-------- 296 
ADAMTS2    264  DDY------------NIEVLLGVDDSVVQFHGKEHVQKYLLTLMNIVNEIYH-------- 303 
ADAMTS6    248  IER------------FVETLVVADKMMVGYHGRKDIEHYILSVMNIVAKLYR-------- 287 
ADAMTS10   237  RER------------YVETLVVADKMMVAYHGRRDVEQYVLAIMNIVAKLFQ-------- 276 
ADAMTS7    240  KEK------------WVETLVVADAKMVEYHGQPQVESYVLTIMNMVAGLFH-------- 279 
ADAMTS12   244  KER------------WVETLVVADTKMIEYHGSENVESYILTIMNMVTGLFH-------- 283 
ADAMTS16   276  RHKRSLLRSHRNEELNVETLVVVDKKMMQNHGHENITTYVLTILNMVSALFK-------- 327 
ADAMTS18   281  RPRRSAGKSQKG--LNVETLVVADKKMVEKHGKGNVTTYILTVMNMVSGLFK-------- 330 
ADAMTS17   231  EHT-------------VETLVVADADMVQYHGAEAAQRFILTVMNMVYNMFQ-------- 269 
ADAMTS19   324  EYN-------------IETVVVADPAMVSYHGADAARRFILTILNMVFNLFQ-------- 362 
ADAMTS13   78   GILH------------LELLVAVGPDVFQAHQ-EDTERYVLTNLNIGAELLR-------- 116 
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The likely effect of the three mutations on ADAMTS13 was analysed using three 
computational based tools: SNPs3D, Polyphen 2 and SIFT (Table 3-3). The SNPs3D 
prediction is based on homology analysis and the predicted effect that the amino acid 
substitutions have on the stability of the protein. A positive score by the SNPs3D 
database indicates non-deleterious, and a negative score, a deleterious mutation. The 
Polyphen2 prediction is based upon phylogenetic and structural information. SIFT is 
a sequence homology based tool, which produces scores ranging from 0 to 1 for each 
substitution analysed. The amino acid substitution is predicted to be damaging if the 
score is ≤0.05 and tolerated if the score is >0.05.  
The p.R102H and p.I143T mutations were predicted to be harmful by one of the 
three tools  (p.R102H: polyphen2, p.I143T: SIFT). The p.Y570C  mutation  on the 
other hand was predicted to be harmful by all three computational tools.  
    SNPs3D 
 svm profile 
Polyphen2  SIFT  
 
Score  Prediction 
M
u
t
a
t
i
o
n
  p.R102H  1.70  Probably damaging  0.28  Tolerated 
p.I143T  0.67  Benign  0.04  Damaging 
p.Y570C  -1.50  Probably damaging  0  Damaging 
 
Table 3-3  In silico analysis of ADAMTS13 mutations and polymorphisms 
3.3  Site directed mutagenesis 
Site  directed  mutagenesis  was  used  to  create  three  expression  vectors,  each 
containing a single different ADAMTS13 gene mutation. Other missense mutants that 
were predicted to cause a type 1 deficiency were also created (p.T196I, p.R409W, 
p.A596V, p.C754R and p.C977F). These mutants were to be analysed in the same 
way as the other type 1 mutants (p.I143T and p.Y570C). However because of initial 
problems  in  the  development  of  some  of  the  experiments,  it  was  decided  that  it 
would be better to focus on a smaller number of mutants in more detail. There were 
initial problems with site directed mutagenesis which was rectified with the use of 
DMSO. In addition, there were problems with the immunofluorescent staining of 
ADAMTS13 expressing cells as discussed in the next chapter. 104 
 
3.4  Transient transfection 
After  site  directed  mutagenesis,  transient  transfection  of  the  WT  and  mutant 
ADAMTS13 cDNA was carried out in order to assess the effect of the mutations on 
the secretion of ADAMTS13 compared to WT. After transient transfection there was 
some  slight  variability  between  experiments.  Consequently  the  results  from  each 
experiment were normalised to take into account slight differences in the efficiency 
of  transfection  between  plated  cells.  Cells  were  co-transfected  with  a  plasmid 
expressing Renilla luciferase as described (Chapter 2.3.3).  
Initial transient transfection experiments were carried out using electroporation in 
Milan. In the UK transient transfection was carried out using PEI but the yield from 
cells expressing WT was lower with PEI (approximately 2-3 fold lower) compared to 
electroporation.  
Levels of expression of both WT and mutant ADAMTS13 protein were compared 
after  transient  transfection  with  either  branched  chain  or  linear  PEI.  Linear  PEI 
appeared to work better, with branched PEI giving approximately 60% of the value 
obtained with linear PEI.  
Preliminary  experiments  were  carried  out  using  an  electroporator  in  another 
department (using an exponential and square wave method of electrical discharge) 
however the results were poor. Experiments were carried out using Lipofectamine 
(Life technologies) (as opposed to PEI) for transfection, but the results were similar 
to PEI. Linear PEI was therefore used for subsequent experiments.  
3.5  Western blot analysis of cell lysate and supernatant samples 
After transient transfection cell lysate and supernatant samples were harvested and 
analysed using western blotting. All three mutant proteins were detectable within cell 
lysate samples using western blotting (Figure 3-6). With the p.R102H mutant, levels 
were similar to WT. With the p.I143T and p.Y570C mutants, levels were slightly 
increased compared to WT. Therefore, all the mutants were synthesised within the 
cell and the mutations did not prevent protein synthesis. The mutant proteins were of 105 
 
a similar molecular weight to WT ADAMTS13, which showed the expected size 
(~190kDa).  
 
Figure 3-6 Cell lysate samples harvested after transient transfection of WT and mutant protein 
Samples loaded according to transfection efficiency, representative of n=3. ADAMTS13 expected size 
~190kDa. 
With the p.I143T and p.Y570C mutants, no ADAMTS13 could be detected using 
western blotting in supernatant samples (concentrated ~20 fold). On the other hand 
the p.R102H mutant could be detected in the cell supernatant, but at a reduced level 
compared  to  WT  (Figure  3-7).  Again  WT  and  mutant  protein  detected  in  the 
supernatant were of the expected molecular weight.  
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Figure  3-7  Supernatant  samples  harvested  after  transient  transfection  of  WT  and  mutant 
protein 
Samples loaded according to transfection efficiency, representative of n=3. ADAMTS13 expected size 
~190kDa.   
3.6  ADAMTS13 antigen and activity in supernatant samples 
Construct  Average ADAMTS13 
antigen (% of WT±SD) 
Average ADAMTS13 
activity (% of WT±SD) 
Specific activity 
(% of WT±SD) 
p.I143T  Undetectable  Undetectable  - 
p.Y570C  Undetectable  Undetectable  - 
p.R102H  30±0.016  15±0.42  50±1.4 
 
Table 3-4 ADAMTS13 antigen and activity in supernatant samples after transient transfection 
Results from n=3 experiments. The specific activity was calculated by dividing the activity levels by 
antigen levels. 
Using an ELISA, ADAMTS13 antigen was undetectable in the p.I143T and p.Y570C 
mutants and no ADAMTS13 activity could be detected within supernatant samples 
using FRETS-VWF73 substrate for analysis (detection limit 2.5% of PNP) (Figure 
3-4). In contrast the p.R102H mutation led to reduced secretion, with low levels of 
antigen  in  the  supernatant  (30%±0.016  of  WT,  mean±SD).  The  quantity  of 
ADAMTS13  antigen  in  the  patient  plasma  was  42%±5.4  of  normal  (mean±SD), 
which is slightly below the normal range. The in vitro results show a reduction in the 
secretion of this mutant similar to that seen in the patient plasma.  
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3.7  Discussion 
The three mutations studied affected the secretion of ADAMTS13. The p.I143T and 
p.Y570C mutations severely affected the secretion whereas the p.R102H mutation 
partially  affected  the  secretion.  The  result  obtained  for  the  p.R102H  mutation  is 
similar to previously published results (Camilleri et al, 2012). The specific activity of 
the p.R102H mutant was on average 50%±1.4 of WT, suggesting that this mutation 
also affects the activity of ADAMTS13. 
The severe defect in secretion observed with the p.I143T and p.Y570C mutations 
correlated with the undetectable antigen levels in the plasma of patients 1 and 2. The 
partial defect in secretion observed with the p.R102H mutant correlated with the 
detectable ADAMTS13 antigen in the plasma of patient 3.  
The  p.I143T  mutation  present  in  patient  1  and  the  p.R102H  mutation  present  in 
patient 3 are within the metalloprotease domain of ADAMTS13. The metalloprotease 
domain  is  necessary  for  the  cleavage  of  VWF  and  contains  the  catalytic  site. 
Although both mutations were situated within this domain they had different effects 
on  the  secretion  of  ADAMTS13:  the  p.I143T  mutation  severely  affecting  the 
secretion and the p.R102H mutation partially affecting the secretion. Both of these 
mutations were also predicted to be damaging by only one of the three computational 
tools, highlighting the importance of in vitro expression in understanding the effect 
of mutations on the secretion and activity of ADAMTS13.  
The isoleucine (I) residue at position p.143 in ADAMTS13 is highly conserved in 
ADAMTS13 orthologs and partially conserved in ADAMTS13 paralogs. Although 
ADAMTS proteins have different functions, the N-terminal region of the proteins are 
similar,  (Figure  1-5),  all  having  a  signal  peptide,  propeptide,  metalloprotease, 
disintegrin, TSP1, cysteine-rich and spacer domain. The C-terminal region of these 
proteins are thought to play an important role in determining function (Huxley-Jones 
et al, 2005). In ADAMTS 1, 4, 5, 8 and 15 the isoleucine (I) 143 residue is replaced 
with a V (valine) residue, both isoleucine and valine are  neutral while the amino 
acid threonine (T) is polar. Isoleucine and threonine have different properties and so 108 
 
the replacement of this amino acid with threonine may have a detrimental effect on 
the overall structure of ADAMTS13.  
The p.I143 residue is situated between two glycosylation sites p.N142 and p.N146. 
The  consensus  sequence  for  N  glycosylation  is  N-X-T/S,  the  amino  acid  143 
therefore is at position X in the consensus sequence for the p.N142 glycosylation site 
(Zheng  et  al,  2001).  This  mutation  therefore  is  unlikely  to  affect  the  consensus 
glycosylation signal. However it may potentially affect the quaternary structure of 
ADAMTS13 and thus indirectly affect the glycosylation recognition site.  
A mutation at the location of amino acid 102 has previously been identified in a 
patient (Levy et al, 2001), where the amino acid arginine (R) was replaced with 
cysteine (C) and the patient presented during the neonatal period. This is in contrast 
to patient 3 whose arginine (R) residue was replaced by a histidine (H) residue and 
presented during adulthood. This particular amino acid is localised in the N terminal 
region of an alpha helix in the metalloprotease domain of ADAMTS13 (Pozzi et al, 
2012)  and  is  predicted  to  stabilise  a  negative  cluster  formed  by  surrounding 
negatively charged amino acids. The authors proposed that the substitution of the 
positively charged arginine residue with the neutral cysteine residue would strongly 
destabilise the metalloprotease domain. In contrast to cysteine, histidine and arginine 
are positively charged. In some ADAMTS paralogs the R residue at position 102 is 
replaced by a H residue. The replacement of arginine by histidine in patient 3 at this 
position may not destabilise the metalloprotease domain to the extent that cysteine is 
predicted  to.  Perhaps  this  could  explain  the  difference  in  disease  onset  between 
patient 3 and the patient reported by Levy et al (Levy et al, 2001). 
The p.Y570C mutation present in patient 2 is located within the spacer domain of 
ADAMTS13. The crystal structure of the disintegrin, TSP-1, cysteine-rich and spacer 
domain of ADAMTS13 has been solved (Akiyama et al, 2009). The spacer domain 
plays an important role in VWF binding (Gao et al, 2006;Jin et al, 2010). Antibody 
epitopes  in  some  patients  with  acquired  TTP  have  been  analysed  and  a  large 
proportion of them have antibodies directed towards the spacer domain (Luken et al, 
2005;Klaus et al, 2004). The tyrosine amino acid at position 570 is highly conserved 
in ADAMTS13 orthologs and paralogs. This amino acid forms part of the surface 109 
 
aromatic  cluster  on  the  outer  surface  of  a  β  sheet    (β2)  which  is  also  highly 
conserved. Cysteine is not an aromatic compound and in fact the spacer domain 
contains so cysteine residues (Akiyama et al, 2009). The properties of Y and C are 
quite different: Y is neutral, C is polar.  
I went on to characterise these mutants further, using different techniques to analyse 
the type 1a mutants, p.I143T and p.Y570C (Chapters 4-6) and the type 2 mutant 
(Chapter 7). With the type 1a defects  I studied elements of the protein secretion 
pathway  to  understand  how  these  mutations  affected  secretion,  analysing  the 
subcellular localisation of WT and mutant protein. With the type 2 the goal was to 
understand why the secreted protein was not functionally active. This was studied 
through biochemical characterisation of WT and mutant protein.  110 
 
Chapter 4   Immunofluorescence (type 1a mutants) 
4.1  Introduction 
The p.I143T and p.Y570C mutations identified in patients 1 and 2 appeared to cause 
a  severe  defect  in  the  secretion  of  ADAMTS13  (Chapter  3)  as  no  ADAMTS13 
antigen was present in the supernatant of cells expressing these proteins (Figure 3-7). 
I characterised these mutants further in order to understand at which stage of the 
secretion pathway the defect occurred, by investigating the localisation of the mutant 
proteins in the ER and Golgi.   
4.1.1  Protein secretion 
The ER consists of an organised network of branching tubules and flattened sacs 
which extend throughout the cytosol, (Figure 4-1). 
 
Figure 4-1 Secreted proteins travel through the ER and Golgi 
Image  from  (URL:  http://cnx.org/content/m45432/latest/?collection=col11551/latest,  accessed  17
th 
June 2014). ER is circled in red and the Golgi circled in blue.  111 
 
Newly synthesised proteins are directed to the ER membrane by a signal sequence 
(signal peptide region in ADAMTS13) (Figure 1-5) and cross over the ER membrane 
from  the  cytosol  to  enter  the  ER  biosynthetic-secretory  pathway.  The  ribosome 
responsible for synthesising the protein is directly attached to the ER membrane, 
these membrane bound ribosomes coat the surface of the ER, creating regions known 
as the rough ER (Figure 4-1) (Alberts et al, 2002). 
Within the ER, asparagine (N) linked glycosylation of proteins takes place which 
involves  the  transfer  of  an  oligosaccharide  to  the  side  chain  NH2  group  of  an 
asparagine  amino  acid  (Alberts  et  al,  2002).  ADAMTS13  has  ten  potential  N-
glycosylation  sites  (N-X-T/S)  (Zheng  et  al,  2001),  with  nine  of  these  identified 
within plasma and recombinant ADAMTS13 (Sorvillo et al, 2014). The N-linked 
oligosaccharide structures may be further modified during the journey of the protein 
through the ER.  
After transport and modification in the ER, proteins are packaged into small transport 
vesicles which bud off from the ER and enter the Golgi. The Golgi consists of a 
collection  of  flattened,  membrane-enclosed  cisternae.  Each  Golgi  stack  has  two 
distinct faces a cis face (entry face) and a trans face (exit face). The Golgi acts as a 
sorting and dispatching centre for products of the ER (Figure 4-1).  
Further modification of N-linked oligosaccharides may take place in the Golgi. O-
linked  glycosylation  may  also  occur  in  the  Golgi  which  involves  the  transfer  of 
oligosaccharides to the hydroxyl group on the side-chain of a serine, threonine or 
hydroxyllysine amino acid (Alberts et al, 2002). Seven of the eight TSP repeats of 
ADAMTS13  contain  the  consensus  sequence  CSX(S/T)CG  for  O-glycosylation 
(Zheng et al, 2001), six of these have been identified within plasma and recombinant 
ADAMTS13 (Sorvillo et al, 2014;Ricketts et al, 2007).  
C-mannosylation of proteins may also occur which involves the attachment of an 
alpha-mannosyl  group to the C-2 atom of the first W in the consensus sequence 
WXXW. ADAMTS13 has two putative C-mannosylation sites (Sorvillo et al, 2014). 
Transport vesicles destined for the plasma membrane normally leave the trans Golgi 
through the process of exocytosis.   112 
 
4.1.2  Principles of confocal microscopy  
When  fluorescent  images  are  viewed  with  a  conventional  microscope  the  entire 
specimen is bathed with light and the image can be viewed directly by eye. The 
fluorescence in the specimen away from the region of interest interferes with the 
resolution  of  structures  in  focus.  The  theoretical  resolution  of  a  widefield  light 
microscope is 0.2μm (Paddock, 1999). 
The lateral and axial resolution is improved when a confocal microscope is used. 
Illumination/excitation  is  achieved  by  scanning  a  more  focused  beam  of  light 
(normally from a laser) across the specimen. After the fluorochromes have absorbed 
the  light  from  the  laser  they  produce  fluorescence.  A  fraction  of  the  emitted 
fluorescence is collected through the confocal pinhole and imaged onto the detector. 
The  detection  pinhole  reduces  the  fluorescence  from  out  of  focus  planes  which 
causes blurred images when a conventional microscope is used (Paddock, 1999).  
4.2  Development of immunofluorescence protocol 
During the development of the immunofluorescence protocol, cells were stained and 
viewed using a fluorescence microscope (Zeiss AxioImager A1) to check that the 
immunofluorescent staining had worked. After the immunofluorescence protocol was 
successfully set up images were then taken using a confocal microscope. Primary 
monoclonal  antibodies  were  used  whenever  possible  as  opposed  to  polyclonal 
antibodies  to  reduce  potential  non-specific  binding.  Antibody  dilutions  were 
optimised  by  testing  two  or  three  different  dilutions  based  upon  the  values 
recommended  by  the  manufacturer  or  dilutions  previously  used  (Garagiola  et  al, 
2008;Palla et al, 2009).  
4.2.1  Culturing cells 
Initially cells were grown on microscope slides and were subsequently fixed and 
permeabilised. Regions rich in cells were selected for incubation with antibodies for 
immunofluorescent  labelling.  However  cells  were  subsequently  grown  on  cover 
glasses  to  improve  resolution.  The  optical  properties  of  the  cover  glasses  were 
matched  to  the  properties  of  the  objective  lens  of  the  confocal  microscope  to 113 
 
minimise refraction as light passed to and from the samples. Additionally growing 
the cells on cover glasses increased the specimen depth that could be probed as the 
cover glasses are much thinner than microscope slides. 
4.2.2  Mounting media 
At first cells were mounted with glycerol after they had been incubated with the 
relevant antibodies for immunofluorescent labelling. A commercial agent with anti-
fading  and  anti-photobleaching  properties  (Vectashield)  was  later  used  as  an 
alternative mounting media. This enabled the slides to be stored in the fridge for a 
longer period of time before being viewed and also increased the length of time the 
immunofluorescent  signal  could  be  detected  when  viewed  under  the  microscope 
(Florijn et al, 1995;Longin et al, 1993). This mounting media also contained DAPI 
which produces blue fluorescence when bound to DNA and excited at the correct 
wavelength. As a result the nuclei of cells could also be viewed under the microscope 
which helped to identify the cells.  
Cover glasses were sealed with clear nail polish to prevent the appearance of air 
bubbles in the samples, air drying and prevented the movement of the slide and cover 
glass during storage as the mounting media Vectashield does not harden.  
4.2.3  Minimising non-specific background staining 
In initial experiments, cells were blocked with 3% BSA overnight. There appeared to 
be a lot of background staining when the cells were viewed under the microscope. To 
the  blocking  buffer  0.3M  glycine  was  added  to  bind  to  free  aldehyde  groups 
introduced  during  fixation.  Paraformaldehyde  reacts  and  cross  links  protein 
molecules but lots of free aldehyde groups remain. This tissue bound free aldehyde 
will combine with any amino acid group available to them including those of the 
primary  and  secondary  antibody.  Adding  glycine  to  the  buffer  blocks  these  free 
aldehyde groups (Renshaw, 2007). Cells were also incubated for half an hour with 
goat and rabbit serum before antibody incubation to prevent non-specific binding of 
the  antibodies.  The  secondary  antibodies  used  were  produced  in  goat  (Cy3)  and 
rabbit (FITC).  114 
 
4.2.4  Detection of the ER  
Staining for the cis Golgi worked well. In early experiments the ER was detected 
using  a  mouse  monoclonal  anti-BiP  antibody  (BD  Biosciences).  BiP  (binding 
immunoglobulin  protein)  is  an  ER  resident  protein  which  aids  the  movement  of 
proteins  post-translationally  into  the  ER.  It  also  acts  as  a  chaperone  recognising 
incorrectly  folded  proteins  that  have  not  yet  assembled  into  their  final  oligomer 
complex  (Alberts  et  al,  2002).  This  antibody  has  been  previously  used  to 
immunofluorescently label the ER in ADAMTS13 expressing COS cells (Garagiola 
et al, 2008;Palla et al, 2009). After attempting immunofluorescent labelling with this 
antibody, the ER was not visible. The concentration of both this antibody (primary 
antibody) and the secondary detection antibody was varied (Cy3 antibody) and a new 
vial of the antibody was also tested but it still didn’t work.  
An alternative antibody which binds to another ER resident protein, PDI was tested 
instead. PDI catalyses the oxidation of free sulfhydryl (SH) groups on cysteine amino 
acids to form disulphide bonds, in proteins (Alberts et al, 2002). A mouse polyclonal 
antibody, TXNDC5 (Abcam) was tested but the ER could still not be detected.  
Both of these antibodies were directed towards two different proteins which localise 
within  the  ER,  but  neither  appeared  to  bind  to  their  target  protein.  Studies  have 
shown  that  different  permeabilisation  methods  are  suitable  for  different  proteins 
(Melan & Sluder, 1992). Cells had been previously permeabilised with Triton X-100. 
This permeabilisation technique appeared to work as the cis Golgi and ADAMTS13 
within the cell could be viewed using immunofluorescence, but not the ER. In order 
to investigate whether alternative methods of cell permeabilisation could enable the 
ER to be detected, cells were permeabilised after fixation as follows: 
i.  20 minutes in 0.2% saponin 
ii.  10 minutes in 0.5% saponin 
iii. 4 minutes in 0.1% Triton X-100 and 0.05% SDS 
iv. 10 minutes in 0.2% Triton X-100 115 
 
Cells were permeabilised using one of these methods and were then incubated with 
one of the following antibodies: i. anti-BiP ER; ii. anti-PDI TXNDC5 ER or iii. anti-
GM130 cis Golgi primary antibody. Cells were incubated with the anti-GM130 cis 
Golgi antibody as a control as this antibody had worked in previous experiments. 
Anti-mouse Cy3 conjugated antibody was used as the secondary antibody.  
The results are shown in Figure 4-2. Neither of these permeabilisation techniques 
enabled detection of the ER using immunofluorescence with either the anti-BiP (a) or 
anti-PDI  TXNDC5  antibody  (c).  The  figure  demonstrates  the  inability  of  the 
antibodies to detect the ER as the images appear red where the nuclei of the cells are 
(column  two  versus  column  three).  The  ER  should  be  distinct  from  the  nucleus 
(Figure  4-1).  All  three  permeabilisation  techniques  worked  successfully  in  cells 
incubated with the anti-GM130 cis Golgi antibody. 116 
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Figure 4-2 Permeabilisation of cells with Triton X-100 or saponin 
HEK 293T cells were stained with either one of three primary antibodies: anti-BiP (a), anti-GM130 
(b) or anti-PDI (c). Cells were all fixed with 4% paraformaldehyde and then either permeabilised with 
0.2% saponin (i) 0.5% saponin (ii) 0.1% Triton X-100 containing 0.05% SDS (iii) or 0.2% Triton X-
100. Cells were permeabilised with 0.2% Triton X-100 (condition iv) for incubation with anti-GM130 
antibody.  This  was  successful  but  images  were  not  taken  at  the  time  of  the  experiment  as  this 
permeabilisation  technique  had  been  previously  used  to  immunofluorescently  label  the  cis  Golgi 
successfully numerous times. The second column shows immunofluorescent labelling of the nuclei, 
third  staining  for  the  ER  or  Golgi,  fourth  shows  images  of  the  cells  taken  using  differential 
interference  contrast.  The  first  column  shows  a  merged  image  of  the  three  channels.  Cells  were 
viewed using a fluorescent microscope with a 100x oil immersion objective.  
In another attempt to detect the ER a different secondary antibody was used to detect 
both  primary  antibodies  (a  goat  anti-mouse  FITC  conjugated  antibody,  Life 
Technologies). The ER could still not be detected. Another antibody was used to 
detect  the  ER.  This  antibody  was  an  anti-PDI  antibody  (RL90,  Abcam).  This 
antibody was successfully used to stain the ER. Images are shown in  Figure 4-3. 
Different concentrations of the antibody were used to optimise the quantity to use as 
shown in the Figure.   118 
 
 
 
Figure 4-3 Optimisation of antibody concentrations 
The figure shows immunofluorescent labelling of HEK293T cells with mouse monoclonal RL90 PDI-
ER  marker.  Three  different  concentrations  of  the  antibody  are  shown.  Top  row  shows 
immunofluorescent labelling of the ER with primary antibody RL90 diluted 1/100, second row with 
primary  antibody  RL90  diluted  1/200,  and  bottom  row  immunofluorescent  labelling  with  RL90 
primary antibody diluted 1/400. First column shows immunofluorescent labelling of nuclei, second 
column labelling using the primary antibody RL90 and the last column a merged image of columns 
one  and  two.  For  all  three  samples  the  secondary  antibody  (Cy3)  was  diluted  1/200.  Cells  were 
viewed with a x100 oil immersion objective using a fluorescent microscope.  
The anti-BiP antibody has been previously used to immunofluorescently label the ER 
(Garagiola et al, 2008;Palla et al, 2009), however this was carried out in COS cells 
(not in HEK293T cells) which may explain why it could not be detected in these 
experiments. The TXNDC5 antibody detects a protein belonging to the PDI family 
and is an ER associated protein. After using this antibody and finding it was unable 
to recognise the ER in HEK293T cells, I tried to understand a possible reason for 
this. I found that although this protein belongs to the PDI family it is not necessarily 
expressed by all cells (Sullivan et al, 2003). So perhaps the protein that the antibody 119 
 
binds to is not expressed in HEK 293T cells, possibly explaining why it could not be 
detected.  
After  the  antibody  concentrations  were  optimised  for  detection  of  the  ER,  cells 
expressing  ADAMTS13  were  incubated  with  antibodies  directed  towards 
ADAMTS13 and either the ER or cis Golgi as described (Chapter 2.8.2). Figure 4-4 
shows  cells  expressing  WT  ADAMTS13  viewed  with  a  fluorescent  microscope 
stained for the ER or cis Golgi and ADAMTS13. An image of the cell was also taken 
under  brightfield  light  using  differential  interference  contrast  (no  v).  This  figure 
demonstrates that the ER and ADAMTS13 occupy the majority of the cell.  120 
 
 
Figure 4-4 Localisation of ADAMTS13 in the ER and cis Golgi 
Images were taken with a fluorescent microscope with a 100x oil immersion objective. Stable line cells expressing WT ADAMTS13 were  incubated with an anti-V5 
ADAMTS13 antibody and either an anti-ER (using RL90 anti-PDI antibody) (a) or anti-cis Golgi antibody (b). Immunofluorescent labelling of nuclei (ii). ER/Golgi (iii), 
ADAMTS13 (iv) and a merged image of channels ii, ii and iv are shown in i. Images v shows the cells viewed using brightfield  differential interference contrast,  to 
demonstrate immunofluorescence labelling in relation to the cell volume.  
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4.3  Localisation in the ER    
Confocal microscopy demonstrated that WT ADAMTS13 and both mutants localised 
within the ER. Representative images are shown in Figure 4-5. Three images from 
three  different  experiments  are  shown  for  WT  and  mutant  ADAMTS13.  WT 
ADAMTS13 can be seen to localise within the ER throughout the whole of the cell 
as depicted by the yellow/orange regions (Figure 4-5). The mutants also localised 
extensively within the ER. 122 
 
 
 
 
 
 
 
 
 
 
Figure 4-5 Localisation of WT or mutant (p.I143T, p.Y570C) ADAMTS13 within the ER of the 
cell 
ADAMTS13 is shown in green (ii), ER in red (iii) nucleus in blue (iv) and a merged image of all 
channels is shown on the far left to demonstrate colocalisation (i). The image appears yellow/orange 
where there is colocalisation of ADAMTS13 with the ER. Cells shown in the first panel were viewed 123 
 
with a magnification of x100 with an oil immersion objective; cells in the second and third panel were 
viewed with a magnification of x63 with an oil immersion objective. Each panel shows cells from 
three separate experiments. 
4.4  Localisation in the cis Golgi  
Confocal  microscopy  demonstrated  that  WT  and  mutant  ADAMTS13  localised 
within the cis Golgi of the cell. Representative images are shown in  Figure 4-6. 
Images  from  three  separate  experiments  are  shown  for  both  WT  and  mutant 
ADAMTS13. The mutants appeared to localise less extensively within the cis Golgi 
compared to WT. 124 
 
                 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-6 Localisation of WT or mutant (p.I143T, p.Y570C) ADAMTS13 within the cis Golgi 
of the cell 
ADAMTS13 is shown in green (ii), cis Golgi in red (iii) nucleus in blue (iv) and a merged image of all 
channels is shown on the far left to demonstrate colocalisation (i). The image appears yellow/orange 
where there is colocalisation of ADAMTS13 with the Golgi. Cells in the first panel were viewed with 125 
 
a magnification of x100 with an oil immersion objective, cells in the second and third panel with a 
magnification of x63 with an oil immersion objective. Each panel shows cells from three separate 
experiments. 
4.5  Localisation in the trans Golgi 
As there appeared to be some localisation of the mutants in the cis Golgi of the cell I 
wondered if there was also localisation in the trans Golgi of the cell which is the area 
of  exit  from  the  Golgi (Figure  4-1).  Cells  were  stained  as  described  in  methods 
(Chapter 2.8.2) except that the trans Golgi antibody (anti-p.230, Abcam) was used. 
The results from one experiment are shown in Figure 4-7. The localisation of the 
mutants in the trans Golgi appeared to be similar to the localisation of the mutants 
within the cis Golgi.   126 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-7 Localisation of WT or mutant (p.I143T, p.Y570C) ADAMTS13 within the trans Golgi 
of the cell  
Three different fields of view from one experiment are shown. ADAMTS13 is shown in green (ii), 
trans Golgi in red (iii) nucleus in blue (iv) and a merged image of all channels is shown on the far left 
to demonstrate colocalisation (i). The image appears yellow/orange where there is colocalisation of 127 
 
ADAMTS13 with the trans Golgi. Cells shown were viewed with a magnification of x100 with an oil 
immersion objective. 
4.6  Quantitation of ADAMTS13 colocalisation in the cis Golgi  
There appeared to be some localisation of the mutants in the cis Golgi, demonstrated 
by  the  merged  images  of  these  samples  (Figure  4-6).  The  degree  of  localisation 
appeared to be different between WT and mutant ADAMTS13. However this was 
not  something  that  could  be  easily  attained  from  the  images.  The  degree  of 
colocalisation  was  quantified  using  the  quantitation  tool,  which  is  part  of  the 
Volocity software. This software was associated with the confocal microscope that 
was used to acquire the images.  
The presence of yellow/orange regions within a merged image (which is often used 
to demonstrate colocalisation) is highly dependent upon the relative signal intensities 
produced by the fluorochromes, collected in both channels. A merged image will 
only give a reliable representation of colocalisation when both images exhibit similar 
grey level dynamics (Bolte & Cordelieres, 2006). Image processing can match the 
fluorescent signal intensities of both fluorochromes; however as a result of this the 
image produced does not reflect the true stoichiometry of the molecules imaged. The 
demonstration of colocalisation in the 2D plane (as in Figure 4-5, Figure 4-6 and 
Figure 4-7) also does not reflect the 3D nature of the sample. Additionally estimating 
the  degree  of  colocalisation  using  merged  images  alone  can  introduce  subjective 
bias.  
4.6.1  Images used for analysis 
Saturated voxels (voxels which have the maximum value for a given channel) should 
not be used for quantitation analysis, as these voxels have lost information. Some of 
the voxels in the images  previously taken could not be used for  the quantitation 
analysis  as  they  contained  saturated  voxels.  As  a  result  new  transfections  were 
performed  and  cells  were  subsequently  immunofluorescently  labelled  for 
ADAMTS13 and the cis Golgi. New images (with unsaturated voxels) were taken; 
images from three separate experiments were used for quantitation analysis. 128 
 
Measuring  the  degree  of  colocalisation  within  the  whole  image  captured  from  a 
particular  field  of  view  would  not  have  accurately  measured  the  degree  of 
colocalisation as not all cells expressed ADAMTS13. Those cells which were not 
expressing the vector (ADAMTS13) would have stained red for Golgi but not green 
for  ADAMTS13.  Therefore,  analysis  was  restricted  to  regions  containing 
ADAMTS13 expressing cells. 
4.6.2  Global Pearson Correlation Coefficient  
The four main coefficients that are produced by the Volocity quantitation tool after 
analysis  are  the  thresholded  Pearson  correlation  coefficient  (TPCC)  the  global 
Pearson correlation coefficient (GPCC), the  Manders overlap coefficient 1 (M1) and 
Manders overlap coefficient 2 (M2). 
The use of the PCC to quantify the degree of colocalisation between two signals 
produced by two different fluorochromes was introduced by Manders et al (Manders 
et al, 1992). The formula is shown in Equation 4-1. 
 
 
 
 
 
 
 
Equation 4-1 Pearson correlation coefficient as described by (Manders et al, 1992) 
Image taken from (URL: http://cellularimaging.perkinelmer.com/pdfs/manuals/VolocityuserGuide.pdf 
Volocity user manual, accessed 17
th June 2014). The PCC shown above is the GPCC. 
This PCC is the GPCC as it includes all voxels in the analysis regardless of whether 
these  voxels  correspond  to  background  or  an  object.  This  coefficient  is  highly 
dependent upon noise, variation in fluorescence intensities between both channels or 
heterogeneous  colocalisation  relationships  throughout  the  sample  (Bolte  & 
Cordelieres, 2006). Evaluation of this coefficient alone may therefore be ambiguous.  129 
 
4.6.3  Colocalisation coefficient M1 and M2 
Manders et al introduced two further coefficients  to be used for analysis, the overlap 
coefficients  M1  and  M2  (Manders  et  al,  1993).  The  GPCC  gives  a  value  of  the 
correlation between the intensity distributions  of the  components  but  the overlap 
between the intensities can be represented by M1 and M2. The formulas are shown in 
Equation 4-2 and 3. 
 
Equation 4-2 Manders overlap coefficient M1 (Manders et al, 1993) 
Image taken from (URL: http://cellularimaging.perkinelmer.com/pdfs/manuals/VolocityuserGuide.pdf 
Volocity user manual, accessed 17
th June 2014). Manders’ original equation has been modified here to 
include voxels only with values above the threshold.  
 
Equation 4-3 Manders overlap coefficient M2 (Manders et al, 1993) 
Image taken from (URL: http://cellularimaging.perkinelmer.com/pdfs/manuals/VolocityuserGuide.pdf 
Volocity user manual, accessed 17
th June 2014). Manders’ original equation has been modified here to 
include voxels only with values above the threshold. 
These coefficients provide a measure of the total colocalised intensity of a channel 
divided by the total intensity for that channel. The coefficients M1 and M2 are not 
sensitive to differences in signal intensities between different channels (Manders et 
al, 1993), unlike GPCC.  130 
 
The coefficients shown in Equation 4-2 and Equation 4-3 are modified slightly from 
Manders original paper (Barlow et al, 2010). Manders original equations included all 
voxels with a value >0 in the analysis. The voxels included in this analysis (and in 
the Volocity software) are only those voxels with a value above a chosen threshold. 
This  threshold  is  set  to  distinguish  between  voxels  representing  background  and 
those representing an object of interest. The use of voxels above the threshold to 
calculate  the  coefficients  M1  and  M2  was  shown  to  more  accurately  describe 
synthetic and biological data (Barlow et al, 2010). 
4.6.4  Thresholded Pearson Correlation Coefficient  
Barlow et al proposed that the inclusion of background voxels in the calculation of 
GPCC generates unrealistically low means, resulting in a disproportionately large 
number of voxels above the mean and so positive differences from the mean become 
very large (Barlow et al, 2010). The authors introduced TPCC so that only voxels 
with values above a set threshold were included in the analysis of PCC. GPCC is 
sensitive  to  differences  in  fluorescence  intensity  but  TPCC  is  not.  The  authors 
proposed  that  M1  and  M2  show  the  extent  of  correlation  but  TPCC  gives  a 
measurement of the quality of the relationship.  
4.6.5  Results of analysis  
An example scatter plot produced by the software is shown Figure 4-8. Voxels above 
the threshold in at least one of the channels are plotted on the graph according to the 
quantity of green ADAMTS13 (x axis) and red Golgi (y axis). Colocalised voxels lie 
diagonally within the scatter plot.  131 
 
 
Figure 4-8 Scatter plot produced by Volocity colocalisation analysis 
An example scatter plot from a WT cell is shown. Voxel values for the green fluorescent protein is 
plotted along the x axis and voxel values for the red labelled cis Golgi is shown along the y axis. 
Voxels in which there is overlap between the two fluorochromes are circled in yellow. To the right of 
this an extended view of the cell used for analysis is shown along with the calculated values for 
TPCC, GPCC, M1 and M2 for that cell. 
The data obtained from all the cells analysed are summarised in Figure 4-9. The 
median values and the 95% CI for these coefficients are shown for both WT and 
mutant ADAMTS13. The GPCC, TPCC, M1 and M2 values obtained after analysis 
varied quite a bit for both WT and mutant proteins, as shown by the 95% CI obtained 
(Figure 4-9). Values for the TPCC and M1 coefficient were lower for both mutants 
compared to WT. The GPCC and M2 were similar for WT and the p.I143T mutant 
but slightly higher/lower for the p.Y570C mutant.  
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Figure 4-9 Results obtained after quantitative analysis 
The  plot  shows  median  values  for  the  GPCC,  TPCC,  M1  and  M2  coefficients,  along  with  the 
approximate 95% CI for these coefficients based on the ranked data. The number of cells analysed 
were: WT (n=35), p.I143T (n=29) and p.Y570C (n=52).  
4.7  Discussion 
4.7.1  Summary 
ADAMTS13 like other secretory proteins is transported to the ER and Golgi before 
secretion and has been previously shown to localise within these regions in cells 
expressing WT ADAMTS13 (Palla et al, 2009;Garagiola et al, 2008). As the mutant 
proteins were synthesised in the cells but not secreted, their localisation within the 
ER and Golgi was investigated in order to determine if these mutants failed to reach 
either of these regions, preventing their secretion. 
Using confocal microscopy, WT and mutant ADAMTS13 were found to localise 
within  the  ER.    WT  and  mutant  ADAMTS13  also  localised  within  the  Golgi. 
However  within  the  cis  Golgi  mutant  ADAMTS13  appeared  to  localise  less 
extensively  than  WT.  This  difference  in  colocalisation  between  WT  and  mutant 133 
 
ADAMTS13 and the cis Golgi was not noticeably apparent from looking at the 2D 
merged  images.  Therefore,  the  degree  of  colocalisation  between  WT  and  mutant 
ADAMTS13 and the cis Golgi was quantified, to confirm that there was a difference.  
Colocalisation quantitative analysis showed that less of the total number of red Golgi 
voxels in the mutants overlapped with the green ADAMTS13 voxels when compared 
to WT (lower M1 values for the mutant). This was more apparent with the p.Y570C 
mutant.  
With the p.Y570C mutant less of the total green ADAMTS13 voxels overlapped with 
the red Golgi voxels compared to WT (lower M2 values). The degree of overlap 
between WT and the p.I143T mutant on the other hand were similar (similar M2 
values).  
The values obtained for M2 for both WT and mutant ADAMTS13 were lower than 
those obtained for M1 because the volume of the Golgi is smaller compared to the 
volume of the cell that ADAMTS13 occupies. Hence a small proportion of the total 
ADAMTS13 present in the cell will be present in the Golgi (giving a small M2 value) 
but a large volume of the Golgi is occupied with ADAMTS13 (high M1 value).  
The biological implications of the PCC are more difficult to interpret (Manders et al, 
1993;Bolte & Cordelieres, 2006), but there appeared to be differences between the 
values for WT and mutant ADAMTS13.  
It  has  been  suggested  that  the  GPCC  may  be  affected  by  a  number  of  factors 
including  differences  in  fluorochrome  intensity  and  noise  (Bolte  &  Cordelieres, 
2006). The proportion of the cell occupied by ADAMTS13 is much greater than the 
proportion  occupied  by  the  Golgi  which  may  affect  the  GPCC  as  it  has  been 
proposed that differences in the proportion of biological molecules may affect this 
value  (Costes  et  al, 2004). The TPCC seems  to  be a more  reliable value to  use 
(Barlow et al, 2010) as it excludes background voxels.  
The results for TPCC and GPCC appear to show differing things, in the mutants 
GPCC is increased whereas with the TPCC this value is decreased. This difference is 134 
 
due  to  the  inclusion  of  background  pixels  in  the  analysis  of  GPCC.  The  values 
obtained for the TPCC appear to be more sensible than the GPCC. The high values 
obtained (for both WT and mutant ADAMTS13) for the GPCC suggests that there is 
a strong correlation between ADAMTS13 and the cis Golgi within the cell. However 
this is not the case as a large amount of the ADAMTS13 is not present in the cis 
Golgi but is present in other regions of the cell such as the ER (Figure 4-5). The 
lower TPCC values obtained for the mutant compared to WT suggest that although 
the relationship between ADAMTS13 and the Golgi is weak (low value for WT), it is 
even weaker for the mutants.   
Together  these  results  suggest  that  less  ADAMTS13  occupies  the  Golgi  in  cells 
expressing  mutant  ADAMTS13  compared  to  those  expressing  WT  ADAMTS13. 
This suggests less of the mutant protein is transported to the Golgi compared to WT 
ADAMTS13.  
4.7.2  Immunofluorescent staining and imaging 
The use of a motorised stage to image multiple random positions would have helped 
to avoid bias when selecting cells to image. However this process is likely to have 
taken more time as a motorised stage may select regions which do not contain cells 
or regions where there are cells not expressing ADAMTS13. The amount of time that 
the  cells  were  exposed  to  light  was  minimised  as  much  as  possible  to  prevent 
photobleaching. 
There  are  a  range  of  different  methods  that  can  be  used  for  fixation  and 
permeabilisation.  Inappropriate  fixation  can  cause  antigen  redistribution  and/or 
reduction  in  antigenicity.  Aldehyde  induced  fixation  can  cause  changes  in  the 
confirmation  of  proteins  and  organelles  (Neuhaus  et  al,  1998).  Glutaraldehyde 
fixation  often  reduces  antigenicity  and  increases  background  autofluorescence 
(North,  2006)  so  it  is  advantageous  to  fix  with  paraformaldehyde  rather  than 
glutaraldehyde. Fixing with 4% rather than 2% paraformaldehyde in HEK293T and 
MDCK cells was shown to lead to better protein preservation compared to lower 
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Methanol,  ethanol  and  acetone  are  common  organic  solvents  used  in 
immunofluorescent microscopy. They simultaneously fix and permeabilise cells by 
precipitating  proteins  and  extracting  lipids.  Fixation  with  methanol  is  commonly 
used for the study of cytoskeletal components, however it can lead cell shrinkage and 
is not suitable for analysis of soluble proteins (Stadler et al, 2010). 
Saponin  appeared  to  be  able  to  permeabilise  membranes  in  HEK293T  cells 
successfully (Figure 4-2) to detect the cis Golgi but this was not tested with the RL90 
ER antibody. Saponin could have been alternatively used as a detergent. Saponin 
treatment has been shown to produce smaller holes in membranes when compared to 
Triton -100 exposure (North, 2006).  
One  of  the  weaknesses  of  using  transiently  transfected  cells  is  that  the  level  of 
expression  in  each  transfected  cell  may  differ  between  cells.  Both  low  and  high 
expressing cells were included in the analysis. Low expressing cells can have higher 
colocalisation (Parmryd et al, 2003) possibly because the higher concentrations of 
fluorescent  protein  saturate  high  affinity  sites  and  also  occupy  sites  with  lower 
affinities, whereas lower concentrations are confined to the high affinity sites (Adler 
et al, 2008). Mixed intensity distributions can affect the analysis of the thresholded 
PCC (Barlow et al, 2010). This may explain the variable degree of colocalisation 
measured between cells in each group (Figure 4-9).  
Splitting cells into high and low expressing cells and then analysing them separately 
may have overcome this problem. Alternatively cells stably expressing the protein 
could have been used; however stable line cells expressing both of the mutants were 
not available at the time of analysis.  
It has been suggested that live cell imaging should be used in conjunction with the 
analysis of fixed cells to analyse protein localisation (Schnell et al, 2012). With live 
cell imaging cells are viewed in the ‘in vivo’ state and not subject to artefacts which 
may be introduced in the process of fixation and permeabilisation. However there are 
also  disadvantages  of  live  cell  imaging.  In  live  cell  imaging,  adding  a  green 
fluorescent tag to proteins could potentially modify protein function. Phototoxicity 
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keeping  the  cells  alive  and  behaving  in  a  physiological  manner.  Approaches  to 
minimise  photobleaching  in  live  cell  imaging  can  lead  to  poorer  resolution  and 
reduced signal-to-noise ratios. An issue during time course experiments is focal drift 
caused by thermal fluctuations in the room. Another challenge is acquiring images 
fast  enough  to  capture  rapid  biological  events  and  accurately  portray  dynamic 
structures (North, 2006).  
The cis Golgi was immunofluorescently labelled as this is the site of entry into the 
Golgi. However it may have been more appropriate to image the whole of the Golgi 
instead of just the cis Golgi. However the results are still valid and show the degree 
of localisation in the cis Golgi.   
4.7.3  Quantitative analysis 
Although quantitative colocalisation analysis tries to overcome some of the problems 
associated with interpreting merged images, it also has problems associated with it 
(Bolte & Cordelieres, 2006). Colocalisation can only go as far as indicating that the 
two proteins are located within close proximity to each other (the same voxel). Due 
to the limits of resolution, uncertainty about the physical dimensions and location of 
small objects within the 3D space arise. Fluorochrome distribution may be in the 
nanometre  range  whereas  the  optical  microscope’s  resolution  is  closer  to  the 
micrometre (Bolte & Cordelieres, 2006). A problem that is inherent to all known 
methods of quantitative colocalisation analysis is that voxels are classified as either 
colocalised or not colocalised, when in fact voxels are the sum of both colocalised 
and non-colocalised signals (Costes et al, 2004).  
The presence of noise within  the images  can affect  colocalisation measurements. 
This noise may arise during the immunofluorescence labelling procedure and also as 
a result of image capture. It was found that even in good quality images there was an 
average  discrepancy  of  about  20%  between  the  measured  and  corrected 
colocalisation, due to the presence of noise (Adler et al, 2008). 
Thresholds for colocalisation analysis were set manually by selecting and cropping 
cells. This may have introduced bias. However a relatively large number of cells 
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threshold could have been set using automatic thresholding as described by Costes et 
al (Costes et al, 2004).  
When selecting cells for quantitation the region of interest was selected based upon 
the ADAMTS13 that was visible. It is possible therefore that the whole cell was not 
selected  but  just  the  regions  in  which  ADAMTS13  was  visibly  expressed.  This 
region however still encompassed the cis Golgi, which is smaller than the total cell 
volume and the purpose of carrying out the colocalisation, was to measure how much 
of the ADAMTS13 was within the Golgi. In addition when cells were viewed with 
the fluorescent microscope in earlier experiments, ADAMTS13 appeared to occupy 
the majority of the volume of the cell (Figure 4-4).   
Alternative methods could have been used to prevent bias in cell selection. A line 
scan could have been performed in order to identify objects. The limit of an object 
may be seen as a sudden variation of the voxel intensities. However this method has 
limitations as structures with a non-uniform fluorescence intensity distribution may 
lead  to  an  artifactual  detection  of  concentric  edges  (Bolte  &  Cordelieres,  2006). 
Alternatively connexity analysis could have been used (Bolte & Cordelieres, 2006). 
This process involves the inspection of the neighbouring voxels of the current voxel 
(reference  pixel).  All  adjacent  voxels  with  intensities  above  the  limit  would  be 
considered to be part of the same structure as the reference voxel. Each voxel would 
then be tagged with a number, with all voxels of the same structure carrying the same 
tag. A voxel lacking at least one of its neighbours is considered to be at the edge of 
the structure.  
One of the limitations of  using  PCC  for  analysis  is  that it  requires that  the two 
populations have a Gaussian distribution which is not required for the Spearman’s 
Rank correlation coefficient (SRC). In addition the PCC is very sensitive to outlying 
values, whereas those near the mean carry relatively little weight. The SRC is less 
sensitive to outlying data points and more sensitive to data points closer to the mean 
(Adler et al, 2008). The process of fluorescent image formation and acquisition may 
include  nonlinear  components  and  fluorescent  images  can  have  outlying  values. 
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reported by the PCC and SRC were broadly similar but some appreciable differences 
were found (Adler et al, 2008).  
4.7.4  Conclusion 
The  immunofluorescence  and  colocalisation  analysis  results  suggested  that  the 
p.I143T and p.Y570C mutants localise within the ER and to some extent within the 
Golgi  of  the  cell.  However  despite  this  these  mutants  are  secreted  at  a  severely 
reduced  level  (Chapter  3).  I  went  on  to  investigate  whether  these  mutants  were 
degraded within the cell by either the cell proteasome or lysosomes before they could 
be secreted (Chapter 5).  139 
 
 
Chapter 5   Proteasome and lysosome inhibition      
(type 1a mutants) 
5.1  Introduction 
The p.I143T and p.Y570C mutants were synthesised within the cell, localised within 
the ER and to some extent the Golgi (Chapter 4), but were secreted at a severely 
reduced  level  (Chapter  3).  I  therefore  investigated  whether  these  proteins  were 
degraded within the cell either by the cell proteasome or lysosomes. 
5.1.1  ER quality control mechanisms 
The  ER  provides  an  environment  that  is  optimised  for  protein  folding  and 
maturation.  Within  the  ER  several  co-translational  and  post-translational 
modifications take place (disulphide bond formation, signal-peptide cleavage and N-
linked glycosylation) which are important for correct protein folding (Ellgaard & 
Helenius, 2003).  
The  quality  control  (QC)  system  operating  within  the  ER  recognises  and  retains 
unfolded proteins. Consequently folded proteins are not retained by this system and 
can exit. This recognition relies upon features such as the exposure of hydrophobic 
regions within the unfolded/misfolded protein, unpaired cysteine residues and the 
tendency to aggregate. By preventing the premature exit of misfolded proteins, these 
proteins spend more time within the ER which improves their chances of correct 
protein  maturation.  In  addition,  incompletely  folded  proteins  are  prevented  from 
being transferred further within the cell where they could potentially cause damage 
(Ellgaard & Helenius, 2003).  
Cells  use  molecular  chaperones  and  enzymes  to  distinguish  between  folded  and 
unfolded  proteins.  Molecular  chaperones  assist  in  the  folding  and  dispatching  of 
improperly folded proteins for destruction. Enzymes selectively and covalently ‘tag’ 
misfolded proteins for recognition by the folding and degradation machinery of the 140 
 
cell. These ‘tags’ include  ubiquitin which acts as a signal for degradation (Hershko 
&  Ciechanover,  1998)  and  glucose  which  is  added  to  the  N-linked  glycans  of 
glycoproteins, acting as a signal for retention within the ER (Hammond et al, 1994). 
Chaperoning  proteins  and  enzymes  include  heat  shock  proteins,  such  as  BiP; 
peptidyl-propyl isomerases which catalyse cis/trans isomerisation of peptidyl-propyl 
bonds; calnexin and calreticulin which interact with and assist the folding of proteins 
carrying monoglucosylated N-linked glycans and thiol-disulphide oxidoreductases, 
such as PDI, which catalyse the oxidation, isomerisation and reduction of disulphide 
bonds (Ellgaard & Helenius, 2003). 
Abnormal  proteins  can  arise  from  genetic  mutations,  errors  in  transcription, 
translation and folding or can be induced under stress, including oxidative stress and 
starvation. Protein misfolding can lead to either reduced or absent functional protein 
at a required location, due to its degradation or accumulation within the cell in the 
form of toxic aggregates.  
 An overload of misfolded or unfolded proteins in the ER can lead to ER stress. This 
stress,  activates  the  unfolded  protein  response  (UPR)  which  attenuates  protein 
synthesis  to  prevent  further  accumulation  of  unfolded  proteins,  induces  the 
transcription  and  synthesis  of  ER  chaperones  to  enhance  folding  capacity  and 
increases  the  expression  of  ER  associated  degradation  (ERAD)  components  to 
enhance  ERAD  ability  (Wang  et  al,  2008).  Prolonged  ER  stress  can  eventually 
trigger apoptosis to safely dispose of cells injured by ER stress (Puthalakath et al, 
2007). For most polypeptides the interaction with molecular chaperones is transient, 
once  correctly  folded  these  polypeptides  no  longer  represent  a  substrate  for 
chaperone interaction.  
5.1.2  Golgi quality control mechanisms 
Protein QC within the ER is relatively well characterised. In recent years however it 
has become apparent that the Golgi complex can also participate in protein QC. The 
QC  protein  ERp44  shuttles  between  the  cis  Golgi  (where  it  engages  incorrectly 
folded proteins) and the ER (where it releases these proteins) in a pH regulated cycle 
(Vavassori  et  al,  2013).  Human  ER  α1,2-mannosidase  a  type  II  transmembrane 141 
 
protein,  capable  of  initiating  the  ERAD  of  numerous  misfolded  N-glycosylated 
proteins has been shown to in fact localise within the Golgi (Pan et al, 2011), where 
it is proposed to interact with γCOP, facilitating the retrieval of captured ERAD 
substrates back to the ER (Pan et al, 2013). In addition Golgi alpha1, 2 mannosidase 
IA, IB and IC play a role in glycoprotein QC (Hosokawa et al, 2007). A number of 
QC proteins therefore also reside in the Golgi where they help to shuttle proteins 
from the Golgi back to the ER.  
5.1.3  Ubiquitin-proteasome system 
If  a  misfolded  or  damaged  protein  fails  to  be  repaired  by  chaperone  mediated 
processes,  it  will  be  degraded.  Disposal  of  proteins  often  occurs  by  ERAD: 
misfolded proteins are retro-translocated from the ER to the cytosol where they are 
degraded by proteasomes (Tsai et al, 2002) (Figure 5-1).  
 142 
 
 
Figure 5-1 Proteins may be degraded by the cell proteasome or lysosomes 
Image adapted from (Su & Wang, 2010). UPS: ubiquitin-proteasome system. 
The ubiquitin-proteasome system (UPS) not only degrades both misfolded/damaged 
proteins but also degrades native proteins that are no longer required within the cell. 
This process begins with the ubiquitination of the protein to be degraded, which 
involves the ATP-dependent covalent attachment of a ubiquitin protein molecule to a 
lysine residue in a target protein molecule via a cascade of biochemical reactions 
(Hershko  &  Ciechanover,  1998).  In  general  the  degradation  of  polyubiquitinated 
proteins is carried out by the 26S proteasome which consists of a barrel-shaped core 
particle (the 20S proteasome) and the activation complex (often the 19S proteasome) 
at one or both ends of the core particle (Stock et al, 1996) (Figure 5-2). 143 
 
 
Figure 5-2 Cell proteasome 
Image from: (Marteijn et al, 2006). The 26S proteasome consists of a 20S core unit and 19S unit. The 
19S unit unfolds and removes ubiquitin from substrates. The 20S unit is the catalytic unit.  
The proteasome mainly degrades ubiquitinated proteins but can also degrade non-
ubiquitinated  proteins  such  as  ornithine  decarboxylase  (Ding  &  Yin,  2008). 
Misfolded  aggregated  proteins  can  impair  the  proteolytic  function  of  the  UPS 
(Bennett et al, 2005) and may instead be degraded by lysosomes. 
5.1.4  Auto-phagolysosomal system 
The autophagy-lysosomal pathway participates in protein QC by helping to remove 
protein aggregates. Protein aggregates or defective organelles are first segregated by 
an isolated double membrane (phagophore) to form an autophagosome which later 
fuses with lysosomes to form an autophagolysosome where the segregated content is 
degraded  by  lysosomal  hydrolases  (Levine  &  Kroemer,  2008).  This  type  of 
autophagy is known as macroautophagy. 
Macroautophagy can degrade all forms of misfolded proteins whereas proteasome 
degradation  is  likely  limited  to  soluble  proteins  (Ding  &  Yin,  2008). 
Macroautophagy  may  be  activated  by  UPS  malfunction  and/or  aberrant  protein 
aggregation  to  help  remove  aggregates  (Rubinsztein,  2006).  For  example  a  toxic 
gain-of-function  point  mutation  in  alpha1-antitrypsin  Z  impairs  correct  protein 
folding,  rendering  the  protein  prone  to  form  aggregated  polymers  within  the 
hepatocyte ER. WT protein is primarily degraded by the proteasome, but the mutant 144 
 
is  thought  to  be  degraded  primarily  by  macroautophagy  (Yorimitsu  &  Klionsky, 
2007).  
5.2  Cycloheximide chase and proteasome inhibition in WT stable 
line cells  
Many  misfolded  proteins  are  unstable  within  the  cell  and  are  rapidly  degraded 
(Waters, 2001). One method by which protein stability can be assessed is by using 
cycloheximide and performing a cycloheximide chase experiment. Cycloheximide is 
produced  by  S.  griseus  and  inhibits  protein  translation  by  inhibiting  peptidyl 
transferase activity of the 60S ribosomal subunit (Schneider-Poetsch et al, 2010). By 
using cycloheximide to inhibit protein synthesis, the fate of the protein synthesised 
before inhibition can be analysed.  
In order to investigate whether the mutants were rapidly degraded within the cell 
cycloheximide  chase  experiments  were  performed.  In  preliminary  experiments 
cycloheximide  (Sigma,  dissolved  in  DMSO  according  to  the  manufacturer’s 
instructions) was first added to confluent stable line cells seeded in six well plates, 
expressing WT ADAMTS13 at various concentrations (ranging from 0 to 100µg/ml). 
The concentrations chosen were based upon those previously shown to be optimal 
for inhibition of protein synthesis (Gorner et al, 2004;Canaff et al, 2012;Park et al, 
2012). After 24 hours cell lysates were harvested. This preliminary experiment was 
carried  out  to  confirm  that  cycloheximide  did  inhibit  protein  synthesis  at  the 
concentrations  chosen  and  also  that  cycloheximide  was  not  toxic  at  these 
concentrations. The cells that were incubated with 100µg/ml cycloheximide appeared 
a  lot  smaller  and  ‘less  healthy’  compared  to  at  the  other  concentrations. 
Consequently this concentration was omitted in subsequent experiments. 
Cell lysate samples are shown in Figure 5-3. The quantity of ADAMTS13 within the 
cell  decreased  in  the  presence  of  cycloheximide  in  a  dose  dependent  manner, 
suggesting that cycloheximide was indeed preventing protein synthesis within the 
cell at the concentrations chosen.  145 
 
 
Figure 5-3  Cycloheximide reduces protein synthesis in cells stably expressing WT ADAMTS13 
Cell  lysates  are  shown  of  cells  stably  expressing  WT  ADAMTS13  incubated  with  different 
concentrations of cycloheximide for 24 hours: 100µg/ml, 50µg/ml, 20µg/ml, 5µg/ml, and 1µg/ml and 
as  a  control  no  cycloheximide.  Expected  size  of  ADAMTS13  is  ~190kDa.  Results  are  from  one 
experiment. 
In order to investigate whether the mutants were degraded by the cell proteasome, 
the  proteasome  was  inhibited  using  MG132,  a  peptide  aldehyde  that  blocks  the 
proteolytic activity of the 26S proteasome complex (Lee & Goldberg, 1998). This 
inhibitor  was  initially  added  to  cells  stably  expressing  WT  ADAMTS13  to 
understand the effect of this inhibitor on the intracellular levels of WT ADAMTS13 
and also how toxic this inhibitor was to the cells. WT ADAMTS13 stable line cells 
seeded  in  six  well  plates  were  incubated  with  various  concentrations  of  MG132 
varying  from  0  to  100µM.  The  concentrations  chosen  were  based  upon  those 
previously  shown  to  be  optimal  for  inhibition  of  the  proteasome  (Gorner  et  al, 
2004;Canaff et al, 2012;Park et al, 2012;Jensen et al, 1995). Cell lysate samples 
were  harvested  24  hours  after  incubation  with  MG132.  Examination  by  light 
microscopy did not reveal any indication of extreme toxicity at these concentrations 
(i.e.  there  was  no  excessive  cell  death).  However  the  cells  were  a  lot  smaller 
compared to negative control cells which had not been incubated with MG132. Cell 
lysate samples are shown in Figure 5-4, lanes 1-6. Although the lanes are heavily 
loaded, MG132 did not appear to cause a large increase or decrease in ADAMTS13 
levels within the cell.  
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Figure 5-4  Proteasome inhibition in cells stably expressing WT ADAMTS13 
Cell  lysates  of  cells  stably  expressing  WT  ADAMTS13  after  24  hours  incubation  with  various 
concentrations of MG132: 100µM, 50µM, 25µM, 10µM, 5µM, 1µM or no MG132 and incubated 
with or without 20µg/ml cycloheximide. Expected size of ADAMTS13 is ~190kDa. Results are from 
one experiment. 
Stable line cells expressing WT ADAMTS13 seeded in six well plates were also 
incubated with these various concentrations of MG132 in the presence of 20µg/ml 
cycloheximide to understand if extreme toxicity occurred to the cells in the presence 
of both of these drugs. Cell lysate samples were harvested after 24 hours and no 
excessive cell death was observed. Cell lysate samples are shown in Figure 5-4, lanes 
7-12. 
The quantity of ADAMTS13 within the cell at the various different concentrations of 
MG132 was similar (Figure 5-4). Levels of ADAMTS13 in lanes 7-12 were lower 
compared to lanes 1-6 due to the additional presence of cycloheximide in the media 
of  cells  shown  in  lanes  7-12.  Protein  synthesis  was  reduced  in  these  samples  in 
agreement  with  the  results  from  Figure  5-3.  Together  these  results  suggest  that 
proteasome inhibition does not have a large effect on the intracellular levels of WT 
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5.3  Cycloheximide chase in transiently transfected cells 
The experiments described indicated the drug concentrations which may be suitable 
to use for subsequent experiments. Next it was investigated whether these inhibitors 
would have the same effect on transiently transfected cells. Stable lines expressing 
either of the mutants were not  available  at  the time of these experiments so  the 
cycloheximide  chase  experiments  and  proteasome  inhibition  experiments  were 
performed in cells transiently expressing ADAMTS13. 
HEK293T cells seeded in T75 flasks were transfected with WT ADAMTS13 and after 
24 hours 50µg/ml cycloheximide was added. Cells were collected before and 24 and 
48 hours after cycloheximide addition (Figure 5-5). As with cells stably expressing 
ADAMTS13  (Figure  5-3)  cycloheximide  inhibited  protein  synthesis  in  cells 
transiently expressing ADAMTS13.  
 
Figure 5-5 Protein synthesis inhibition in transiently transfected cells 
Cells were incubated with 50µg/ml of cycloheximide for 24 (t=24) and 48 (t=48) hours. Cells were 
also collected before the addition of cycloheximide (t=0) as a control. Cell lysate samples are shown. 
Expected size of ADAMTS13 is ~190kDa. Results are from one experiment.  
Subsequently  the  cycloheximide  chase  experiments  were  carried  out  in  cells 
transiently expressing WT or mutant ADAMTS13. HEK 293T cells seeded in six 148 
 
well  plates  were  transiently  transfected  with  vectors  expressing  WT  or  mutant 
ADAMTS13  (p.I143T  and  p.Y570C).  To  the  cells  50μg/ml  cycloheximide  was 
added. Cell lysate and supernatant samples were collected before and 2, 4, 8, 10 and 
24 hours after drug addition (Figure 5-6). These experiments were repeated using 
longer time intervals of 24 and 48 hours (Figure 5-7). 
 
Figure 5-6 Cycloheximide reduces protein synthesis in transiently transfected cells expressing 
WT or mutant ADAMTS13 over a 24 hour period 
Cells were incubated with 50µg/ml cycloheximide for 2 (t=2), 4 (t=4), 8 (t=8), 10 (t=10) or 24 (t=24) 
hours. Cell lysate samples are shown. Expected size of ADAMTS13 is ~190kDa. Results are from one 
experiment.  
 
Figure 5-7 Cycloheximide reduces protein synthesis in transiently transfected cells expressing 
WT or mutant ADAMTS13 over a 48 hour period 
Cells  were  incubated  with  50µg/ml  cycloheximide  for  24  (t=24)  or  48  (t=48)  hours.  Cell  lysate 
samples are shown. At each time point cells which had not been incubated with cycloheximide were 
also  harvested  as  a  control.  Expected  size  of  ADAMTS13  is  ~190kDa.  Results  are  from  one 
experiment. 
For both WT and mutant proteins, the levels of ADAMTS13 decreased within the 
cell over time (Figure  5-6  and Figure  5-7). However it was  unclear  whether the 
a.                                                                 b.                                                                
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mutants decreased faster than WT. In Figure 5-7 levels of the p.Y570C mutant at 24 
hours  are  lower  than  WT  so  the  mutant  appears  to  decrease  quicker  than  WT. 
However in Figure 5-6 at the same time point WT levels are lower than the p.Y570C 
mutant  and  so  WT  appears  to  decrease  quicker  at  24  hours.  Similarly  with  the 
p.I143T mutant at 24 hours (Figure 5-6) more of the mutant appears to be present 
compared  to  WT,  whereas  in  Figure  5-7  levels  are  similar.  Despite  these 
discrepancies it is clear that the mutants are not degraded rapidly within the cell.  
ADAMTS13  antigen  was  measured  in  the  supernatant  of  the  mutants  and  was 
undetectable at all times. Levels of WT ADAMTS13 in the supernatant increased 
with each time point measured (from 0 to 48 hours). 
5.4  Proteasome and lysosome inhibition in transiently transfected 
cells 
5.4.1  Protein aggregation 
As described earlier, misfolded proteins can be degraded by the cellular QC system 
or can aggregate within the cell. One concern was that the mutants studied were 
aggregating within the cell and that the method of cell lysis that was used to harvest 
the cells may not be able to solubilise aggregated protein. This would be important if 
the mutations caused increased protein aggregation.  
A protocol for the crude subcellular lysis of cells was followed (Holden & Horton, 
2009), which enabled the extraction of cytosolic proteins (buffer 1), membranous 
organelles such as ER, Golgi and mitochondria (buffer 2), nuclear membrane and 
nuclear proteins (buffer 3) and insoluble proteins (buffer 4). Cells were also lysed 
with Renilla luciferase lysis buffer, which had been used in previous experiments and 
some cells were also lysed with two alternative cell lysis buffers: NP40 (nonidet P-
40) and RIPA (radioimmunoprecipitation assay) buffer.   
This  protocol  was  tested  on  cells  transiently  transfected  with  WT  or  one  of  the 
mutants (p.I143T). Cells seeded in six well plates were transiently transfected with 
WT or with the p.I143T mutant. Two days after transfection cell lysate samples were 
harvested using different lysis buffers. Cells were lysed with a.) Renilla luciferase 150 
 
lysis buffer (prepared as described in methods); b.) NP40 lysis buffer (150mM NaCl, 
1%  NP40,  50mM  Tris  pH  8);  c.)  RIPA  buffer  (150mM  NaCl,  1%  NP40,  0.5% 
sodium  deoxycholate,  0.1%  SDS,  50mM  Tris  pH  8);  d.)  crude  subcellular  lysis 
protocol buffer. For the crude subcellular lysis protocol  four (i-iv) samples  were 
collected which originated from one well of cells (d).  
Buffers 1-4 which were used to collect samples di-div. were prepared as described 
(Holden & Horton, 2009). Buffer 1 (Digitonin buffer): 150mM NaCl, 50mM HEPES 
pH 7.4, 25μg/ml digitonin. Buffer 2 (NP40 buffer): 150mM NaCl, 50mM HEPES, 
pH 7.4, 1% NP40. Buffer 3 (RIPA buffer): 150mM NaCl, 50mM HEPES, pH 7.4, 
0.5% sodium deoxycholate, 0.1% SDS, 1U/ml Benzonase. Benzonase was added just 
before use. Buffer 4 (E-RIPA extraction buffer): 150mM NaCl, 50mM HEPES pH 
7.4, 0.5% sodium deoxycholate, 1% SDS, 100mM Dithiothreitol. PMSF was added 
to buffer 1 and to Renilla luciferase, NP40 and RIPA buffer.  
For  crude  subcellular  lysis  the  protocol  was  followed  as  described  (Holden  & 
Horton, 2009). In brief, media was removed from the cells followed by incubation 
with trypsin to remove the cells from the surface of the six well plate. Cells were 
resuspended in 1ml of media and then spun at 100g at 4⁰C for 5 minutes to pellet the 
cells. The supernatant was removed and cells were resuspended in 1ml of ice cold 
PBS to wash the cells, followed by spinning at 100g at 4⁰C to pellet the cells. PBS 
was removed and cells were resuspended in 400μl of buffer 1, followed by agitation 
at 45rpm at 4⁰C for 10 minutes. Cells were then spun at 2000g for 5 minutes at 4⁰C. 
The supernatant from this was harvested and kept (fraction i). 
Cells were washed in PBS and then resuspended by vortexing with 400μl of ice cold 
buffer 2. This was incubated on ice for 30 minutes followed by centrifugation at 
7000g  to  pellet  nuclei  and  cell  debris.  The  supernatant  was  collected  and  kept 
(fraction ii).  
Cells were washed in PBS and then resuspended by vortexing with 400μl of ice cold 
buffer 3. This was incubated for 1 hour at 4⁰C with shaking at 45rpm. This was then 
centrifuged  at  7000g  for  10  minutes.  The  supernatant  was  collected  and  kept 
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Cells were again washed in PBS and then resuspended using vortexing and boiling 
with  400μl  of  buffer  4.  This  was  spun  at  16,000g.  The  supernatant  remaining 
corresponded to fraction iv.   
For NP40 and RIPA lysis, cells were washed two times in cold PBS followed by 
addition of 250μl buffer to the cells in each well. Cells were incubated with buffer on 
ice for 10 minutes followed by removal of the cells from the surface of the plate. The 
cells were spun at 16,000g for 15 minutes at 4⁰C and the supernatant from this was 
kept. 
   
Figure 5-8 Crude subcellular lysis of cells 
Cells  were transiently transfected  with WT or  p.I143T mutant ADAMTS13. Cells  were collected 
using  different  lysis  methods:  Renilla  luciferase  NP40,  RIPA  and  crude  subcellular  fractionation 
(buffers i-iv). Expected size of ADAMTS13 is ~190kDa. Results are from one experiment. 
Results from the various lysis methods are shown in Figure 5-8. The results after 
lysis with Renilla luciferase lysis buffer and NP40 appear to be similar. Levels of 
ADAMTS13 within the cell appear to be lower using the RIPA lysis method. This 
may be because the samples obtained after RIPA extraction were very viscous and 
difficult to load onto the gel. The levels of protein in fractions i-iv are lower than 
levels  obtained  with  the  Renilla  luciferase  and  NP40  lysis  buffer.  The  Renilla 
luciferase and NP40 lysis samples contain ‘all proteins’ whereas the proteins have 
been fractionated for samples i-iv. 
Most  of  the  protein  appears  to  be  within  fractions  ii  and  iii,  these  fractions 
correspond to membranous organelles such as the ER and Golgi (ii) and nuclear 
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membrane proteins (iii). The nuclear membrane is continuous with the ER membrane 
so it is expected that most of the proteins would localise into these fractions.  
Buffer iv corresponds to insoluble protein (i.e. aggregated protein). A very small 
amount was present in WT and the p.I143T mutant ADAMTS13. Additionally the 
quantity of insoluble protein in WT and mutant appeared to be similar. These results 
suggest  that  this  mutant  protein  is  not  prone  to  aggregation  any  more  than  WT 
ADAMTS13 and that the method of cell lysis used in previous experiments was 
sufficient.  
5.4.2  Proteasome inhibition 
With WT ADAMTS13, the decrease in the quantity of ADAMTS13 within the cell 
over time in the presence of cycloheximide is likely to be due to secretion. This is 
supported by the finding that increasing levels of ADAMTS13 could be detected in 
the supernatant of cells expressing WT ADAMTS13 when measured at increasing 
time points. Levels of the mutant within the cell also decreased over time. However 
the  secretion  of  the  mutants  was  severely  reduced  (Chapter  3)  and  in  the 
cycloheximide  chase  experiments  the  mutants  could  not  be  detected  in  the 
supernatant. One hypothesis was that the decrease in the levels of the mutants within 
the  cell  over  time  was  due  to  degradation  of  the  mutants  by  the  proteasome. 
Cycloheximide  chase  experiments  in  the  presence  of  the  proteasome  inhibitor 
MG132  were  performed  to  investigate  this,  to  see  if  the  levels  within  the  cell 
increased after the addition of this inhibitor.  
Cells seeded in six well plates were transiently transfected with vectors expressing 
either WT or mutant ADAMTS13. After 24 hours 50μg/ml cycloheximide was added 
to  the  supernatant  of  the  cells.  In  addition  100μM  MG132  was  added  to  the 
supernatant of some cells. Cells were collected before and 20, 24, 30 and 48 hours 
after cycloheximide/MG132 addition. Results are shown in Figure 5-9. 
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Figure 5-9 Cycloheximide chase in the presence or absence of MG132 
Transiently  transfected  cells  were  incubated  with  cycloheximide  and  in  some  cases  with  100µM 
MG132.  Samples  were  collected  at  t=20,  24,  30  and  48  hours.  Expected  size  of  ADAMTS13  is 
~190kDa. Results are from one experiment. 
From this experiment no conclusion could be made regarding whether these mutants 
were degraded by the cell proteasome. At 24 and 30 hours levels of the p.Y570C 
mutant were greater in the presence of the proteasome inhibitor but not at 48 hours. 
With the p.I143T mutant levels appeared lower in the presence of the proteasome 
inhibitor after 24 hours but were increased 30 and 48 hours. The differences may be 
due to slight differences in the transfection efficiency between plates.  
5.4.3  Lysosome inhibition 
Alternatively the mutants may have been degraded by cell lysosomes. To investigate 
this  preliminary  experiments  were  performed  by  adding  two  different  lysosome 
inhibitors (ammonium chloride and Bafilomycin A1), to transiently transfected cells 
expressing WT or mutant ADAMTS13, to assess which concentration to use. Cells 
were seeded in six well plates (cycloheximide was not used in these experiments). 
Ammonium chloride prevents acidification of lysosomes (Gordon et al, 1980) and 
Bafilomycin A1 is a specific inhibitor of vacuolar-type H(+)-ATPase (Bowman et al, 
1988). The concentrations chosen were previously shown to be optimal for lysosome 
inhibition (Orenstein et al, 2013;Sala et al, 2013;Park et al, 2012;Yoshimori et al, 
1991).  Bafilomycin  A1  concentrations  ranged  from  0  to  1µM  and  ammonium 
chloride  from  0  to  16mM.  Cell  lysate  samples  were  collected  24  hours  after 
lysosome addition.  
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Figure 5-10 Incubation of transiently transfected cells with lysosome inhibitors 
Cells  were  incubated  with  Bafilomycin  A1  (a,b)  or  with  ammonium  chloride  (c,d).  Cells  were 
incubated  in  the  absence  or  presence  of  0.1µM,  0.2µM  or  1µM  Bafilomycin  A1.  In  separate 
experiments cells were incubated in the absence or presence of 3mM, 6mM, 10mM, 13mM or 16mM 
ammonium  chloride.  Cell  lysate  samples  are  shown.  Expected  size  of  ADAMTS13  is  ~190kDa. 
Results from one experiment. 
The  cells  appeared  to  tolerate  the  various  concentrations  of  inhibitors.  There 
appeared to be a slight increase in WT and mutant ADAMTS13 within the cell with 
increasing concentrations of both inhibitors. However this increase was similar for 
both WT and mutant. These results suggest that a small proportion of WT and mutant 
ADAMTS13 is degraded by lysosomes. 
5.4.4  Normalisation of transfection efficiency  
From  the  earlier  cycloheximide  chase/proteasome  inhibition  experiments,  it  was 
unclear whether levels of the mutant within the cell were increased in the presence of 
the proteasome inhibitor. One of the reasons this may have been unclear was because 
of the transient nature of the experiments. Cycloheximide experiments were carried 
out in the presence of lysosome and proteasome inhibitors in transiently transfected 
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cells which were cotransfected with the Renilla luciferase vector to normalise the 
transfection efficiency. Cells were collected before and 22, 28 and 32 hours after 
drug addition. 
The volume of cell lysate added to the gel was normalised either for all time points 
or  for  each  time  point.  Western  blots  were  analysed  but  the  results  from  these 
experiments were not consistent and unclear (n=3). In retrospect it may not have 
been valid to use the reporter vector to normalise the results after the addition of 
cycloheximide or proteasome and lysosome inhibitors, since the reporter may be 
affected differently to ADAMTS13 in the presence of these inhibitors. Therefore, 
cells were not cotransfected with Renilla luciferase in subsequent experiments.  
5.4.5  Simultaneous inhibition of proteasome and lysosomes 
One possibility is that by blocking the proteasome the cells could be rerouted for 
degradation  by  lysosomes.  It  has  been  shown  that  inhibition  of  the  proteasome 
activates  autophagy  which  is  critical  for  the  removal  of  the  polyubiquitinated 
misfolded proteins (Iwata et al, 2005;Ding et al, 2007). In earlier experiments cells 
were  incubated  for  many  hours  with  inhibitors  (up  to  48  hours).  Cycloheximide 
chase experiments were performed in the presence of both proteasome and lysosome 
inhibitors. Cells transiently expressing WT or mutant ADAMTS13 seeded in six well 
plates were incubated with 50μg/ml cycloheximide, 10mM ammonium chloride and 
100μM MG132. Cells were collected before and 20, 24, 30, 44 and 48 hours after 
drug addition. Supernatant was also harvested and concentrated 10-15 fold.  
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Figure 5-11 Cycloheximide chase in the presence of both proteasome and lysosome inhibitors 
Transiently transfected cells were incubated with 100µM MG132 (proteasome inhibitor) and 10mM 
ammonium chloride (lysosome inhibitor) for 24 hours. Cell lysate samples are shown. Expected size 
of ADAMTS13 is ~190kDa. Results are from one experiment.  
For both WT and mutant ADAMTS13 there was a big difference in the levels of 
protein before and after 20 hours of drug addition. This large difference may be 
because of the time delay between drug addition and effect. In WT ADAMTS13 
between t=20 and t=30 hours there was a slight decrease in levels. On the other hand 
with the mutants, levels remained similar between these time points. These results 
suggest that the ADAMTS13 mutants were being degraded by either the proteasome 
or lysosome.  
Between 44 and 48 hours, ADAMTS13 levels greatly decreased for WT and mutant 
ADAMTS13. This is a long time for the cells to be incubated with the drugs and so 
perhaps  at  these  time  points  cells  were  beginning  to  die.  The  mutants  were 
undetectable within the supernatant.  
5.5  Proteasome inhibition in cells stably expressing ADAMTS13 
From the above experiments it was not clear whether the proteasome or lysosome 
was  responsible  for  protein  degradation.  This  may  have  been  partly  due  to 
differences  in  the  transfection  efficiency  between  cells  seeded  in  different  petri 
dishes.  Experiments  instead  were  carried  out  using  stable  line  cells  to  try  and 
eliminate this problem. Stable line cells were initially not used as it was thought that 
cells  transiently  expressing  ADAMTS13  would  be  adequate  for  analysis  and  in 
addition  stable  line  cells  expressing  either  of  the  mutants  had  not  been  created. 
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During the course of these experiments however a stable line expressing the p.I143T 
mutant was created.  
Cycloheximide  was  eliminated  from  these  experiments.  The  addition  of 
cycloheximide to the cells ensured that the effect of the proteasome or lysosome 
inhibitors on protein already synthesised was under investigation and would control 
for  the  possibility  that  the  inhibitors  increased/decreased  protein  synthesis. 
Cycloheximide was eliminated partly because of the additional toxicity introduced to 
the cells with its use. In addition if a small amount of mutant protein was secreted 
after inhibition of the proteasome or lysosome, it was less likely to be detected in the 
presence of cycloheximide as cycloheximide reduces protein synthesis and so the 
amount  of  protein  secreted  generally  would  be  reduced  in  the  presence  of 
cycloheximide compared to its absence. Furthermore other groups have performed 
proteasome and lysosome inhibition experiments in secretion defect mutants in the 
absence of cycloheximide (Hunault et al, 1999;Tjeldhorn et al, 2011).  
Shorter time points were also used to  reduce toxicity to the  cells. As mentioned 
before inhibition of the proteasome can lead to autophagy (Iwata et al, 2005;Ding et 
al, 2007). Therefore, prolonged incubation of cells with a proteasome inhibitor could 
trigger autophagy.  
Preliminary  experiments  were  performed  in  six  well  plates.  Stable  line  cells 
expressing WT or p.I143T mutant ADAMTS13 were incubated with MG132 or with 
another proteasome inhibitor ALLN, which inhibits the 20S proteasome, along with 
calpain I and II, cathepsin B and L and neutral cysteine proteases (Lee & Goldberg, 
1998). Concentrations chosen were based on those used by others (Hunault et al, 
1999;Sidoryk-Wegrzynowicz et al, 2010). Cells were incubated with these inhibitors 
for 5 hours.  158 
 
 
Figure 5-12 Proteasome and lysosome inhibition in stable line cells 
Cells were incubated with 10µM MG132, 50mM ammonium chloride (NH4Cl), 50µg/ml (i), 10μM 
(ii) or 6µM (iii) ALLN in duplicate. Cell lysate samples are shown. Expected size of ADAMTS13 is 
~190kDa. Results are from one experiment. 
Addition of both proteasome inhibitors (MG132 and ALLN) led to an increase in the 
intracellular levels of the p.I143T mutant ADAMTS13 but not WT ADAMTS13. 
Within the supernatant no antigen could be detected for the mutant. The addition of 
ammonium  chloride  did  not  appear  to  increase  the  intracellular  levels  of  WT  or 
mutant protein. 
Experiments were scaled up and instead cells were grown in petri dishes and the 
supernatant concentrated ~100 fold to increase the chances of detecting antigen in 
the supernatant of the mutant. Addition of the proteasome inhibitor (MG132) and the 
proteasome and cathepsin inhibitor (ALLN) to cells stably expressing the p.I143T 
mutant led to an increase in the intracellular levels of ADAMTS13 (Figure 5-13). 
This increase was not observed in cells stably expressing WT ADAMTS13 after the 
addition of either drug. DMSO was added to cells stably expressing WT or mutant 
ADAMTS13 as a control, as this was the solvent used for both inhibitors (MG132 
and  ALLN).  DMSO  caused  a  slight  increase  in  the  intracellular  levels  of  WT 
ADAMTS13 but not for the mutant. 
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Figure 5-13 Incubation of WT and p.I143T mutant ADAMTS13 with proteasome and lysosome 
inhibitors 
Western blotting was used to analyse cell lysate (a) and supernatant (b) samples from cells stably 
expressing WT  or p.I143T mutant  ADAMTS13. Cells  were incubated  with proteasome  inhibitors 
MG132 (10μM) and ALLN (6μM) or the lysosome inhibitor ammonium chloride (NH4Cl 50mM). 
Cells  were  also  incubated  with  DMSO  as  a  negative  control.  Cells  were  incubated  with  these 
inhibitors for 5  hours and  supernatant  was concentrated  ~100 fold for analysis. Expected size of 
ADAMTS13 is   ~190 kDa. Western blots are representative of 3 experiments. 
The quantity of WT and p.I143T mutant ADAMTS13 present in the supernatant of 
stable line cells in the presence of either proteasome inhibitor was also measured. In 
these experiments the supernatant was concentrated to a greater degree (~100 fold) 
compared  to  the  supernatant  from  transient  transfections.  At  this  degree  of 
concentration the p.I143T mutant could be detected in the majority of experiments. 
The  addition  of  ALLN  to  stable  line  cells  expressing  either  WT  or  mutant 
ADAMTS13,  led  to  similar/slightly  increased  levels  of  ADAMTS13  antigen  and 
activity in the supernatant (Table 5-1). In WT ADAMTS13 the addition of MG132 
led to a slight decrease in the quantity and activity of ADAMTS13 measured in the 
supernatant. With the p.I143T mutant however the opposite occurred, there was a 
slight increase in the quantity secreted and as  a result the activity of the mutant 
(Table  5-1).  The  antigen  and  activity  of  the  mutant  measured  in  the  supernatant 
incubated in the presence of MG132 however was similar to the values obtained after 
incubation with DMSO, suggesting that the DMSO that MG132 was dissolved in 
was mainly responsible for the increase in the values obtained. Although the increase 
in ADAMTS13 activity and antigen observed with DMSO was relatively small (1.3-
1.5), it’s addition did appear to aid the secretion of ADAMTS13. 
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Levels relative to no drug (mean±SD) 
No 
drug  MG132  ALLN  DMSO  Bafilo-
mycin A1 
Ammonium 
chloride 
A
n
t
i
g
e
n
  WT  1  0.73±0.18  1.2±0.058 
 
1.5±0.15  0.93±0.32  0.19±0.051 
 
p.I143T  1  1.7±0.89  1.5±0.64  1.5±0.56  0.91±0.031  0.31±0.13 
A
c
t
i
v
i
t
y
  WT  1  0.73±0.10  1.0±0.18  1.3±0.058  0.82±0.12  0.21±0.032 
p.I143T  1  3.1±3.2
$  
 
2.3±2.1
$ 
  
2.3±1.9
$ 
 
0.82*  0.42±0.51
$  
 
 
Table  5-1  ADAMTS13  antigen  and  activity  in  supernatant  samples  after  the  addition  of 
proteasome or lysosome inhibitors 
Cells stably expressing WT or p.I143T mutant ADAMTS13 were incubated in the presence of either 
MG132  (10μM),  ALLN  (6μM),  Bafilomycin  A1  (0.1μM)  or  ammonium  chloride  (50mM).  As 
controls no inhibitor was added to some cells and DMSO to others. ADAMTS13 antigen and activity 
were measured and values for each condition were expressed as a proportion of control (no drug) 
which was given a value of 1. These proportions were calculated for each independent experiment, 
experiments were repeated three times. Median values are shown, with range in brackets. *In 2 of the 
Bafilomycin A1 experiments activity was undetectable both in the presence and absence of drug so 
the value shown in the table is the result from one experiment. Antigen on the other hand was detected 
in all experiments. 
$In one experiment each for MG132, ALLN, DMSO and ammonium chloride, 
activity was undetectable in the control (no drug) so the control was assigned a value of 1.25% (half 
of the detection limit) for the purposes of calculation in this experiment. 
5.6  Lysosome inhibition in cells stably expressing ADAMTS13 
In  cells  stably  expressing  WT  or  mutant  ADAMTS13  a  higher  concentration  of 
ammonium  chloride  was  used  (50mM)  compared  to  the  concentration  used  in 
transiently transfected cells to increase the chances of detecting a difference if a 
difference did exist. This concentration had been used by other groups in similar 
experiments (Tjeldhorn et al, 2011;Wolins et al, 1997;Hunault et al, 1999). Addition 
of  ammonium  chloride  (50mM)  to  cells  stably  expressing  WT  or  mutant 
ADAMTS13 led to severely reduced levels of ADAMTS13 secreted from the cell 
(Figure 5-13 and Table 5-1). Intracellular levels within the cell increased perhaps 
slightly but this increase was similar for WT and mutant protein.  161 
 
Instead a more specific lysosome inhibitor (Bafilomycin A1) was used. Addition of 
Bafilomycin A1 to both WT and mutant ADAMTS13 did not lead to an increase in 
the intracellular levels of ADAMTS13 (Figure 5-14) suggesting that no or very little 
WT  or  mutant  ADAMTS13  is  targeted  to  the  lysosome  for  degradation. 
Similar/slightly decreased levels of ADAMTS13 antigen was detected in both WT 
and  mutant  ADAMTS13  in  the  supernatant  after  the  addition  of  Bafilomycin  A 
(Figure 5-14, Table 5-1). 
     
Figure 5-14 Incubation of WT and p.I143T mutant ADAMTS13 with proteasome and lysosome 
inhibitors 
Western blotting was used to analyse cell lysate (a) and supernatant (b) samples from cells stably 
expressing WT or p.I143T mutant ADAMTS13. Cells were incubated in the presence or absence of 
Bafilomycin A1 (Bafilomycin) or DMSO as a negative control. Cells were incubated for 5 hours and 
supernatant was concentrated ~100 fold for analysis. Expected size of ADAMTS13 is  ~190 kDa. 
Western blots are representative of 3 experiments. 
5.7  Discussion 
If  mutant  ADAMTS13  was  degraded  by  either  the  proteasome  or  lysosomes, 
inhibition of these organelles would lead to accumulation of the mutant within the 
cell as it would no longer be degraded. Initially proteasome and lysosome inhibition 
experiments  were  carried  out  in  cells  transiently  transfected  with  either  WT  or 
mutant ADAMTS13. From these experiments it was not clear if the mutants were 
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degraded by either of these organelles. This was partly due to slight differences in the 
efficiency of transfection between cells plated in either six well plates or petri dishes. 
To try to compensate for this, cells were cotransfected with a reporter vector (Renilla 
luciferase).  However  the  results  from  this  were  not  consistent.  The  behaviour  of 
Renilla luciferase after proteasome or lysosome inhibition is not known, for example 
a large proportion of this protein may be degraded by the cell proteasome and so 
inhibiting the proteasome may lead to a large increase in the levels of the protein 
within the cell. As a result an increased luminescence may be observed which may 
be interpreted as a better efficiency of transfection which may not be the case. To 
overcome this problem cells stably expressing WT or mutant ADAMTS13 were used 
instead.   
Inhibition of the proteasome (with MG132 or ALLN) in cells stably expressing the 
p.I143T  mutant  led  to  increased  levels  within  the  cell  suggesting  that  a  large 
proportion of the p.I143T mutant is targeted to the proteasome for degradation. The 
same effect was not observed with WT ADAMTS13, which is instead secreted. In 
contrast, inhibition of lysosomes with ammonium chloride or Bafilomycin A1 led to 
similar/slightly increased levels of both WT and mutant ADAMTS13 within the cell 
suggesting the mutant was not degraded by lysosomes to a greater extent than WT 
ADAMTS13. 
When supernatant samples were concentrated ~100 fold the p.I143T mutant could be 
detected within the supernatant using both an ELISA and Western blotting, (Figure 
5-13, Figure 5-14, Table 5-1). After proteasome inhibition there was a slight increase 
in the levels of the p.I143T mutant ADAMTS13 secreted into the supernatant. These 
increased  levels  however  were  similar  to  the  levels  observed  in  the  presence  of 
DMSO  (Table  5-1);  MG132  was  dissolved  in  DMSO  suggesting  that  this  was 
probably responsible for the increased levels of ADAMTS13 antigen measured in the 
supernatant.  It  should  be  noted  that  the  levels  of  antigen  and  activity  in  these 
experiments  varied  from  undetectable  to  48ng/ml  and  undetectable  to  10.4% 
respectively, and at these lower levels the assay CVs were relatively high (Chapter 
2.6 and 2.7).  163 
 
As stated DMSO caused an increase in the quantity of WT and mutant ADAMTS13 
secreted (Table 5-1). DMSO has been shown to act as a chemical chaperone aiding 
the folding and secretion of some proteins (Brown et al, 1996;Tamarappoo et al, 
1999;Robben et al, 2006). Although there was  an increase, the magnitude of the 
change was relatively small perhaps because a relatively small amount of DMSO 
was  added  to  the  cells  (0.1%,  which  was  equal  to  the  greatest  quantity  of  drug 
added). The concentrations of DMSO used in previous experiments and shown to 
have  a  chaperoning  effect  was  higher  than  this  (1-2%).  Perhaps  if  higher 
concentrations  of  DMSO  were  used,  similar  to  those  in  previous  experiments 
(Robben  et  al, 2006;Tamarappoo  & Verkman,  1998;Bebok  et  al, 1998), a larger 
increase  may  have  been  observed.  Another  possibility  is  that  the  higher  levels 
detected could be as a consequence of the high CV associated with the assays used to 
measure  low  levels  of  ADAMTS13  activity  and  antigen.  However  ADAMTS13 
activity and antigen was consistently increased in the presence of DMSO, in all three 
experiments.  
The proteasome inhibitor MG132 can be toxic to cells initiating apoptosis (Park et al, 
2011) which may explain why in WT ADAMTS13, decreased antigen and activity 
was measured in the presence of MG132 (Table 5-1). MG132 would also be toxic for 
the cells expressing the p.I143T mutant protein however this may have been offset 
by  the  beneficial  effect  of  the  DMSO  solvent  which  aided  the  secretion  of  the 
mutant.  
After  the  addition  of  Bafilomycin  A1,  ADAMTS13  antigen  levels  within  the 
supernatant were similar to those observed in its absence. The addition of ammonium 
chloride  on  the  other  hand,  which  also  inhibits  lysosomes,  severely  reduced  the 
secretion  of  ADAMTS13.  Bafilomycin  A1  is  a  more  specific  lysosome  inhibitor 
compared  to  ammonium  chloride.  Ammonium  chloride  may  have  affected  other 
processes within the cell which may have led to the reduced levels of ADAMTS13 
measured in the supernatant.  
An additional way to analyse the effect of these inhibitors could have been through 
the use of pulse chase experiments. This method would have enabled the protein to 
be tracked inside and outside the cell after proteasome and lysosome inhibition. This 164 
 
was not performed because of time constraints but may be something worth carrying 
out in the future.  
The  behaviour  of  the  protein  within  the  cell  was  initially  studied  in  transiently 
transfected  cells  using  cycloheximide  chase  experiments.  Cycloheximide  was  not 
used in subsequent experiments with stable line cells in order to reduce toxicity to 
the  cells.  Additionally  other  groups  have  performed  these  types  of  experiments 
(lysosome/proteasome inhibition) in the absence of cycloheximide (Hunault et al, 
1999;Tjeldhorn  et  al,  2011).  The  cycloheximide  experiments  did  demonstrate 
however that the mutants were not unstable within the cell or rapidly degraded. 
It may have been useful to carry out the cycloheximide chase experiments in the 
presence of these inhibitors using stable line cells, to be sure that the inhibitors did 
not increase the synthesis of the proteins. This is unlikely to have occurred however 
because addition of the inhibitors (MG132, Bafilomycin A1, ammonium chloride) to 
WT ADAMTS13 did not lead to an increase in levels, in fact levels decreased.  
Furthermore, cycloheximide has been shown to inhibit macroautophagy (Watanabe-
Asano et al, 2014). Therefore, adding lysosome inhibitors to cycloheximide treated 
cells  may  not  have  been  informative  as  the  cycloheximide  may  have  already 
inhibited the lysosomes in these cells.  
In initial experiments, relatively long time points were used. This was to increase the 
chance of detecting protein in the supernatant and in case shorter time points would 
not be long enough to detect changes in the cell (<20 hours). However shorter time 
points were later used to reduce the toxicity associated with these inhibitors.  
In  pulse  labelled  experiments  in  HeLa  cells  (Majerus  et  al,  2003),  ADAMTS13 
appeared in the media within 3 hours of chase with a half-life of secretion of ~7 
hours. After 35 hours no radiolabelled ADAMTS13 could be detected in the cell. 
Similarly in  HEK 293  cells, radiolabelled ADAMTS13 within  the  cell  started to 
decrease  after  7  hours  (Palla  et  al,  2009),  was  barely  detectable  at  3  hours  and 
reached the maximum concentration at 24 hours. Looking at Figure 5-6 the results 
appear to broadly agree with these estimates of the half-life, at 8 hours levels of 165 
 
ADAMTS13 in WT and mutant appear to be approximately half of the level before 
drug addition. ADAMTS13 appears to have a relatively long half-life within the cell; 
30-75% of proteins that are synthesised are degraded within 20 minutes (Ellgaard & 
Helenius, 2003). 
Inhibition of the proteasome led to the accumulation of the p.I143T mutant within 
the  cell.  The  proteasome  inhibitor,  MG132  has  been  shown  to  activate  the  UPR 
leading to up regulation of chaperones and folding enzymes that can enhance the 
folding  efficiency  of  mutant  enzymes  (Engin  &  Hotamisligil,  2010).  However 
inhibition of the proteasome did not appear to enhance secretion of the mutant in 
three experiments. Although slightly increased levels were found in the supernatant 
this appeared to be due to the DMSO solvent, MG132 was dissolved in. I went on to 
investigate whether the addition of the chemical chaperone betaine could enhance the 
secretion of the misfolded protein (Chapter 6).  166 
 
Chapter 6   Betaine experiments (type 1a mutants) 
6.1  Introduction 
The p.I143T ADAMTS13 mutation appeared to cause misfolding of the ADAMTS13 
enzyme, which was recognised by the cells QC system and degraded by the cell 
proteasome  (Chapter  5).  Consequently,  little  or  no  ADAMTS13  was  secreted 
(Chapter 3). I aimed to investigate whether it was possible to prevent the degradation 
of this mutant within the cell, thus promoting its secretion.  
In  the  previous  chapter  (Chapter  5),  it  was  shown  that  after  inhibition  of  the 
proteasome in  cells  stably expressing the  p.I143T mutant, levels  of ADAMTS13 
antigen in the supernatant increased. However this affect appeared to be due to the 
solvent that the inhibitor was dissolved in (DMSO) rather than the inhibitor itself. 
DMSO is a chemical chaperone and has been shown to aid the secretion of some 
proteins.  I  investigated  whether  another  chemical  chaperone,  betaine  (which  is 
approved for the treatment of homocystinuria) (Lawson-Yuen & Levy, 2006), could 
alternatively help promote the folding and subsequent secretion of this mutant.  
6.1.1  Chemical chaperones 
As  described  in  Chapter  5  cells  synthesise  and  produce  a  number  of  chaperone 
proteins  which  aid  the  correct  folding  of  proteins.  These  molecular  chaperones 
recognise  particular  regions  of  unfolded  proteins.  Chemical  chaperones  are 
molecules which can be acquired from the environment (sometimes synthesised in 
the cell) that exert a non-specific effect (unlike molecular chaperones), facilitating 
correct  protein  folding,  by  stabilising  native  or  native-like  states  or  by  reducing 
aggregation (Ellgaard & Helenius, 2003). These molecules are normally osmolytes, 
small solutes which can equilibrate cellular osmotic pressure. There are three main 
classes  of  osmolytes  including,  amino  acid  derivatives,  carbohydrates  and 
methylamines (Table 6-1). 167 
 
  
Table 6-1 Osmolyte classes 
Taken from (Welch & Brown, 1996). 
6.1.2  Osmolytes in organisms 
Osmolytes accumulate in the cytoplasm of cells exposed to water stress and protect 
the  cells  from  osmotic  pressure  (Yancey,  2005).  A  number  of  experiments  have 
shown that to varying degrees organic osmolytes have the ability to stabilise and 
protect intracellular proteins against commonly occurring denaturing environmental 
stresses  (Yancey  et  al,  1982;Yancey  &  Somero,  1979;Somero,  1986).  These 
osmolytes  do  not  interfere  with  cellular  function  or  protein  structure  (Lee  & 
Timasheff, 1981;Arakawa & Timasheff, 1983;Arakawa & Timasheff, 1985). 
During osmotic stress for example, yeast increase their intracellular levels of glycerol 
(Reed  et  al,  1987)  and  elasmobranchs  (sharks)  increase  levels  of  TMAO 
(Trimethylamine N-oxide) (Forster & Goldstein, 1976). Urea is  an osmolyte, but 
unlike  other  osmolytes  it  does  not  protect  cellular  proteins.  While  protective 
osmolytes push the equilibrium of protein folding towards the native form denaturing 
osmolytes  such  as  urea  push  the  equilibrium  towards  the  unfolded  state.  Urea 
accumulates in renal medulla cells but these cells contain ‘counteracting osmolytes’ 
to offset the protein denaturing effects of urea. In the kidney, osmolytes such as 
sorbitol and glycerophosphorylcholine are produced by de novo synthesis. Others 
such as betaine and taurine are taken up from the extracellular media via the action of 
specific transporters present in the plasma membrane (Welch & Brown, 1996).  168 
 
6.1.3  Chemical chaperones  
A number of groups have analysed the effect of chemical chaperones on the folding 
of mutant proteins. A variety of chemical chaperones have been tested in a variety of 
different proteins associated with various different diseases. Some of these are shown 
in Table 6-2. These chemicals have been able to rescue defects in protein function 
caused by mutations, to various degrees. 
These molecules have been an attractive therapeutic option in some diseases, with 
some of the molecules being tested in clinical trials. For example approximately 90% 
of patients with cystic fibrosis have a common deletion mutation (ΔF508)  in the 
cystic fibrosis transmembrane receptor (CFTR). This mutation leads to misfolding 
and  subsequent  degradation  of  the  chloride  ion  channel  (Loo  &  Clarke,  2007). 
Chemical chaperones have been able to ‘rescue’ this mutant, enabling it to traffic to 
the plasma membrane and perform its function. Rescuing this mutant is clinically 
relevant as a large number of patients could be potentially treated with the same 
drug. In fact one of these chaperones 4-phenylbutyric acid (4PBA) has been tested in 
clinical trials and is approved for the use of cystic fibrosis. 
As well as rescuing misfolded mutants which are degraded by the cells QC system, 
these  chemicals  have  been  able  to  ‘rescue’  aggregated  proteins.  Tatzelt  et  al 
incubated scrapie infected mouse neuroblastoma cell lines with 1M glycerol, 100mM 
DMSO or 100mM TMAO which all reduced the amount of insoluble prion protein 
(Tatzelt et al, 1996). Administration of 4PBA to mice in a Parkinson’s like disease 
mouse model prevented neurodegeneration (Inden et al, 2007). Oral administration 
of trehalose decreased polyglutamine aggregates in the cerebrum and liver, improved 
motor dysfunction and extended lifespan in a transgenic model of Huntington disease 
(Tanaka et al, 2004).  169 
 
Disease  Protein  Function  Chemical chaperone  References  Clinical trial/mice 
Cystic fibrosis  CFTR  Membrane channel  Glycerol, DMSO, TMAO,  
Glycerophosphorylcholine, Myoinositol, 
Sorbitol, Taurine, betaine(10mM), 4PBA 
(Sato et al, 1996;Brown et al, 
1996;Rubenstein et al, 
1997;Bebok et al, 1998;Zhang 
et al, 2003) 
4PBA Phase I/II 
(Zeitlin et al, 2002) 
Emphysema and liver 
disease 
α1-antitrypsin  Secreted protein  Glycerol, 4PBA  (Burrows et al, 2000)  4PBA mice (Burrows et al, 2000) 
Phase I/II (Teckman, 2004) 
NDI  Aquaporin-2  Membrane channel  Glycerol, TMAO, DMSO  (Tamarappoo et al, 
1999;Tamarappoo & Verkman, 
1998) 
- 
NDI  Vasopressin V2 receptor  Membrane receptor  Glycerol, DMSO  (Robben et al, 2006)  - 
Haemophilia A  FVIII  Secreted protein  Betaine (25-100mM)  (Roth et al, 2012)  Betaine mice (Roth et al, 2012)  
Machado-Joseph disease  Ataxin-3  Nuclear and cytoplasmic  DMSO, glycerol, TMAO, Ectoine, 10mM 
betaine 
(Yoshida et al, 2002;Furusho et 
al, 2005) 
- 
Primary hyperoxaluria 
type I 
alanine: 
glyoxylate 
aminotransferase 
Peroxisome enzyme  Betaine (75-100mM), Glycerol, DMSO, TMAO, 
4PBA 
(Santana et al, 2003)  Betaine Phase II NCT00283387 
Homocystinuria  Cystathionine beta 
synthase 
Cytoplasmic and nuclear 
enzyme 
Betaine (100mM), delta-ALA, Glycerol, TMAO, 
DMSO, proline, sorbitol 
(Singh et al, 2007;Kopecka et 
al, 2011) 
- 
Branched chain 
ketoaciduria 
Branched chain α-
ketoacid dehydrogenase 
Mitochondrial enzyme  TMAO  (Song & Chuang, 2001)  - 
Long QT syndrome  HERG channel  Membrane channel  Glycerol  (Zhou et al, 1999)  - 
Cataracts  αA-crystallin  Intracellular protein  TMAO  (Gong et al, 2009)  - 
Cataracts  CRYGD  Intracellular protein  4PBA  (Gong et al, 2010)  - 
Retinitis pigmentosa  Carbonic anhydrase  Intracellular enzyme  4PBA  (Bonapace et al, 2004)  - 
Zellweger spectrum 
disorder 
Peroxin 1/6/12  Peroxisome enzyme  TMAO, glycerol Betaine (100mM), Arginine  (Zhang et al, 2010;Berendse et 
al, 2013) 
Betaine Phase III NCT01838941  
Interstitial lung disease  Surfactant protein C  Secreted protein  4PBA  (Stewart et al, 2012)  - 
Parkinson Disease  PaeI-R  Membrane protein  4PBA  (Kubota et al, 2006)  - 
Intrahepatic cholestasis 
type 2 
BSEP E297G  Membrane protein  4PBA  (Hayashi & Sugiyama, 2007)  - 
Dystrophic mineralisation  ABCC6  Membrane protein  4PBA  (Le et al, 2011)  - 
Nephritic syndrome  Nephrin  Membrane protein  4PBA  (Liu et al, 2004)  - 
Neurodegenerative 
disease 
Insulin Amyloid  Intracellular protein  Trehalose Ectoine Betaine (300mM),  (Arora et al, 2004)  Trehalose mice (Perucho et al, 2012) 
Oculopharyngeal 
muscular dystrophy 
PABPN1  Nuclear protein  Trehalose  (Davies et al, 2006)  Trehalose mice (Davies et al, 2006) 
Table 6-2 Chemical chaperones in vitro and in vivo 
4PBA: 4-phenylbutyric acid, CFTR: cystic  fibrosis transmembrane receptor.  NDI: Nephrogenic diabetes insipidus. Herg: Human ether-a-go-go-related  gene. CRYGD: 
GammaD-crystallin. PaeI-R: Parkin-associated endothelin-receptor-like receptor. BSEP: Bile salt export pump, ABCC6: ATP-binding cassette sub-family c membrane 6. 
PABPN1: Polyadenylate-binding nuclear protein 1. Clinical trial numbers obtained from URL: https://clinicaltrials.gov/, accessed 17
th June 2014. 170 
 
6.1.4  Pharmacological chaperones 
Some  groups  have  subsequently  developed  pharmacological  chaperones.  These 
chaperones  are  small  molecules,  generally  a  ligand,  antagonists  (receptors)  or 
competitive inhibitors (enzymes), that reversibly bind and stabilise the protein rather 
than assisting the general folding properties (Engin & Hotamisligil, 2010). They are 
more  specific  than  chemical  chaperones  which  can  be  advantageous  as  only  the 
protein of interest is ‘rescued’. Some of these chaperones are shown in Table 6-3. 171 
 
 
Disease  Protein  Protein 
function 
Pharmacological chaperone 
references 
Tested in clinical 
trial 
Cystic fibrosis  CFTR  Membrane 
channel 
(Wang et al, 2006;Pedemonte et 
al, 2005;Van et al, 2006) 
VX-809, 
NCT00865904 
Phase II 
(Clancy et al, 
2012) 
NDI  Vasopressin V2 
receptor 
Membrane 
Receptor 
(Morello et al, 2000;Tan et al, 
2003;Bernier et al, 2006) 
- 
ND1  Aquaporin-2  Membrane 
receptor 
(Bouley et al, 2005;Bouley et al, 
2011) 
Calcitonin, 
sildenafil, Phase II 
NCT00478335  
Fabry  α-Galactosidase A  Lysosome 
Enzyme 
(Okumiya et al, 1995;Fan et al, 
1999;Ishii et al, 2007;Shin et al, 
2008;Wu et al, 2011;Frustaci et 
al, 2001) 
AT1001, Phase III 
NCT00925301, 
NCT01458119, 
NCT01218659 
GM1-gangliosidosis & 
Morquio B disease 
β-Galactosidase  Lysosome 
Enzyme 
(Matsuda et al, 2003)  - 
Tay-Sachs & Sandhoff  β-hexosaminidase A 
(αβ) 
Lysosome 
Enzyme 
(Tropak et al, 2004;Maegawa et 
al, 2007;Rountree et al, 2009) 
Pyrimethamine, 
Phase I/II, 
NCT01102686 
Pompe disease  α-glucosidase  Lysosome 
Enzyme 
(Okumiya et al, 2007;Parenti et 
al, 2007) 
AT2220, Phase II 
NCT00688597  
Gaucher disease  β-glucosidase  Lysosome 
Enzyme 
(Benito et al, 2011)  AT2101, Phase 2 
NCT00433147, 
NCT00813865, 
NCT00446550 
Miglustat, Phase 
III NCT00319046,  
ISU302, Phase II 
NCT02053896 
Phenylketonuria  Phenylalanine 
hydroxylase 
Cytosol 
Enzyme 
(Pey et al, 2008;Santos-Sierra et 
al, 2012) 
Yes on market 
Hypogonadotropic 
hypogonadism 
GNRHR  Membrane 
Receptor 
(Janovick et al, 2002;Leanos-
Miranda et al, 2002) 
- 
Long QT syndrome  HERG  Membrane 
channel 
(Zhou et al, 1999)  - 
Retinitis pigmentosa  Rhodopsin  Membrane 
receptor 
(Krebs et al, 2010), (Ohgane et 
al, 2010) 
- 
Retinitis pigmentosa  Opsin  Membrane 
receptor 
(Noorwez et al, 2003;Noorwez 
et al, 2004) 
- 
Metabolic disorders  hMCHR1  Membrane 
receptor 
(Fan et al, 2005)  - 
Obesity  Melanocortin-4  Membrane 
receptor 
(Fan & Tao, 2009;Rene et al, 
2010) 
RM-493, Phase II 
NCT02041195 
Mucopolysaccharidosis 
III Type C 
HGSNAT  Lysosomal 
enzyme 
(Feldhammer et al, 2009)  - 
Krabbe disease  Galactocerebrosidase  Lysosomal 
enzyme 
(Lee et al, 2010;Berardi et al, 
2014) 
- 
Long QT syndrome  Kv11.1 channel  Membrane 
channel 
(Smith et al, 2013)  - 
Intrahepatic cholestasis 
type 2 
BSEP E297G  Membrane 
protein 
(Misawa et al, 2012)  - 
 
Table 6-3 Pharmacological chaperones  
CFTR:  cystic  fibrosis  transmembrane  receptor,  NDI:  Nephrogenic  diabetes  insipidus,  GNRHR: 
Gonadotropin-releasing  hormone  receptor,  HERG:  Human  ether-a-go-go-related  gene,  hMCHR1: 
human  melanin  concentrating  hormone  receptor  1,  HGSNAT:  Heparan  sulphate  acetyl-coA:  α-
glucosaminide N-acetyltransferase, BSEP: Bile salt export pump. Clinical trial numbers obtained from 
URL: https://clinicaltrials.gov/, accessed 17
th June 2014. 172 
 
6.2  Addition of betaine to transiently transfected cells 
The effect of the chemical chaperone betaine on the secretion of secretion defect 
mutants (p.I143T and p.Y570C) was investigated. Betaine was chosen as it has been 
previously shown to aid the secretion of a haemophilia A Factor VIII mutant in vitro 
and in vivo (Roth et al, 2012). Additionally it can be used safely in humans as it is 
approved  for  the  treatment  of  homocystinuria  where  it  acts  as  a  methyl  donor, 
lowering  homocystinuria  by  remethylating  methionine  (Lawson-Yuen  &  Levy, 
2006).  
Initially betaine was added to cells transiently expressing ADAMTS13. Cells seeded 
in six well plates were incubated with various concentrations of betaine (0-150mM). 
Betaine was added 24 hours after transfection and 72 hours after incubation, cell 
lysate and supernatant were harvested. Supernatant was concentrated approximately 
15 fold for analysis. Results are shown in Figure 6-1 and Table 6-4. 
 
Figure 6-1 Incubation of transiently transfected cells with betaine 
Cells transiently expressing WT or mutant (p.I143T, p.Y570C) ADAMTS13 were incubated with 
various concentrations of betaine (150mM, 100mM, 75mM, 50mM, 25mM and none) 24 hours after 
transfection. Cell lysate (a, b) and supernatant (c, d) were harvested after three days. Results are from 
one experiment. Expected size of ADAMTS13 is ~190kDa. 
 
c.                                                       d.                                                      
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  Concentration of betaine (mM) 
150  100  75  50  25  0 
WT antigen  0.8  0.9  0.8  0.9  0.9  1 
 
Table 6-4 ADAMTS13 antigen in supernatant samples from cells transiently transfected with 
WT ADAMTS13 and incubated with betaine for three days  
ADAMTS13  antigen  was  undetectable  in  the  supernatant  of  both  mutants  after  incubation  with 
betaine. Results are from one experiment. Antigen levels are expressed relative to no betaine (1). 
In cell lysate samples the quantity of ADAMTS13 within the cell of both WT and 
mutant  ADAMTS13  decreased  with  increasing  concentrations  of  betaine.  WT 
ADAMTS13 could be detected in the supernatant (Figure 6-1 and Table 6-4).  Levels 
were  similar/slightly  decreased  with  increasing  concentrations  of  betaine.  In  the 
mutants,  no  ADAMTS13  could  be  detected  in  the  supernatant,  regardless  of  the 
concentration  of  betaine  used  during  incubation  (Figure  6-1).  The  level  of  WT 
ADAMTS13 detected in the supernatant was relatively low (6.5→8.3% of PNP) as 
the cells were grown in six well plates, so the effect of betaine on the secretion of the 
mutants (if any) may have been too low to be detected.  
6.3  Addition of varying concentrations of betaine to cells stably 
expressing ADAMTS13 
The results from the transient transfection experiments demonstrated that betaine had 
an  effect  on  ADAMTS13.  Subsequent  experiments  were  carried  out  using  cells 
stably expressing ADAMTS13 to try and overcome the potential problems that may 
have been encountered if transiently transfected cells had been used (i.e. difference 
in transfection efficiency). At the time of these experiments a stable line expressing 
the p.Y570C mutant was also not available so the effect of betaine was investigated 
with only the p.I143T mutant.  
Cells stably expressing WT or p.I143T mutant ADAMTS13 seeded in petri dishes 
were incubated with various concentrations of betaine (ranging from 0 to 150mM). 
After three days supernatant and cell lysate samples were harvested. Supernatant was 
concentrated ~100 fold. Results are shown in Figure 6-2 and Figure 6-4. 
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Figure  6-2  Incubation  of  cells  stably  expressing  WT  or  mutant  p.I143T  ADAMTS13  with 
betaine 
Cells  stably  expressing  either  WT  or  p.I143T  mutant  ADAMTS13  were  incubated  with  various 
concentrations of betaine (150mM, 100mM, 75mM, 50mM, 25mM or 0), for three days. Cell lysate 
(a) and supernatant (b) samples are shown. Results from 1 of 2 experiments are shown. Expected size 
of ADAMTS13 is ~190kDa. 
 
 
Figure  6-3  ADAMTS13  antigen  and  activity  measured  in  the  supernatant  of  cells  stably 
expressing either WT or p.I143T mutant ADAMTS13 after incubation with betaine 
The  results  shown  are  from  two  experiments.  The  value  r  represents  the  Pearson  correlation 
coefficient, the 95% CI are also shown.  
Following the addition of betaine there appeared to be similar/slightly reduced levels 
of WT ADAMTS13 within the supernatant. With the mutant there appeared to be a 
partial increase in the activity at a concentration of 100mM. The results from the two 
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experiments were not always consistent at the different concentrations and so instead 
in subsequent experiments one concentration of betaine (100mM) was added to the 
cells (as opposed to a number of different concentrations). For each independent 
experiment this concentration of betaine was tested in triplicate (cells seeded in three 
different plates). A concentration of 100mM betaine was chosen as this concentration 
appeared to lead to an average increase in the activity measured in the supernatant of 
the mutant.  
6.4  Addition of 100mM betaine to cells stably expressing 
ADAMTS13 
Betaine was added to the cells as described in the methods (Chapter 2.11). Results 
are shown in Figure 6-4. 
                                              
Figure 6-4 Incubation of WT and p.I143T mutant ADAMTS13 with betaine 
Western blotting was used to analyse cell lysate (a) and supernatant (b) samples from cells stably 
expressing WT or p.I143T mutant ADAMTS13. Cells were incubated in the absence or presence of 
100mM betaine for 96 hours. Supernatant was concentrated ~100 fold for analysis. Expected size of 
ADAMTS13 is ~190kDa. Western blots are representative of n=4 experiments. 
The addition of betaine led to a slight decrease in the quantity and activity of WT 
ADAMTS13 detected in the supernatant (measured using an ADAMTS13 antigen 
ELISA).  After  12  experiments  the  median  WT  ADAMTS13  antigen  in  the 
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supernatant in the presence of betaine was 0.9 of the value obtained in the absence of 
betaine (i.e. 0.1 fold decrease, compared to in the absence of betaine). The median 
ADAMTS13 activity in the presence of betaine was slightly decreased, 0.9 of the 
value obtained in its absence.  
After the addition  of betaine to  cells  expressing the  p.I143T mutant  there was  a 
median 1.8 fold increase in ADAMTS13 antigen in the supernatant compared to in 
the absence of betaine. In cells stably expressing the p.I143T mutant, antigen could 
be detected in the supernatant in all (11/11) experiments carried out in the presence 
of betaine and in 9/11 of the experiments in the absence of betaine. In these two 
experiments for the purpose of calculating the effect of betaine on antigen levels, a 
value of 5ng/ml was assigned (half the detection limit for the ELISA). The median 
antigen  value  obtained  in  the  absence  of  betaine  was  17ng/ml,  (range  :<  10-
197ng/ml), median values in the presence of betaine on the other hand was 28ng/ml 
(12- 354ng/ml). In 7/9 experiments in which antigen could be detected in both the 
absence and presence of betaine, antigen was increased in the presence of betaine. 
However  in  two  of  these  experiments,  antigen  did  not  appear  to  increase  in  the 
presence of betaine. The antigen values were low (<15ng/ml) in these experiments 
and therefore differences may not have been observed so easily.   
For the p.I143T mutant, activity in the absence of betaine was undetectable (<2.5% 
of PNP) in all experiments, but could be detected in 6/11 experiments in the presence 
of betaine. Activity was not detected in the remaining 5 experiments because smaller 
amounts of protein were secreted in these experiments.  In the six experiments in 
which activity could be detected in the presence of betaine, there was a several fold 
increase in the activity of the mutant in the presence of betaine. The median activity 
of the mutant in the presence of betaine for these six experiments was: 5.5% of PNP, 
ranging from 2.7%-7.1% of PNP. 
In order to test that the betaine within the supernatant was not directly affecting the 
measurement of ADAMTS13 activity betaine  was  added  to supernatant  collected 
from WT stable line cells which had not been incubated with betaine during culture. 
The  activity  in  this  supernatant  (+  betaine)  was  then  compared  to  the  activity 
measured in the supernatant of cells which had not been incubated with betaine. The 177 
 
results were similar. Together these results suggest that betaine aids the folding of 
the p.I143T mutant within the cell enabling its subsequent secretion by the cell. 
6.5  Endoglycosidase H and PNGase F digestion 
The  band  which  was  produced  from  cell  lysate  samples  after  western  blotting 
appeared to consist of two bands merged together (Figure 6-4). These western blots 
were run on 4-12% gels. Samples were subsequently run on 3-8% Tris-Acetate gels 
(also under reducing conditions) to enable better separation, and it became apparent 
that  two  bands  were  present  (Figure  6-5).  The  upper  band  appeared  to  be  more 
prominent in the stable line cells that had been incubated with betaine (for both WT 
and mutant ADAMTS13). The presence of two bands was also evident in repeated 
experiments.  
Figure 6-5 Cell lysate samples run on a 3-8% Tris-Acetate gel 
Cell lysate samples harvested from stable line cells incubated in the presence or absence of 100mM 
betaine underwent electrophoresis on 3-8% Tris-Acetate gels, demonstrating the appearance of two 
bands in cell lysate samples. Expected size of ADAMTS13 ~190kDa.   
To  investigate  whether  these  bands  represented  different  glycosylated  forms  of 
ADAMTS13,  cell  lysate  samples  were  digested  with  Endoglycosidase  H  which 
cleaves  high  mannose  and  some  hybrid  oligosaccharides  from  N-linked 
glycoproteins but not complex glycans. The addition of Endoglycosidase H to cell 
lysates harvested from both WT and the p.I143T mutant stable line cells led to the 
appearance of just one band (Figure 6-6). This occurred regardless of whether the 
cells had been previously incubated in the absence or presence of 100mM betaine 178 
 
(Figure 6-6) and all bands were approximately the same molecular weight. This band 
was approximately the same weight as the lower band which had been observed in 
the cell lysate samples before Endoglycosidase H digestion (WT lower band). The 
addition of Endoglycosidase H therefore led to the disappearance of the upper band 
present in cell lysate samples, this band had been more prominent in those cells that 
had  been  incubated  with  betaine.  The  lower  band  present  in  cell  lysate  samples 
however did not appear to be sensitive to Endoglycosidase H, as after digestion the 
band appeared to be of the same size.  
 
Figure 6-6 Endoglycosidase H digestion of cell lysate samples 
Cell lysate samples harvested from stable line cells incubated in the presence or absence of 100mM 
betaine underwent deglycosylation with Endoglycosidase H, followed by electrophoresis on 3-8% 
Tris-Acetate gels. Expected size of ADAMTS13 ~190kDa.   
Digestion of the cell lysate samples with PNGase F which unlike Endoglycosidase H 
can cleave complex glycans led to the appearance of one band within all cell lysate 
samples, similar to the results obtained with Endoglycosidase H (Figure 6-7). This 
band was of approximately the same molecular weight as the lower band present in 
undigested cell lysate samples.  179 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-7 PNGase F digestion of cell lysate samples 
Cell lysate samples harvested from stable line cells incubated in the presence or absence of 100mM 
betaine underwent deglycosylation with PNGase F followed by electrophoresis on 3-8% Tris-Acetate 
gels. Expected size of ADAMTS13 ~190kDa.   
In the supernatant samples only one band was present after running the samples on 3-
8% Tris-Acetate gels and this protein was resistant to Endoglycosidase H digestion 
as expected (Figure 6-8).   180 
 
 
Figure 6-8 Endoglycosidase H digestion of supernatant samples 
Supernatant samples harvested from stable line cells incubated in the presence or absence of betaine 
underwent  deglycosylation  with  Endoglycosidase  H  followed  by  electrophoresis  on  3-8%  Tris-
Acetate gels. Expected size of ADAMTS13 ~190kDa. Endo H: Endoglycosidase H.   
Some of the cell lysate samples from the transient transfection experiments described 
in Chapter 3 (harvested ~96 hours after the cells were confluent) and the cell lysate 
samples from stable line cells incubated with proteasome and lysosome inhibitors 
(Chapter 5), (harvested ~5 hours after confluent) were also loaded onto 3-8% Tris-
Acetate gels to see if two bands were also present in these samples (Figure 6-9). Two 
bands were present in the cell lysate samples from transiently transfected cells but 
only one band, corresponding to the upper band was present in the stable line cells 
harvested from the drug experiments. 181 
 
 
Figure 6-9 Transiently transfected and stable line cell lysate samples run on 3-8% Tris-Acetate 
gels 
Cell lysate samples harvested from transiently transfected cells (collected ~96 hours after confluency) 
and from stable line cells (collected ~5 hours after confluency) were run on 3-8% Tris-Acetate gels.N: 
negative control. Expected size of ADAMTS13 ~190kDa.   
6.6  Discussion 
6.6.1  Betaine results 
The addition of betaine to cells stably expressing the p.I143T mutant increased the 
secretion approximately two fold and led to detectable ADAMTS13 activity in the 
supernatant.  The  increase  in  activity  detected  fits  with  the  increase  in  secretion 
observed in the presence of betaine. It should be noted however that the intra and 
inter assay CVs are relatively high at the low levels measured in these experiments 
(Chapter 2.6 and 2.7).  
One might argue that the increase in secretion of the p.I143T mutant in the presence 
of betaine could be due to increased cell division and subsequently increased protein 
secretion. Although this was not tested it seems unlikely because WT ADAMTS13 
levels did not increase in the presence of betaine. In fact there was a slight decrease 
in antigen and activity. This may have been due to toxicity of betaine to the cells. 
Despite this apparent slight toxicity increased levels of the mutant were still detected 
in the supernatant after betaine treatment.  
6.6.2  Deglycosylation experiments 
In cell lysate samples, two distinct bands were present, with the upper band more 
prominent in cells treated with betaine. This band was sensitive to Endoglycosidase 182 
 
H  digestion,  which  cleaves  most  N-linked  glycans  except  for  complex  glycans. 
Complex glycans are formed in the Golgi so ER associated proteins are sensitive to 
Endoglycosidase H digestion, suggesting that the upper band that was present in cell 
lysate samples corresponded to ER associated ADAMTS13. 
The lower band did not appear to be sensitive to Endoglycosidase H digestion as the 
band which remained after digestion appeared to be approximately the same size as 
the  band  before  digestion.  This  band  could  therefore  correspond  to  glycosylated 
ADAMTS13  present  in  the  Golgi  of  the  cell  (resistant  to  Endoglycosidase  H 
digestion)  or  unglycosylated  protein.  It  seems  more  likely  to  be  unglycosylated 
protein because of its lower molecular weight. Glycosylation increases the molecular 
weight of a protein causing it to run slower on an SDS-gel and hence lies closer to 
the top of the gel. If this lower band did correspond to glycosylated protein present in 
the Golgi of the cell then it would be sensitive to PNGase F digestion as this enzyme 
can cleave complex glycans. After PNGase digestion one band remained and again 
this was approximately the same size as the lower band present before digestion. 
This  suggests  that  the  lower  band  in  the  undigested  samples  corresponds  to 
unglycosylated protein as opposed to glycosylated protein present within the Golgi.  
The appearance of the lower unglycosylated band appeared to be time dependent, 
being  present  in  cells  that  that  were  confluent  ~96  (cell  lysate  samples  from 
transiently  transfected  cells)  hours  but  not  ~5  hours  (cell  lysate  samples  from 
proteasome/lysosome inhibition experiments). Majerus et al found that intracellular 
ADAMTS13  is  predominantly located in  compartments  of the secretory pathway 
prior to the cis-Golgi (Majerus et al, 2003) suggesting that the rate limiting step for 
ADAMTS13 synthesis is folding in the ER. Perhaps after 96 hours there is more 
protein ‘waiting’ to be glycosylated, leading to more unglycosylated protein present 
in  the  cell  (lower  band).  Betaine  was  associated  with  a  higher  proportion  of 
glycosylated compared to unglycosylated protein. This fits with the role of betaine 
acting as a chaperone within the cell to aid folding. The ability of betaine to aid 
folding  of  ADAMTS13  appears  to  promote  glycosylation  of  the  protein,  in  turn 
leading to a greater proportion of glycosylated compared to unglycosylated protein 
within the ER of the cell. This in turn promotes the secretion of the protein.    183 
 
Glycosylated and unglycosylated forms of other proteins have been demonstrated in 
cell lysate samples (cystic fibrosis, Long QT syndrome), with misfolded mutants 
having more of the unglycosylated compared to glycosylated forms present within 
the cell. When cells were incubated with chaperones an increase in the glycosylated 
form could be detected in the cell (Zhou et al, 1999;Brown et al, 1996).  
Looking back at Figure 6-1 it appeared that with increasing concentrations of betaine 
there was less ADAMTS13 within the cell. In the experiments described above (with 
100mM betaine), this was not always the case (Figure 6-4, more total ADAMTS13 in 
the presence of betaine). However in the presence of betaine the upper band was 
always more prominent. This band corresponded to glycosylated protein. The cell 
lysate samples from Figure 6-1 were not run on 3-8% gels but looking at the cell 
lysate samples at 150mM, although there appears to be less total ADAMTS13, the 
ADAMTS13 that is present does appear to be of a higher molecular weight. In Figure 
6-2  looking  at  the  p.I143T  mutant  in  the  absence  of  betaine  compared  to  the 
presence,  the  band  in  the  absence  of  betaine  appears  to  have  a  lower  molecular 
weight than the others. Similarly comparing the WT 150mM band with the 100mM 
band, the 150mM band appears to be slightly higher.  
6.6.3  Protein folding and the osmophobic effect 
The  hydrophobic  effect  is  one  of  the  important  determinants  of  protein  folding. 
Osmolytes are thought to produce an additional force, the osmophobic effect, for 
protein folding. The mechanism behind the stabilisation of proteins in the presence of 
osmolytes was first investigated by Lee and Timasheff (Lee & Timasheff, 1981). The 
authors  studied  the  thermal  transition  of  three  proteins  in  the  presence  of  an 
osmolyte,  sucrose  and  found  that  sucrose  was  preferentially  excluded  from  the 
vicinity of the protein, with an increase in the Gibbs free energy (more negative 
value). The presence of sucrose did not significantly change the confirmation of the 
the proteins studied. 
This  preferential  exclusion  phenomena  has  been  subsequently  found  for  other 
naturally occurring osmolytes (Arakawa & Timasheff, 1983;Arakawa & Timasheff, 
1985), including betaine (Arakawa & Timasheff, 1983). This increase in negative 184 
 
Gibbs  free  energy  enhances  the  thermodynamic  stability  of  proteins,  thereby 
enhancing protein folding.  
It has been shown that an unfavourable interaction exists between an osmolyte and 
the peptide backbone (Qu et al, 1998). On the other hand a favourable interaction 
occurs between amino acid side chains. The unfavourable interaction of the peptide 
backbone with an osmolyte, however, is the thermodynamic force responsible for 
raising  the  chemical  potential  of  both  the  native  and  unfolded  states  upon  their 
transfer  from  water  to  osmolyte  solution.  The  unfavourable  interaction  causes  a 
preferential exclusion of the osmolyte (Qu et al, 1998). Relative to the native state, a 
denatured protein exposes much more of the protein fabric to the solvent. Thus the 
denatured  state  of  the  protein  is  more  solvophobic  (has  a  greater  preferential 
exclusion) toward osmolyte than the native state. By focusing the solvophobic effect 
force  on  the  denatured  state,  the  native  state  is  left  free  to  function  relatively 
unaffected by the presence of osmolyte.  
6.6.4  Therapeutic use of chaperones 
Betaine could potentially be a good candidate for therapy. It is present in various 
organisms  including animals and plants (Yancey et al, 1982) and is used in the 
treatment  of  homocystinuria  (Lawson-Yuen  &  Levy,  2006).  It  is  used  as  a  food 
supplement  (Zeisel  et  al,  2003)  and  can  be  taken  orally.  The  activity  of  many 
enzymes in vitro was shown not to be affected by high concentrations of betaine (up 
to 1M) (Pollard & Wyn Jones, 1979).  
Betaine could be potentially administered to patients prophylactically and would be a 
more  practical  method  of  prophylaxis  than  plasma  infusion.  It  could  also  be 
administered orally. This would have its advantages over plasma infusion which is an 
invasive procedure.  
Organic solutes such as betaine can be transported into cells via sodium and chloride-
coupled  cotransporters.  Betaine  can  be  transported  by  the  betaine/GABA 
cotransporter (BGT-1). These cotransporters are present in many cells including the 
kidney, brain, liver, heart, muscle and placenta  (Borden et al, 1995;Rasola et al, 
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The  use  of  betaine  or  other  chemical  chaperones  or  the  development  of 
pharmacological chaperones may be something worth considering in the treatment of 
TTP,  particularly  as  the  majority  of  mutations  in  ADAMTS13  which  have  been 
identified and investigated in vitro have been shown to reduce its secretion.   
Besides Haemophilia A, the use of chaperones to rescue mutant proteins in other 
haematological disorders has not been investigated in vitro or in vivo. The results 
summarised  in  Table  6-2  and  Table  6-3  demonstrate  that  a  variety  of  proteins 
(nuclear, cytoplasmic, plasma membrane and secreted proteins) can be rescued by 
chemical  or  pharmacological  chaperones,  although  sometimes  the  effect  of  these 
chaperones  is  mutation  dependent.  Chemical  or pharmacological  chaperones  may 
have  the  potential  therefore  to  rescue  mutant  proteins  defective  in  other 
haematological disorders, i.e. not just secretory proteins such as ADAMTS13 and 
FVIII.  
It is important to consider also that the concentrations of chemical chaperones that 
were  shown  to  have  an  effect  in  vitro  may  not  be  achievable  in  humans.  The 
concentrations  of  glycerol  and  TMAO  needed  for  chaperone-like  effects  in  cell 
culture have been in the range of 0.5-1.2M and 50-100mM, respectively. Studies in 
mice administered glycerol or TMAO have indicated that it is possible to achieve 
these concentrations for TMAO but not for glycerol in vivo (Bai et al, 1998).   
Pharmacological  rather  than  chemical  chaperones  may  have  a  broader  and  more 
potent  effect  than  chemical  chaperones  for  the  protein  of  interest.  For  example 
Robben  et  al  added various  pharmacological  and chemical chaperones  to  mutant 
vasopressin V2 receptors. Chemical chaperones could rescue 1 of 9 mutants, whereas 
pharmacological chaperones rescued 2 of 9 of these mutants (Robben et al, 2006). 
Additionally higher concentrations  of  chemical  chaperones  are  generally  required 
than  pharmacological  chaperones.  In  Gaucher  disease  the  development  of  new 
generations of pharmacological chaperones has increased the number of mutations 
that can be treated with these chaperones (Benito et al, 2011). As pharmacological 
chaperones are more specific they would also reduce the risk of possible side effects.  186 
 
Chemical/pharmacological chaperone treatment in combination with enzyme/factor 
replacement strategies could improve their efficacy. Incubation of fibroblasts from 
patients  with  Fabry  disease  with  the  pharmacological  chaperone  DGJ  and 
recombinant  α-Galactose  A  resulted  in  up  to  4  fold  higher  enzyme  levels  than 
enzyme alone. Coadministration in rats led to an increase in the circulating half-life 
of recombinant α-Galactose A by >2.5 fold and in α-Galactose A KO mice up to 5 
fold (Benjamin et al, 2012). This strategy of co-administration of a pharmacological 
chaperone with enzyme replacement therapy is currently being tested in a Phase III 
clinical  trial  in  patients  with  Fabry  disease  (NCT01218659,  URL: 
www.clinicaltrials.gov, accessed 17
th June 2014). 
6.6.5  Osmolytes and the kidney 
As explained earlier kidney cells contain urea which denatures protein. To offset this 
cells produce/acquire osmolytes to counteract the effect of urea. It is interesting that 
the kidney (which produces ADAMTS13) is generally unaffected in patients with 
TTP. ADAMTS13 is produced by podocytes in the renal cortex (Manea et al, 2007a) 
and is also expressed in glomerular endothelial cells, microvascular endothelial cells 
(Tati et al, 2011) and in renal cortex tubular endothelial cells (Manea et al, 2010). 
Similarly  the  CFTR  protein  which  is  defective  in  patients  with  cystic  fibrosis  is 
expressed at high levels in the kidney but patients have little or no apparent kidney 
dysfunction. Howard et al found that hyperosmotic stress in kidney cells cultured in 
vitro expressing a CFTR mutant, increased levels of different osmolytes within the 
cell and additionally promoted the correct maturation of the CFTR mutant (Howard 
et al, 2003). 
6.6.6  Weaknesses 
It should be noted that the supernatant samples analysed in these experiments were 
highly concentrated ~100 fold for analysis. Therefore, in unconcentrated media it is 
likely  that  there  would  only  be  a  small  increase  in  secretion  and  activity  of  the 
mutant in the presence of betaine. If betaine was to be used in vivo its effects on 
ADAMTS13  secretion  may  appear  to  be  small  or  may  not  be  easily  detectable. 
However, in vivo it has been shown that residual ADAMTS13 activity (undetectable 187 
 
by  assays  currently  used  to  measure  ADAMTS13  activity  in  patient  plasma)  is 
associated with disease severity (Lotta et al, 2012). Therefore. even a small increase 
in ADAMTS13 activity may be beneficial and change significantly the picture of 
clinical severity of congenital TTP patients. 
6.6.7  Future work  
In the future it would be interesting to express the mutant in different cells types such 
as hepatic stellate cells and to analyse whether betaine or other osmolytes have the 
same effect on the secretion of the mutant. Furthermore expression of the mutant in 
transgenic mice administered betaine would help to understand whether betaine is 
likely to have an effect in vivo. 
6.6.8  Conclusion 
 The p.I143T mutant severely affected the secretion of ADAMTS13. This mutant is 
degraded by the cell proteasome. The use of a chemical chaperone (betaine) led to 
increased secretion and as a result increased activity of the mutant. Betaine appears 
to aid the folding of the mutant within the cell (preventing its degradation by the 
proteasome) thereby promoting its secretion.  188 
 
Chapter 7   ADAMTS13 catalytic characterisation  
(type 2 mutant) 
7.1  Introduction 
When the p.R102H mutant  was  expressed  in  vitro it led to  reduced secretion of 
ADAMTS13 (on average 30% of WT ADAMTS13) (Chapter 3). The activity of the 
mutant was also reduced. I aimed to characterise further how this mutation affected 
the enzyme activity using purified protein.  
7.1.1  Order of reaction 
The rate of catalysis of an enzyme can often be calculated by measuring product 
formation or substrate depletion over time. The velocity of an enzymatic reaction 
may or may not depend on the concentration of a particular reactant. The relationship 
between the initial concentration of a substrate and the rate of a reaction can be 
described by the order of the reaction. A reaction can be described as zero order with 
respect  to  substrate,  if  substrate  concentration  decreases  and  product  formation 
increases in a linear fashion over time (Figure 7-1). In a zero order reaction the rate 
of the reaction is independent of substrate concentration.  
In  a  first  order  reaction  the  rate  of  the  reaction  is  proportional  to  substrate 
concentration. The relationship between substrate concentration and time is not linear 
because during the course of the reaction the concentration of substrate decreases 
which affects the rate of the reaction (Figure 7-1). If a reaction is second order with 
respect to a substrate the rate of reaction is proportional to the square of the substrate 
concentration.  
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Figure  7-1  Changes  in  substrate  and  product  concentration  in  zero,  first  and  second  order 
reactions 
The graphs show the relationship between substrate concentration and product concentration over 
time in zero, first and second order reactions. The relationship between substrate concentration and 
time is represented by the equation within each plot. The rate of reaction or velocity in relation to a 
particular substrate is shown on the far right hand side. In a zero order reaction, the reaction does not 
depend on substrate concentration, but on the rate constant (k). In a first order reaction it depends 
upon the concentration of substrate and k, whereas in a second order reaction it depends on the square 
of the substrate concentration and k. The constant k is a specific constant for a given reaction (Segel, 
1993). [S]: substrate concentration, [S]0: substrate concentration at time 0. 
7.1.2  Michaelis-Menten kinetics 
The relationship between an enzyme, its substrate(s) and product(s) can be thought to 
follow the scheme shown in Figure 7-2. Enzyme combines with substrate to form an 
enzyme/substrate complex which is dependent upon the rate constant (k1). This can 190 
 
lead to product formation with separation of the product from the enzyme (rate of 
which depends upon the rate constant k2) or alternatively the enzyme and substrate 
can seperate without catalysis occuring (rate of which depends upon the rate constant     
k  -1).  The  enzyme  and  product  can  sometimes  revert  back  to  form  the  enzyme 
substrate complex (the rate of this is dependent upon the rate constant k-2).  
 
Figure 7-2 Enzyme catalysis 
Where E is enzyme, S is substrate, P is product, and ES is enzyme/substrate complex. The terms k1,   
k-1, k2 and k-2 represent rate constants (Berg et al, 2002). 
Reaction rates () are often defined as the rate of increase in product, when product 
concentrations  are  low,  at  times  close  to  0.  The  reaction  rate  is  almost  linearly 
proportional  to  substrate  concentration  when  substrate  concentration  is  low  (first 
order kinetics). Under these conditions the reaction is said to behave like a pseudo 
first order reaction (Segel, 1993).  
The  rate  of  a  reaction  is  almost  independent  of  substrate  concentration  when 
substrate  concentration  is  large  (zero  order  kinetics)  (Figure  7-3).  As  substrate 
concentration increases the velocity plateaus and approaches the maximum velocity 
of the enzyme. Michaelis and Menten proposed a model to explain these kinetics 
(Equation 7-1). 191 
 
 
Figure 7-3 Michaelis-Menten kinetics 
The reaction rate (y axis) is plotted against substrate concentration (x axis) for a reaction obeying 
Michaelis-Menten kinetics. Where v is the rate of catalysis, Vmax is the maximum rate of a reaction, 
[S] is substrate concentration, KM is the Michaelis constant, kcat is the catalytic concentration, [E]0 is 
the initial enzyme concentration. Image from: (Fersht, 1985). 
 
Equation 7-1 Michaelis-Menten equation 
Where  is the initial rate of reaction, [E]0 is the initial enzyme concentration, [S] is the substrate 
concentration, Km is the Michaelis constant and kcat is the catalytic constant. The kcat is the same 
constant as k2 shown in Figure 7-2 and Figure 7-4 (Berg et al, 2002). 
The Michaelis-Menten equation assumes that none of the product reverts back to the 
original product (substrate) (Figure 7-4). This condition holds for the initial stage of 
a reaction, where products have not significantly accumulated and substrates have 
not been significantly depleted. This equation also assumes that the concentration of 
substrate is in excess of enzyme (Berg et al, 2002). 
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Figure 7-4 Enzyme catalysis according to the Michaelis-Menten equation 
Where E is enzyme, S is substrate, P is product, and ES is enzyme/substrate complex. The symbols k1, 
k-1 and k2 represent rate constants (Berg et al, 2002).  
7.1.3  Michaelis constant (Km) 
The Michaelis-Menten equation (Equation 7-1) includes the term Km, the Michaelis- 
Menten  constant.  This  constant  (Equation  7-2)  is  an  important  characteristic  of 
enzyme-substrate  interactions  and  is  independent  of  enzyme  and  substrate 
concentrations. This constant is equal to the substrate concentration at  which the 
reaction rate is half of its maximal value (Figure 7-3 and Equation 7-2). It therefore 
provides a measure of the substrate concentration required for significant catalysis to 
occur.  For  many  enzymes,  experimental  evidence  suggests  that  Km  provides  an 
approximation of substrate concentration in vivo  (Berg et al, 2002).  
Km  also  equals  the  dissociation  constant  of  the  ES  complex  (ES→E+S)  if  the 
constant k2 is much smaller than k-1. If this condition is met then it can be a measure 
of the strength of the ES complex, a high Km indicates weak binding, a low Km 
indicates strong binding.  
 
Equation 7-2 Michaelis constant 
The Michaelis constant can be expressed by the two equations above. Where Km is the Michaelis 
constant, Vmax is the maximum velocity and k1, k-1 and k2 and rate constants (Berg et al, 2002).  193 
 
7.1.4  Kinetic constant (kcat) 
The maximal rate of a reaction (Vmax) describes the turnover number of an enzyme 
which is the number of substrate molecules converted into product by an enzyme 
molecule per unit time when the enzyme is fully saturated with substrate. It depends 
on the enzyme concentration and the constant k2. The constant k2 is also known as 
the kcat (Figure 7-2).   
7.1.5  Catalytic efficiency (kcat/Km) 
The ratio kcat/Km also known as the catalytic efficiency is often used to characterise 
an  enzyme.  It  depends  upon  the  enzymes  ability  to  bind  substrate  and  then 
subsequently catalyse the reaction. When the concentration of a substrate is much 
lower than the Km, of the enzyme then the velocity depends upon kcat/Km, [S] and [E] 
as shown in Equation 7-3. This can be used to measure the kcat/Km of the enzyme.  
 
Equation 7-3 Michaelis-Menten equation when substrate concentration is lower than Km 
When substrate concentration is much lower than the Km,  in Equation 7-1 can be expressed as shown 
above. Where  is the initial rate of the reaction, kcat is the catalytic constant, Km is the Michaelis 
constant, [S] is the substrate concentration and [E]0 is the initial enzyme concentration (Berg et al, 
2002).  
7.1.6  Assays to measure ADAMTS13 activity 
A variety of assays have been developed to measure ADAMTS13 activity in routine 
laboratories.  These  assays  vary  in  terms  of  the  substrate  used  (full  length  VWF 
multimers vs recombinant VWF peptides) and the method of detection (direct or 
indirect  detection  of  VWF  products)  (Peyvandi  et  al,  2010).  The  VWF  cleaved 
products  can  be  detected  using  electrophoresis,  measuring  platelet  aggregation, 
measuring FRET or using immunobinding (Peyvandi et al, 2010).  194 
 
The sensitivity of these methods varies. Assays using multimeric VWF can detect 
activities as low as 3-6% of normal, whereas VWF peptide assays are more sensitive, 
with the ability to detect activity 1-3% of normal. Assays based on the analysis of 
full length VWF multimers are time consuming (2-3 days) and are performed with 
the use of denaturing agents. On the other hand VWF peptide based assays are rapid 
(1-4 hours) and are performed in the absence of denaturing agents; however these 
assays use non-physiological VWF as a substrate (Peyvandi et al, 2010). There are 
advantages  and  disadvantages  therefore  of  the  various  methods  to  detect 
ADAMTS13 activity.  
7.1.7  ADAMTS13 polymorphisms 
Polymorphisms and mutations are genetic changes which can lead to amino acid 
changes such as missense mutations and deletions, but are distinguished based upon 
the frequency of occurrence of these genetic changes in the ‘normal’ population. 
Single nucleotide polymorphisms  are defined here as  single nucleotide  variations 
with a minor allele frequency (MAF) >0.01 in the population, whereas mutations are 
defined as having a MAF<0.01. ADAMTS13 polymorphisms are shown in Figure 
7-5. 
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Figure 7-5 ADAMTS13 polymorphisms 
ADAMTS13 polymorphisms as described by  (Lotta et al, 2010) and (Tseng & Kimchi-Sarfaty, 2011). 
Polymorphisms which have been expressed in vitro are shown underlined and in bold.  
Patient 3, a Caucasian patient, was homozygous for the mutation p.R102H and three 
polymorphisms:  p.Q448E  (cysteine-rich  region),  p.P618A  (spacer  domain)  and 
p.A900V (TSP-1:5 domain) (Figure 7-6).  
 
Figure  7-6  Location  of  ADAMTS13  mutation  and  polymorphisms  in  the  ADAMTS13  gene, 
mRNA and protein in patient 3  
Image adapted from (Zheng et al, 2001). Mutations are shown in red and polymorphisms in blue. 196 
 
Analysis  of  the  crystal  structure  of  ADAMTS13  has  shown  that  the  amino  acid 
p.Q448 is located within an α-helix in the N-terminal region of the cysteine-rich 
domain (Akiyama et al, 2009). The amino acid p.P618 is located in a loop proximal 
to the N-terminal cysteine-rich region, following a β6 sheet in the spacer domain. 
This loop which lies between β6 and β7 sheets plays a pivotal role in the interaction 
between the spacer domain and the N-terminal cysteine-rich domain (Akiyama et al, 
2009). Comparative modelling of ADAMTS13 with similar structures has suggested 
that the p.A900V polymorphism lies within a beta sheet (Edwards et al, 2012).  
The frequency of the two alleles of the polymorphic amino acids identified in patient 
3 is shown in Table 7-1. The reported frequencies are based upon results from phase 
I  of  the  1000  genomes  project,  which  are  reported  in  Ensembl  (URL: 
www.Ensembl.org, accessed 17
th June 2014).  
As  shown  in  Table  7-1,  in  Caucasians  (and  in  the  total  number  of  individuals 
studied),  the  MAF  of  these  three  polymorphisms  is  >0.01.  The  p.Q448E 
polymorphism in Caucasians appears to be the most common polymorphism (studied 
here),  whereas  the  p.P618A  polymorphism  appears  to  be  less  common.  In  other 
ethnic groups some of these polymorphisms have a MAF<0.01 (African: p.P618A 
and Eastern Asians: p.A900V). 197 
 
rs number  cDNA change  Protein  
change 
Allele Frequency 
ALL  AFR  AMR  ASN  EUR 
rs2301612  c.1342C>G  p.Q448E 
CAA  GAA  CAA  GAA  CAA  GAA  CAA  GAA  CAA  GAA 
0.725  0.275  0.943  0.057  0.635  0.365  0.811  0.189  0.562  0.438 
rs28647808  c.1852C>G  p.P618A 
CCC  GCC  CCC  GCC  CCC  GCC  CCC  GCC  CCC  GCC 
0.956  0.044  0.994  0.006  0.961  0.039  0.979  0.021  0.912  0.088 
rs685523  c.2699C>T  p.A900V 
GCG  GTG  GCG  GTG  GCG  GTG  GCG  GTG  GCG  GTG 
0.914  0.086  0.839  0.161  0.914  0.086  1  0  0.897  0.103 
Table 7-1 Allele frequency of ADAMTS13 polymorphisms within different populations included in the 1000 genomes project 
ALL-all  individuals  studied,  AFR-African,  AMR-American,  ASN-Eastern  Asian,  EUR-European  individuals  from  phase  I  of  the  1000  genome  project.  African  sub-
populations included Americans of African ancestry in South-Western USA, Luhya in Webuye, Kenya and Yoruba in Ibadan Nigeria. American sub-populations included 
Columbian from Medellin, Columbia, Mexican ancestry from Los Angeles, USA and Puerto Ricans from Puerto Rica. Asian sub-populations included Han Chinese in 
Beijing, Southern Han Chinese and Japanese in Tokyo, Japan. Europeans included Utah residents with Northern and Western European ancestry, Finnish in Finland, British in 
England and Scotland, Iberian population in Spain and Toscani in Italy. The nucleotide which differs between the two amino acids is shown underlined. The allele which is 
less common is highlighted in pink. Information from Ensembl (URL: http://www.ensembl.org/index.html, accessed 17
th June 2014).  198 
 
7.2  Purification of WT and p.R102H mutant ADAMTS13 
A  stable  line  of  WT  and  p.R102H  mutant  ADAMTS13  was  produced  to  stably 
express large quantities of protein for catalytic analysis. WT and p.R102H mutant 
ADAMTS13  were  purified  as  described  in  methods  (Chapter  2.12).  After 
purification of WT and p.R102H mutant recombinant ADAMTS13, samples of the 
purified material  were  viewed using  a  Coomassie stain  (Figure  7-7), which non-
specifically  stains  proteins,  to  assess  the  purity  of  the  samples.  Along  with  the 
purified  WT and  p.R102H mutant  ADAMTS13  samples,  unpurified material and 
some of the flow through obtained after the purification procedure were also run.  
 
Figure 7-7 Coomassie staining 
Unpurified, purified and the flow through obtained after purification of WT and  p.R102H mutant 
ADAMTS13 were analysed using Coomassie staining. Expected molecular weight of ADAMTS13 
~190kDa. 
Multiple  bands  could  be  observed  in  the  unpurified  supernatant  from  WT  and 
p.R102H mutant ADAMTS13 (Figure 7-7). A number of bands could be observed in 
the flow through also (particularly between 75 and 50kDa).  Within the purified 
material  a band could  be seen at  the expected molecular weight  of ADAMTS13 
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(~190kDa).  A  faint  band  of  the  same  size  could  be  observed  in  the  unpurified 
material  from  WT  but  not  in  the  flow  through.  The  band  corresponding  to 
ADAMTS13 was clearly visible in the purified, as opposed to the unpurified material 
as the purified material was more concentrated.  
Western blotting was additionally carried out on the samples. This method is more 
sensitive and specific in its ability to detect the protein of interest (i.e. ADAMTS13). 
As shown in Figure 7-8 a band corresponding to ADAMTS13 was present at the 
expected molecular weight, confirming that the band visible in the Coomassie stain 
was ADAMTS13.  
 
 
Figure 7-8 Purified and unpurified ADAMTS13 
Unpurified, purified and the flow through obtained after purification of WT and  p.R102H mutant 
ADAMTS13 were analysed using western blotting. Expected size of ADAMTS13~190kDa. 
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In  WT  ADAMTS13  a  lower  molecular  weight  band,  approximately  20kDa  was 
present. The purified samples were later concentrated using an Amicon centrifugal 
device with a 100kDa cut-off, which would have removed these lower molecular 
weight bands. WT protein was produced and analysed using Coomassie staining and 
western blotting first. Consequently the purified p.R102H mutant was concentrated 
before Coomassie staining and western blotting was carried out and as shown these 
lower molecular weight bands are not present in this sample 
7.3  Calculating the catalytic efficiency (kcat/Km) 
Time course experiments were set up to assess the catalytic efficiency (kcat/Km) of 
WT and  p.R102H  mutant  ADAMTS13.  In order to  assess this  ADAMTS13 was 
incubated  with  FRETS-VWF73  substrate  and  fluorescence  was  measured,  as  a 
measure of product formation over time as shown in Figure 7-9.  
 
Figure 7-9 Time course experiment 
Initial reaction values were used to calculate kcat/Km.  
The reaction was set up under pseudo first order conditions, so that the concentration 
of VWF (2μM) was smaller than the Km of FRETS-VWF73. Anderson et al found 
that ADAMTS13 cleaved FRETS-VWF73 with a Km app of 3.2±1.1μM, Di Stasio et 
al measured a Km of 4.5ﾱ0.5μM and Feys et al 2010 measured a Km of 2.3ﾱ0.3μM 
(Anderson et al, 2006;Di Stasio et al, 2008;Feys et al, 2009b). Under these pseudo 
first  order  conditions  the  rate  of  reaction  should  be  proportional  to  the  substrate 201 
 
concentration,  =k[S]  (Figure  7-1).  Equation  7-3  shows  the  value  of    when 
substrate concentrations are low so substituting =k[S] into this equation gives the 
equation shown in Equation 7-4. The kcat/Km can then be calculated from this. The 
observed value of k (kobs) was derived from the curve obtained after fluorescence 
production.  
 
 
Equation 7-4 Experimental determination of kcat/Km 
Where E0 is the enzyme concentration (Fersht, 1985). 
The kcat/Km for WT was 2.8 x 10
5 M
-1sec
-1 and for the p.R102H mutant this value 
was 0.75 x 10
5 M
-1sec
-1, so there was an approximate 4 fold difference between the 
two. 
7.4  VWF multimer analysis 
The activity of WT and p.R102H mutant ADAMTS13 was analysed further using 
VWF multimer analysis. Equal quantities of WT or p.R102H mutant ADAMTS13 
was incubated with full length VWF and VWF multimeric pattern was analysed over 
time (Figure 7-10). At 30 minutes there appeared to be a slight difference between 
WT and  p.R102H  mutant  ADAMTS13, with more of the intermediate  molecular 
weight multimers present in the mutant. However at the remaining time points there 
did not appear to be a noticeable difference between the two.  202 
 
 
Figure 7-10 VWF multimer analysis 
Equal quantities of WT and p.R102H mutant ADAMTS13 were incubated with full length VWF and 
VWF multimeric pattern over time was analysed using electrophoresis. Representative of n=2.  
7.5  In silico analysis of polymorphisms 
The p.R102H mutation affected the secretion and activity of ADAMTS13. However 
the activity of the p.R102H mutant was not as severely affected as hypothesised 
based upon the undetectable ADAMTS13 activity measured in the patient plasma. 
The patient with the p.R102H mutation was also homozygous for three ADAMTS13 
polymorphisms  (p.Q448E,  p.P618A  and  p.A900V).  The  effect  of  these 
polymorphisms  in  combination  with  the  p.R102H  mutation  was  investigated  to 
understand whether they could further affect the activity of ADAMTS13. 
The predicted effects of the polymorphisms present in patient 3 on ADAMTS13 was 
analysed using three computational tools: SNPs3D, Polyphen2 and SIFT (Table 7-2). 
All three polymorphisms appeared to be tolerated as predicted by SIFT, although the 
p.P618A  polymorphism  had  the  lowest  score.  The  p.Q448E  and  p.A900V 
polymorphisms were not predicted to be deleterious by SNPs3D are were predicted 
to be benign by Polyphen2, whereas the p.P618A polymorphism was predicted to be 
probably damaging by Polyphen2 and had a negative score by SNPs3D, indicating 203 
 
that it may be deleterious. Of the three polymorphisms, the p.P618A polymorphism 
appeared to be the most likely to have an effect in vivo and in vitro.  
  SNPs3D 
 svm profile 
Polyphen2  SIFT  
 
Score  Prediction 
p.Q448E  1.35  Benign  1  Tolerated 
p.P618A  -1.09  Probably damaging  0.14  Tolerated 
p.A900V  0.33  Benign  0.29  Tolerated 
 
Table 7-2 In silico prediction of the effect of ADAMTS13 polymorphisms 
Positive SNPs3D score indicated to be non-deleterious whereas a negative score deleterious. Accuracy 
is significantly increased with scores above 0.5 and below  -0.5. Scores >0.05 are predicted to be 
tolerated by SIFT.  
The conservation of the amino acids affected by polymorphisms in patient 3 was 
investigated by aligning the protein sequence of human ADAMTS13 with either the 
protein sequence of ADAMTS13 in other animals (ADAMTS13 orthologs) or with 
the protein sequence of other human ADAMTS proteins (ADAMTS13 paralogs). 
Results  of  this  analysis  in  the  region  of  the  amino  acids  affected  by  these 
polymorphisms are shown in Figure 7-11 and Figure 7-12. The polymorphic amino 
acids in the patient are highlighted in yellow. 
In 20/21 ADAMTS13 orthologs studied (Figure 7-11) the glutamine (Q) at position 
448 was replaced with glutamic acid (E). This suggests that the polymorphism may 
have little or no effect on the structure or activity of ADAMTS13. Glutamic acid (E) 
and glutamine (Q) are both surface exposed polar molecules, glutamic acid however 
is negatively charged whereas glutamine is neutral.  
In 20/21 ADAMTS13 orthologs studied (Figure 7-11) there was a proline residue (P) 
at position 618 whereas in 1/21 there was an alanine (A) residue at this position. This 
amino acid therefore (p.P618) is more highly conserved in ADAMTS13 orthologs in 
comparison to p.Q448, suggesting it may be important to have a proline (P) residue 
at position 618. Proline (P) and alanine (A) are hydrophobic and neutral amino acids; 204 
 
proline (P) is normally a surface exposed amino acid, whereas the amino acid alanine 
(A) is normally buried within a protein.  
The amino acid at position 900 was more variable in terms of conservation (Figure 
7-11). In 2/21 orthologs studied there was an alanine (A) at this position and in 7/21 
there was a valine (V) at this position. Therefore, in 12/21 orthologs an amino acid 
other  than  alanine  (A)  or  (V)  was  present.  Alanine  and  valine  are  hydrophobic, 
buried and neutral amino acids.  
These amino acids are not so well conserved in ADAMTS paralogs (Figure 7-12). In 
paralogs glutamine (Q) was present in 5/18 ADAMTS proteins and a glutamic acid 
(E) was present in 6/18 paralogs at position 448. In ADAMTS paralogs there was 
neither a proline (P) nor alanine (A) present at the position corresponding to amino 
acid  618.  Polymorphisms  p.Q448E  and  p.P618A  are  present  in  the  cysteine  and 
spacer  domains  of  ADAMTS13  respectively.  These  domains  within  ADAMTS 
proteins are thought to confer substrate specificity to the ADAMTS proteins (Apte, 
2004). Therefore, the functions of these domains are slightly different in different 
ADAMTS proteins and so it is not surprising that they are not so well conserved.  
The amino acid at position 900 in ADAMTS13 is present in the TSP-5 domain of 
ADAMTS13.  The  number  of  TSP  repeats  within  ADAMTS  proteins  is  variable 
(Apte,  2004)  which  is  evident  in  Figure  7-12.  This  region  is  absent  from  many 
ADAMTS paralogs. 205 
 
p.Q448 
Taeniopygia 481 RQRFCNNPRPAFGGQECHGASMQAEMCNTQACLMTQQDFMAEQCAATNLKPLYLDVET-P 539 
Gallus      345 RQRFCNNPRPAFGGKECQGASIQAEMCNTQACLMTQLDFMAEQCAATNLKPLYLTVGV-P 403 
Bos         396 RRRRCNNPRPAFGGRTCVGSDLQAEMCNTQACEKTQLEFMSEQCAQTDSEPLRLSPGGST 455 
Ovis        435 RRRRCDNPRPAFGGRACVGSDLQAEMCNTQACETTQLEFMSEQCAQTDGEPLHLSPGGST 494 
Gorilla     411 RRRQCNNPRPAFGGRACVGADLQAEMCNTQACEKTQLEFMSEQCARTDGQPLRSSPGG-A 469 
Pan         365 RRRQCNNPRPAFGGRACVGADLQAEMCNTQACEKTQLEFMSEQCARTDGQPLRSSPGG-A 423 
ADAMTS13    407 RRRQCNNPRPAFGGRACVGADLQAEMCNTQACEKTQLEFMSQQCARTDGQPLRSSPGG-A 465 
Nomascus    401 ---QGGIPVPAFGGRACVGADLQAEMCNTQACEKTQLEFMSEQCARTDGQPLHSSPGG-A 456 
Pango       429 RRRQCNNPRPAFGGRACVGADLQAEMCNTQACEKTQLEFMSEQCARTDGQPLRSSPAG-A 487 
Papio       409 RRRQCNNPRPAFGGRACVGADLQAEMCNTQACEKTQLEFMSEQCARTDGQPLHSSPGG-A 467 
Callithrix  387 RRRQCSNPRPAFGGRVCVGADLQAEMCNTQACEKTQLEFMSEQCARTDGQPLPSSPGG-T 445 
Saimin      372 RRRQCSNPRPAFGGRACVGADLQAEMCNTQACEKTQLEFMSEQCSRTDGQPLHSSPGG-T 430 
Otolemur    391 RRRWCNNPRPAFGGRACVGADLQAEMCNTQACDKTQLEFMSEQCAETDDQPLHLSPGS-R 449 
Mus         412 RRRWCNNPRPAFGGRACVGEDLQAKMCNTQACEKTQLEFMSEQCAQTDRQPLQLSQGT-A 470 
Cricetulus  412 RRRWCNNPRPAFGGRTCVGEDLQAKMCNTQACEKTQLEFMTEQCAQTDSQPLHLPQGG-A 470 
Cava        408 RRRRCDNPRPAFGGRACAGADLQAEMCNTQACEKTQLEFMSEQCAQTDRQPLSLSLGG-T 466 
Canus       558 RRRHCNNPRPAFGGHVCVGADLQAEMCNTQACEKTQLEFMSEQCSQTDRKPLYLTPGN-A 616 
Felis       537 RRRQCSNPRPAFGGRACVGDDLQAEMCNTQACEKTQLDFMSEQCSRTDRKPLHLSPGH-A 595 
Ailuropoda  490 RRRQCNNPRPAFGGRACVGADLQAEMCNTQACEKTQLEFMSEQCSQTDRKPLHLSPGN-A 548 
Equus       399 RRRQCNNPRPAFGGRACVGADLQAEMCNTQACEKTQLEFMSEQCAETNGKPLSLSPGS-T 457 
Sarcophilus 510 RRRHCNNPRPAFGGRDCVGADLKAELCNTQACGKTQLEFMSEQCAATDGKPLYLTPGI-P 568 
Danio       383 RRRQCNNPRSAFGGTICKGQNTEAELCNLQLCDSTQLEFMARQCSATDQQPLSVSTDS-K 441 
                                                                              
p.P618 
Taeniopygia 649 SLPYNTTSAH-VTNRRPLFTHLAVKVKGEYVVAGKGKISLNVTYPSVLEDNQ-IKYQVFL 706 
Gallus      512 SLPYNATSVH-VINQRPLFTHLAVKVKGEYVVAGKGKISLNVTYPSVLEDRQ-IEYKVFL 569 
Bos         565 TVTPNLTSIY-IINRRPLFTHLAVRVRGRYVVAGNGSASASTSYPSLLEDNR-VEYRVTL 622 
Ovis        604 TVTPNLTSIS-VINRRPLFTHLGELARRSRLPNAGCRAVLLASFAAQIETQIPRSCSGPL 662 
Gorilla     579 TVTPNLTSVY-IANHRPLFTHLAVRIGGRYVVAGKMSISPNTTYPSLLEDGR-VEYRVAL 636 
Pan         533 TVTPNLTSVY-IANHRPLFTHLAVRIGGRYVVAGKMSISPNTTYPSLLEDGR-VEYRVAL 590 
ADAMTS13    575 TVTPNLTSVY-IANHRPLFTHLAVRIGGRYVVAGKMSISPNTTYPSLLEDGR-VEYRVAL 632 
Nomascus    566 TVTPNLTSVY-IANHRPLFTHLAVRIGGRYVVAGKTSISPNTTYPSLLEDGR-VEYRVAL 623 
Pango       608 TVTPSLTSVYXXPTHRPLFTHLAVRLGGRYVVAGKTSISPNTTYPSLLEDGR-IEYRVAL 666 
Papio       577 TVTPNLTSVY-IANHRPLFTHLAVRIGGRYVVAGKTSISSNTTYPSLLEDGR-VEYRVAL 634 
Callithrix  555 TVTPNLTSVY-VANHRPLFTHLAVRIGARYVVAGKSSISPSTTYPSLLEDGR-VEYRVTL 612 
Saimin      540 TVTPNLTSVY-VANHRPLFTHLAVRIGARYVVAGKSSISPSTTYPSLLEDGR-VEYRVAL 597 
Otolemur    559 TVTPNLTSVY-IANHRPLFSHLAVKVGGRYVVAGKASISPSTIFPSLLEDSR-VEYRVAL 616 
Mus         580 IVTPNMTNAH-IVNRRPLFTHLAVRIQGHYIVAGKTSISPNTTYPSLLEDYR-VEYRVTL 637 
Cricetulus  580 TVTPNMTSVH-IVNRRPLFTHLAVRIQGHYIVAGKTSISPSIMYPSLLEDCR-VEYRVTL 637 
Cava        576 TVTPNMTSVH-IVNRRPLFTHLAVKIGGRYVVAGEAGLAPSTTHPSLLEDSR-VEYRVAL 633 
Canus       726 TVTRNLTSVH-ITNRRPLFTHLAVRIRGHYIVAGNSSISPSTTYPSLLEDSR-VEYRVTL 783 
Felis       705 TVTRNLTSIY-VTNQRPLFTHLAVRIGGRYIVAGNSSISPSTTYPSLLEDSR-VEYRVTL 762 
Ailuropoda  658 TVTRNLTSVH-ITNRRPLFTHLAVRIRGRYVVAGNSSISPSTTYPSLLEDSR-VEYRVAL 715 
Equus       567 TVTPNLTSIY-VANQRPLFTHLAVRIRGRYVVAGNSSISPSTTYPSLLEDSR-VEYKVTL 624 
Sarcophilus 678 TIPPNFTTVH-ITNQKPLFTHLAVKVRGQYVVSGKKSISFNTTYPSVLEDNQ-IEYKVFL 735 
Danio       551 TLPLNASQVH-VFNTRSIFTHLAVLLNDKYVVSGNGKPGLSNTYPSPLEKSL-ITYKLYL 608 
                                                                              
p.A900 
Taeniopygia 908 SPVAGECSVSCGRGKTQLHY---------------------------------------- 927 
Gallus      772 SPLPGECSVSCGRGKTQIQWH--------------------------------------- 792 
Bos         883 TPLAGPCSVSCGQGLVELRFVCMDTALRTPVREELCDLASKPGSRREACQAAPCPARWR- 941 
Ovis        917 TPLAGPCSASCGQGLAELHFVCMDPALRTPVREELCDLASKPGSRREACQAAPCPARWR- 975 
Gorilla     902 TPAAGSCSVSCGRGLMELRFLCMDSALRVPVQEELCGLASKPGSRQEVCQAVPCPARWR- 960 
Pan         856 TPAAGSCSVSCGRGLMELRFLCMDSALRVPVQEELCGLASKPGSRREVCQAVPCPARWR- 914 
ADAMTS13    898 TPAAGSCSVSCGRGLMELRFLCMDSALRVPVQEELCGLASKPGSRREVCQAVPCPARWQ- 956 
Nomascus    889 TPVAGPCSVSCGRGLMELRFLCMDSALRVPVQEELCGLASKPGSRREVCQAVPCPARWR- 947 
Pango       932 TPVAGPCSVSCGRGLMELRFVCTDSALRVPVQEELCGLASKPGSRREVCQAVLCPAEWR- 990 
Papio       980 TPLAGPCSVSCGRGLMELRFLCMDSALRVPVQEELCGLASKPGSRWEVCQAVPCPARWQ- 958 
Callithrix  877 TPVAGLCSVSCGRGLMELRFLCMDSALRVPAQEELCGLANKPGSRWEVCQAVPCPARWR- 935 
Saimin      804 TPLAGPCSVSCGRGLMKLRFLCMDSALRVPAQEELCGLASKPGSRWEVCQAVPCPARWR- 862 
Otolemur    807 TPLVGPCSVSCGRGLMELWFLCTDSALRVPVEEVLCDLAGKPGSRWMVCQADPCPAQWR- 865 
Mus         905 TPLVGLCSISCGRGLKELYFLCMDSVLKMPVQEELCGLASKPPSRWEVCRARPCPARWET 964 
Cricetulus  902 TPVTGLCSTSCGRGLMELHFLCMDSVLKMPVQEELCDLASKPSSRWEVCRAGPCPARWET 961 
Cava        864 TPVPGLCSVSCGQGLVELRSLCVDPVLRTPVQEKLCNLASRPGSRWEVCWAGPCPAHWEA 923 
Canus       987 TPLAGPCSASCGQGLTELNFMCMDSALGTPVREELCDLESKPGSRQEVCQAAPCPAWWR- 1045 
Felis       965 TPVAGPCSVSCSRGLKELHFVCVDSVLGTPVQEELCDLGSKPGSRREVCQAAPCPAWWQ- 1023 
Ailuropoda  978 TPLAGPCSASCGRGLMELHFVCMDSALGTSVREELCDLESKPGSRQEACQAAPCPAGWR- 1036 
Equus          ------------------------------------------------------------ 
Sarcophilus 999 SPLVGECSVSCGTGLRELRYVCLDFASRKEVQEEKCNPVNPPANQMMVCHAAACPPRWR- 1057 
Danio       813 SPRTGECSKTCGNGSQQVQFSCVDHKSRLEVPETLCDPTTKPAQDTQPCRISLCLPIWR- 871 
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p.Q448 
ADAMTS1    603  VRYRSCNLEDCPD-NNGKTFREEQCEAHNEFSKASFGSGPAVEWIPKYAGVS-PKDRCKL 660 
ADAMTS4    564  TRFRSCNTEDCPT-GSALTFREEQCAAYNHRTDLFKSFPGPMDWVPRYTGVA-PQDQCKL 621 
ADAMTS15   560  VKYRSCNLEPCPSSASGKSFREEQCEAFNGYNHSTNRLTLAVAWVPKYSGVS-PRDKCKL 618 
ADAMTS8    570  AKYQSCHTEECPP--DGKSFREQQCEKYNAYNYTDMDGN-LLQWVPKYAGVS-PRDRCKL 625 
ADAMTS5    611  AIYRSCSLMPCPP--NGKSFRHEQCEAKNGYQSDAKGVKTFVEWVPKYAGVL-PADVCKL 667 
ADAMTS9    632  MKFKSCNTEPCLK--QKRDFRDEQCAHFDGKHFNINGLLPNVRWVPKYSGIL-MKDRCKL 688 
ADAMTS20   600  MKFRSCNTDSCPK--GTQDFREKQCSDFNGKHLDISGIPSNVRWLPRYSGVG-TKDRCKL 656 
ADAMTS3    595  FEYQLCNTEECQK--HFEDFRAQQCQQRNSHFEYQNTKHHWLPYEHPDP-----KKRCHL 647 
ADAMTS14   596  FEYQVCNSEECPG--TYEDFRAQQCAKRNSYYVHQNAKHSWVPYEPDDD-----AQKCEL 648 
ADAMTS2    605  YDFQLCSRQDCPD--SLADFREEQCRQWDLYFEHGDAQHHWLPHEHRDA-----KERCHL 657 
ADAMTS6    602  KRYRSCNTDPCPL--GSRDFREKQCADFDNMPFRGKYYN-----WKPYTGG--GVKPCAL 652 
ADAMTS10   591  RRHRSCNTDDCPP--GSQDFREVQCSEFDSIPFRGKFYK-----WKTYRGG--GVKACSL 641 
ADAMTS7    582  KRFRLCNLQACPA--GRPSFRHVQCSHFDAMLYKGQLHT-----WVPVVN---DVNPCEL 631 
ADAMTS12   586  KRYRLCNVHPCRS--EAPTFRQMQCSEFDTVPYKNELYH-----WFPIFN---PAHPCEL 635 
ADAMTS16   630  RTLKLCNSQKCPR--DSVDFRAAQCAEHNSRRFRGRHYK-----WKPYTQVE-DQDLCKL 681 
ADAMTS18   633  RIYQLCNINPCNE--NSLDFRAQQCAEYNSKPFRGWFYQ-----WKPYTKVE-EEDRCKL 684 
ADAMTS17   587  VEHAVCENLPCPK--GLPSFRDQQCQAHDR--LSPKKKG-----LLTAVVV--DDKPCEL 635 
ADAMTS19   675  KQYRICENPPCPA--GLPGFRDWQCQAYSVRTSSPKHIL-----QWQAVLD--EEKPCAL 725 
ADAMTS13   428  LQAEMCNTQACEK--TQLEFMSQQCARTDGQPLRSSPGGASFYHWGAAVPHSQGDALCRH 485 
 
p.P618 
ADAMTS1    739  HDIITIPTGATNIEVKQRNQRGSRNNGSFLAIKAADGTYILNGDYTLSTLEQDIMYKG-V 797 
ADAMTS4    700  NNVVTIPAGATHILVRQQGNPGHRS--IYLALKLPDGSYALNGEYTLMPSPTDVVLPGAV 757 
ADAMTS15   697  NFVVAIPAGASSIDIRQRGYKGLIGDDNYLALKNSQGKYLLNGHFVVSAVERDLVVKG-S 755 
ADAMTS8    704  NDIVTIPAGATNIDVKQRSHPGVQNDGNYLALKTADGQYLLNGNLAISAIEQDILVKG-T 762 
ADAMTS5    746  TDVVRIPEGATHIKVRQFKAKDQTRFTAYLALKKKNGEYLINGKYMISTSETIIDING-T 804 
ADAMTS9    767  NTVVRIPAGATNIDVRQHSFSGETDDDNYLALSSSKGEFLLNGNFVVTMAKREIRIGN-A 825 
ADAMTS20   735  NVVVKIPAGATNVDIRQYSYSGQPDD-SYLALSDAEGNFLFNGNFLLSTSKKEINVQG-T 792 
ADAMTS3    729  LKMFDIPPGARHVLIQED----EASPHILAIKNQATGHYILNGKG-EEAKSRTFIDLG-- 781 
ADAMTS14   730  LKLVQIPAGARHIQIEAL----EKSPHRIVVKNQVTGSFILNPKG-KEATSRTFTAMG-- 782 
ADAMTS2    739  IKMFEIPAGARHLLIQEV----DATSHHLAVKNLETGKFILNEENDVDASSKTFIAMG-- 792 
ADAMTS6    733  MEVVQIPRGSVHIEVREV-----AMSKNYIALKSEG-DDYYINGAWTIDWPRKFDVAG-T 785 
ADAMTS10   722  EDVVWIPKGSVHIFIQDL-----NLSLSHLALKGDQ-ESLLLEGLPGTPQPHRLPLAG-T 774 
ADAMTS7    713  VDVGLIPAGAREIRIQEV-----AEAANFLALRSEDPEKYFLNGGWTIQWNGDYQVAG-T 766 
ADAMTS12   717  VDIGLIPKGARDIRVMEI-----EGAGNFLAIRSEDPEKYYLNGGFIIQWNGNYKLAG-T 770 
ADAMTS16   762  YHMVTIPSGARSIRIYEM-----NVSTSYISVRNAL-RRYYLNGHWTVDWPGRYKFSG-T 814 
ADAMTS18   765  YPVVLIPAGARSIEIQEL-----QVSSSYLAVRSLS-QKYYLTGGWSIDWPGEFPFAG-T 817 
ADAMTS17   713  ------------------------------ALKDSG--KGSINSDWKIELPGEFQIAG-T 739 
ADAMTS19   805  VEVLVIPAGARRIKVVEE-----KPAHSYLALRDAG--KQSINSDWKIEHSGAFNLAG-T 856 
ADAMTS13   571  VTFLTVTPNLTSVYIANHRPLFTHLAVRIGGRYVVAGKMSISPNTTYPSLLEDGRVEYRV 630 
 
p.A900 
ADAMTS1         ------------------------------------------------------------ 
ADAMTS4         ------------------------------------------------------------ 
ADAMTS15        ------------------------------------------------------------ 
ADAMTS8         ------------------------------------------------------------ 
ADAMTS5         ------------------------------------------------------------ 
ADAMTS9         ------------------------------------------------------------ 
ADAMTS20        ------------------------------------------------------------ 
ADAMTS3         ------------------------------------------------------------ 
ADAMTS14        ------------------------------------------------------------ 
ADAMTS2         ------------------------------------------------------------ 
ADAMTS6    989  ------------------------------------------SDLSKTFPA--------- 997 
ADAMTS10   974  ------------------------------------------ADHRATLPP--------- 982 
ADAMTS7    1379 WDSPANSHRVPETQPLAPSLAEAGPPADPLVVRNAGWQAGNWSECSTTCGLGAVWRPVRC 1438 
ADAMTS12   1285 LTEEDATSLITEGFLLNASNYKQLTNGH----GSAHWIVGNWSECSTTCGLGAYWRRVEC 1340 
ADAMTS16   1019 ------------------------------------------SARAQLLPD--------- 1027 
ADAMTS18   1022 --------------------------------------------AAETLPE--------- 1028 
ADAMTS17        ------------------------------------------------------------ 
ADAMTS19        ------------------------------------------------------------ 
ADAMTS13   868  -WGHLDATSAGEKAPSPWGSIRTGAQAAHVWTPAAGSCSVSCGRGLMELRFLCMDSALRV 926 
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7.6  Creation of vectors expressing polymorphisms 
Site  directed  mutagenesis  was  used  to  add  the  three  polymorphisms  (p.Q448E, 
p.P618A  and  p.A900V)  to  either  WT  or  p.R102H  mutant  ADAMTS13.  The 
following constructs were created: 
i.  p.R102H+p.Q448E+p.P618A+p.A900V 
ii.  WT+p.Q448E 
iii.  WT+p.P618A 
iv.  WT+p.A900V 
v.  WT+p.Q448E+p.P618A+p.A900V 
Construct i. was created to mimic the genotype of patient 3. Constructs ii-iv were 
created  to  investigate  the  effect  of  each  individual  polymorphism  on  WT 
ADAMTS13.  Construct  v.  was  created  to  investigate  the  effect  of  the  three 
polymorphisms  expressed  together,  in  the  absence  of  p.R102H.  The  three 
polymorphisms added to constructs i. and v. were added sequentially in separate site 
directed  mutagenesis  reactions.  Constructs  i-iv  were  created  first  followed  by 
expression in vitro. Western blotting is shown in Figure 7-13. 
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Figure 7-13 In vitro expression of ADAMTS13 polymorphisms 
This western blot was developed using a colorimetric detection kit, (Bio-Rad 170-8235, Opti 4CN 
substrate), as described by the manufacturer. Images were captured using Genesnap software (Gbox, 
Syngene). Cell lysate samples are shown on the left and supernatant on the right. 
All  proteins  except  the  p.R102H+p.Q448E+p.P618A+p.A900V  mutant  could  be 
detected by western blotting within cell lysate samples. The results suggested that 
either something went wrong during the transfection procedure and the vector was 
not taken up by the transfected cells or the mRNA of this recombinant protein was 
recognised as abnormal and degraded within the cell before protein synthesis could 
take  place.  It  was  unlikely  to  be  the  first  problem  (i.e.  a  problem  with  the 
transfection)  as  all  the  other  transfections  worked  well  and  nothing  abnormal 
occurred  during  the  transfection  procedure.  A  problem  at  the  mRNA  level  was 
unexpected because when these polymorphisms were expressed separately in vitro as 
shown in Figure 7-13, protein synthesis was not abolished. It was hypothesised that 
the problem was likely to be with the vector that was used to express this mutant.  
The  whole  of  the  ADAMTS13  gene  within  the  vector  expressing  the 
p.R102H+p.Q448E+p.P618A+p.A900V construct was sequenced to check for any 
abnormalities. A deletion within the ADAMTS13 gene in the vector was found which 
led to the presence of a premature stop codon. After sequencing the constructs that 
had  been  used  to  create  this  vector  (i.e.  p.R102H+p.P618A  and 
p.R102H+p.P618A+p.Q448E), within the same region, it was found that the deletion 
had been introduced after the addition of the second polymorphism (p.Q448E) to the 
vector.  
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Consequently the polymorphisms were reintroduced into the vector expressing the 
p.R102H  mutant.  Different  primers  were  used  to  introduce  the  p.Q448E 
polymorphism.  After  the  addition  of  all  three  polymorphisms  the  whole  of  the 
ADAMTS13 sequence within the vector was sequenced to make sure that there were 
no deletions/insertions or amino acid substitutions and there were no problems with 
this vector. Additionally the whole of the ADAMTS13 region in other vectors created 
earlier  were  retrospectively  sequenced  (p.I143T,  p.Y570C,  WT+p.Q448E, 
WT+p.P618A,  WT+p.A900V)  and  subsequent  vectors  created 
(WT+p.Q448E+p.P618A+p.A900V) to make sure that there were not  any similar 
problems. There were no problems in these vectors.  
7.7  In vitro expression of ADAMTS13 polymorphisms 
After constructs i-v were created they were expressed transiently in vitro. Results are 
shown in Table 7-3 and Figure 7-14. These results have not been normalised and are 
representative of n=2 experiments.  
Construct  Mean antigen   
(% of WT±SD) (n=2) 
Mean activity  
(% of WT±SD) (n=2) 
Specific 
activity 
WT  100  100  100 
W+PQA  54±5.6  34±14  63±32 
R102H  46±0.6  10±0.1  22±0.51 
R+PQA  6±2.0  -  - 
W+P  9±3.0  10±6.3  111±86 
W+Q  72±7.5  80±14  111±25 
W+A  129±1.9  86±11  67±21 
 
Table  7-3  ADAMTS13  antigen  and  activity  measured  in  the  supernatant  of  transiently 
transfected cells  
Mean antigen and activity from n=2 experiments are shown. The specific activity was calculated by 
dividing the activity levels by antigen levels.  210 
 
                        
             
Figure  7-14  Supernatant  and  cell  lysate  samples  harvested  after  transient  transfection  of 
ADAMTS13 polymorphisms 
Supernatant  samples  are  shown  in  a  and  c.  Cell  lysate  samples  are  shown  in  b  and  d.  PQA: 
P618A+Q448E+A900V. Representative of n=2 experiments.  
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When expressed separately, the p.P618A polymorphism had the greatest effect on the 
secretion  of  ADAMTS13,  reducing  the  secretion  of  ADAMTS13  more  than  the 
p.R102H  mutant.  The  p.Q448E  polymorphism  appeared  to  slightly  decrease  the 
secretion of ADAMTS13, whereas the p.A900V polymorphism increased it. When 
all three polymorphism were expressed in WT ADAMTS13 or in combination with 
the  p.R102H  mutant  they  reduced  the  secretion  of  both  molecular  forms  of 
ADAMTS13, when compared to WT or p.R102H alone.  
The p.Q448E and p.P618A polymorphisms did not appear to additionally affect the 
activity  of  ADAMTS13,  whereas  the  p.A900V  polymorphism  did.  The  specific 
activity of WT and p.R102H mutant with all three polymorphisms was also reduced. 
No  activity  could  be  detected  in  the  p.R102H+p.Q448E+p.P618A+p.A900V 
construct. The quantity of WT ADAMTS13 in these experiments was ~160% of that 
in PNP. 
A stable line of the p.R102H+p.Q448E+p.P618A+p.A900V mutant has been created. 
The various clones have been collected and in the future they will be analysed for 
further experiments. 
7.8  Discussion 
The results from the time course experiments, using FRETS-VWF73 as a substrate, 
demonstrated that the p.R102H mutation affects the kcat/Km of ADAMTS13 with the 
mutant having an approximately 4 fold reduction in its catalytic efficiency (WT: 2.8 
x 10
5 M
-1sec
-1, p.R102H mutant: 0.75 x 10
5 M
-1sec
-1). The mutation may affect the 
turnover number (kcat) or Km of the enzyme or both. In the circulation this mutant is 
likely to be less efficient at cleaving VWF than WT.  
When degradation of full length VWF was carried out using equal quantities of either 
WT or p.R102H mutant ADAMTS13, there was no obvious difference between the 
two at later time points. Assays using full length VWF as a substrate have a lower 
sensitivity  and  poorer  precision  compared  to  those  using  a  peptide  substrate 
(Peyvandi  et  al,  2010).  Together  these  results  suggest  that  although  there  was  a 
difference  between  WT  and  the  p.R102H  mutant,  the  mutant’s  activity  was  not 212 
 
severely reduced as expected based upon the undetectable activity measured in the 
patient plasma. It is true that the mutant is secreted at a reduced level (Chapter 3) 
which would also impact on the activity measured in the patient plasma but this was 
still not enough to severely reduce the activity measured in the supernatant.  
A stable line of WT and p.R102H mutant ADAMTS13 was created to produce large 
quantities of ADAMTS13 protein to be purified. The purified protein was eluted in a 
buffer with a composition closer to physiological conditions (150mM NaCl, 20mM 
HEPES, pH7.4). The unpurified protein was present in OptiMEM media which had 
been collected after incubation with respiring cells. The media is likely to have been 
slightly acidic due to the CO2 dissolved in it. ADAMTS13 has been shown to be 
affected by pH (Di Stasio et al, 2008), therefore the measured activity may have been 
slightly higher in a lower pH. This is one of the reasons it is important to purify and 
change the media of the buffer the protein is in.  Additionally the purification of 
ADAMTS13 removed other proteins which may have also been present in the media 
and potentially interfered with the measured activity.  
The kcat/Km was calculated by measuring product formation with a peptide fragment, 
as it is quicker and easier to carry out the analysis with this substrate compared to 
full length VWF. In addition measuring ADAMTS13 activity using FRETS-VWF73 
as  a  substrate  may  be  a  more  relevant  assay  to  measure  ADAMTS13  activity 
(Tripodi et al, 2008;Mancini et al, 2014).  
The kcat/Km values reported by others for WT using FRETS-VWF73 as a substrate 
varied from 0.30-1.2x10
6M
-1s
-1 (Anderson et al, 2006;Di Stasio et al, 2008;Feys et 
al, 2009b). My results agree with these values as I obtained a value of 2.8x10
5M
-1s
-1 
(or 0.28x10
6M
-1s
-1) for WT ADAMTS13. 
The  kcat/Km  value  measured  depends  upon  the  substrate  used.  The  kcat/Km  using 
VWF74  peptide  (with  Cys1669  replaced  with  alanine)  gave  values  ranging  from 
0.31-1.24x10
5M
-1s
-1  (Lancellotti  et  al,  2010).  The  kcat/Km  using  VWF115  (1554-
1668) varied from 7.5-8.7x10
4M
-1s
-1 (Zanardelli et al, 2006;Lam et al, 2007;Xiang et 
al,  2011).  The  kcat/Km  using  guanidine  HCl  treated  multimeric  VWF  was 
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VWF  in  the  presence  of  150mM  NaCl  was  0.34x10
4M
-1s
-1  (De  Cristofaro  et  al, 
2005). These differences probably exist because of the different subsites available for 
interaction in the different VWF fragments (Anderson et al, 2006). 
The  p.S119F  ADAMTS13  mutant  was  found  to  cause  an  approximate  2  fold 
reduction in the kcat/Km of ADAMTS13 compared to WT (Feys et al, 2009b). The 
authors  also  measured  activity  using  FRETS-VWF73  substrate.  However  the 
secretion  of  the  p.S119F  mutant  was  more  severely  reduced  compared  to  the 
p.R102H mutant studied here. The p.S119F could be detected using western blotting 
but  not  quantified  with  an  antigen  ELISA  (below  the  detection  limit)  (personal 
communication). So the severe defect introduced by the p.S119F mutation was likely 
responsible for the undetectable activity measured in the patient plasma. 
Analysis of ADAMTS13 activity using full length VWF requires unfolding of VWF 
to enable exposure of the A2 cleavage site, which is buried in its globular form. Urea 
is commonly used as a denaturant for multimer analysis; guanidine chloride may also 
be used for analysis. Ristocetin was used in these experiments to denature VWF; this 
has been used by other groups to measure ADAMTS13 activity (De Cristofaro et al, 
2005;Lancellotti et al, 2010;Chen et al, 2012). 
 Ristocetin is commonly used to assess the functional state of VWF, by inducing the 
interaction  of  VWF  and  the  platelet  glycoprotein  (GP)  Ib-IX-V  complex  in  the 
absence of shear stress or VWF immobilisation. It induces an allosteric change in 
VWF that exposes the binding site for glycoprotein Ibα (GPIbα) (Kang et al, 2008). 
Two  binding  sites  for  ristocetin  have  been  identified  within  VWF  flanking  the 
platelet-binding  A1  domain  (Girma  et  al,  1990;Berndt  et  al,  1992;Azuma  et  al, 
1993).  
Chen  et  al  found  that  when  ristocetin  (1mg/ml)  was  added  to  plasma,  it  could 
enhance the ability of endogenous ADAMTS13 to cleave VWF in a manner similar 
to  1.5mol/L  urea  (Chen  et  al,  2012).  De  Cristofaro  et  al  demonstrated  that  the 
conformational change induced by urea in VWF appears to be different from that 
induced by ristocetin (De Cristofaro et al, 2005).  214 
 
Ristocetin may be a more specific reagent than chaotropic agents such as urea, to 
evaluate the ability of ADAMTS13 to cleave multimeric VWF in vitro (Chen et al, 
2012).  Urea  unfolds  VWF  whereas  ristocetin  causes  a  conformational  change  in 
VWF, holding it in a GPIb bound like state. Furthermore as urea non-specifically 
affects protein folding, it may also alter the folding of ADAMTS13.  
The various assays used to measure ADAMTS13 activity in patient plasma generally 
give similar results; however there can be discrepancies between the assays (Palla et 
al, 2011;Mackie et al, 2013). Consequently I analysed ADAMTS13 activity using 
both a VWF peptide substrate and full length VWF. 
The ADAMTS13 activity assays used routinely are performed under static conditions 
but in vivo ADAMTS13 cleaves VWF under conditions of flow, shear stress aids the 
unfolding of VWF and exposes the ADAMTS13 cleavage site. Static assays require 
denaturation to unfold full length VWF or the assays use a VWF peptide in which the 
cleavage  site  is  already  exposed.  Flow  based  assays  are  not  practical  in  routine 
laboratories and are technically difficult to set up.  
Activity of the mutants was not assessed using a flow based assay system but this is 
something planned for the future. I hypothesise that the flow based assays would 
show  similar  results,  i.e.  a  small  difference  in  the  activity  of  WT  and  p.R102H 
mutant ADAMTS13. Investigation of ADAMTS13 activity in C-terminal mutants 
would be particularly important under flow because the C-terminal regions appear to 
be dispensable for ADAMTS13 activity under static conditions but important under 
conditions of flow (Soejima et al, 2003;Zheng et al, 2003;Zhang et al, 2007;Zhou et 
al, 2007;De Maeyer et al, 2010). Subsequent research has shown that the C-terminal 
region binds to VWF in its globular state, so the C-terminal region may be important 
for localisation of ADAMTS13 to the site of thrombus formation (Zanardelli et al, 
2009;Feys et al, 2009a). The p.R102H mutation however is within the N-terminal 
region. Although it will be important to measure the activity of this mutant under 
flow, I hypothesise that the results will not disagree with the above results, but will 
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As the p.R102H mutation did not severely affect the activity of ADAMTS13 to the 
effect predicted, the effect of polymorphisms in combination with this mutation was 
investigated. In vitro expression of the p.R102H mutant, present in patient 3 along 
with  the  three  ADAMTS13  polymorphisms  also  present  in  this  patient  (p.Q448E, 
p.P618A,  p.A900V)  led  to  a  further  reduction  in  the  secretion  and  consequently 
activity of the p.R102H mutant. No ADAMTS13 activity could be detected in the 
supernatant of cells expressing the mutant with polymorphisms. This is in contrast to 
the  mutant  alone  in  which  activity  could  be  detected,  on  average  10%  of  WT 
ADAMTS13. The patient had undetectable (<5%) activity in her plasma and so these 
results suggest that the polymorphisms in combination with the mutation as opposed 
to the mutation alone was responsible for the undetectable activity measured in the 
patient plasma.  
Due to the small amount of protein secreted in the mutant with polymorphisms (6%) 
and  the  observation  that  the  p.R102H  mutation  itself  leads  to  a  decrease  in 
ADAMTS13 specific activity, it is difficult to conclude whether the polymorphisms 
reduce the specific activity of the mutant further. In the future purified ADAMTS13 
mutant  plus  polymorphisms  will  be  used  to  investigate  whether  and  how  the 
polymorphisms further affect the activity of ADAMTS13.  
When the three polymorphisms were expressed with WT ADAMTS13 there was 
similarly a reduction in the antigen and activity of ADAMTS13. However although 
activity  was  reduced  (34%),  it  was  still  much  greater  that  5%,  so  these 
polymorphisms alone are not responsible for the reduced activity (<5%) measured in 
the patient plasma. This further suggests that the combination of the mutation with 
the three polymorphisms is responsible for the reduced activity in the patient plasma 
(i.e. not the polymorphisms alone). 
In these experiments WT ADAMTS13 antigen was on average 150% of PNP and 
therefore the proteins detected using this transiently transfected system were at a 
level similar to quantities we would expect to find in plasma.  
The effect of polymorphisms in combination with a mutation was studied also by 
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mutation (p.R1336W) with 4 different polymorphisms which were identified in two 
brothers. One brother was heterozygous for the mutation and three polymorphisms 
and the other brother was heterozygous for this mutation and four polymorphisms 
(p.R7W, p.Q448E, p.P618A, p.A732V). Antigen in the supernatant of the p.R1336W 
mutant alone was 23%±3 and activity was 12%±1 of PNP. When the mutant was 
expressed  with  the  4  polymorphisms,  ADAMTS13  antigen  and  activity  were 
undetectable. Similar to my results when WT ADAMTS13 was expressed with the 4 
polymorphisms  ADAMTS13  antigen  and  activity  were  reduced  (80%  and  40% 
respectively), but this was not enough to severely reduce the antigen and activity 
alone. 
The  patients  studied  by  Plaimauer  were  heterozygous  for  four  (or  three)  of  the 
ADAMTS13  polymorphisms  and  were  heterozygous  for  the  p.R1336W  mutation 
(Plaimauer et al, 2006). The authors did not analyse whether the polymorphisms 
were on the same ADAMTS13 allele and the patients were also heterozygous for 
another ADAMTS13 mutation p.Q449X, which would have also contributed to the 
undetectable ADAMTS13 activity  measured in the patient  plasma. The  p.Q449X 
mutation leads to a protein with undetectable ADAMTS13 activity (Kokame et al, 
2002;Plaimauer et al, 2006). Therefore, in these patients it is difficult to determine 
whether the p.R1336W mutation was sufficient (in the absence of polymorphisms) to 
lead to the reduced activity measured in the patient plasma, as the contribution of the 
p.Q449X protein also has to be considered.     
The patient studied here was homozygous for the p.R102H mutation and the three 
polymorphisms. Therefore, this was the only ADAMTS13 mutation present in this 
patient and it can be clearly seen in this patient that the 3 polymorphisms along with 
the  mutation  are  necessary  to  reduce  the  activity  of  ADAMTS13  to  levels 
comparable to those measured in the patient plasma.  
The  ADAMTS13  antigen  measured  in  the  supernatant  of  the  mutant  with 
polymorphisms was approximately 6% of WT. In patient 3 (in which the mutations 
and  polymorphisms  were  identified),  ADAMTS13  antigen  was  higher,  42%±5.4 
(mean±SD), of PNP. It is unclear why these differences exist. This patient was also 
homozygous  for  a number of synonymous  ADAMTS13 polymorphisms (p.P118P, 217 
 
p.140A,  p.G194G,  p.1407T)  which  may  have  modulated  the  secretion  (or  even 
activity)  of  ADAMTS13  further.  Edwards  et  al  showed  that  non-synonymous 
polymorphisms can modulate the secretion and activity of ADAMTS13 (Edwards et 
al, 2012). The authors studied three of the silent polymorphisms present in patient 3 
(p.P118P,  p.A40A  and  p.T1407T),  in  vitro.  ADAMTS13  antigen  and  specific 
activity  of  these  silent  polymorphisms  were  as  follows:  p.P118P  (antigen  137%, 
specific activity 208%), p.A140A (antigen 120%, specific activity 169%), p.T1470T 
(antigen 63%, specific activity 88%). Silent polymorphisms therefore appear to have 
a significant effect on the secretion and activity of ADAMTS13.   
When the three polymorphisms were expressed separately in WT ADAMTS13 they 
had different effects on ADAMTS13 secretion and activity. These polymorphisms 
have been expressed in vitro by other groups. In the supernatant of WT ADAMTS13 
expressing the p.Q448E ADAMTS13 polymorphism, the mean antigen was 72%±7.5 
and  the  activity  was  80%±14  of  WT  ADAMTS13.  Others  have  found  reduced 
ADAMTS13  antigen  with  this  polymorphism  (95-99%)  (Plaimauer  et  al, 
2006;Edwards et al, 2012;Rurali et al, 2013). Levels of ADAMTS13 antigen in the 
experiments described here are slightly lower than these values. However the results 
need  to  be  repeated  and  normalised  to  take  into  account  differences  in  the 
transfection  efficiency  between  experiments.  The  specific  activity  of  this  mutant 
appears to be greater than 100% which agrees with the results of Rurali et al and 
Edwards et al but disagrees with the results of Plaimauer et al.  
Plaimauer  et  al  found  that  p.Q448E  was  a  positive  modifier  in  the  context  of 
p.P618A but could not rescue the severely reduced specific activity conferred by 
p.P618A.  In  contrast  when  expressed  with  the  p.R1336W  mutant  and  p.R7W, 
another positive modifier, the polymorphisms enhanced the detrimental effect of the 
p.R1336W mutation (Plaimauer et al, 2006). The p.Q448E polymorphism therefore 
may  act  to  increase  or  decrease  ADAMTS13  activity,  when  expressed  with  the 
p.R102H mutation, along with the other two polymorphisms.  
In the supernatant of WT ADAMTS13 expressing the p.P618A polymorphism the 
average antigen was 9%±3 and activity was 10±6.3. This is slightly lower than the 
antigen levels measured by others (27-75%) (Plaimauer et al, 2006;Edwards et al, 218 
 
2012;Rurali et al, 2013). In the experiments described here polymorphism did not 
appear to affect the activity of ADAMTS13; others have found that this mutant also 
has  reduced  specific  activity  (49-68%)  (Plaimauer  et  al,  2006;Edwards  et  al, 
2012;Rurali et al, 2013). A reduction in activity may not have been detected here as a 
small amount of protein was secreted and a small number of experiments performed.  
In the supernatant of WT expressing the p.A900V polymorphism the average antigen 
was 129%±1.9 and the activity was 86±11. Others have found reduced levels (86%, 
95%, (Rurali et al, 2013;Edwards et al, 2012)). The specific activity measured by 
others was similar or slightly reduced (Rurali et al, 2013;Edwards et al, 2012)(100%, 
73%,  respectively).  Similar  to  Edwards  et  al,  a  reduced  specific  activity  in  WT 
ADAMTS13 expressing this polymorphism was found. 
The  differences  in  antigen  and  activity  obtained  here  after  expression  of  each 
polymorphism  in  WT  ADAMTS13,  may  be  partly  because  a  small  number  of 
experiments  were  performed  (n=2)  and  also  because  the  results  have  not  been 
normalised to take into account differences in the transfection efficiency. This may 
also explain why levels of antigen in the p.R102H mutant measured and shown in  
Table 7-3, are slightly higher than those reported in Chapter 3. Also different cell 
lines, methods of transfection and measurement of ADAMTS13 antigen and activity 
have been used in the experiments described here and by others, which may also 
account for some of these differences. For example quantities of the p.P618A antigen 
measured in the supernatant in vitro by others are quite variable, ranging from 27-
75% of WT (Plaimauer et al, 2006;Edwards et al, 2012;Rurali et al, 2013).   
In  vivo  ADAMTS13  activity  in  the  Japanese  population  heterozygous  and 
homozygous for p.E448 was slightly but significantly higher than those homozygous 
for  p.Q448  (97%±25  vs  91%±24  in  men  and  111%±28  vs  104%±26  in  women, 
mean±sd). These results suggest that the p.E448 amino acid increases ADAMTS13 
activity (Kokame et al, 2011), which is in contrast to the results obtained in vitro and 
also obtained by Plaimauer et al, but agrees with the results obtained by Edwards et 
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In diabetic patient’s serum ADAMTS13 activity was found to be significantly lower 
in  alanine  carriers  than  in  proline  carriers  (77.8  vs  68%)(Rurali  et  al,  2013).  In 
addition  there  were  significant  differences  in  102  healthy  subjects  in  terms  of 
ADAMTS13 activity in patients with PP genotype compared to AA genotype. These 
results agree with the in vitro results obtained here and the results obtained by others 
(Plaimauer et al, 2006;Edwards et al, 2012;Rurali et al, 2013). In contrast in another 
study the p.P618A polymorphism was not associated with changes in plasma activity 
(Kokame et al, 2011). However the MAF for p.A618 in this population was 0.027 in 
346 patients and so the number of patients may have been too small to detect a 
difference. This MAF is smaller than the MAF of p.E448 in this study (0.192) in 
which they found an association. 
The amino acids affected by polymorphisms within ADAMTS13 orthologs do not 
appear to be as conserved as the amino acids affected by mutations and studied here 
(Chapter 3). This is consistent with these variants being polymorphisms as opposed 
to  mutations.  Conservation  of  these  amino  acids  within  paralogs  may  not  be  as 
informative as conservation within orthologs as these domains (cysteine-rich, spacer, 
TSP-1) may have a different function in other ADAMTS proteins, as the substrate 
they recognise differs (Nicholson et al, 2005;Gao et al, 2008). 
The tyrosine (Y) residue at position p.570, present in patient 1, (Chapter 3), lies 
within a β2 sheet whereas the glutamine (Q) at position 448 lies within an α helix 
and the proline (P) at position 618 lies in a loop after the β6 sheet (Akiyama et al, 
2009). In terms of location within ADAMTS13 it can be seen why the p.Y570C 
mutation  appears  to  cause  a  severe  defect  in  the  secretion  and  activity  of 
ADAMTS13  in  vitro  (Chapter  3),  which  is  in  contrast  to  the  polymorphisms 
(p.Q448E and p.P618A).  Beta-sheets are generally thermodynamically more stable 
than  α  helices  and  hence  their  impact  on  protein-folding/stability  is  greater. 
Therefore, variants in beta-sheets are expected to produce a greater impact on protein 
folding (Henzler Wildman et al, 2002).  
Proline in p.P618 adopts a cis conformation and therefore substitution by non proline 
residues could cause structural differences (Akiyama et al, 2009). The loop that the 
p.P618 amino  acid  lies  in  plays  a  pivotal role in the interaction between the N-220 
 
terminal cysteine-rich region and the spacer domain (Akiyama et al, 2009). This may 
explain  why  this  polymorphism  has  a  large  effect  on  ADAMTS13  in  terms  of 
secretion. 
In  the  future  I  hope  to  produce  and  purify  large  amounts  of  the 
p.R102H+p.Q448E+p.P618A+p.A900V mutant and to analyse it under flow along 
with the p.R102H mutant. It will be particularly interesting to compare the activity of 
the  mutant  with  polymorphisms  under  flow  and  static  conditions  because  the  C-
terminal region of ADAMTS13 appears to be important under conditions of flow but 
not static conditions (Soejima et al, 2003;Zheng et al, 2003;Zhang et al, 2007;Zhou 
et al, 2007;De Maeyer et al, 2010). The p.A900V polymorphism is located in the C-
terminal region of ADAMTS13.  
ADAMTS13 polymorphisms may also have an important role other than in TTP. In 
1,163 type 2 diabetic patients interactions between p.P618A and ACE inhibitors was 
significant in predicting both renal and combined renal and cardiovascular events 
increasing in risk in the order alanine (A) carriers on ACE inhibitors→proline (P) 
homozygotes  not  on  ACE  inhibitors→  proline  (P)  homozygotes  on  ACE 
inhibitors→alanine carriers not on ACE inhibitors (Rurali et al, 2013). Alanine (A) 
carriers therefore had a higher risk of chronic complications and responded better to 
ACE inhibitors (Rurali et al, 2013). Furthermore serum ADAMTS13 activity was 
significantly lower in alanine carriers than in proline homozygotes (77.8 vs 68%) and 
in  case  subjects  with  renal,  cardiovascular  or  combined  events  than  in  diabetic 
control subjects without events (Rurali et al, 2013).  
A  significant  association  was  observed  between  the  ADAMTS13  p.A900V 
polymorphism  and  risk  of  death  from  cardiac  causes  (OR:  2.67,  CI:  1.59-4.49, 
p=0.0009) in 559 patients with coronary artery disease (Schettert et al, 2010). This 
association was not found with p.Q448E or p.P618A. In this study there was only 6 
patients  homozygous  for  the  p.A900V  polymorphism  and  so  heterozygous  and 
homozygous patients were grouped together (464 patients homozygous for alanine 
[A] vs 95 patients heterozygous or homozygous for valine [V]). The relatively small 
number of patients with the valine amino acid suggests that there may be some false 
positive results. Additionally cholesterol levels (p=0.02) were lower in individuals 221 
 
with the valine amino acid which may have contributed to these results. Furthermore 
the authors did not measure ADAMTS13 activity or antigen levels in the patients. 
This study suggests that there could potentially be an association but this is unclear. 
The  combination  of  the  p.R102H  mutation  present  in  patient  3  with  the  three 
ADAMTS13  polymorphisms  also  present  appears  to  lead  to  the  reduced  activity 
measured  in  vivo.  The  p.R102H  mutation  by  itself  or  the  three  polymorphisms 
expressed together in WT ADAMTS13 was not enough to cause this reduction. This 
study demonstrates firstly the importance of in vitro expression as before expression 
it was hypothesised that the mutation was responsible for the disease phenotype. 
However in vitro expression showed that the mutation was not enough to lead to the 
reduced  activity  levels  measured  in  the  patient  plasma.  Secondly  this  study 
demonstrates the importance of polymorphisms. Expression of the mutant with the 
three  polymorphisms  also  present  in  the  patient,  highlighted  the  importance  and 
contribution of these polymorphisms to the decreased activity measured in the patient 
plasma. 222 
 
Chapter 8   ADAMTS13 splice site mutant (type 1b) 
8.1  Introduction 
8.1.1  Overview of the splicing process 
Transcription of the DNA sequence of a gene into mRNA occurs within the nucleus 
of the cell. After transcription, mRNA is capped at the 5’ end and polyadenylation 
occurs at the 3’ end. These modifications enable the cell to assess whether both ends 
of an mRNA molecule are intact before export from the nucleus for translation into 
protein. 
The genomic DNA of a gene typically consists of protein coding sequences (exons), 
which are separated by long introns. Both  exons and introns are transcribed into 
mRNA.  Splicing  of  mRNA  is  important  to  enable  removal  of  introns  and  join 
together  protein  coding  sequences.  Splicing  enables  cells  to  synthesise  several 
proteins from the same gene (Alberts et al, 2002).  
Each  splicing  event  removes  one  intron,  occurring  through  two  phosphoryl 
transferase  reactions,  which  join  together  two  exons  while  removing  the  intron 
(Figure  8-1a).  Introns  range  in  size  from  10  to  over  100,000  nucleotides.  The 
‘machinery’ that catalyses this process consists of many proteins and other RNA 
molecules. Intron sequence removal involves three positions on the RNA molecule, 
the 5’ splice site, 3’ splice site and the branch point. Each of these sites have a 
consensus DNA sequence (Figure 8-1b) (Alberts et al, 2002).  
Only  when  all  the  steps  of  mRNA  production  have  occurred  (5’  capping,  3’ 
polyadenylation and splicing) can an mRNA molecule be exported from the nucleus. 
Eukaryotic cells have an additional mechanism, nonsense mediated mRNA decay 
that  can  eliminate  mRNA  containing  premature  stop  codons,  before  they  can  be 
translated into protein. Stop codons can arise from mutations or from incomplete 
splicing.  The  ability  of  the  nonsense-mediated  decay  system  to  detect  these 
premature stop codons within mRNA depends upon the spatial relationship between 
the first in frame termination codon and exon-exon boundaries.  If the codon lies 
downstream (3’) of an exon-exon boundaries the mRNA does not undergo nonsense 223 
 
mediated decay. If on the other hand it is upstream (5’) of an exon-exon boundary 
the mRNA is degraded (Alberts et al, 2002).  
 
Figure 8-1 Splicing process 
Figure a shows a simplified diagram of the splicing process. A specific nucleotide within the intron 
(A) attacks the 5’ splice site, cutting the sugar-phosphate backbone of the RNA at this point. The 
released free 3’-OH end of the exon then reacts with the start of the next exon sequence. The two 
exons  are  joined  together  and  the  intronic  sequence  is  released.  Figure  b  shows  the  consensus 
sequence required for splicing. The three blocks of nucleotide sequences highlighted are required to 
remove an intron sequence. R stands for an A or G nucleotide, Y stands for a C or U nucleotide. Only 
the  GU  at  the  start  of  the  intron  and  the  AG  at  its  end  are  invariant  nucleotides  in  the  splicing 
consensus sequence. The remaining positions can be occupied by a variety of nucleotides but the ones 
shown are preferred. Images from: (Alberts et al, 2002).  
8.1.2  ADAMTS13 splice site mutations 
In  patients  with  congenital  TTP  nine  different  splice  site  mutations  (6%  of  all 
mutations) have been described (Lotta et al, 2012;Uchida et al, 2004;Matsumoto et 
al, 2004;Studt et al, 2005;Veyradier et al, 2004;Levy et al, 2001;Prestidge et al, 
2012). The effect of these mutations on the splicing process has been analysed for 
three of these mutations. Matsumoto et al analysed in vivo two splice site mutations: 
c.414+1G>A within intron 4 and c.1244+2T>G within intron 10 (Matsumoto et al, 
2004). The mRNA from patients with these mutations was reverse transcribed and 
analysed and the authors found that these mutations did affect splicing. Uchida et al 
analysed the splice site mutation c.330+1G>A, within intron 3, through the creation 
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of  a  mini  gene  (Uchida  et  al,  2004).  The  authors  similarly  found  this  mutation 
affected the splicing process.  
8.1.3  Predicted effect of splice site mutation 
At the start of this project a mutation (c.106-1G>C) predicted to affect splicing, not 
previously characterised in vitro or in vivo, was analysed as described in the methods 
(Chapter 2.14) to assess the effect of the mutation on splicing. The predicted effect of 
this mutation is illustrated in Figure 8-2. 
The c.106-1G>C splice site mutation results in the exchange of a G residue with a C 
residue in the last nucleotide of the intron just before exon 2. For splicing to occur an 
‘AG’ acceptor site is required at the end of the intron. In this patient the AG acceptor 
site at the end on intron 1 is affected by the mutation. The cell splicing machinery is 
predicted to use the AG residue at the beginning of exon 2 instead as the acceptor 
site. If this new acceptor site was to be used then these two nucleotides (AG) are no 
longer part of exon 2 and  instead  exon 2  would begin with  the third  nucleotide 
present, which is a T nucleotide. The deletion of these two nucleotides would lead to 
a frame shift and the introduction of a stop codon 102 amino acids later at the end of 
exon 4.  
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Figure 8-2 Predicted effect of mutation on splicing 
nt: nucleotide. The mutation is predicted to lead to the use of an alternative acceptor site, located at 
the beginning of exon 2. 
8.1.4  Patient information 
The  patient  with  the  c.106-1G>C  (p.S36_C37delfs*102,  r.106_107del)  mutation 
(patient 4) had no exonic mutations or non-synonymous polymorphisms. This patient 
is female and first presented with TTP at 8 months. The patient has had 3 subsequent 
episodes  which  were  triggered  by  viral  infections.  The  patient  had  undetectable 
ADAMTS13 antigen and activity in her plasma. The patient plasma activity was also 
measured using SELDI-TOF and was 0.67% of PNP (Lotta et al, 2012).  
8.2  ADAMTS13 whole blood RNA extraction   
One way to assess whether this mutation affects splicing is to analyse the patient’s 
RNA. If this mutation affects  splicing as predicted then the RNA of this patient 
would be slightly different to that of normal controls as two nucleotides would be 
deleted from the patients RNA. Others have demonstrated that ADAMTS13 RNA is 
present within leukocytes (Matsumoto et al, 2004). The RNA of this patient was to 226 
 
be extracted, but first RNA was extracted from two healthy controls to ensure that 
the technique was working. 
RNA extraction, RT and PCR amplification were carried out  as described in the 
methods (Chapter 2.15). Two primer pairs were used to amplify ADAMTS13 cDNA: 
F6/R6  to  produce  a  fragment  of  169bp  and  F6/RevJP  to  produce  a  fragment  of 
542bp. Another set of primers (G3PDH F’/R’) were used to amplify a housekeeping 
gene G3PDH as a control. Figure 8-3a shows the PCR fragments obtained after using 
the  primer  pair  F6/R6  and  G3PDHF’/R’.  Figure  8-3c  shows  the  PCR  fragments 
obtained after using the primer pair F6/RevJP and G3PDHF’/R’. 
The G3PDH gene (expected size 983bp) could be detected in the positive control 
sample (Figure 8-3a) but ADAMTS13 could not be detected. Neither ADAMTS13 nor 
G3PDH  could  be  detected  in  the  normal  controls.  Importantly  nothing  could  be 
detected in the negative control samples. In the PCR fragments shown in Figure 8-3c 
nothing could be detected in any of the samples when loaded onto a 2% agarose gel. 
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Figure 8-3 A 2% agarose gel of RT-PCR products 
RT cDNA was amplified using PCR (shown in Figure a and c). For the PCR products obtained in b 
and d, the PCR products from a and c were used (respectively) as a template. Three reactions each 
were set up for two healthy controls, a positive control and a negative control. In a and b primers F6 
and R6 were used in i and ii and G3PDH primers were used in iii. For c and d, F6 and RevJP were 
used  for  i  and  ii  and  G3PDH  primers  were  used  for  iii.  For  samples  i.  and  ii.  slightly  different 
quantities of cDNA were used in the PCR. In the gel shown in Figure c samples ii. and iii. for normal 
2 were not loaded as a small amount of sample was available for analysis. The expected size of the 
products for each pair of primers was as follows: F6/R6:169bp, F6/RevJP: 542bp, G3PDH:983bp. The 
DNA ladder pUC mix marker 8 (ThermoFischer Scientific) was used. 
 The  samples  obtained  from  the  first  PCR  (Figure  8-3a  and  c)  were  used  as  a 
template for the second PCR using the same conditions as the first PCR (Figure 8-3b 
and d). ADAMTS13 could be detected using primer F6/R6 in both normal controls 
(Figure  8-3b),  the  housekeeping  gene  G3PDH  could  be  detected  in  the  positive 
control but not in normal control samples. Nothing could be detected in the negative 
controls. ADAMTS13 could be detected in the positive control and in normal control 
1  using  primer  pair  F6/RevJP  (Figure  8-3d).  Nothing  could  be  detected  in  the 
negative controls.  
8.2.1  Purification of PCR products 
The PCR products from the second PCR (Figure 8-3b) obtained from normal control 
1 using primer pair F6/R6 were pooled and purified as described in methods. This 
was similarly done for the PCR products obtained from normal control 1 (primer pair 
a.  b. 
c.  d. 
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F6/RevJP) and normal control 2 (primer pair F6/R6).The purified PCR products were 
run on a 2% agarose gel and are shown in Figure 8-4. The purified products are 
barely visible on the agarose gel. 
 
Figure 8-4 Purified ADAMTS13 PCR products obtained from RT of normal control mRNA 
Figure a shows the pooled PCR product obtained from normal control 1 using primer pair F6/R6. 
Figure b shows purified product obtained from normal control 1 using primer pair F6/RevJP and from 
normal control 2 using primer pair F6/R6. The expected size of products for each pair of primers was 
as  follows:  F6/R6:169bp  and  F6/RevJP:  542bp.  The  ladder  pUC  mix  marker  8  (ThermoFischer 
Scientific) was used. 
The purified PCR products were sequenced and were confirmed to be ADAMTS13. 
ADAMTS13  RNA  was  therefore  successfully  extracted,  RT  into  cDNA  and  PCR 
amplified  from  leukocytes.  The  technique  was  developed  so  that  RNA  could  be 
extracted from the blood of the patient with the splice site mutation. The blood could 
not be obtained from the patient during the time of this study however, despite trying 
to obtain a sample. 
8.3  Creating a mini gene to analyse splice site mutation in vitro 
An alternative way to assess whether the mutation affects splicing is to construct a 
mini gene in vitro. The vector which had been used in previous experiments Chapter 
3 -7 contained the complete cDNA sequence of ADAMTS13, i.e. all 29 exons and no 
introns.  This  vector  has  a  T7  promoter/priming  site  which  enables  in  vitro 
transcription of genomic DNA in the sense orientation. It also had a bovine growth 
hormone  (BGH)  polyadenylation  site  which  allows  its  efficient  transcription 229 
 
termination and adenylation of mRNA. This vector therefore is suitable to analyse 
transcription in vitro.   
The predicted splice site mutation lies within intron 1, just before exon 2. First it was 
investigated whether it was possible to remove exon 1 and exon 2 or 3 within the 
vector expressing ADAMTS13 cDNA using restriction digestion and then replace this 
region of the vector with genomic DNA of exon 1→exon 2 or exon1→exon3. A 
restriction enzyme that could be used to cleave the vector only once within exon 1, 2 
or  3  was  searched  for  using  web  cutter  (URL:  http://rna.lundberg.gu.se/cutter2/; 
accessed 17
th June 2014). This tool lists the restriction enzymes which cut a given 
DNA  sequence  and  also  shows  where  in  the  sequence  the  enzyme  cuts  it.  A 
restriction enzyme which cut the vector only once within exon 1 or 2 could not be 
identified.  
Instead it was decided that a fragment containing either exon 1 + intron 1 + exon 2 or 
exon 1 + intron 1 + exon 2 + intron 2 + exon 3 would be cloned into an empty 
pcDNA  3.1  D/V5-His-TOPO®  vector  using  a  pcDNA  3.1  Directional  TOPO 
expression kit (Life technologies). 
Genomic  DNA  from  a  normal  control  and  from  the  patient  with  the  splice  site 
mutation was to be cloned. In order to clone directionally within the TOPO vector 
the forward primer should contain a Kozak sequence (CACCATG) at the 5’end of 
the primer (Kozak, 1987). The first 4 nucleotides CACC, base pair with the overhang 
sequence GTGG within the TOPO vector. The ATG following this is the initiation 
codon of the protein of interest. Primer SpliceA for TOPO® cloning was designed so 
that it contained this Kozak sequence. 
The C-terminal tag and V5 epitope were also to be included in the protein produced 
by the vector and so the reverse primer was designed so that the WT open reading 
frame was in frame with the C-terminal tag encoded by the vector. Three primers 
were designed (SpliceA, SpliceB and SpliceC). SpliceA was designed to bind within 
exon 1. Two reverse primers were designed, one to bind within exon 2 (SpliceB) and 
one to bind within exon 3 (SpliceC). These primers were designed to produce the 
products illustrated in Figure 8-5. 230 
 
 
Figure 8-5 Primers and products designed for TOPO cloning 
Primers were designed to amplify either exon1→exon 2 of ADAMTS13 genomic DNA (PCR 1) or 
exon 1→exon 3 of ADAMTS13 genomic DNA (PCR 2). 5’ to 3’ sequence of primers are shown. UTR, 
untranslated region. The CACC region introduced into the PCR product by the primer is shown in red. 
The brown line indicates that the complete exonic sequence is not included in the PCR fragment.  
8.4  PCR amplification of WT ADAMTS13 using primers SpliceA/B 
and SpliceA/C 
PCR was set up to amplify genomic DNA using primers SpliceA/B and SpliceA/C 
with an annealing temperature of 55⁰C. Multiple bands were observed on the agarose 
gel  so  the  PCR  was  repeated  varying  the  annealing  temperature.  An  annealing 
temperature of 58⁰C produced the expected product for SpliceA/B and SpliceA/C 
(Figure 8-6a). 
The  products  obtained  from  the  PCR  using  primers  SpliceA/C  were  used  as  a 
template for another PCR which was set up under the same conditions. A band of the 
expected size was observed on the gel (Figure 8-6b). 231 
 
 
Figure 8-6 PCR amplification and purification of WT ADAMTS13 
Figure a shows the products formed using primer SpliceA and primer SpliceB (lanes 1 and 2). Lanes 3 
and 4 show the product formed using primer SpliceA and SpliceC. Different quantities of genomic 
DNA were used in lanes 1 and 2 and also in lanes 3 and 4. Figure b shows the results of another PCR 
set up under the same conditions using the product in lane 3 of figure a as a template and primers 
SpliceA and SpliceC. Figure c shows the purified product in figure b. Expected size of product using 
SpliceA/B was 724bp and for SpliceA/C was 2020bp. DNA ladder marker X (Roche) was used.  
The product from the reaction was PCR purified. The purified product is shown in 
Figure 8-6c. Some of this product was sequenced and confirmed to be ADAMTS13. 
The whole PCR product was not sequenced as there was a limited amount of the 
product available.   
8.5  PCR amplification of splice site mutant ADAMTS13 using 
primers SpliceA/B or SpliceA/C 
PCR was set up for the splice mutant using the same conditions that had been used 
for WT ADAMTS13 genomic DNA. A band of the expected size could be detected 
using Splice A/B but no band could be detected using the primers Splice A/C (Figure 
8-7a). A second PCR was set up using the product formed with primers SpliceA/C as 
a template and using the same PCR conditions  that had been used to  create the 
product. Multiple bands were present on the agarose gel (Figure 8-7b), one of which 
was the expected size. 
A  number  of  PCRs  were  set  up  with  mutant  genomic  DNA  and  the  annealing 
temperature was varied but still multiple bands were obtained. Touchdown PCR was 
set up in order to try and eliminate the non-specific bands, after which a band could 
a.  b.  c. 
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be detected of the incorrect size. The PCR was repeated in the presence of DMSO 
and again a band of the incorrect size could be detected.  
All of the PCR products that were obtained from the initial PCR set up for the mutant 
(shown in Figure 8-7b) (consisting of many PCR fragments of different sizes) was 
run on an agarose gel and the DNA of the desired size was cut from the gel (top 
band) (as shown in Figure 8-7c). The cut piece of gel containing the desired band of 
DNA  was  purified.  The  purified  product  is  shown  in  Figure  8-7d.  Part  of  this 
fragment was sequenced and was confirmed to be ADAMTS13.  
 
Figure 8-7 PCR amplification and purification of splice site mutant ADAMTS13 
Figure  a  shows  the  products  formed  using  primer  SpliceA  and  primer  SpliceB  (lanes  1)  and  the 
product formed using primer SpliceA and SpliceC (lane 2). Figure b shows the results of a second 
PCR using the product in lane 2 of figure a as a template and primers SpliceA and SpliceC. Figure c 
shows the PCR product that was used for gel DNA extraction. The top band was cut from the gel and 
extracted.  Figure  d  shows  the  purified  gel  extracted  product.  Expected  size  of  product  using 
SpliceA/B was 724bp and for SpliceA/C was 2020bp. The ladders pUC mix marker 8 (ThermoFischer 
Scientific) or DNA ladder marker X (Roche) were used. 
8.6  TOPO cloning of PCR fragment product using primers 
SpliceA/C 
For TOPO cloning the product containing exon1→exon 3 was used as opposed to the 
product  containing  exon  1→exon  2  as  there  would  be  more  of  the  sequence 
following the mutation in the product exon1→exon 3. TOPO cloning was set up for 
WT and mutant ADAMTS13 as described in the methods (Chapter 2.17). For cloning 
4μl of each PCR fragment was used (purified fragment shown in Figure 8-6c and 
Figure 8-7d). The day after transformation six colonies each were picked for mini 
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preparation  from  the  plates  containing  E.  coli  transformed  with  WT  or  mutant 
ADAMTS13.  No  DNA  could  be  detected  using  a  nanodrop  or  by  agarose  gel 
electrophoresis.  
A further three colonies underwent mini preparation; DNA could be detected in these 
clones. Sequencing of this DNA was set up using primers which were part of the 
TOPO cloning kit (T7 and BGH) which bound to the vector before and after the 
region which should contain the insert. Nothing could be detected after sequencing. 
Instead restriction digests were set up to investigate if the cloned fragment could be 
detected this way. Three restriction enzymes (BstXI, StuI, and XbaI) that would cut 
both the vector and the insert once were used. If the vector contained the insert two 
bands would be present after restriction digest, whereas if the vector was empty one 
band would be present. The DNA obtained from mini preparation was digested with 
these  restriction  enzymes  but  the  amount  of  DNA  from  this  was  too  low  to  be 
observed on a gel. 
In a last attempt to investigate whether ADAMTS13 could be detected within these 
clones,  PCR  was  used.  Two  PCRs  were  set  up,  one  using  primer  SpliceA  and 
SpliceC and another using primers T7 and BGH. Primers were added to 3µl of the 
DNA obtained after mini preparation and the PCRs were set up using the conditions 
used to create the products for cloning. In WT no bands could be observed, in the 
mutant multiple bands could be seen but these were not of the correct size.   
8.7  New primers for TOPO cloning 
New  primers  were  created  to  produce  a  new  PCR  fragment  for  TOPO  cloning. 
Primer SpliceA which was used to create the PCR fragment previously was very rich 
in C nucleotides which may have contributed to the non-specific binding problems 
that were experienced in the PCR reactions. The basic local alignment search tool 
(BLAST) was used (URL: http://blast.ncbi.nlm.nih.gov/Blast.cgi; accessed 17
th June 
2014) to investigate whether the primers that had been used to create the fragment 
(Primer SpliceA/B/C) were likely to bind to other regions within ADAMTS13. This 
appeared to be the case so new primers were designed. These primers were designed 234 
 
using  NCBI  primer  blast  (URL:  http://www.ncbi.nlm.nih.gov/tools/primer-blast/, 
accessed 17
th June 2014). 
The primer SpliceD binds to the untranslated region of genomic DNA before the 
ADAMTS13  ATG  start  codon  within  the  signal  peptide  region  of  ADAMTS13. 
SpliceE binds within the middle of exon 3. These two new primers were used to 
produce the fragment shown in Figure 8-8. 
Primer SpliceD does not have ‘CACC’ at the beginning of its sequence and so the 
PCR fragment produced with this primer could not be cloned directly into the TOPO 
vector.  In addition due to the design of the SpliceE primer, the end of the fragment 
produced by this primer pair would not be in frame with the V5/His tag encoded by 
the vector. It was desirable to clone the fragment so that it was in frame with this so 
that the protein produced by the vector could be detected using an anti-V5 antibody, 
as with the other ADAMTS13 proteins produced previously.   
In order to produce a PCR fragment that could be inserted into the TOPO vector and 
was in frame with the V5/His tags when expressed, another PCR step was carried out 
(nested PCR). The DNA fragment produced in the first PCR was used as a template 
for the second PCR (Figure 8-8). For nested PCR the forward primer used was the 
same one that had been used previously (SpliceA). This primer should bind within 
the first PCR fragment. As this primer starts with CACC and is followed by the 
initiation ATG start codon, it would enable cloning of the fragment into the TOPO 
vector.  A  reverse  primer  was  designed,  SpliceF  which  bound  within  exon  3  to 
produce a fragment that was in frame with the V5/His tag (Figure 8-8).   235 
 
 
Figure 8-8 PCR plan 
The brown line at the end of an exon indicates that the whole of the exon sequence is not included in 
the  PCR  fragment.  The  red  region  at  the  beginning  of  PCR  fragment  2  illustrates  the  CACC 
nucleotides  introduced  at  the  beginning  of  the  PCR  fragment  by  the  primer  SpliceA.  UTR: 
untranslated region. 5’ to 3’ sequence of primers are shown. 
8.8  PCR amplification of WT and mutant ADAMTS13 using 
primers SpliceD/E and SpliceA/F 
PCR was initially set up using WT ADAMTS13 with an annealing temperature of 
55⁰C in the absence of DMSO. Multiple bands were observed on the agarose gel 
(Figure 8-9a). PCR was repeated at 58⁰C in the presence and absence of DMSO 
(Figure 8-9b). A clear band could be seen in the presence of DMSO. This band was 
PCR  purified  (Figure  8-9c)  and  partially  sequenced.  This  was  confirmed  to  be 
ADAMTS13.   
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Figure 8-9 PCR amplification and PCR purification of WT ADAMTS13 
Figure a shows the PCR amplification of WT ADAMTS13 genomic DNA at an annealing temperature 
of 55⁰C. Figure b shows the PCR amplification of WT ADAMTS13 genomic DNA at an annealing 
temperature of 58⁰C in the absence (lane 1) and presence (lane 2) of DMSO. Figure c shows the 
purification of the product in lane 2 of figure b. DNA ladder marker X (Roche) or gene ruler 100bp 
plus DNA ladder (ThermoFischer Scientific) was used. 
More  of  this  product  was  produced  so  that  the  entire  PCR  fragment  could  be 
sequenced to be sure that there were no unexpected polymorphisms or mutations in 
the intronic region of the control. The PCR was repeated using the same conditions 
but this time multiple bands were obtained, unlike previously. The PCR machine and 
the annealing temperature (higher and lower) were changed. DMSO was added to the 
reaction mix and touchdown PCR was used and the volume of the enzyme and buffer 
were changed to try and obtain one single band. However multiple bands were still 
obtained.  
One possible reason for this problem could be related to the genomic DNA used for 
PCR, for example if it had sheared during DNA extraction. An agarose gel of the 
genomic DNA encoding normal and mutant ADAMTS13 were run on an agarose gel. 
There did not however appear to be a problem with the genomic DNA (Figure 8-10).  
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Figure 8-10 Agarose gel of genomic DNA 
Genomic DNA from WT ADAMTS13 and splice site mutant genomic DNA was run on a 2% agarose 
gel. Gene ruler 100bp plus DNA ladder was used (ThermoFischer Scientific). 
As one single band could no longer be obtained (Figure 8-11a) I proceeded with 
nested PCR. Initially the PCR was set up using an annealing temperature of 63⁰C 
and multiple bands were obtained. A single band was obtained when the annealing 
temperature was changed to 61⁰C (Figure 8-11b). This product was PCR purified and 
partially sequenced. It was confirmed to be ADAMTS13.  
There was not enough of the purified nested PCR fragment to sequence the whole 
fragment so the nested PCR was repeated. PCR was carried out using the nested PCR 
product as a template,  using the same conditions as before. Multiple bands were 
observed on the gel, which were not of the correct size. Nested PCR was carried out 
using the same PCR 1 sample that had been used previously. Strangely one band was 
not obtained (as had been the case previously) but multiple bands were obtained 
instead. The annealing temperature and the concentration of DMSO were varied. 
Additionally a lower concentration of primer and formamide were used but this did 
not produce any bands. Instead all of the products that had been obtained from nested 
PCR were pooled together and were run on an agarose gel for DNA gel extraction 
(Figure 8-11c). The top band was cut for gel extraction; the purified product is shown 
in Figure 8-11d. This was sequenced and confirmed to be ADAMTS13.  
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Figure 8-11 PCR amplification and gel purification of WT ADAMTS13 
Figure a shows PCR amplification of WT (lane 1) and ADAMTS13 splice mutant (lane 2) genomic 
DNA  using  primers  SpliceD  and  SpliceE.  Figure  b  shows  PCR  amplification  of  WT  (lane  1) 
ADAMTS13 genomic DNA using primers SpliceD and SpliceE (lane 1). This DNA was used as a 
template for a subsequent PCR using primers SpliceA and SpliceF. The product of this is shown in 
lane 2. Figure c shows the WT ADAMTS13 PCR fragment that was used for agarose gel extraction 
(top  band).  Figure  d  shows  the  purified  product.  Expected  size  of  product  using  SpliceD/E  was 
2078bp and using SpliceA/F was 2023bp. DNA ladder marker X (Roche) was used. 
The entire exonic DNA of this product was sequenced and some of the intronic DNA 
within this fragment. However because of the limited material and the amount of 
work required to produce this  fragment, this fragment  was to be cloned into the 
TOPO vector and the intronic regions of the fragment sequenced after cloning.  
With the mutant multiple bands were obtained after the first PCR, with very little of 
the correct size (Figure 8-11a). I decided therefore to create one mini gene, using WT 
genomic DNA and then carry out site directed mutagenesis on this vector to create 
the splice site mutant.  
8.9  TOPO cloning of PCR fragment produced using primers 
SpliceA/F 
This time for TOPO cloning a control reaction was set up. The PCR fragment used 
for  the  control  TOPO  cloning  reaction  was  produced  as  recommended  by  the 
manufacturers (Figure 8-12) 
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Figure 8-12 TOPO PCR cloning reaction 
Control PCR was set up for subsequent TOPO cloning. The expected size of the fragment is 750bp. 
The TOPO cloning reaction was carried out using 4μl of the WT PCR product. The 
positive and vector only controls were set up as recommended by the manufacturer. 
After transformation clones were picked and grown for mini preparation. Restriction 
digest  on  the  DNA  obtained  after  mini  preparation  was  carried  out.  Before  this 
however a restriction digest of the TOPO vector expressing full length ADAMTS13 
cDNA using the enzyme StuI was performed to check that the enzyme was working 
and cleaved at the expected sites.  
StuI was predicted to cleave the vector expressing full length WT ADAMTS13 cDNA 
at multiple sites and was predicted to cleave the WT splice ADAMTS13 fragment at 
one point to produce fragments of 1138bp and 881bp. Results are shown in Figure 
8-13. The enzyme cleaved both of the products as expected.  
The  expected  size  of  the  fragments  obtained  after  StuI  digestion  if  the  vector 
contained the WT splice product was 2085bp and 5451bp. No band could be detected 
at 2085bp suggesting that the vectors were empty or did not contain the full fragment 
(Figure 8-14). After this three more colonies were picked and the same results were 
obtained.  
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Figure 8-13 StuI restriction digest of WT ADAMTS13 
Figure  a  shows  the  results  before  and  after  restriction  digest  of  the  TOPO  vector  containing 
ADAMTS13 full length cDNA. Figure b shows the results after restriction digest of the WT PCR 
splice fragment used for cloning. The expected size of the PCR splice fragments  were 1138 and 
889bp. DNA ladder marker X (Roche) was used.  
 
Figure 8-14 StuI restriction digest of TOPO clones 
Restriction  digest  with  StuI  was  carried  out  of  DNA  obtained  after  mini  preparation  of  E.  coli 
transformed for TOPO cloning. A vector containing the full length PCR fragment should produce 
fragments of 2085 and 5451bp. In lane 1 the vector expressing full length ADAMTS13 cDNA was also 
run as a control. DNA ladder marker X (Roche) was used.  
The TOPO cloning reaction was repeated. This time 2μl of the DNA was used for the 
cloning  reaction,  however  no  colonies  grew.  The  cloning  reaction  was  repeated 
again, this time using 10ng of DNA. In the previous cloning reactions the amount of 
DNA  used  for  the  reaction  was  not  quantified.  This  transformation  worked  and 
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colonies were picked for mini preparation and sequenced (twelve colonies). All of 
these colonies contained empty vectors except for one which appeared to contain 
ADAMTS13. However this clone contained the beginning and end of the ADAMTS13 
fragment, with the region in the middle absent.  
Another transformation was carried out using the same conditions as previously. This 
time many more colonies (86) were picked and sequenced to check if they contained 
ADAMTS13. From this five clones were found which contained DNA resembling 
ADAMTS13. However there were large deletions of the ADAMTS13 sequence within 
these  vectors.  These  deletions  were  particularly  within  the  intronic  region  of 
ADAMTS13. The deletions present in each of the clones were different suggesting 
that the deletion occurred during the cloning process. Due to time constraints I was 
not able to perform another transformation.  
8.10 Discussion 
RNA was successfully extracted from normal controls, reverse transcribed and used 
to PCR amplify the ADAMTS13 gene. Although a sample from the patient with the 
splice site mutation was not available for mRNA analysis, this technique could be 
used to analyse other patients which have potential splice site mutations in the future.  
A fragment was successfully produced using PCR encoding exon1, intron 1, exon 2, 
intron 2 and exon 3 of ADAMTS13. There were some difficulties in producing a 
single band using PCR. To try and optimise the PCR, the annealing temperature, 
DMSO  concentration,  DNA  concentration,  primer  concentration  and  dNTP 
concentration  were  varied  and  new  primers  were  designed.  When  successful  in 
producing a single PCR band, the results were not always reproducible. Often after 
repeating a PCR using the same conditions and components multiple bands  were 
obtained rather than a single band as previously obtained. Due to the difficulties in 
producing a single PCR band, a DNA PCR band of the desired size was extracted 
from an agarose gel.  
After obtaining a PCR fragment it was cloned into a TOPO vector. TOPO cloning 
was  carried  out  four  times  but  no  clones  were  found  which  contained  the  full 242 
 
ADAMTS13 sequence. In the initial cloning procedures this may have been because 
too much of the PCR fragment was used for cloning, which would have reduced the 
efficiency.  
In the last cloning reaction 86 clones were analysed but only 5 of them contained a 
sequence  resembling  ADAMTS13.  This  shows  that  the  efficiency  of  the  cloning 
procedure was poor (the kit states that the cloning efficiency should be 90%). This 
poor cloning efficiency may have been because a gel purified PCR fragment was 
used (as opposed to a purified PCR fragment). Additionally the gel purified products 
were  not  freshly  produced  before  cloning,  which  may  have  further  reduced  the 
efficiency.  
Although ADAMTS13 could be detected in 5 clones these clones did not contain the 
entire  expected  sequence  of  ADAMTS13.  These  clones  had  large  regions  of  the 
ADAMTS13 DNA deleted from them (particularly the intronic regions). The regions 
that were deleted in each of the clones were different suggesting that the problem 
occurred  during  the  cloning  and  transformation  steps.  This  problem  could  be 
overcome in the future by using an alternative type of E. coli. There are some types 
of E. coli which have been specially modified to prevent the deletion of large regions 
of DNA such as Sure 2 supercompetent cells (Agilent technologies). These E. coli 
lack components of the pathways that catalyse the rearrangement and deletion of 
non-stranded secondary and tertiary structures that may occur in eukaryotic DNA, 
which prevents their cloning.  
After these problems have been resolved the vector expressing WT ADAMTS13 
genomic DNA could be used as a template for site directed mutagenesis to introduce 
the splice site mutation. The vectors containing WT and mutant ADAMTS13 exonic 
and intronic DNA could then be transiently transfected in HEK 293T cells. The RNA 
produced could then be extracted and analysed to check if the splice site mutation did 
affect splicing leading to the formation of different RNA products. Unfortunately all 
of these experiments could not be performed during the time of this project, but this 
is something that could be continued in the future.  243 
 
Chapter 9   Summary and conclusions 
The clinical presentation of patients with TTP is highly variable. Patients vary with 
respect  to  the  age  of  disease  onset,  number  of  relapses  and  need  for  plasma 
exchange/infusion. There is evidence to suggest that the ADAMTS13 genotype of 
patients  may  contribute  to  some  of  this  heterogeneity.  Relationships  have  been 
shown to exist between ADAMTS13 genotype and age of disease onset (Lotta et al, 
2010) and residual ADAMTS13 activity (Lotta et al, 2012). Residual ADAMTS13 
activity in turn has been shown to be associated with the annual rate of TTP episodes 
(Lotta et al, 2012). This thesis was based upon the hypothesis that the clinical and 
laboratory  phenotype  of  patients  with  congenital  TTP,  relates  to  the  ADAMTS13 
mutations that the patients have. The aim of this study was to express ADAMTS13 
mutants which had been identified in a homozygous form in congenital TTP patients 
to assess their effect on the secretion and activity of ADAMTS13. I used a variety of 
methods to assess the effect of three types of ADAMTS13 mutations: type 1a, type 2 
and type 1b. 
Two type 1a ADAMTS13 mutants (p.I143T and p.Y570C) were studied in vitro. The 
p.I143T mutation (present in patient 1) and p.Y570C mutation (present in patient 2) 
were both identified in a homozygous form in the affected patients. Both patients 
first  presented  with  the  disease  during  adolescence  and  had  undetectable 
ADAMTS13 activity and antigen in their plasma, in the absence of detectable anti-
ADAMTS13 antibodies.  
When  vectors  expressing  these  mutants  were  transiently  expressed  in  vitro  in 
HEK293T cells, the levels of the mutants within the cell were slightly increased 
compared to WT ADAMTS13. Therefore, both mutants were synthesised within the 
cell,  demonstrating  that  the  mutations  did  not  prevent  protein  synthesis.  No 
ADAMTS13  could  be  detected  using  western  blotting  in  supernatant  samples 
(concentrated  ~20  fold)  and  ADAMTS13  antigen  in  the  supernatant  was  also 
undetectable using an ADAMTS13 antigen ELISA. No ADAMTS13 activity could 
be detected within supernatant samples using FRETS-VWF73 substrate for analysis 
(detection  limit  2.5%  of  PNP).  Both  mutations  therefore  severely  affected  the 244 
 
secretion and subsequently measureable ADAMTS13 activity, which correlated with 
the undetectable antigen and activity present in the plasma of patients 1 and 2. 
These  mutants  were  studied  further  in  order  to  investigate  their  subcellular 
localisation.  Immunofluorescence  staining  and  confocal  microscopy  were  used  to 
analyse the localisation of these mutants within the ER and cis Golgi of the cell. WT 
and mutant ADAMTS13 appeared to localise extensively within the ER but appeared 
to localise less extensively within the cis Golgi. Colocalisation quantitative analysis 
showed  that  less  of  the  cis  Golgi  voxels  within  cells  expressing  the  mutants 
overlapped with the ADAMTS13 voxels in the same cell, when compared to cells 
expressing WT ADAMTS13. Together these results suggest that less of the mutant 
protein is transported to the Golgi compared to WT ADAMTS13.  
As both mutants appeared to localise within the ER and the cis Golgi of the cell but 
were secreted at a severely reduced level I investigated whether these proteins were 
degraded  within  the  cell  by  either  the  cell  proteasome  or  lysosomes.  I  initially 
investigated  this  by  inhibiting  the  proteasome  or  lysosomes  in  HEK293T  cells 
transiently expressing these mutants. However the results from these experiments 
were unclear and so I decided instead to investigate the effect of proteasome and 
lysosome inhibition in HEK293 cells stably expressing mutant ADAMTS13. At the 
time of analysis I did not have a stable line expressing the p.Y570C mutant and so 
the effect of proteasome and lysosome inhibition was investigated for the p.I143T 
mutant only. 
Addition of the proteasome inhibitor (MG132) and the proteasome and cathepsin 
inhibitor (ALLN) to HEK 293 cells stably expressing the p.I143T mutant led to an 
increase in the intracellular levels of ADAMTS13. This increase was not observed in 
cells  stably  expressing  WT  ADAMTS13  after  the  addition  of  either  drug.  These 
results  suggest  that  a  large  proportion  of  the  p.I143T  mutant,  but  not  WT 
ADAMTS13 is targeted to the proteasome for degradation.  
The quantity of WT and p.I143T mutant ADAMTS13 present in the supernatant of 
stable line cells in the presence of proteasome inhibitors was also measured. In these 
experiments  the  supernatant  was  concentrated  to  a  greater  degree  (~100  fold) 245 
 
compared to the supernatant obtained from transient transfections. At this degree of 
concentration the p.I143T mutant could be detected in the majority of experiments. 
In WT ADAMTS13 the addition of MG132 led to a slight decrease in the quantity 
and activity of ADAMTS13 measured in the supernatant. With the p.I143T mutant 
however the opposite occurred, there was a slight increase in the quantity secreted 
and as a result the activity of the mutant. The antigen and activity of the mutant 
measured  in  the  supernatant  incubated  in  the  presence  of  MG132  however  was 
similar  to  the  values  obtained  after  incubation  with  DMSO,  suggesting  that  the 
DMSO solvent was mainly responsible for the increase in the values obtained. In 
contrast, inhibition of lysosomes with ammonium chloride or Bafilomycin A1 led to 
similar/slightly  increased  levels  in  cells  expressing  either  WT  or  mutant 
ADAMTS13, suggesting that the mutant was degraded by lysosomes to a similar 
extent as WT ADAMTS13. 
The  addition  of  DMSO  to  cells  stably  expressing  WT  or  p.I143T  mutant 
ADAMTS13 appeared to lead to an increase in the secretion of ADAMTS13. DMSO 
is a chemical chaperone and has been shown to aid the secretion of some proteins. I 
investigated whether another chemical chaperone, betaine, could alternatively help 
promote the folding and subsequent secretion of the p.I143T mutant. 
The addition of 100mM betaine led to a slight decrease in the quantity and activity of 
WT  ADAMTS13  detected  in  the  supernatant  (expressed  by  stable  line  HEK293 
cells). After the addition of betaine to cells expressing the p.I143T mutant there was 
a median 1.8 fold increase in ADAMTS13 antigen in the supernatant compared to in 
the absence of betaine. The median antigen value obtained in the absence of betaine 
was 17ng/ml, range :< 10-197ng/ml, the median value in the presence of betaine on 
the other hand was 28ng/ml, range: 12- 354ng/ml.  
For the p.I143T mutant activity in the absence of betaine was undetectable (<2.5% of 
PNP) in all experiments, but could be detected in 6/11 experiments in the presence of 
betaine. In the six experiments in which activity could be detected in the presence of 
betaine there was a several fold increase in the activity of the mutant in the presence 
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experiments was: 5.5% of PNP, ranging from 2.7%-7.1% of PNP. The addition of 
betaine therefore appeared to promote the secretion of the p.I143T mutant.  
In cell lysate samples two distinct bands were present, with the upper band more 
prominent in cells treated with betaine. This band was sensitive to Endoglycosidase 
H  digestion,  which  cleaves  most  N-linked  glycans  except  for  complex  glycans. 
Complex glycans are formed in the Golgi so ER associated proteins are sensitive to 
Endoglycosidase H digestion, suggesting that the upper band that was present in cell 
lysate  samples  corresponded  to  ER  associated  ADAMTS13.  The  lower  band 
appeared  to  be  unglycosylated  ADAMTS13,  as  it  was  not  sensitive  to 
Endoglycosidase H or PNGase F digestion. The ability of betaine to aid the folding 
of ADAMTS13 appeared to promote glycosylation of the protein, in turn leading to a 
greater proportion of glycosylated compared to unglycosylated protein within the ER 
of the cell. This in turn promoted the secretion of the protein.    
In summary, the p.Y570C mutation severely affected the secretion of ADAMTS13 in 
vitro and subsequently  no activity  could  be measured in  the supernatant  of cells 
expressing the mutant. This mutant localised within the ER of the cell but appeared 
to  localise  less  extensively  within  the  cis  Golgi.  Similarly  the  p.I143T  mutant 
severely affected the secretion and activity of ADAMTS13 in vitro. This mutant also 
localised within the ER but less extensively within the cis Golgi compared to WT 
ADAMTS13. This mutant appeared to be targeted within the cell to the proteasome 
for  degradation.  Addition  of  the  chemical  chaperone  betaine  to  cells  stably 
expressing the mutant led to increased secretion of the mutant and consequently in 
some experiments detectable ADAMTS13 activity in the supernatant.   
The  two  patients  with  the  type  1a  mutations  also  had  polymorphisms  in  the 
ADAMTS13 gene. Patient 1 (with the p.I143T mutation) was homozygous for the 
non-synonymous polymorphism (p.Q448E). Patient 2 (with the p.Y570C mutation) 
was  homozygous  for  two  polymorphisms  (p.R7W  and  p.P618A).  These 
polymorphisms have been expressed in vitro by other groups (Plaimauer et al, 2006) 
and  two  of  these  polymorphisms  (p.Q448E  and  p.P618A)  have  been  expressed 
separately in WT ADAMTS13 in this study. The effect of these polymorphisms in 
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time constraints but they may have modulated slightly the secretion of either of these 
two  mutants.  The  p.P618A  polymorphism  significantly  affected  the  secretion  of 
ADAMTS13 when expressed in WT ADAMTS13 as shown in Chapter 7 and by 
other groups (Plaimauer et al, 2006;Edwards et al, 2012;Rurali et al, 2013) and so it 
is  likely  to  have  further  decreased  the  secretion  and  activity  of  the  p.Y570C 
ADAMTS13  mutant.  Plaimauer  et  al  showed  that  the  expression  of  p.R7W  and 
p.Q448E  in  combination  with  a  mutation  (p.R1336W)  enhanced  the  detrimental 
effect of the mutation (Plaimauer et al, 2006). These polymorphisms therefore may 
have  further  reduced  the  secretion  of  ADAMTS13  when  expressed  with  their 
respective mutations.    
One type 2 ADAMTS13 mutant (p.R102H) was analysed in vitro to study the effect 
of this mutation on the secretion and activity of ADAMTS13. The patient with this 
mutation  developed  TTP  during  her  third  trimester  of  pregnancy.  She  had 
undetectable ADAMTS13 activity in her plasma in the absence of detectable anti-
ADAMTS13 antibodies. However the patient had detectable ADAMTS13 antigen in 
her plasma, 42%±5.4 of PNP (mean±SD).  
After  transient  transfection  of  the  p.R102H  mutant  in  HEK293T  cells,  reduced 
ADAMTS13 could be detected in the supernatant by western blotting. ADAMTS13 
antigen within the supernatant was measured using an ADAMTS13 antigen ELISA 
and was found to be partially reduced (30% of WT). The partial defect in secretion in 
vitro observed with the p.R102H mutant correlated with the detectable ADAMTS13 
antigen in the plasma of patient 3. Decreased ADAMTS13 activity could also be 
measured in the supernatant (15% of WT), giving an average specific activity of 
48%. The activity of this mutant was studied further  using purified ADAMTS13 
protein.  
Supernatant was collected from HEK293 cells stably expressing WT or p.R102H 
mutant  ADAMTS13  and  ADAMTS13  was  purified  using  FPLC.  Time  course 
experiments were set up using FRETS-VWF73 as a substrate and equal quantities of 
WT  and  mutant  ADAMTS13  to  assess  the  catalytic  efficiency  (kcat/Km)  of  both 
proteins. The kcat/Km for WT was 2.8 x 10
5(M
-1sec
-1), whereas for the mutant this 
value was approximately 4 fold lower with a value of 0.75 x 10
5(M
-1sec
-1). In the 248 
 
circulation therefore this mutant is likely to be less efficient at cleaving ADAMTS13 
than WT. 
The  activity  of  the  purified  material  was  analysed  further  using  VWF  multimer 
analysis. Equal quantities of WT or mutant ADAMTS13 were incubated with full 
length VWF and VWF multimeric pattern was analysed over time. At 30 minutes 
there appeared to be a slight difference between WT and mutant ADAMTS13, with 
more of the intermediate molecular weight multimers present in the mutant. However 
at  the  remaining  time  points  there  did  not  appear  to  be  a  noticeable  difference 
between WT and mutant ADAMTS13.  
Together these results suggested that there is a difference in the activity of WT and 
the p.R102H mutant ADAMTS13. However the activity of the p.R102H mutant was 
not severely reduced as expected based on the undetectable activity measured in the 
patient plasma. The results from the transient transfection experiments showed that 
this mutant is secreted at a reduced level, which would also impact on the activity 
measured in the patient plasma. However this defect in secretion did not appear to be 
sufficient to severely reduce the activity to the levels measured in the patient plasma 
in vivo. 
The patient with the p.R102H mutation was also homozygous for three ADAMTS13 
non-synonymous polymorphisms (p.Q448E, p.P618A and p.A900V). I investigated 
whether  these  polymorphisms  in  combination  with  the  p.R102H  mutation  could 
further affect the activity of ADAMTS13. Each polymorphism was also expressed 
separately in WT ADAMTS13.  
When expressed separately the p.P618A polymorphism had the greatest effect on the 
secretion  of  ADAMTS13,  reducing  the  secretion  of  ADAMTS13  more  than  the 
p.R102H mutation. The p.Q448E polymorphism appeared to decrease slightly the 
secretion of ADAMTS13 whereas the p.A900V polymorphism increased it. When all 
three polymorphisms were expressed in WT ADAMTS13 or in combination with the 
p.R102H  mutation  they  reduced  the  secretion  of  ADAMTS13  further,  when 
compared to WT or the p.R102H mutant alone.  249 
 
The p.Q448E and p.P618A polymorphisms did not appear to affect the activity of 
ADAMTS13, whereas the p.A900V polymorphism did. The specific activity of WT 
and the p.R102H mutant in the presence of all three polymorphisms was reduced.  
No  activity  could  be  detected  in  the  p.R102H+p.Q448E+p.P618A+p.A900V 
construct which correlated with the undetectable ADAMTS13 activity measured in 
the patient plasma. This suggests that the p.R102H mutation in combination with the 
three polymorphisms was responsible for the reduced activity measured in the patient 
plasma. However the quantity of ADAMTS13 in the supernatant was reduced (6% of 
PNP), which is lower than the quantity of antigen measured in the patient plasma 
(42%±5.4 of PNP, mean±SD). So although ADAMTS13 antigen could be detected in 
the supernatant it was lower than the quantity measured in the patient plasma.  
In summary the p.R102H mutation partially affects both the secretion and the activity 
of ADAMTS13. However this mutation did not appear to severely affect the activity 
of  ADAMTS13  as  predicted  based  upon  the  undetectable  ADAMTS13  activity 
measured in the patient plasma. When this mutation was expressed in combination 
with three ADAMTS13 polymorphisms also present in the patient with this mutation, 
the secretion was further reduced and the activity was undetectable, suggesting that 
the mutation in combination with the three polymorphisms was responsible for the 
undetectable ADAMTS13 activity measured in the patient plasma.  
I attempted to analyse the effect of a splice site mutation (p.S36_C37delfs*102) on 
the splicing process by creating a mini gene. I successfully created the ADAMTS13 
coding  fragment  (exon  1exon  3)  to  be  inserted  into  the  expression  vector  for 
cloning; however the cloning reaction was not successful despite trying a number of 
different technical procedures. Further work is required in order to assess the effect 
of this mutation on splicing.  
In this study I fulfilled my aim to assess how ADAMTS13 mutations can lead to some 
of the laboratory features measured in patient plasma (i.e. ADAMTS13 antigen and 
activity).  I  successfully  studied  type  1a  and  type  2  ADAMTS13  mutants  and 
investigated  whether  and  how  these  mutations  contributed  to  the  undetectable 
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splice site mutant in addition but during the time of this study I have not been able to 
complete this.   
It is difficult to assess how these mutations relate to other features of the disease 
phenotype because of the small number of mutations analysed. In order to study how 
these ADAMTS13 mutations relate to other features of the disease would require a 
large number of patients to be studied with the same genotype. To the best of my 
knowledge, patients 1,2 and 4 are the only congenital TTP patients described in the 
literature  with  the  mutations  studied  here  and  only  one  other  patient  with  the 
p.R102H mutation has been described (Scully et al, 2014). In fact for the majority of 
ADAMTS13 mutations that have been described to date, most of them have been 
described in only one patient in the literature. The exceptions to this is the p.R1060W 
mutation, predominantly present in patients with adult onset TTP (Moatti-Cohen et 
al, 2012;Scully et al, 2014) and the p.E1382RfsX6 mutation, predominantly present 
in patients with childhood onset TTP (Schneppenheim et al, 2006).    
If  looking  at  just  the  effect  of  the  mutations  (i.e.  not  in  combination  with 
ADAMTS13 polymorphisms also present in the patient), then the p.R102H mutation 
does  not  appear  to  affect  ADAMTS13  function  as  severely  as  the  p.I143T  and 
p.Y570C mutations. The p.I143T and p.Y570C mutations were identified in patients 
with adolescent onset TTP, who both require regular plasma infusion. On the other 
hand the p.R102H mutation was identified in a patient with a less severe disease, 
who  developed  the  disease  during  adulthood  and  only  requires  plasma 
infusion/exchange  when  pregnant  or  after  an  episode.  However  the  effect  of 
ADAMTS13 polymorphisms also needs to be considered as my results have shown. 
Ideally residual ADAMTS13 activity should be measured in all of the mutants, when 
expressed in combination with their respective polymorphisms in order to establish 
whether residual ADAMTS13 activity is higher in the type 2 mutant compared to the 
type 1a mutants.  
Residual ADAMTS13 activity appears to be associated with disease severity and 
with ADAMTS13 genotype (Lotta et al, 2012) so it is important to understand the 
mechanisms  and  to  what  extent  different  mutations  within  ADAMTS13  affect  its 
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vitro (Lotta et al, 2010;Feys et al, 2009b;Camilleri et al, 2012;Taguchi et al, 2012). 
Patients homozygous for ADAMTS13 mutations are particularly useful in order to 
study genotype phenotype relationships that may exist. Of the 43 mutations which 
have been expressed only 16 are present in a homozygous form in at least one patient 
in the literature. The results from my study have contributed another three mutations 
to this list. However more of these homozygous mutations need be expressed in vitro 
in order to assess this relationship more fully. 
ADAMTS13 appears to play an important role in determining a patient’s phenotype 
but  other  factors  should  also  be  considered.  Other  genetic  modifiers  may  be 
important  in  the  development  of  TTP.  Noris  et  al  described  two  sisters  with 
congenital  TTP  who  presented  with  TTP  during  pregnancy  and  with  a  slightly 
different clinical course. One sister had a predominance of neurological symptoms 
and the other renal symptoms. The sister with renal involvement had a mutation 
within complement factor H (Noris et al, 2005). Complement deficiencies have been 
found  in  patients  with  atypical  HUS  patients,  a  disease  characterised  by  renal 
impairment (Malina et al, 2012).   
My  work  has  highlighted  the  importance  of  ADAMTS13  polymorphisms  to  the 
contribution  of  laboratory  disease  phenotype.  Other  groups  have  shown  the 
importance  of  ADAMTS13  polymorphisms  (Plaimauer  et  al,  2006;Edwards  et  al, 
2012;Rurali et al, 2013) and their effects in combination with ADAMTS13 mutations 
(Plaimauer  et  al,  2006).  My  work  has  shown  however  that  the  ADAMTS13 
polymorphisms present in patient 3 along with the mutation identified are vital for 
disease laboratory phenotype.  
The effect of chemical chaperones on the secretion of ADAMTS13 mutants has not 
been  investigated  before  and  is  a  novel  concept  in  the  treatment  of  TTP.  The 
ADAMTS13 mutations which have been identified in patients with congenital TTP 
and  expressed in  vitro, affect  to various degrees  the secretion pathways  of these 
proteins and the activity of ADAMTS13 (Lotta et al, 2010). The majority (86%), 
lead to reduced (<50% of WT) secretion of mutant recombinant ADAMTS13. The 
use  of  a  chemical  chaperone  such  as  betaine,  to  aid  the  secretion  of  misfolded 252 
 
ADAMTS13 proteins may be an attractive therapeutic option as potentially a large 
number of secretion defect mutants could be treated using a similar mechanism.  
In my experiments, betaine caused a slight increase in ADAMTS13 activity. It has 
been shown that residual ADAMTS13 activity is associated with disease severity so 
even a small increase in activity could be beneficial clinically (Lotta et al, 2012). I 
investigated  the  effect  of  betaine,  but  there  are  a  number  of  other  chemical 
chaperones that could be investigated that could potentially lead to a larger increase 
in secretion and activity. The development of pharmacological chaperones could lead 
to  a  more  potent  effect.  Currently  patients  with  congenital  TTP  are  treated  with  
plasma  infusion  or  an  intermediate  purity  FVIII  concentrate  with  measurable 
ADAMTS13 activity and plasma exchange for acute episodes (Scully & Goodship, 
2014;Scully  et  al,  2012).  Plasma  exchange  can  be  expensive,  citrate  reactions, 
allergic reactions can occur and there is also the risk of venous thromboembolism 
(McGuckin  et  al,  2014).  It  also  requires  specialised  equipment,  personnel,  and 
insertion  of  a  central  venous  access  line  (George,  2010).  Chemical  chaperones 
however  can  be  orally  administered  so  if  these  could  one  day  be  used  as  a 
replacement for plasma exchange or infusion it would be highly beneficial.  
Chemical chaperones or the development of pharmacological chaperones could be 
used in combination with current therapies or potentially by themselves as a novel 
therapeutic option in the treatment of congenital TTP. 
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Appendix 
Paralog  GI number  Ortholog  GI number 
Ailuropoda melanoleuca   301770673  ADAMTS1  50845384 
Bos taurus  297480872  ADAMTS2  3928000 
Calithrix jacchus  296191110  ADAMTS3  333360873 
Canis lupus familiaris   337298368  ADAMTS4  12643637 
Cavia porcellus   348574536  ADAMTS5  12643903 
Cricetulus griseus   354499351  ADAMTS6  64276808 
Danio Rerio   326670284  ADAMTS7  38197242 
Equus caballus   194225985  ADAMTS8  153792351 
Felis catus  410979457  ADAMTS9  33624896 
Gallus gallus   363740569  ADAMTS10  56121815    
Gorilla gorilla gorilla    426363476  ADAMTS12  51558724   
Homo Sapiens   15963593  ADAMTS13  15963593 
Mus musculus   47604978  ADAMTS14  21265052 
Nomascus leucogenys    332255397  ADAMTS15  21265058 
Otolemur garretti   395844537  ADAMTS16  32363141 
Ovis aries   426226011  ADAMTS17  37999850 
Pan troglodytes   332833255  ADAMTS18  76800647 
Pango abelli  395741139  ADAMTS19  29336810 
Papio anubis  402896179  ADAMTS20  28316229 
Saimiri boliviensis boliviensis    403301620  -  - 
Sarophilus harrisii   395506393  -  - 
Taeriopygia guttata  449478260  -  - 
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Primer Name  Sequence  Exon position 
T7 (Life technologies)  TAATACGACTCACTATAGGG  Vector sequence 
For1  ATGCACCAGCGTCACCCCCG  1 
For2  GAGCCACAGGCCGTGTCTTCTTA  2 
For3  GTCTTCAGGCTTTGGAGCCAC  2 
Rev1  CCTGGTGAGCCTGGAAGACATCG  3 
For4  GCTGACCTGGTCCTCTATATCAC  5 
Rev2  AATGGTGACTCCCAGGTCGA  6 
For5  TGCGCAGCCTGGCCTCTACTACA  8 
Rev3  GCAGGAGAGGGCCTGGCACATATC  9 
For6  CATAGCAGCAGTGCATGGGC  10 
For7  CCCCAGACCTGCCTTTGGGGGGCGTG  10/11 
For8  GACATTTGGCTGTGATGGTAGG  13/14 
For9  AGAGTGGCCCTCACCGAGGACCGG  16 
Rev4  AAACCTGGATGTCAGCATCTTC  16/17 
For10  TACTTCCAGCCTAAGCCACGG  17 
For11  GGACCAGGCCAGGAAGGAGTTGGT  18 
For12  AGACTTCGGCCCATGCAGCG  19 
For13  GCGGGAGGTCTGCCAGGCTGTC  22 
Rrv5  GCTGCAGGCCGCCAGCTTGTACT  23 
For14  GCCAACAGGAACCATTGACATGC  26 
For15  CGCTGAGTCCAGCCACGAGTAAT  28 
BGH Reverse 
 (Life technologies) 
TAGAAGGCACAGTCGAGG  Vector sequence 
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Mutation  Forward Primer  Reverse Primer  Primer 
position  Domain 
c.106-1G>C 
CCATCTCTTTTT
GTCTTGCACAG 
TTGTCTTCAGGC 
GCCTGAAGACAA
CTGTGCAAGACA
AAAAGAGATGG 
Intron 1/ 
Exon 2  Propeptide 
p. R102H 
(c.305G>A) 
CAGGAGGACAC
AGAGCACTATG
TGCTCACCAAC 
GTTGGTGAGCAC
ATAGTGCTCTGT 
GTCCTCCTG 
Exon 3  Metalloprotease 
p. I143T 
(c.428T>C) 
GAGGGTGCTCC
AAATACCACAG
CCAACCTCACC 
GGTGAGGTTGGC
TGTGGTATTTGG 
AGCACCCTC 
Exons 4/ 
Exon 5  Metalloprotease 
p.T196I 
(c.C587T) 
GTGCGGGGCGT
CATCCAGCTGG
GCGG 
CCGCCCAGCTGG
ATGACGCCCCGC
AC 
Exon 6  Metalloprotease 
p.R409W 
(c.C1225T) 
GTGGTCACCAG
GAGGTGGCAGT
GCAACAACC 
GGTTGTTGCACTG
CCACCTCCTGGTG
ACCAC 
Exon 10  TSP-1 
p. Y570C 
(c.1709A>G) 
GGCAGAGCGAG
AGAATGTGTCA
CGTTTCTGAC 
GTCAGAAACGTG
ACACATTCTCTCG
CTCTGCC 
Exon 14/  
Exon 15  Spacer 
p.A596V 
(c.C1787T) 
CTCTTCACACAC
TTGGTGGTGAG
GATCGGAGGG 
CCCTCCGATCCTC
ACCACCAAGTGT
GTGAAGAG 
Exon 15/ 
Exon 16  Spacer 
p.C754R 
(c.T2260C) 
GACTTCGGCCC
ACGCAGCGCCT
CCTG 
CAGGAGGCGCTG
CGTGGGCCGAAG
TC 
Exon 19  TSP-1:3 
p.C977F 
(c.G2930T) 
GAGGATCCTGT
ATTTTGCCCGG 
GCCCATG 
CATGGGCCCGGG
CAAAATACAGGA
TCCTC 
Exon 23  TSP-1:6 
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Polymorphism  Forward Primer  Reverse Primer  Primer 
position  
Domain 
p. Q448E (i) 
(c.1342C>G) 
GCTGGAGTTC
ATGTCGGAAC
AGTGCGCCAG
GAC 
GTCCTGGCGCAC 
TGTTCCGACATG 
AACTCCAGC 
Exon 11  Cysteine-rich 
p. Q448E (ii) 
(c.1342C>G) 
CCAGCTGGAG
TTCATGTCGGA
ACAGTGCGCC
AGGACCGACG 
CGTCGGTCCTGGC
GCACTGTTCCGAC
ATGAACTCCAGCT
GG 
Exon 11  Cysteine-rich 
p. P618A 
(c.1852C>G) 
CTAACACCAC
CTACGCCTCCC
TCCTGGAG 
CTCCAGGAGGGA
GGCGTAGGTGGT
GTTA 
Exon 16  Spacer 
p. A900V 
(c.2699C>T) 
GTGTGGACCC
CTGTGGCAGG
GTCGTGC 
GCACGACCCTGC
CACAGGGGTCCA
CAC 
Exon 21  TSP 1-5 
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  Primer  Forward Primer  Exon/Intron 
position 
R
N
A
  F6  GAGCCACAGGCCGTGTCTTCTTA  Exon 2 
R6  CCTGGTGAGCCTGGAAGACATCG  Exon 3 
RevJP  AATGGTGACTCCCAGGTCGA  Exon 6 
M
i
n
i
-
g
e
n
e
:
 
c
r
e
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t
i
o
n
 
a
n
d
 
s
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SpliceA (F)  CACCATGCACCAGCGTCACCCCCGG  Exon 1 
SpliceB (R)  TAAGGGAGCACCAGGGCTCAAGTA  Exon 2 
SpliceC (R)  GGTGAGCACATAGCGCTCTGTGTC  Exon 3 
SpliceD (F)  AGATTCCCAGTCACCAAGGC  Untranslated region 
SpliceE (R)   CATAGCGCTCTGTGTCCTCC  Exon 3 
SpliceF (R)   ATAGCGCTCTGTGTCCTCCT  Exon 3 
M
i
n
i
-
g
e
n
e
:
 
s
e
q
  F3/4  TGTTAGCTTTCCACTGCTTG  Intron 3 
T7 (LT)  TAATACGACTCACTATAGGG  Vector sequence 
BGH Reverse  
(LT) 
TAGAAGGCACAGTCGAGG  Vector sequence 
 
Table S 5 Primers used for splicing 
RNA: Primers used for RNA extraction, LT: Primers provided by Life technologies, seq: sequencing, 
F: forward primer, R: reverse primer. 
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  No  Type  Location   DNA  Protein  Reference 
S
 
1  Insertion  Exon 1  c.82dupT  p.W28LfsX111  (Donadelli et al, 2006) 
P
r
o
  2  Splice  Intron 1  c.106-1G>C  p.S36_C37delfs*102  (Lotta et al, 2012) 
3  Nonsense  Exon 2  c.130C>T  p.Q44X   (Antoine et al, 2003) 
M
e
t
a
l
l
o
p
r
o
t
e
a
s
e
 
4  Missense  Exon 3  c.237C>G  p.I79M  (Veyradier et al, 2004) 
5  Missense  Exon 3  c.262G>A  p.V88M  (Bestetti et al, 2003) 
6  Missense  Exon 3  c.262G>C  p.V88L  (Moatti-Cohen et al, 
2012) 
7  Missense  Exon 3  c.283G>C  p.A95P  (Moatti-Cohen et al, 
2012) 
8  Missense  Exon 3  c.286C>G  p.H96D  (Levy et al, 2001) 
9  Deletion  Exon 3  c.291_319del  p.E98PfsX31  (Garagiola et al, 2008) 
10  Missense  Exon 3  c.304C>T  p.R102C  (Levy et al, 2001) 
11  Missense  Exon 3  c.305G>A  p. R102H  (Camilleri et al, 2012) 
12  Splice   Intron 3  c.330+1G>A  r.[330_331ins105,  
330_331ins27] 
(Uchida et al, 2004) 
13  Deletion  Exon 4  c.334del  p.A111QfsX18 
(Scully et al, 2014) 
14  Missense  Exon 4  c.356C>T  p.S119F  (Meyer et al, 2008) 
15  Insertion  Exon 4  c.372_373insGT  p.R125VfsX6  (Fujimura et al, 2009) 
16  Splice   Intron 4  c.414+1G>A   r.spl?  (Matsumoto et al, 2004) 
17  Missense  Exon 5  c.428T>C  p.I143T  (Lotta et al, 2012) 
18  Missense  Exon 5  c.448T>C  p.S150P  (Lotta et al, 2012) 
19  Missense  Exon 5  c.533T>C  p.I178T  (Fujimura et al, 2009) 
20  Missense  Exon 6  c.577C>T  p.R193W  (Matsumoto et al, 2004) 
21  Missense  Exon 6  c.578G>A  p.R193Q  (Lotta et al, 2012) 
22  Missense  Exon 6  c.581G>T  p.G194V  (Ma et al, 2006) 
23  Missense  Exon 6  c.587C>T  p.T196I  (Levy et al, 2001) 
24  Missense  Exon 6  c.607T>C  p.S203P    (Veyradier et al, 2004) 
25  Missense  Exon 6  c.649G>C  p.D217H  (Camilleri et al, 2012) 
26  Missense  Exon 6  c.681G>C  p.G227R   (Fujimura et al, 2011) 
27  Splice   Intron 6  c.686+1G>A    (Matsumoto et al, 2004) 
28  Splice   Intron 6  c.687-2 A>G     (Studt et al, 2005) 
29  Missense  Exon 7   c.695T>A   p.L232Q  (Schneppenheim et al, 
2003) 
30  Missense  Exon 7  c.702C>A   p.H234Q  (Shibagaki et al, 2006) 
31  Missense  Exon 7  c.701A>G  p.H234R  (Fujimura et al, 2011) 
32  Missense  Exon 7  c.703G>C  p.D235H  (Assink et al, 2003) 
33  Missense  Exon 7  c.703G>T  p.D235Y  (Lotta et al, 2012) 
34  Missense  Exon 7  c.706G>T  p.G236C  (Lotta et al, 2012) 
35  Deletion  Exon 7  c.718_724del  p.S240AfsX9  (Assink et al, 2003) 
36  Deletion  Exon 7  c.719_724del  p.G241_C242del  (Camilleri et al, 2012) 
37  Deletion 
Exon 7 
c.746_987+ 
373del1782 
p.M249TdelfsX50  (Eura et al, 2014) 
38  Missense  Exon 7  c.749C>T   p.A250V  (Uchida et al, 2004) 
39  Deletion  Exon 7  c.768_774del  p.R257AfsX13  (Prestidge et al, 2012) 259 
 
40  Missense  Exon 7  c.788C>G  p.S263C  (Schneppenheim et al, 
2003) 
41  Missense  Exon 7  c.788C>T  p.S263F  (Rossio et al, 2013) 
42  Missense  Exon 7  c.794G>C_ 
796A>T 
p.C265S+S266C  (Camilleri et al, 2012) 
43  Missense  Exon 7  c.803G>C  p.R268P  (Kokame et al, 2002) 
44  Deletion  Intron 8_ 
Exon 8 
c.825-10_843del    (Veyradier et al, 2004) 
45  Missense  Exon 8  c.841T>A  p.C281S 
(Eura et al, 2014) 
D
i
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46  Missense  Exon 8  c.911A>G  p.Y304C  (Fujimura et al, 2009) 
47  Missense  Exon 8  c.932G>A  p.C311Y  (Assink et al, 2003) 
48  Missense  Exon 8  c.?  p.R312C  (Fujimura et al, 2011)  
49  Missense  Exon 8  c.964T>G (+)  
968C>G (+)  
969C>A (+)  
970T>C 
p.C322G +  
T323R +  
F324L 
(Kokame et al, 2008)  
50  Missense  Exon 9  c.1039T>A  p.C347S  (Schneppenheim et al, 
2006) 
51  Missense  Exon 9  c.1045C>T  p.R349C  (Fujimura et al, 2009) 
52  Missense  Exon 9  c.1058C>T  p.P353L  (Schneppenheim et al, 
2003) 
53  Deletion  Exon 10  c.1095_1112del  p.W365_R370del  (Tao et al, 2006) 
54  Missense  Exon 10  c.?  p.G385E  (Fujimura et al, 2011) 
T
1
 
55  Nonsense  Exon 10  c.1169G>A  p.W390X  (Schneppenheim et al, 
2003) 
56  Missense  Exon 10  c.1170G>C  p.W390C  (Licht et al, 2004) 
57  Missense  Exon 10  c.1192C>T  p.R398C  (Fujimura et al, 2011) 
58  Missense  Exon 10  c.1193G>A  p.R398H  (Levy et al, 2001) 
59  Missense  Exon 10  c.1201G>A  p.G401R 
(Scully et al, 2014) 
60  Missense  Exon 10  c.1225C>T  p.R409W  (Camilleri et al, 2012) 
61  Splice   Intron 10  c.1244+2T>G  r.spl?  (Matsumoto et al, 2004) 
62  Missense  Exon 11  c. 1308G>C  p.Q436H  (Camilleri et al, 2012) 
63  Splice   Intron 11  c.1309_?G>A    (Veyradier et al, 2004)  
64  Missense  Exon 12  c.?  p.C438S  (Fujimura et al, 2011) 
C
y
s
t
e
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65  Nonsense  Exon 12  c.1345C>T  p.Q449X  (Kokame et al, 2002) 
66  Missense  Exon 12  c.1368G>T  p.Q456H  (Camilleri et al, 2012) 
67  Missense  Exon 12  c.1370C>T  p.P457L  (Assink et al, 2003) 
68  Deletion  Exon 13  c.1456_1457del  p.M486VfsX47 
(Scully et al, 2014) 
69  Missense  Exon 13  c.1492C>T  p.R498C 
(Scully et al, 2014) 
70  Missense  Exon 13  c.1520G>A  p.R507Q  (Veyradier et al, 2004) 
71  Missense  Exon 13  c.1523G>A  p.C508Y  (Kokame et al, 2002) 
72  Missense  Exon 13  c.1574G>A   p.G525D  (Fujimura et al, 2009) 
73  Missense  Exon 13  c.1582A>G   p.R528G  (Levy et al, 2001) 
74  Splice   Intron 13  c.1584+5G>A    (Levy et al, 2001) 
75  Missense  Exon 14  c.1648G>A  p.G550R  (Fujimura et al, 2011) 
76  Deletion  Exon 14  c.1649_1664del  p.D551QfsX58  (Alsultan et al, 2013) 
S
p
a
c
e
r
  77  Missense  Exon 15  c.1709A>G  p.Y570C  (Metin et al, 2013) 
78  Deletion  Exon 15  c.1783_1784del   p.L595GfsX19  (Savasan et al, 2003) 
79  Splicing  Exon 15  c.1786+1G>A  p.E569_A596 
delinsA 
(Prestidge et al, 2012) 260 
 
80  Missense  Exon 16   c.1787C>T  p.A596V  (Veyradier et al, 2004) 
81  Missense  Exon 16  c.1816G>C   p.A606P  (Fujimura et al, 2009) 
82  Deletion  Exon 16  c.1885del  p.R629EfsX69  (Fujimura et al, 2011) 
83  Missense  Exon 16  c.1892C>T  p.A631V  (Moatti-Cohen et al, 
2012) 
84  Missense  Exon 16  c.1921G>A  p.E641K 
(Scully et al, 2014) 
85  Deletion  Exon 16  c.1922del  p.E641GfsX57  (Alsultan et al, 2013) 
86  Missense  Exon 16  c.1973A>G  p.Y658C  (Lee et al, 2011) 
87  Deletion  Exon 17  c.1999del  p.N667TfsX31 
(Scully et al, 2014) 
88  Missense  Exon 17  c.2012C>T  p.P671L   (Schneppenheim et al, 
2006) 
89  Missense  Exon 17  c.2017A>T  p.I673F  (Matsumoto et al, 2004) 
90  Deletion  Exon 17  c.2042del  p.K681CfsX16  (Rank et al, 2014) 
T
2
 
91  Missense  Exon 17  c.2068G>A  p.A690T  (Camilleri et al, 2012) 
92  Missense  Exon 17   c.2074C>T  p.R692C   (Levy et al, 2001) 
93  Missense  Exon 18  c.2167C>A  p.Q723K  (Fujimura et al, 2011)  
94  Nonsense  Exon 18  c.2203G>T  p.E735X  (Borgi et al, 2013) 
T
3
 
95  Deletion  Exon 19  c.2259del  p.C754AfsX24  (Fujimura et al, 2011) 
96  Missense  Exon 19   c.2260T>C  p.C754R  (Camilleri et al, 2012) 
97  Missense  Exon 19  c.2272T>C  p.C758R  (Veyradier et al, 2004) 
98  Deletion  Exon 19  c.2279del  p.G760AfsX18  (Assink et al, 2003) 
99  Deletion  Exon 19  c.2376_2401del  p.A793PfsX43  (Levy et al, 2001) 
T
4
 
100  Nonsense  Exon 20   c.2434G>T  p.E812X  (Moatti-Cohen et al, 
2012) 
101  Deletion  Exon 20   c.2455del  p.A819LfsX24  (Moatti-Cohen et al, 
2012) 
102  Deletion  Exon 20   c.2549_2550del  p.D850GfsX7  (Schneppenheim et al, 
2003) 
T
5
 
103  Missense  Exon 21  c.2723G>C   p.C908S  (Veyradier et al, 2004) 
104  Missense  Exon 21  c.2723G>A  p.C908Y   (Matsumoto et al, 2004) 
105  Missense  Exon 21  c.2725G>C  p.G909R  (Fujimura et al, 2011) 
106  Nonsense  Exon 21  c.2728C>T  p.R910X  (Schneppenheim et al, 
2003) 
107  Missense  Exon 22  c.2746C>T  p.R916C  (Deal et al, 2012) 
108  Nonsense  Exon 22  c.2785C>T  p.Q929X  (Fujimura et al, 2009) 
109  Missense  Exon 22  c.2851T>G  p.C951G  (Levy et al, 2001) 
T
6
  110  Deletion  Exon 23  c.2930_2935del  p.C977_R979 
delinsW 
(Palla et al, 2009) 
111  Missense  Exon 23  c.2930G>T  p.C977F  (Camilleri et al, 2012) 
T
7
 
112  Nonsense  Exon 24  c.3047G>A  p.W1016X  (Donadelli et al, 2006) 
113  Missense  Exon 24  c.3070T>G  p.C1024G  (Levy et al, 2001) 
114  Missense  Exon 24  c.?  p.C1024R  (Fujimura et al, 2011) 
115  Nonsense  Exon 24  c.3100A>T  p.R1034X  (Schneppenheim et al, 
2003) 
116  Nonsense  Exon 24  c.3107C>A  p.S1036X  (Klukowska et al, 2010) 
117  Missense  Exon 24  c.3178C>T  p.R1060W  (Tao et al, 2006) 
118  Deletion  Exon 24  c.3198_3199del  p.C1067SfsX30  (Fujimura et al, 2011) 
119  Deletion  Exon 24  c.3220_3223del   p.Y1074AfsX46  (Fujimura et al, 2011) 
T
8
  120  Nonsense  Exon 24  c.?  p.W1081X  (Fujimura et al, 2011) 
121  Missense  Exon 25  c.3251G>A  p.C1084Y  (Lotta et al, 2012) 261 
 
122  Deletion  Exon 25  c.3254_3255del  p.S1085CfsX12   (Veyradier et al, 2004) 
123  Missense  Exon 25  c.3283C>T  p.R1095W  (Lotta et al, 2012) 
124  Missense  Exon 25  c.3284G>A  p.R1095Q  (Camilleri et al, 2012) 
125  Missense  Exon 25  c.3313C>T  p.Q1105X  (Moatti-Cohen et al, 
2012) 
126  Missense  Exon 25  c.3367C>T   p.R1123C  (Matsumoto et al, 2004) 
127  Missense  Exon 25  c.3368G>A  p.R1123H  (Rank et al, 2014) 
C
U
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128  Nonsense  Exon 26  c.3616C>T  p.R1206X  (Shibagaki et al, 2006) 
129  Missense  Exon 26  c.3638G>A  p.C1213Y  (Levy et al, 2001) 
130  Missense  Exon 26  c.3650T>C  p.I1217T  (Park et al, 2008) 
131  Missense  Exon 26  c.3655C>T   p.R1219W  (Donadelli et al, 2006) 
132  Missense  Exon 26  c.3656G>A  p.R1219Q 
(Scully et al, 2014) 
133  Missense  Exon 27  c.3716G>T  p.G1239V   (Bestetti et al, 2003) 
134  Nonsense  Exon 27  c.3735G>A  p.W1245X   (Licht et al, 2004) 
135  Deletion  Eon 27  c.3751_3892 
+587del729  p.R1251SfsX2 
(Eura et al, 2014) 
136  Insertion  Exon 27   c.3770dupT  p.L1258VfsX36  (Levy et al, 2001) 
C
U
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137  Nonsense  Exon 28  c.3904C>T  p.Q1302X  (Fujimura et al, 2009) 
138  Missense  Exon 28  c.4006C>T   p.R1336W  (Antoine et al, 2003) 
139  Deletion  Exon 28  c.4015del  p.I1339SfsX21 
(Scully et al, 2014) 
140  Missense  Exon 29  c.4085A>T  p.D1362V  (Calderazzo et al, 2012) 
141  Deletion  Exon 29  c.4119del  p.Q1374SfsX22  (Fujimura et al, 2011) 
142  Insertion  Exon 29  c.4143dupA  p.E1382RfsX6  (Schneppenheim et al, 
2003) 
 
Table S 6 ADAMTS13 mutations identified in patients with congenital TTP and published in the 
literature 
S: Signal Peptide, Pro: Propeptide. Reference refers to the first case published in the literature in 
which mutation was identified. T1→TSP-1; T2→TSP-1:2; T3→TSP-1:3; T4→TSP-1:4; T5→TSP-
1:5; T6→TSP-1:6; T7→TSP-1:7 and T8→TSP-1:8. 262 
 
 
No  DNA  Protein  Domain  Reference 
1  c.130C>T  p.Q44X   P  (Plaimauer et al, 2006) 
2  c.262G>A  p.V88M  MP  (Donadelli et al, 2006;Peyvandi 
et al, 2006) 
3  c.291_319del  p.E98PfsX31  MP  (Garagiola et al, 2008) 
4  c.305G>A  p. R102H  MP  (Camilleri et al, 2012) 
5  c.330+1G>A  r.[330_331ins105, 
330_331ins27] 
MP  (Uchida et al, 2004) 
6  c.356C>T  p.S119F  MP  (Feys et al, 2009b) 
7  c.577C>T  p.R193W  MP  (Matsumoto et al, 2004) 
8  c.587C>T  p.T196I  MP  (Camilleri et al, 2012) 
9  c.607T>C  p.S203P   MP  (Hommais et al, 2007) 
10  c.649G>C  p.D217H  MP  (Camilleri et al, 2012) 
11  c.749C>T   p.A250V  MP  (Uchida et al, 2004) 
12  c.794G>C_796A>T  p.C265S+S266C  MP  (Camilleri et al, 2012) 
13  c.803G>C  p.R268P  MP  (Kokame et al, 2002;Hommais 
et al, 2007;Camilleri et al, 2012) 
14  c.719_724del  p.G241_C242del  MP  (Camilleri et al, 2012) 
15  c.1058C>T  p.P353L  Dis  (Manea et al, 2007a) 
16  c.1095_1112del  p.W365_R370del  Dis  (Tao et al, 2006) 
17  c.1192C>T  p.R398C  TSP1  (Camilleri et al, 2012) 
18  c.1225C>T  p.R409W  TSP1  (Camilleri et al, 2012) 
19  c. 1308G>C  p.Q436H  TSP1  (Camilleri et al, 2012) 
20  c.1345C>T  p.Q449X  Cys  (Kokame et al, 2002;Soejima et 
al, 2003) 
21  c.1368G>T  p.Q456H  Cys  (Camilleri et al, 2012) 
22  c.1370C>T  p.P457L  Cys  (Manea et al, 2007a) 
23  c.1520G>A  p.R507Q  Cys  (Hommais et al, 2007) 
24  c.1523G>A  p.C508Y  Cys  (Kokame et al, 2002) 
25  c.1787C>T  p.A596V  Spac  (Hommais et al, 2007;Camilleri 
et al, 2012) 
26  c.2017A>T  p.I673F  Spac  (Matsumoto et al, 2004) 
27  c.2068G>A  p.A690T  TSP-1:2  (Camilleri et al, 2012) 
28  c.2260T>C  p.C754R  TSP-1:3  (Camilleri et al, 2012) 
29  c.2723G>A  p.C908Y   TSP-1:5  (Matsumoto et al, 2004) 
30  c.2728C>T  p.R910X  TSP-1:5  (Camilleri et al, 2012) 
31  c.2930_2935del  p.C977_R979delinsW  TSP-1:6  (Palla et al, 2009) 
32  c.2930G>T  p.C977F  TSP-1:6  (Camilleri et al, 2012) 
33  c.3047G>A  p.W1016X  TSP-1:7  (Soejima et al, 2003) 
34  c.?  p.C1024R  TSP-1:7  (Taguchi et al, 2012) 
35  c.3178C>T  p.R1060W  TSP-1:7  (Camilleri et al, 2008;Tao et al, 
2006) 
36  c.3367C>T   p.R1123C  TSP-1:8  (Matsumoto et al, 
2004;Donadelli et al, 2006) 
37  c.3638G>A  p.C1213Y  CUB-1  (Zhou et al, 2009b) 
38  c.3655C>T   p.R1219W  CUB-1  (Donadelli et al, 2006) 
39  c.3716G>T  p.G1239V   CUB-1  (Donadelli et al, 2006;Peyvandi 
et al, 2006) 
40  c.3735G>A  p.W1245X   CUB-1  (Zhou et al, 2009b) 
41  c.3770dupT  p.L1258VfsX36  CUB-1  (Zhou et al, 2009b) 
42  c.4006C>T   p.R1336W  CUB-2  (Plaimauer et al, 2006) 
43  c.4143dupA  p.E1382RfsX6  CUB-2  (Pimanda et al, 2004;Garagiola 
et al, 2008) 
 
Table S 7 ADAMTS13 mutations identified in patients with congenital TTP expressed in vitro 
P: propeptide, MP: metalloprotease, Dis: disintegrin-like, Cys: cysteine-rich, Spa: spacer  263 
 
>NG_011934 reference sequence, modifications in red according to vector ADAMTS13 
▼ Signal peptide   
1/1                   31/11   
atg  cac cag cgt cac ccc cgg gca aga tgc cct ccc ctc tgt gtg gcc gga atc ctt gccExon1   
 M   H   Q   R   H   P   R   A   R   C   P   P   L   C   V   A   G   I   L   A  
                                                    ▼ Propeptide   
61/21              91/31           
tgt ggc ttt ctc ctg ggc tgc tgg gga ccc tcc cat ttc cag cag agc tgt ctt cag gctExon 2 
 C   G   F   L   L   G   C   W   G   P   S   H   F   Q   Q   S   C   L   Q   A  
 
121/41              151/51   
ttg gag cca cag gcc gtg tct tct tac ttg agc cct ggt gct ccc tta aaa ggc cgc cct 
 L   E   P   Q   A   V   S   S   Y   L   S   P   G   A   P   L   K   G   R   P  
                                                       ▼ Metalloprotease 
181/61              211/71       
cct tcc cct ggc ttc cag agg cag agg cag agg cag agg cgg gct gca ggc ggc atc ctaExon 3 
 P   S   P   G   F   Q   R   Q   R   Q   R   Q   R   R   A   A   G   G   I   L  
 
241/81              271/91 
cac ctg gag ctg ctg gtg gcc gtg ggc ccc gat gtc ttc cag gct cac cag gag gac aca 
 H   L   E   L   L   V   A   V   G   P   D   V   F   Q   A   H   Q   E   D   T  
 
301/101              331/111 
gag cgc tat gtg ctc acc aac ctc aac atc ggg gca gaa ctg ctt cgg gac ccg tcc ctgExon 4 
 E   R   Y   V   L   T   N   L   N   I   G   A   E   L   L   R   D   P   S   L  
 
361/121              391/131 
ggg gct cag ttt cgg gtg cac ctg gtg aag atg gtc att ctg aca gag cct gag ggt gct 
 G   A   Q   F   R   V   H   L   V   K   M   V   I   L   T   E   P   E   G   A  
 
421/141              451/151 
cca aat atc aca gcc aac ctc acc tcg tcc ctg ctg agc gtc tgt ggg tgg agc cag accExon 5 
 P   N   I   T   A   N   L   T   S   S   L   L   S   V   C   G   W   S   Q   T  
 
481/161              511/151 
atc aac cct gag gac gac acg gat cct ggc cat gct gac ctg gtc ctc tat atc act agg 
 I   N   P   E   D   D   T   D   P   G   H   A   D   L   V   L   Y   I   T   R  
 
541/181              571/191 
ttt gac ctg gag ttg cct gat ggt aac cgg cag gtg cgg ggc gtc acc cag ctg ggc ggtExon 6 
 F   D   L   E   L   P   D   G   N   R   Q   V   R   G   V   T   Q   L   G   G  
 
601/201              631/211 
gcc tgc tcc cca acc tgg agc tgc ctc att acc gag gac act ggc ttc gac ctg gga gtc 
 A   C   S   P   T   W   S   C   L   I   T   E   D   T   G   F   D   L   G   V  
 
661/221              691/231 
acc att gcc cat gag att ggg cac agc ttc ggc ctg gag cac gac ggc gcg ccc ggc agc 
 T   I   A   H   E   I   G   H   S   F   G   L   E   H   D   G   A   P   G   S  
 
721/241              751/251 
ggc tgc ggc ccc agc gga cac gtg atg gct tcg gac ggc gcc gcg ccc cgc gcc ggc ctcExon 7 
 G   C   G   P   S   G   H   V   M   A   S   D   G   A   A   P   R   A   G   L  
 
781/261              811/271 
gcc tgg tcc ccc tgc agc cgc cgg cag ctg ctg agc ctg ctc agc gca gga cgg gcg cgc 
 A   W   S   P   C   S   R   R   Q   L   L   S   L   L   S   A   G   R   A   R  
                                   ▼ Disintegrin-like 
841/281                      871/291  
tgc gtg tgg gac ccg ccg cgg cct caa ccc ggg tcc gcg ggg cac ccg ccg gat gcg cagExon 8 
 C   V   W   D   P   P   R   P   Q   P   G   S   A   G   H   P   P   D   A   Q  
 
901/301                                 931/311 
cct ggc ctc tac tac agc gcc aac gag cag tgc cgc gtg gcc ttc ggc ccc aag gct gtc 
 P   G   L   Y   Y   S   A   N   E   Q   C   R   V   A   F   G   P   K   A   V  
 
961/321                                 991/331 
gcc tgc acc ttc gcc agg gag cac ctg gat atg tgc cag gcc ctc tcc tgc cac aca gac 
 A   C   T   F   A   R   E   H   L   D   M   C   Q   A   L   S   C   H   T   D  
 
 
1021/341                                 1051/351 
ccg ctg gac caa agc agc tgc agc cgc ctc ctc gtt cct ctc ctg gat ggg aca gaa tgtExon 9 
 P   L   D   Q   S   S   C   S   R   L   L   V   P   L   L   D   G   T   E   C  
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1081/361                                 1111/371 
ggc gtg gag aag tgg tgc tcc aaa ggt cgc tgc cgc tcc ctg gtg gag ctg acc ccc ata 
 G   V   E   K   W   C   S   K   G   R   C   R   S   L   V   E   L   T   P   I  
                    ▼ TSP-1 
1141/381                                 1171/391 
gca gca gtg cat ggg cgc tgg tct agc tgg ggt ccc cga agt cct tgc tcc cgc tcc tgcExon10 
 A   A   V   H   G   R   W   S   S   W   G   P   R   S   P   C   S   R   S   C  
 
1201/401                                 1231/411 
gga gga ggt gtg gtc acc agg agg cgg cag tgc aac aac ccc aga cct gcc ttt ggg gggExon11 
 G   G   G   V   V   T   R   R   R   Q   C   N   N   P   R   P   A   F   G   G  
                                                            Cysteine-rich   ▼ 
1261/421                                 1291/431                           
cgt gca tgt gtt ggt gct gac ctc cag gcc gag atg tgc aac act cag gcc tgc gag aag 
 R   A   C   V   G   A   D   L   Q   A   E   M   C   N   T   Q   A   C   E   K  
 
1321/441                                 1351/451 
acc cag ctg gag ttc atg tcg caa cag tgc gcc agg acc gac ggc cag ccg ctg cgc tccExon12 
 T   Q   L   E   F   M   S   Q   Q   C   A   R   T   D   G   Q   P   L   R   S  
 
1381/461                                 1411/471 
tcc cct ggc ggc gcc tcc ttc tac cac tgg ggt gct gct gta cca cac agc caa ggg gat 
 S   P   G   G   A   S   F   Y   H   W   G   A   A   V   P   H   S   Q   G   D  
 
1441/481                                 1471/491 
gct ctg tgc aga cac atg tgc cgg gcc att ggc gag agc ttc atc atg aag cgt gga gacExon13 
 A   L   C   R   H   M   C   R   A   I   G   E   S   F   I   M   K   R   G   D  
 
1501/501                                 1531/511 
agc ttc ctc gat ggg acc cgg tgt atg cca agt ggc ccc cgg gag gac ggg acc ctg agc 
 S   F   L   D   G   T   R   C   M   P   S   G   P   R   E   D   G   T   L   S  
 
1561/521                                 1591/531 
ctg tgt gtg tcg ggc agc tgc agg aca ttt ggc tgt gat ggt agg atg gac tcc cag cagExon14 
 L   C   V   S   G   S   C   R    T   F   G   C   D   G   R   M   D   S   Q   Q  
                                                            ▼ Spacer 
1621/541                                 1651/551           
gta tgg gac agg tgc cag gtg tgt ggt ggg gac aac agc acg tgc agc cca cgg aag ggc 
 V   W   D   R   C   Q   V   C   G   G   D   N   S   T   C   S   P   R   K   G  
 
1681/561                                 1711/571         
tct ttc aca gct ggc aga gcg aga gaa tat gtc acg ttt ctg aca gtt acc ccc aac ctgExon15 
 S   F   T   A   G   R   A   R   E   Y   V   T   F   L   T   V   T   P   N   L  
 
1741/581                                 1771/591 
acc agt gtc tac att gcc aac cac agg cct ctc ttc aca cac ttg gcg gtg agg atc gga 
 T   S   V   Y   I   A   N   H   R   P   L   F   T   H   L   A   V   R   I   G  
 
1801/601                                 1831/611 
ggg cgc tat gtc gtg gct ggg aag atg agc atc tcc cct aac acc acc tac ccc tcc ctcExon16 
 G   R   Y   V   V   A   G   K   M   S   I   S   P   N   T   T   Y   P   S   L  
 
1861/621                                 1891/631 
ctg gag gat ggt cgt gtc gag tac aga gtg gcc ctc acc gag gac cgg ctg ccc cgc ctg 
 L   E   D   G   R   V   E   Y   R   V   A   L   T   E   D   R   L   P   R   L  
 
1921/641                                 1951/651 
gag gag atc cgc atc tgg gga ccc ctc cag gaa gat gct gac atc cag gtt tac agg cgg 
 E   E   I   R   I   W   G   P   L   Q   E   D   A   D   I   Q   V   Y   R   R  
 
1981/661                                 2011/671 
tat ggc gag gag tat ggc aac ctc acc cgc cca gac atc acc ttc acc tac ttc cag cctExon17 
 Y   G   E   E   Y   G   N   L   T   R   P   D   I   T   F   T   Y   F   Q   P  
                    ▼ TSP-1:2              
2041/681                                 2071/691 
aag cca cgg cag gcc tgg gtg tgg gcc gct gtg cgt ggg ccc tgc tcg gtg agc tgt ggg 
 K   P   R   Q   A   W   V   W   A   A   V   R   G   P   C   S   V   S   C   G  
 
2101/701                                 2131/711 
gca ggg ctg cgc tgg gta aac tac agc tgc ctg gac cag gcc agg aag gag ttg gtg gagExon18 
 A   G   L   R   W   V   N   Y   S   C   L   D   Q   A   R   K   E   L   V   E  
 
 
2161/721                                 2191/731 
act gtc cag tgc caa ggg agc cag cag cca cca gcg tgg cca gag gcc tgc gtg ctc gaa 
 T   V   Q   C   Q   G   S   Q   Q   P   P   A   W   P   E   A   C   V   L   E  265 
 
 
                    ▼ TSP-1:3 
2221/741                                 2251/751 
ccc tgc cct ccc tac tgg gcg gtg gga gac ttc ggc cca tgc agc gcc tcc tgt ggg ggt 
 P   C   P   P   Y   W   A   V   G   D   F   G   P   C   S   A   S   C   G   G  
 
2281/761                                 2311/771 
ggc ctg cgg gag cgg cca gtg cgc tgc gtg gag gcc cag ggc agc ctc ctg aag aca ttgExon19 
 G   L   R   E   R   P   V   R   C   V   E   A   Q   G   S   L   L   K   T   L  
 
2341/781                                 2371/791 
ccc cca gcc cgg tgc aga gca ggg gcc cag cag cca gct gtg gcg ctg gaa acc tgc aac 
 P   P   A   R   C   R   A   G   A   Q   Q   P   A   V   A   L   E   T   C   N  
                            ▼ TSP-1:4 
2401/801                                 2431/811 
ccc cag ccc tgc cct gcc agg tgg gag gtg tca gag ccc agc tca tgc aca tca gct ggt 
 P   Q   P   C   P   A   R   W   E   V   S   E   P   S   S   C   T   S   A   G  
 
2461/821                                 2491/831 
gga gca ggc ctg gcc ttg gag aac gag acc tgt gtg cca ggg gca gat ggc ctg gag gctExon20 
 G   A   G   L   A   L   E   N   E   T   C   V   P   G   A   D   G   L   E   A  
 
2521/841                                 2551/851 
cca gtg act gag ggg cct ggc tcc gta gat gag aag ctg cct gcc cct gag ccc tgt gtc 
 P   V   T   E   G   P   G   S   V   D   E   K   L   P   A   P   E   P   C   V  
 
2581/861                                 2611/871 
ggg atg tca tgt cct cca ggc tgg ggc cat ctg gat gcc acc tct gca ggg gag aag gct 
 G   M   S   C   P   P   G   W   G   H   L   D   A   T   S   A   G   E   K   A  
                                                        ▼ TSP-1:5 
2641/881                                 2671/891       
ccc tcc cca tgg ggc agc atc agg acg ggg gct caa gct gca cac gtg tgg acc cct gcgExon21 
 P   S   P   W   G   S   I   R   T   G   A   Q   A   A   H   V   W   T   P   A  
 
2701/901                                 2731/911 
gca ggg tcg tgc tcc gtc tcc tgc ggg cga ggt ctg atg gag ctc cgt ttc ctg tgc atg 
 A   G   S   C   S   V   S   C   G   R   G   L   M   E   L   R   F   L   C   M  
 
2761/921                                 2791/931 
gac tct gcc ctc agg gtg cct gtc cag gaa gag ctg tgt ggc ctg gca agc aag cct gggExon22 
 D   S   A   L   R   V   P   V   Q   E   E   L   C   G   L   A   S   K   P   G  
                                                ▼ TSP-1:6 
2821/941                                 2851/951 
agc cgg cgg gag gtc tgc cag gct gtc ccg tgc cct gct cgg tgg cag tac aag ctg gcg 
 S   R   R   E   V   C   Q   A   V   P   C   P   A   R   W   Q   Y   K   L   A  
 
2881/961                                 2911/971 
gcc tgc agc gtg agc tgt ggg aga ggg gtc gtg cgg agg atc ctg tat tgt gcc cgg gccExon23 
 A   C   S   V   S   C   G   R   G   V   V   R   R   I   L   Y   C   A   R   A  
 
2941/981                                 2971/991 
cat ggg gag gac gat ggt gag gag atc ctg ttg gac acc cag tgc cag ggg ctg cct cgc 
 H   G   E   D   D   G   E   E   I   L   L   D   T   Q   C   Q   G   L   P   R  
                                                            ▼ TSP-1:7   
3001/1001                                 3031/1011 
ccg gaa ccc cag gag gcc tgc agc ctg gag ccc tgc cca cct agg tgg aaa gtc atg tcc 
 P   E   P   Q   E   A   C   S   L   E   P   C   P   P   R   W   K   V   M   S  
 
3061/1021                                 3091/1031 
ctt ggc cca tgt tcg gcc agc tgt ggc ctt ggc act gct aga cgc tcg gtg gcc tgt gtg 
 L   G   P   C   S   A   S   C   G   L   G   T   A   R   R   S   V   A   C   V  
 
3121/1041                                 3151/1051 
cag ctc gac caa ggc cag gac gtg gag gtg gac gag gcg gcc tgt gcg gcg ctg gtg cggExon24 
 Q   L   D   Q   G   Q   D   V   E   V   D   E   A   A   C   A   A   L   V   R  
                                                           ▼ TSP-1:8 
3181/1061                                 3211/1071 
ccc gag gcc agt gtc ccc tgt ctc att gcc gac tgc acc tac cgc tgg cat gtt ggc acc 
 P   E   A   S   V   P   C   L   I   A   D   C   T   Y   R   W   H   V   G   T  
 
3241/1081                                 3271/1091 
tgg atg gag tgc tct gtt tcc tgt ggg gat ggc atc cag cgc cgg cgt gac acc tgc ctc 
 W   M   E   C   S   V   S   C   G   D   G   I   Q   R   R   R   D   T   C   L  
 
3301/1101                                 3331/1111 
gga ccc cag gcc cag gcg cct gtg cca gct gat ttc tgc cag cac ttg ccc aag ccg gtgExon25 
 G   P   Q   A   Q   A   P   V   P   A   D   F   C   Q   H   L   P   K   P   V  266 
 
 
3361/1121                                 3391/1131 
act gtg cgt ggc tgc tgg gct ggg ccc tgt gtg gga cag ggt acg ccc agc ctg gtg ccc 
 T   V   R   G   C   W   A   G   P   C   V   G   Q   G   T   P   S   L   V   P  
 
3421/1141                                 3451/1151 
cac gaa gaa gcc gct gct cca gga cgg acc aca gcc acc cct gct ggt gcc tcc ctg gag 
 H   E   E   A   A   A   P   G   R   T   T   A   T   P   A   G   A   S   L   E  
 
3481/1161                                 3511/1171 
tgg tcc cag gcc cgg ggc ctg ctc ttc tcc ccg gct ccc cag cct cgg cgg ctc ctg ccc 
 W   S   Q   A   R   G   L   L   F   S   P   A   P   Q   P   R   R   L   L   P  
                                           ▼ CUB-1 
3541/1181                                 3571/1191 
ggg ccc cag gaa aac tca gtg cag tcc agt gcc tgt ggc agg cag cac ctt gag cca aca 
 G   P   Q   E   N   S   V   Q   S   S   A   C   G   R   Q   H   L   E   P   T  
 
3601/1201                                 3631/1211 
gga acc att gac atg cga ggc cca ggg cag gca gac tgt gca gtg gcc att ggg cgg cccExon26 
 G   T   I   D   M   R   G   P   G   Q   A   D   C   A   V   A   I   G   R   P  
 
3661/1221                                 3691/1231 
ctc ggg gag gtg gtg acc ctc cgc gtc ctt gag agt tct ctc aac tgc agt gcg ggg gac 
 L   G   E   V   V   T   L   R   V   L   E   S   S   L   N   C   S   A   G   D  
 
3721/1241                                 3751/1251 
atg ttg ctg ctt tgg ggc cgg ctc acc tgg agg aag atg tgc agg aag ctg ttg gac atgExon27 
 M   L   L   L   W   G   R    L  T   W   R   K   M   C   R   K   L   L   D   M  
 
3781/1261                                 3811/1271 
act ttc agc tcc aag acc aac acg ctg gtg gtg agg cag cgc tgc ggg cgg cca gga ggt 
 T   F   S   S   K   T   N   T   L   V   V   R   Q   R   C   G   R   P   G   G  
                                                                        ▼ CUB-2 
3841/1281                                 3871/1291 
ggg gtg ctg ctg cgg tat ggg agc cag ctt gct cct gaa acc ttc tac aga gaa tgt gac 
 G   V   L   L   R   Y   G   S   Q   L   A   P   E   T   F   Y   R   E   C   D  
 
3901/1301                                 3931/1311 
atg cag ctc ttt ggg ccc tgg ggt gaa atc gtg agc ccc tcg ctg agt cca gcc acg agtExon28 
 M   Q   L   F   G   P   W   G   E   I   V   S   P   S   L   S   P   A   T   S  
 
3961/1321                                 3991/1331 
aat gca ggg ggc tgc cgg ctc ttc att aat gtg gct ccg cac gca cgg att gcc atc cat 
 N   A   G   G   C   R   L   F   I   N   V   A   P   H   A   R   I   A   I   H  
 
4021/1341                                 4051/1351 
gcc ctg gcc acc aac atg ggc gct ggg acc gag gga gcc aat gcc agc tac atc ttg atc 
 A   L   A   T   N   M   G   A   G   T   E   G   A   N   A   S   Y   I   L   I  
 
4081/1361                                 4111/1371 
cgg gac acc cac agc ttg agg acc aca gcg ttc cat ggg cag cag gtg ctc tac tgg gag 
 R   D   T   H   S   L   R   T   T   A   F   H   G   Q   Q   V   L   Y   W   E  
 
4141/1381                                 4171/1391 
tca gag agc agc cag gct gag atg gag ttc agc gag ggc ttc ctg aag gct cag gcc agcExon29 
 S   E   S   S   Q   A   E   M   E   F   S   E   G   F   L   K   A   Q   A   S  
 
4201/1401                                 4231/1411 
ctg cgg ggc cag tac tgg acc ctc caa tca tgg gta ccg gag atg cag gac cct cag tcc 
 L   R   G   Q   Y   W   T   L   Q   S   W   V   P   E   M   Q   D   P   Q   S  
 
4261/1421                                  
tgg aag gga aag gaa gga acc tga 
 W   K   G   K   E   G   T   -   
 
Figure S 1 ADAMTS13 DNA vector sequence. Exons and domains are highlighted. Domains 
highlighted based on annotation by (Zheng et al, 2001) 
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a. 
Taeniopygia 1   -------MRVGWALRALAVLPLGLCWLPQKFLGALDGEDVLSYFGTSSVPDVP------- 46 
Gallus      1   ------------------------------------------------------------ 
Bos         1   --------------------------------MPAASLRKDSWAQPGWESALS------- 21 
Ovis        1   -----MKKVMFGLKLDCEDQRKRLRVNPASWSSPAALPARHSRSTPGFRQMIAGSMAPST 55 
Gorilla     1   --------------------------------MHQRHP--RARCPPLCVAGFL------- 19 
Pan         1   --------------------------------MHQRHP--RARCPPLCVAGIL------- 19 
ADAMTS13    1   --------------------------------MHQRHP--RARCPPLCVAGIL------- 19 
Nomascus    1   --------------------------------MRQHHPRARARCPPLCVAGIL------- 21 
Pango       1   --------------------------------MYQRHP--RARCPPLCVAGIL------- 19 
Papio       1   --------------------------------MRQRHP--QARCPSLCVAGIL------- 19 
Callithrix  1   --------------------------------MRQRHP--WARCPPFCVAGIL------- 19 
Saimin      1   --------------------------------MCQRHL--RARCPSLCVAGIL------- 19 
Otolemur    1   --------------------------------MHTDWG---------------------- 6 
Mus         1   ------------------------------MSQLCLWLTCQPCYAVSVRGILT------- 23 
Cricetulus  1   ------------------------------MSELCLWVTCQPFHAASIRGVLT------- 23 
Cava        1   ---------------------------------MSPWARGTLLQAASAGGILT------- 20 
Canus       1   --------------------------------MREPRP-----WGRCVGAILT------- 16 
Felis       1   --------------------------------MREPRP-----WGRCVGATLT------- 16 
Ailuropoda  1   --------------------------------MRK----------HCNNAVL-------- 10 
Equus       1   --------------------------------MSELQL-----WGRCVQGILT------- 16 
Sarcophilus 1   MSFHSFILAHLRKGRRQPSRQNHSSSLSSPFTPPPPHLPLVAPRSSSARRDRTKADNQSE 60 
Danio       1   -------------------------------------------MRLYIRPVLEQ------ 11 
                                                                              
b. 
ADAMTS1    1    ---------------SGSETPLPETDLAHCFYSGTVN--GDPSSAAALSLCEG-VRGAFY 150 
ADAMTS4    1    -----------------QAPELLGGAEPGTYLTGTIN--GDPESVASLHWDGGALLGVLQ 154 
ADAMTS15   1    ---------------PLQGLTGGSSDLRRCFYSGDVN--AEPDSFAAVSLCGG-LRGAFG 128 
ADAMTS8    1    ---------------GSGRATGGERGLRGCFFSGTVN--GEPESLAAVSLCRG-LSGSFL 127 
ADAMTS5    1    -------------------TSAPWRHRSHCFYRGTVD--ASPRSLAVFDLCGG-LDGFFA 157 
ADAMTS9    1    -------------NQTKFYSEE-EAELKHCFYKGYVN--TNSEHTAVISLCSG-MLGTFR 177 
ADAMTS20   1    -------------ERGAWESDAGPSDLRHCFYRGQVN--SQEDYKAVVSLCGG-LVGTFK 156 
ADAMTS3    1    PGNITDPINNHQPGSATYRIRRTEPLQTNCAYVGDIV--DIPGTS-VAISNCDGLAGMIK 173 
ADAMTS14   1    -----------------FRELFRQPLRQECVYTGGVT--GMPGAA-VAISNCDGLAGLIR 179 
ADAMTS2    1    -----------------KGTTRVEPLLGSCLYVGDVA--GLAEASSVALSNCDGLAGLIR 183 
ADAMTS6    1    ------------------GPQWKHDFLDNCHYTGYLQ-DQRSTT-KVALSNCVGLHGVIA 159 
ADAMTS10   1    ------------------GLAWQRAARPHCLYAGHLQ-GQASTS-HVAISTCGGLHGLIV 150 
ADAMTS7    1    -----------------LGRAHIRAHTPACHLLGEVQ-DPELEGGLAAISACDGLKGVFQ 157 
ADAMTS12   1    -----------------SHVKMMASSAPLCHLSGTVL-QQGTRVGTAALSACHGLTGFFQ 168 
ADAMTS16   1    -----------------TKSVQTLPPEDFCFYQGSLR-SHRNSS--VALSTCQGLSGMIR 172 
ADAMTS18   1    -----------------ASETQ-KPEVQQCFYQGFIR-NDSSSS--VAVSTCAGLSGLIR 170 
ADAMTS17   1    ----------------AGAARRRGRPAELCFYSGRVLGHPGSLVSLSACGAAGGLVGLIQ 155 
ADAMTS19   1    G-----------PTGAASAPQPPAPPDAGCFYTGAVLRHPGSLASFSTCG--GGLMGFIQ 248 
ADAMTS13   1    --------------------MHQRHPRARCPPLCVAG-----------ILACGFLLGCWG 29 
 
Figure  S  2  Alignment  of  human  ADAMTS13  with  ADAMTS13  orthologs  and  paralogs, 
showing conservation of the p.R7W polymorphism 
Figure a shows conservation in orthologs and b shows conservation in paralogs.  Polymorphism is 
shown in yellow. 268 
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Bethyl laboratories Inc, Montogomery, USA 
Bio-rad Laboratories Ltd, Hemel Hempstead, UK 
BMG Labtech, Aylesbury, UK 
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Katholieke Universiteit Leuven, Laboratory for thrombosis research, Kortruk, 
Leuven 
LGC standards, Teddington, UK 
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Santa Cruz Biotechnology Inc, Heidelberg, Germany 
Sekisui Diagnostics, Stamford, USA 
Sigma, Dorset, UK 
Takara Bio Europe/Clontech, Saint-Germain-en-Laye, France 
ThermoFischer Scientific, Basingstoke, UK 
Vector Laboratories Ltd, Peterborough, UK 
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Roche, Burgess Hill, UK 
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Publications and presentations arising from work performed for this 
thesis 
Publications 
Congenital  thrombotic  thrombocytopenic  purpura  with  novel  mutations  in  three 
unrelated Turkish children. A. Metin, S. Unal, F. Gumruk, R. Palla, A. Cairo, M. 
Underwood & A. Gurgey (2013). Pediatric Blood & Cancer. 
Oral presentations 
In  vitro  characterisation  of  the  p.R102H  mutation  identified  in  a  patient  with 
congenital thrombotic thrombocytopenic purpura (TTP) and detectable ADAMTS13 
antigen in their plasma. M. Underwood, I. Garagiola, I. Mackie, S. Machin, R. De 
Cristofaro,  S.  Lancellotti  &  F.  Peyvandi.  Presented  at  British  Society  for 
Haemostasis and Thrombosis/Belgian Society on Thrombosis and Haemostasis joint 
meeting October 10
th-11
th 2013, Nottingham. 
The  effect  of  ADAMTS13  mutations  on  its  secretion,  activity  and  subcellular 
location.  M.  Underwood,  I.  Garagiola,  I.  Mackie,  S.  Machin  &  F.  Peyvandi. 
Presented at British Society for Haemostasis and Thrombosis/UK Platelet Group 
Joint Meeting October 18
th-19
th 2012, Bath. 
Poster presentations 
In vitro characterisation of two ADAMTS13 mutants (p.I143T, p.Y570C) identified 
in  two  patients  with  congenital  thrombotic  thrombocytopenic  purpura  (TTP).  M. 
Underwood, I. Garagiola, I. Mackie, S. Machin, A. Metin, A. Gurgey, F. Peyvandi. 
Presented at ISTH XXIV congress June 29
th-July 4
th 2013, Amsterdam. 
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